Page last updated: 2024-10-23

aspirin and Recrudescence

aspirin has been researched along with Recrudescence in 1237 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group."9.51Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022)
" Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China."9.34Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020)
"The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)."9.30Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019)
"We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source."9.30Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019)
"Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4."9.30Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019)
"For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin."9.24Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017)
"Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis."9.24Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017)
"Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA)."9.22Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G, 2022)
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."9.22Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours."9.22Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016)
"The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization."9.22A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016)
"An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups."9.19Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014)
"We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention."9.17CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013)
"To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death."9.17Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013)
"To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution."9.16Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012)
"Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death."9.16Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."9.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
"In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)."9.14Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."9.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin."9.14Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010)
"We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)."9.14Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."9.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance."9.13Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008)
"Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)."9.13Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)
"To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period."9.13Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008)
"Fluctuations in urinary 11-DTB2 after cerebral infarction in blacks do not correlate with changes in aspirin doses, except perhaps when the dose changes by a factor of 4 or more."9.11Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. ( Bang, NU; Bruno, A; Cohen, SN; Gorelick, PB; McConnell, JP; Tietjen, GE; Wallis, RA, 2004)
"To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)."9.11Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004)
"0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk."9.11A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005)
"Colchicine seems to be a good drug for treating recurrences of pericarditis after conventional treatment failure, but no clinical trial has tested the effects of colchicine as first-line drug for the treatment of the first recurrence of pericarditis."9.11Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. ( Belli, R; Bobbio, M; Cecchi, E; Demarie, D; Ghisio, A; Imazio, M; Moratti, M; Pomari, F; Trinchero, R, 2005)
"Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0."9.10Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003)
"To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients."9.10Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003)
"To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan."9.10Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003)
"The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion."9.10The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003)
"To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms."9.10Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. ( Darbà, J; Izquierdo, I; Navas, C; Pontes, C; Rovira, J, 2002)
"The dose of aspirin for secondary stroke prevention and the clinical meaning of ex vivo platelet abnormalities are debated."9.09Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. ( Chamorro, A; Escolar, G; Obach, V; Ordinas, A; Reverter, JC; Revilla, M; Vila, N, 1999)
"A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years."9.09Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000)
"To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction."9.09Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000)
"Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation."9.09Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
"The aim of the present study was to evaluate the possible interaction between chronic aspirin therapy and angiotensin-converting enzyme inhibitor (ACE-I) on left ventricular ejection fraction (LVEF) in patients surviving an acute myocardial infarction (AMI)."9.09Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. ( Arnesen, H; Hole, T; Hurlen, M; Seljeflot, I, 2001)
"We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis."9.09Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001)
"We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence."9.09Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001)
"To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction."9.08A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996)
"The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined."9.08Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997)
"Healing with bFGF (and cimetidine) was associated with reduced NSAID induced ulcer relapse in this model of gastric ulceration."9.08Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration. ( Brough, JL; Filipowicz, B; Hawkey, CJ; Hull, MA; Knifton, A; Vautier, G, 1997)
"The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial."9.07Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991)
"To ascertain whether predischarge arteriography is beneficial in patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA), heparin and aspirin, the outcome of 197 patients in the Thrombolysis in Myocardial Infarction (TIMI) IIA study assigned to conservative management and routine predischarge coronary arteriography (routine catheterization group) was compared with the outcome of 1,461 patients from the TIMI IIB study assigned to conservative management without routine coronary arteriography unless ischemia recurred spontaneously or on predischarge exercise testing (selective catheterization group)."9.07Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. ( Babb, JD; Baim, DS; Braunwald, E; Chesebro, JH; Frederick, M; Gore, JM; Passamani, ER; Roberts, R; Rogers, WJ; Williams, DO, 1991)
"We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis."9.07Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. ( Bauman, JE; Domoto, DT; Joist, JH, 1991)
"Recently, it was shown that aspirin given early in acute myocardial infarction (AMI) improves hospital survival, but the mechanisms involved are unclear."9.06Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. ( Funke-Küpper, AJ; Galema, TW; Roos, JP; Sterkman, LG; van der Laarse, A; Verheugt, FW, 1990)
"A randomized, controlled study was conducted in 51 patients to investigate the effect of aspirin administration on traumatic hyphema."9.06Aspirin and secondary bleeding after traumatic hyphema. ( Biedner, B; Lifshitz, T; Marcus, M; Yassur, Y, 1988)
" Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients."9.06Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987)
"The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction."9.05British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983)
"The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period."9.05A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. ( , 1980)
" Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina")."9.05Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. ( FitzGerald, GA; Friesinger, GC; Maas, RL; Oates, JA; Roberts, LJ; Robertson, D; Robertson, RM, 1981)
"Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose."9.05A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. ( , 1982)
"The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study."9.05Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985)
"A randomized controlled trial is reported in which a single dose of aspirin (300 mg) was given to patients with myocardial infarction on first contact with a general practitioner."9.04A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. ( Elwood, PC; Williams, WO, 1979)
"Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention."9.01Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019)
"The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin."9.01Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019)
"To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)."8.98Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018)
"Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain."8.95Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017)
"Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014."8.93Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016)
"Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke."8.93Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016)
"Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events."8.91Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015)
"The clinical significance of colchicine in the treatment of acute idiopathic (viral) pericarditis (IP) was only elucidated less than a decade ago."8.91Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. ( Schwier, NC, 2015)
"To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack."8.91[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015)
"Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk."8.90Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014)
"To review all randomised controlled trials (RCTs) that assess the effects of colchicine alone or combined, compared to any other intervention to prevent further recurrences of pericarditis, in people with acute or recurrent pericarditis."8.90Colchicine for pericarditis. ( Alabed, S; Burls, A; Cabello, JB; Irving, GJ; Qintar, M, 2014)
"The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study."8.82[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003)
" In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i."8.80[Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000)
"Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction."8.79Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996)
"To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone."8.79Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996)
" Administration of aspirin and heparin has been shown to improve mortality when combined with thrombolytic therapy in acute myocardial infarction, probably by enhancing lysis and reducing subsequent reocclusion of infarct related artery."8.78[Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction]. ( López Bescós, L, 1992)
"In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina."8.77Prevention of recurrent myocardial infarction and sudden death with aspirin therapy. ( Goldstein, GS; Rumore, MM, 1987)
" A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality."8.12Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022)
"Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period."8.12No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022)
"Background Because of a nonresponse to aspirin (aspirin resistance), patients with acute coronary syndrome (ACS) are at increased risk of developing recurrent event."8.02Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome. ( Chan, MY; Creemers, EE; de Ronde, MWJ; Hwee Tan, S; Mark Richards, A; Meijering, R; Pinto-Sietsma, SJ; Singh, S; Tang Chin, C; Troughton, RW; Van der Made, I; Yan, BP; Yean Yip Fong, A, 2021)
"To evaluate whether initial treatment with low-dose compared with high-dose aspirin in children with KD is associated with an increase in fever recrudescence."7.96Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. ( Belarski, E; Carroll, AE; John, CC; Manaloor, J; Ofner, S; Platt, B; Wood, JB, 2020)
"To investigate the association of aspirin resistance (AR) with the plasma 4-hydroxynonenal (4-HNE) level and its impact on recurrent cerebral infarction (CI) in patients with acute cerebral infarction (ACI) who were receiving aspirin therapy."7.96Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction. ( Feng, J; Guo, J; Guo, Y; Wang, J, 2020)
"Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial."7.96Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020)
"This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score."7.96Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020)
"In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention."7.96Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020)
"All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)."7.96Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020)
" Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0."7.91Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019)
"In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier."7.91Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019)
"The addition of colchicine to prednisone in patients admitted for acute idiopathic pericarditis does not reduce the risk of recurrence."7.88Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids? ( Chezar Azzerad, C; Hasdai, D; Iakobishvili, Z; Kornowski, R; Mager, A; Porter, A; Talmor, Y, 2018)
"To determine the association between ruptured saccular aneurysms and aspirin use/aspirin dose."7.88Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: A case-control study. ( Cai, T; Can, A; Castro, VM; Dligach, D; Du, R; Finan, S; Gainer, V; Murphy, S; Rudy, RF; Savova, G; Shadick, NA; Weiss, ST; Yu, S, 2018)
"WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG."7.88Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018)
"Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS."7.85Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017)
"To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset."7.85Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."7.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
"The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF)."7.83The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. ( Arı, ME; Azak, E; Çetin, İİ; Çevik, BŞ; Ekici, F; Eminoğlu, S; Kibar, AE; Kocabaş, A; Orgun, A; Sürücü, M, 2016)
"To explore the correlation between the recurrence of cerebral infarction and aspirin resistance (AR)/Chinese medical (CM) constitutions."7.81[Recurrence of Cerebral Infarction Associated Aspirin Resistance or Chinese Medical Constitutions: a Correlation Study]. ( Li, YH; Lu, QA; Wang, DX; Wang, XC; Yu, LH; Zong, SJ, 2015)
" We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population."7.80Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014)
"Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke."7.80Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014)
"Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)."7.80Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014)
"To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients."7.80Low-dose aspirin use and recurrent gout attacks. ( Chaisson, C; Chen, C; Choi, H; Hunter, DJ; Neogi, T; Zhang, Y, 2014)
"The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths."7.79Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013)
"Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin."7.79Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013)
"The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects."7.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction."7.77Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011)
"9 years) with confirmed diagnoses of cerebral infarction and PAS, treated with anticoagulants (n = 54) or aspirin (n = 38) were retrospectively analyzed."7.77[Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome]. ( Arauz, A; Artigas, C; Barinagarrementeria, F; Cantu-Brito, C; Hernandez, B; Marquez, JM; Merlos, M; Perez, A; Roa, LF, 2011)
"The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke."7.76Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010)
"The effect of biochemical aspirin resistance (BAR) on ischemic stroke has not been well established."7.76Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. ( Jeon, SB; Kang, DW; Kim, BJ; Kim, HJ; Kim, JS; Kwon, SU; Song, HS, 2010)
"To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)."7.75Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009)
"Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction."7.75Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009)
"Gastric ulcers were induced with acetic acid in rats; aspirin was administrated by gavage from day 25 to day 54 after ulcer induction."7.74Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. ( Guo, CJ; Huang, GP; Jia, BB; Wang, GZ; Wang, JF; Xie, CG; Yin, GL; Zhou, G, 2007)
"Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease."7.74Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008)
"Six patients with a history of recurrent anaphylaxis associated with wheat ingestion were diagnosed as having WDEIA by the provocation test, which included wheat ingestion, exercise, aspirin intake and a combination of these challenges."7.73Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. ( Akaki, T; Hide, M; Kaneko, S; Kuroda, T; Kusatake, K; Matsuo, H; Morimoto, K; Morita, E; Niihara, H, 2005)
"During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited."7.72High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003)
"Aspirin is a common antiplatelet drug used in the prevention of ischemic stroke due to its inhibitory effect on platelet cyclooxygenase-1 (Cox-1)."7.72Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. ( Hillarp, A; Lethagen, S; Mattiasson, I; Palmqvist, B; Villoutreix, BO, 2003)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."7.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"We studied 30 patients with postsurgical ulcer and aspirin abuse."7.70Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. ( Hirschowitz, BI; Lanas, A, 1998)
"To investigate the prevalence of aspirin use in older patients with prior myocardial infarction at the time of admission to a nursing home."7.70Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. ( Aronow, WS, 1998)
"To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome."7.70Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998)
"The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient."7.70Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998)
"For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death."7.70Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? ( Goldberg, RJ; Gore, JM; Gurwitz, JH; Lessard, D; McCormick, D; Yarzebski, J, 1999)
"Aspirin-induced asthma (AIA) is frequently accompanied by nasal polyps."7.70Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient. ( Ogata, Y; Okinaka, Y; Takahashi, M, 1999)
"This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance."7.70[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999)
"The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established."7.70Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000)
"The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke."7.70Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000)
"Adding NTG to a thrombolytic regimen with rt-PA, aspirin and heparin increases the magnitude of restored flow and total patency duration following recanalization in a rabbit model of arterial thrombosis."7.69Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model. ( Battler, A; Chernine, A; Hasdai, D; Kornowski, R; Ovadia, Z, 1995)
"To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival."7.69Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1996)
"Asthmatic triad (AT) is a clinical syndrome incorporating bronchial asthma (BA), recurrent nasal and sinus polyps, intolerance of aspirin, derivatives of pirasolone and other nonsteroid antiinflammatory drugs."7.69[The in-vivo test of the inhibition of leukocyte natural migration with aspirin and analgin in the specific diagnosis of the asthmatic triad]. ( Kanchurina, NA; Poroshina, IuA; Prasolova, NI; Zemskov, VM, 1996)
"One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin."7.68Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992)
"Fifty-six patients who presented with non-steroidal anti-inflammatory drug-associated duodenal ulcers received maintenance treatment with ranitidine."7.67Ranitidine maintenance treatment of non-steroidal anti-inflammatory drug-induced duodenal ulceration. ( Penston, JG; Wormsley, KG, 1989)
"Aspirin has been reported to induce the adult respiratory distress syndrome (ARDS) in humans."7.67Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress syndrome. ( Krieger, BP; Suarez, M, 1986)
"Hydroxyurea has been rarely implicated as a cause of drug fever."7.66Fever caused by hydroxyurea. ( Bauernfeind, RA; Bauman, JL; Hartsough, N; Hasegawa, GR; Roden, R; Shulruff, S, 1981)
"We have studied seventy-five patients with recurrent urticaria and angio-oedema of more than 4 months duration and with positive provocation tests to aspirin, azo dyes, and/or benzoates."7.65A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes. ( Juhlin, L; Michaëlsson, G; Ros, AM, 1976)
"Often used as an oral analgesic in the management of pain associated with traumatic hyphema, aspirin has an inhibitory effect on the blood clotting mechamism by its action on platelets."7.65The effect of aspirin on rebleeding in traumatic hyphema. ( Chan, W; Crawford, JS; Lewandowski, RL, 1975)
"The primary outcome is IS recurrence."6.80Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."6.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"Piracetam was significantly superior to ASA in the secondary endpoint (P=0."6.69Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000)
"Acute idiopathic pericarditis is complicated by recurrence in 15 to 30% of cases."6.69[Efficacy of colchicine in recurrent acute idiopathic pericarditis]. ( Amoura, Z; Cacoub, P; Godeau, P; Piette, JC; Sbaï, A; Wechsler, B, 2000)
"Aspirin (ASA) has become a well-documented therapeutic adjunct in patients with coronary heart disease."6.68Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) ( Aursnes, I; Kjekshus, J; Nguyen, KN, 1997)
"Main outcomes were stroke recurrence and major bleeding."6.66Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020)
"Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke."6.61Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019)
"To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups."6.19Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. ( Chen, ZM; Collins, R; Counsell, C; Liu, LS; Pan, HC; Peto, R; Sandercock, P; Warlow, C; Xie, JX, 2000)
"In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group."5.51Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022)
"Chest pain recurrence was defined as the first revisit to the emergency room with angina."5.48Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018)
"Stroke recurrence and mortality rates in patients receiving aspirin (N=34 679) were compared with those receiving clopidogrel (N=7611) during a 12-month follow-up period."5.48Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data. ( Chang, WL; Chen, CH; Chi, NF; Hsu, CY; Hu, CJ; Jeng, JS; Li, JY; Lien, LM; Lin, CH; Liu, CH; Sun, Y; Wen, CP, 2018)
"The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations."5.46Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017)
"The primary end point was recurrence of ACS or death >30days after the index event."5.46Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017)
"The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage."5.43[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016)
"Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke."5.43High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016)
"Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality in ESUS but do not appear to influence effects of rivaroxaban on clinical outcomes."5.41Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Berkowitz, SD; Connolly, SJ; Field, TS; Hart, RG; Kasner, SE; Liu, YY; Lutsep, H; Martí-Fàbregas, J; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Olavarria, V; Santo, GC; Sharma, M; Shoamanesh, A; Smith, EE; Uchiyama, S; Veltkamp, R, 2021)
" We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis."5.41Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Mac Grory, B; Rostanski, S; Yaghi, S, 2021)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."5.35Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively."5.34Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020)
" Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China."5.34Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020)
"In STEMI patients with HPR, identified by vasodilator stimulated phosphoprotein (VASP)-determined PFT, switching clopidogrel to ticagrelor could significantly improve 1-year clinical outcomes without increasing the risk of bleeding."5.34Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study. ( Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q, 2020)
" There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis."5.34Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. ( Amarenco, P; Ameriso, SF; Bereczki, D; Berkowitz, SD; Connolly, SJ; Ferrari, J; Firstenfeld, A; Hart, RG; Kasner, SE; Lang, W; Lavados, P; Mikulik, R; Mundl, H; Ntaios, G; Pearce, LA; Perera, KS; Povedano, GP; Uchiyama, S; Yoon, BW, 2020)
"We performed an exploratory analysis of the interaction of the treatment effects of aspirin plus clopidogrel versus aspirin monotherapy, stratified by presence of ipsilateral nonstenotic carotid disease in patients with minor ischemic stroke in the POINT trial."5.34Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial. ( Brorson, JR; Bulwa, Z; Pinto, CB; Saleh Velez, FG, 2020)
"Aspirin users were older on average than nonusers (59 years of age compared with 53 years; p = 0."5.32Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. ( Atkinson, JL; Friedman, JA; McClelland, RL; McIver, JI; Meyer, FB; Nichols, DA; Pichelmann, MA; Piepgras, DG; Toussaint, LG; Wijdicks, EF, 2004)
"Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events."5.30Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019)
" In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2."5.30Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019)
"The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)."5.30Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019)
" The aim was to assess whether the effect of clopidogrel plus aspirin versus aspirin alone on recurrent stroke would be affected by admission activated partial thromboplastin time (aPTT)."5.30Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time. ( Laskowitz, DT; Li, H; Liu, L; Meng, X; Miao, Z; Wang, X; Wang, Y; Xie, X; Zhao, X, 2019)
"We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source."5.30Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019)
"Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4."5.30Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019)
"Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study."5.27Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. ( Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K, 2018)
"These results suggest that patients who have undergone EVT have similar risks for major and life-threatening bleeding events with edoxaban and aspirin compared with clopidogrel and aspirin."5.27Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. ( Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T, 2018)
"For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin."5.24Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017)
"Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis."5.24Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017)
"Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA)."5.22Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G, 2022)
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."5.22Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours."5.22Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016)
" In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone."5.22The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016)
"The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization."5.22A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016)
"The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone."5.20Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. ( Li, J; Lin, J; Liu, L; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015)
" Treatment with rivaroxaban may prevent more cerebrovascular events with an acceptable risk profile after TIA or minor stroke, compared with aspirin, thus helping to improve the outcome of the disease."5.20Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial. ( Bai, Y; Han, J; Jiang, W; Liu, X; Yang, F; Zhang, G; Zhao, G, 2015)
"In this study, patients taking 100 mg aspirin daily (orally) were examined after admittance to the stroke unit due to a stroke or stroke recurrence."5.19[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients]. ( Kolb, GF; Nosul, M, 2014)
"Altogether 574 patients with acute (≤2 days) large-artery atherosclerosis stroke were randomly assigned to receive either combined clopidogrel and aspirin or aspirin alone."5.19A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014)
"An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups."5.19Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014)
"We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention."5.17CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013)
"To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death."5.17Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013)
"To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution."5.16Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012)
"A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)."5.16Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012)
"Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death."5.16Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."5.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
"We compared baseline features and the rates of stroke or vascular death and stroke in the territory of the symptomatic artery between patients ON (n=299) versus OFF (n=269) antithrombotics at the time of their qualifying event for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial."5.14Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. ( Chimowitz, MI; Cotsonis, G; Levine, SR; Lynn, MJ; Maidan, L; Romano, JG; Turan, TN, 2009)
"Patients with thrombolysis in myocardial infarction (TIMI) 3 flow <48 hours after fibrinolysis for ST-elevation myocardial infarction were randomized to aspirin plus coumarin, with prolonged heparinization until the target international normalized ratio (2-3) was reached, or aspirin with standard heparinization."5.14Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome. ( Aengevaeren, WR; Brouwer, MA; Kievit, PC; van den Bergh, PJ; Veen, G; Verheugt, FW, 2009)
"We evaluated the location, type (lacunar vs nonlacunar), cause, and severity of stroke in patients who had an ischemic stroke endpoint in the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial."5.14Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. ( Chimowitz, MI; Famakin, BM; George, MG; Lynn, MJ; Stern, BJ, 2009)
"In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)."5.14Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."5.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin."5.14Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010)
"We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)."5.14Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."5.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"The safety and efficacy of a new surgical method of intravitreal tamponade using silicone oil suspended with aspirin (acetylsalicylic acid) was investigated for the treatment of proliferative vitreoretinopathy."5.14Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study. ( Binder, S; Egger, S; Haas, A; Kieselbach, GF; Kralinger, MT; Parel, JM; Stolba, U; Velikay, M; Wedrich, A, 2010)
"The daily dose of aspirin in desensitization in aspirin-sensitive asthmatics with nasal polyps is still a matter of debate."5.13Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. ( Deutschle, T; Keck, T; Polzehl, D; Riechelmann, H; Rozsasi, A; Smith, E; Wiesmiller, K, 2008)
"All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance."5.13Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008)
"Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)."5.13Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)
"To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period."5.13Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008)
" Randomized clinical trials that compared cilostazol to aspirin and reported the endpoints of ischemic stroke, intracranial hemorrhage and any bleeding were included."5.12Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. ( Barrett, KM; Brott, TG; Ertekin-Taner, N; Gopal, N; Lin, MP; Meschia, JF; Ross, OA, 2021)
"We examined the outcomes of 627 noncardioembolic stroke patients who were double-blindly assigned to either warfarin or aspirin therapy and assessed VaT using transesophageal echocardiography."5.12Impact of valvular thickness on stroke recurrence in medically treated patients with stroke. ( Abe, Y; Di Tullio, MR; Homma, S; Jin, Z; Mohr, JP; Okajima, K; Sacco, RL; Salameh, MJ; Suzuki, K, 2007)
"Fluctuations in urinary 11-DTB2 after cerebral infarction in blacks do not correlate with changes in aspirin doses, except perhaps when the dose changes by a factor of 4 or more."5.11Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. ( Bang, NU; Bruno, A; Cohen, SN; Gorelick, PB; McConnell, JP; Tietjen, GE; Wallis, RA, 2004)
"To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)."5.11Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004)
" Platelet-leukocyte conjugate formation (induced by thrombin receptor activating peptide (TRAP)) and platelet aggregation (induced by ADP and arachidonic acid) were assessed in 30 patients with unstable angina or non-ST elevation myocardial infarction."5.11Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. ( Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP, 2004)
"We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel."5.11Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004)
" Three subjects with multiple-drug induced urticaria complained of a generalized reaction after challenge (Two due to celecoxib and one due to meloxicam)."5.11Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. ( Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G, 2004)
"We evaluated stroke incidence, subtypes, and outcomes, in addition to demographics and clinical risk characteristics associated with stroke among patients enrolled in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials."5.11Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. ( Bhapkar, MV; Califf, RM; Graffagnino, C; Kassem-Moussa, H; Mahaffey, KW; Newby, LK; Sila, CA; Simes, RJ; Tasissa, G; White, HD, 2004)
"A total of 335 patients (206 men; mean age 72+/-9 years) with intermittent claudication were randomized according to a 2x2 factorial design to 1 of the 4 groups: probucol, placebo, EVBT, and EVBT+probucol."5.11Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. ( Alerci, M; Amann-Vesti, B; Aschwanden, M; Baumgartner, I; Bernier, J; Canevascini, R; Cozzi, L; Do, DD; Gallino, A; Greiner, R; Jacob, AL; Jäger, K; Kann, R; Kellner, F; Mahler, F; Schneider, E; Segatto, JM; Studer, G; Triller, J; Tutta, P, 2004)
"Although full platelet inhibition with aspirin and thienopyridines before coronary stenting has significantly reduced the risk of acute stent thrombosis, peri-procedural myonecrosis still occurs frequently and is associated with increased death rate."5.11Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. ( Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL, 2005)
"0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk."5.11A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005)
"Evaluate aspirin challenge as a means to distinguish single from multiple NSAID intolerance in patients with a clinical history of acute urticaria induced by a single NSAID."5.11Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. ( Asero, R, 2005)
"Colchicine seems to be a good drug for treating recurrences of pericarditis after conventional treatment failure, but no clinical trial has tested the effects of colchicine as first-line drug for the treatment of the first recurrence of pericarditis."5.11Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. ( Belli, R; Bobbio, M; Cecchi, E; Demarie, D; Ghisio, A; Imazio, M; Moratti, M; Pomari, F; Trinchero, R, 2005)
"Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0."5.10Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003)
"To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients."5.10Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003)
"Five previously suspected risk factors (valve surgery, prior protamine exposure, history of pulmonary hypertension, fish allergy, and vasectomy), aspirin ingestion within 7 days of surgery, and demographic information were recorded."5.10Effect of site of venous protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction. ( Comunale, ME; Haering, JM; Lowenstein, E; Mashikian, JS; Maslow, A; Robertson, LK, 2003)
"To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan."5.10Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003)
"The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion."5.10The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003)
"To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms."5.10Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. ( Darbà, J; Izquierdo, I; Navas, C; Pontes, C; Rovira, J, 2002)
"Despite use of heparin and aspirin, 5-10% of patients with unstable angina develop myocardial infarction (MI) or refractory angina in the hospital."5.09Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. ( Yusuf, S, 1999)
"The dose of aspirin for secondary stroke prevention and the clinical meaning of ex vivo platelet abnormalities are debated."5.09Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. ( Chamorro, A; Escolar, G; Obach, V; Ordinas, A; Reverter, JC; Revilla, M; Vila, N, 1999)
"A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years."5.09Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000)
"To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction."5.09Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000)
"Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation."5.09Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
"The aim of the present study was to evaluate the possible interaction between chronic aspirin therapy and angiotensin-converting enzyme inhibitor (ACE-I) on left ventricular ejection fraction (LVEF) in patients surviving an acute myocardial infarction (AMI)."5.09Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. ( Arnesen, H; Hole, T; Hurlen, M; Seljeflot, I, 2001)
"We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis."5.09Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001)
"We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence."5.09Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001)
"This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction."5.08Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. ( Brown, MA; Cross, DB; French, JK; Hamer, AW; Ormiston, JA; White, HD; Williams, BF, 1995)
"1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections."5.08Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996)
"To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction."5.08A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996)
"One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62)."5.08Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. ( Alt, E; Blasini, R; Dirschinger, J; Hadamitzky, M; Hausleiter, J; Kastrati, A; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; Walter, H; Zitzmann-Roth, EM, 1997)
"The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined."5.08Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997)
"Healing with bFGF (and cimetidine) was associated with reduced NSAID induced ulcer relapse in this model of gastric ulceration."5.08Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration. ( Brough, JL; Filipowicz, B; Hawkey, CJ; Hull, MA; Knifton, A; Vautier, G, 1997)
"Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase."5.08A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997)
"In a multicenter trial of antithrombotic therapy in unstable angina or non-Q wave myocardial infarction, 358 patients admitted within 48 h of chest pain were randomized to antithrombotic therapy with either 1) aspirin alone, or 2) aspirin plus heparin followed by aspirin plus warfarin, and were prospectively followed up for 12 weeks."5.07Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Fuster, V; McBride, R; Parry, G; Wieczorek, I; Xiong, J, 1993)
"The purpose of this study was to compare combination antithrombotic therapy with aspirin plus anticoagulation versus aspirin alone, when added to conventional antianginal therapy in patients with unstable rest angina or non-Q-wave myocardial infarction who were nonprior aspirin users."5.07Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Keller, C; Parry, G; Strain, J; Wieczorek, I; Xiong, J, 1994)
"The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial."5.07Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991)
"To ascertain whether predischarge arteriography is beneficial in patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA), heparin and aspirin, the outcome of 197 patients in the Thrombolysis in Myocardial Infarction (TIMI) IIA study assigned to conservative management and routine predischarge coronary arteriography (routine catheterization group) was compared with the outcome of 1,461 patients from the TIMI IIB study assigned to conservative management without routine coronary arteriography unless ischemia recurred spontaneously or on predischarge exercise testing (selective catheterization group)."5.07Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. ( Babb, JD; Baim, DS; Braunwald, E; Chesebro, JH; Frederick, M; Gore, JM; Passamani, ER; Roberts, R; Rogers, WJ; Williams, DO, 1991)
"We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis."5.07Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. ( Bauman, JE; Domoto, DT; Joist, JH, 1991)
"Recently, it was shown that aspirin given early in acute myocardial infarction (AMI) improves hospital survival, but the mechanisms involved are unclear."5.06Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. ( Funke-Küpper, AJ; Galema, TW; Roos, JP; Sterkman, LG; van der Laarse, A; Verheugt, FW, 1990)
"We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years."5.06European Stroke Prevention Study. ESPS Group. ( , 1990)
"In a randomized pilot study we compared the efficacy of temporary anticoagulation with intravenous heparin sodium to the efficacy of aspirin in preventing cerebral infarction in hospitalized patients with recent (less than 7 days) transient ischemic attacks (TIAs)."5.06A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. ( Adams, HP; Banwart, KJ; Biller, J; Bruno, A; Godersky, JC; Jones, MP; Loftus, CM; Mitchell, VL, 1989)
"In the Persantine-Aspirin Reinfarction Study, Part II (PARIS II), 3,128 persons who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously, were randomized into two groups: dipyridamole (Persantine) plus aspirin (n = 1,563) and placebo (n = 1,565)."5.06Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. ( Klimt, CR; Knatterud, GL; Meier, P; Stamler, J, 1986)
"A randomized, controlled study was conducted in 51 patients to investigate the effect of aspirin administration on traumatic hyphema."5.06Aspirin and secondary bleeding after traumatic hyphema. ( Biedner, B; Lifshitz, T; Marcus, M; Yassur, Y, 1988)
" Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients."5.06Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987)
" Dual-antiplatelet therapy is the standard of care for secondary prevention in patients with acute coronary syndrome (ACS), whereas single antiplatelet therapy, generally with aspirin, is the standard of care for secondary prevention in stable patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease."5.05Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. ( Angiolillo, DJ; Geisler, T; Heitmeier, S; Weitz, JI, 2020)
"The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction."5.05British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983)
"The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period."5.05A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. ( , 1980)
" Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina")."5.05Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. ( FitzGerald, GA; Friesinger, GC; Maas, RL; Oates, JA; Roberts, LJ; Robertson, D; Robertson, RM, 1981)
" These trials were prompted by earlier observations that aspirin takers seemed to fare better after acute myocardial infarction and were further stimulated by the recent growth of knowledge about the role of vascular and platelet prostaglandins."5.05Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials. ( Castaldi, PA, 1981)
"Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose."5.05A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. ( , 1982)
"The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study."5.05Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985)
"A randomized controlled trial is reported in which a single dose of aspirin (300 mg) was given to patients with myocardial infarction on first contact with a general practitioner."5.04A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. ( Elwood, PC; Williams, WO, 1979)
"Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention."5.01Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019)
"The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin."5.01Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019)
" Data from one randomised controlled trial showed no significant difference in benefit with aspirin versus placebo in asymptomatic carotid stenosis, but it is still reasonable to recommend aspirin (81-325 mg daily) for prevention of vascular events in these patients."5.01Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. ( de Borst, GJ; Halliday, A; Hamilton, G; Kakkos, S; McCabe, DJH; Murphy, SJX; Naylor, AR; Ricco, JB; Sillesen, H; Vega de Ceniga, M, 2019)
"To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)."4.98Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018)
"Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain."4.95Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017)
"Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014."4.93Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016)
"Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke."4.93Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016)
"Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events."4.91Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015)
"The clinical significance of colchicine in the treatment of acute idiopathic (viral) pericarditis (IP) was only elucidated less than a decade ago."4.91Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. ( Schwier, NC, 2015)
"A systematic review and meta-analysis to determine the risks (major bleeding) and benefits (recurrent VTE and mortality) of extended anticoagulation with vitamin k antagonists (VKA), DOACs and aspirin in patients with an unprovoked VTE and in those patients with clinical equipoise regarding continuation or cessation of anticoagulant therapy."4.91Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. ( Cavallazzi, R; Marik, PE, 2015)
"To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack."4.91[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015)
"Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk."4.90Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014)
"To review all randomised controlled trials (RCTs) that assess the effects of colchicine alone or combined, compared to any other intervention to prevent further recurrences of pericarditis, in people with acute or recurrent pericarditis."4.90Colchicine for pericarditis. ( Alabed, S; Burls, A; Cabello, JB; Irving, GJ; Qintar, M, 2014)
"To summarise and compare the efficacy and safety of various oral anticoagulants (dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) for the secondary prevention of venous thromboembolism."4.89Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. ( Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS, 2013)
" In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3."4.88Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012)
"The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study."4.82[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003)
"Based on current references four clinical scenarios were discussed and different management strategies were compared for secondary and primary prophylaxis of ulcer or peptic ulcer bleeding under continuous therapy with non-steroidal antiinflammatory drugs (NSAID) or low-dose-aspirin, for H."4.82[Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios]. ( Ittel, TH; Limmer, S; Wietholtz, H, 2003)
"Although intra-uterine fetal death is considered at high risk of recurrence in case of antiphospholipid syndrome (APS), a uniform management protocol including aspirin and heparin and close obstetrical follow-up led to a favorable outcome in most cases."4.82Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy. ( Bats, AS; Carbonne, B; Cynober, E; Gonzales, M; Lejeune, V; Milliez, J; Safar, E, 2004)
" Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%."4.82[Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005)
"Combination therapy with aspirin and heparin may reduce pregnancy loss in women with antiphospholipid antibodies by 54%."4.81Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. ( Craig, JC; Empson, M; Lassere, M; Scott, JR, 2002)
" In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis."4.81From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002)
" The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events."4.80Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. ( Boysen, G, 1999)
"At the acute phase of cerebral infarction, two recent large studies found that the use of aspirin reduces both mortality and the risk of the recurrence of stroke."4.80[Aspirin and cerebral ischemic accidents]. ( Bousser, MG; Crassard, I; Niclot, P, 2000)
" In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i."4.80[Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000)
"Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects."4.80Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000)
" Smoking cessation, increased physical activity and lipid lowering are key lifestyle objectives, while beta blockade and aspirin should be routinely prescribed for all patients following acute myocardial infarction, unless there are specific contraindications."4.79What do we really know about secondary prevention after myocardial infarction? ( Wielgosz, AT, 1995)
"English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders."4.79Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994)
"Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction."4.79Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996)
"To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone."4.79Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996)
"Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely."4.79Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. ( Appleby, P; Baigent, C; Collins, R; Flather, M; Godwin, J; MacMahon, S; Mortensen, S; Peto, R; Remvig, L; Yusuf, S, 1996)
" Administration of aspirin and heparin has been shown to improve mortality when combined with thrombolytic therapy in acute myocardial infarction, probably by enhancing lysis and reducing subsequent reocclusion of infarct related artery."4.78[Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction]. ( López Bescós, L, 1992)
" Secondary prevention strategies include smoking cessation; the control of hyperlipidemia, obesity and diabetes; the management of hypertension and stress; exercise; the use of drugs such as beta blockers and aspirin, and increased attention to general health."4.77Secondary prevention in elderly survivors of heart attacks. ( Davenport, J; Whittaker, K, 1988)
"In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina."4.77Prevention of recurrent myocardial infarction and sudden death with aspirin therapy. ( Goldstein, GS; Rumore, MM, 1987)
"Tartrazine, a common additive in foods and drugs, often causes adverse reactions such as recurrent urticaria, angioedema, and asthma and is frequently implicated in hyperkinesis."4.77Clinical spectrum of adverse reactions to tartrazine. ( Collins-Williams, C, 1985)
"Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score."4.12Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. ( Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H, 2022)
" A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality."4.12Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022)
"Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period."4.12No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022)
"Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients."4.02Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2021)
"Background Because of a nonresponse to aspirin (aspirin resistance), patients with acute coronary syndrome (ACS) are at increased risk of developing recurrent event."4.02Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome. ( Chan, MY; Creemers, EE; de Ronde, MWJ; Hwee Tan, S; Mark Richards, A; Meijering, R; Pinto-Sietsma, SJ; Singh, S; Tang Chin, C; Troughton, RW; Van der Made, I; Yan, BP; Yean Yip Fong, A, 2021)
" Anticipated bleeding event rates (including both minor and major bleeds) with aspirin, dabigatran 150 mg, and rivaroxaban 20 mg were sourced from published meta-analyses, whilst a 30% ischaemic stroke reduction for both DOACs was assumed."4.02Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. ( de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD, 2021)
"We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke."4.02Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021)
"To evaluate whether initial treatment with low-dose compared with high-dose aspirin in children with KD is associated with an increase in fever recrudescence."3.96Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. ( Belarski, E; Carroll, AE; John, CC; Manaloor, J; Ofner, S; Platt, B; Wood, JB, 2020)
"To investigate the association of aspirin resistance (AR) with the plasma 4-hydroxynonenal (4-HNE) level and its impact on recurrent cerebral infarction (CI) in patients with acute cerebral infarction (ACI) who were receiving aspirin therapy."3.96Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction. ( Feng, J; Guo, J; Guo, Y; Wang, J, 2020)
"In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin."3.96Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020)
"Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial."3.96Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020)
"This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score."3.96Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020)
"In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention."3.96Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020)
"All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)."3.96Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020)
" Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0."3.91Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019)
"In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier."3.91Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019)
"The addition of colchicine to prednisone in patients admitted for acute idiopathic pericarditis does not reduce the risk of recurrence."3.88Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids? ( Chezar Azzerad, C; Hasdai, D; Iakobishvili, Z; Kornowski, R; Mager, A; Porter, A; Talmor, Y, 2018)
"To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions."3.88Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction. ( Abenhaim, L; Benichou, J; Bonello, L; Cottin, Y; Dallongeville, J; Danchin, N; Delarche, N; Falissard, B; Furber, A; Ghanem, F; Grimaldi-Bensouda, L; Leclercq, F; Morel, O; Puymirat, E, 2018)
"To determine the association between ruptured saccular aneurysms and aspirin use/aspirin dose."3.88Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: A case-control study. ( Cai, T; Can, A; Castro, VM; Dligach, D; Du, R; Finan, S; Gainer, V; Murphy, S; Rudy, RF; Savova, G; Shadick, NA; Weiss, ST; Yu, S, 2018)
"WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG."3.88Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018)
"From January 2014 to September 2014, a single center continuously enrolled patients with minor ischemic stroke or high-risk TIA and gave them antiplatelet therapy consisting of aspirin with clopidogrel."3.85The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. ( Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H, 2017)
" Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation."3.85Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017)
"Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS."3.85Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017)
"To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset."3.85Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017)
"Acute coronary syndrome patients infected with HIV (n = 80) were matched to ACS patients without HIV (n = 160) on age, sex, diabetes, and DAPT (aspirin 100%, clopidogrel 68%, prasugrel 31%, ticagrelor 1%)."3.85Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. ( Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."3.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
"The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF)."3.83The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. ( Arı, ME; Azak, E; Çetin, İİ; Çevik, BŞ; Ekici, F; Eminoğlu, S; Kibar, AE; Kocabaş, A; Orgun, A; Sürücü, M, 2016)
" Prevention with aspirin or heparin was administered in ten cases during pregnancy, and in all the cases with heparin in postpartum."3.81[Thrombosis risk during pregnancy after history of cerebral venous thrombosis]. ( Neau, JP; Pierre, F; Pouget-Abadie, JF; Pourrat, O, 2015)
"In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke."3.81Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015)
"To explore the correlation between the recurrence of cerebral infarction and aspirin resistance (AR)/Chinese medical (CM) constitutions."3.81[Recurrence of Cerebral Infarction Associated Aspirin Resistance or Chinese Medical Constitutions: a Correlation Study]. ( Li, YH; Lu, QA; Wang, DX; Wang, XC; Yu, LH; Zong, SJ, 2015)
" We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population."3.80Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014)
"Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke."3.80Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014)
"We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke."3.80Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014)
"Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)."3.80Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014)
"To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients."3.80Low-dose aspirin use and recurrent gout attacks. ( Chaisson, C; Chen, C; Choi, H; Hunter, DJ; Neogi, T; Zhang, Y, 2014)
"The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths."3.79Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013)
"Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin."3.79Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013)
"The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects."3.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction."3.77Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011)
"We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)."3.77Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011)
"9 years) with confirmed diagnoses of cerebral infarction and PAS, treated with anticoagulants (n = 54) or aspirin (n = 38) were retrospectively analyzed."3.77[Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome]. ( Arauz, A; Artigas, C; Barinagarrementeria, F; Cantu-Brito, C; Hernandez, B; Marquez, JM; Merlos, M; Perez, A; Roa, LF, 2011)
"We present a 19-month-old boy with a history of asthma who presented to the pediatric emergency department with noisy breathing and tachypnea partially responsive to albuterol."3.76A 19-month-old boy with recurrent respiratory distress. ( Cross, KP; Herr, SM; Randell, KA, 2010)
"Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization."3.76Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010)
" Thrombolysis in myocardial infarction (TIMI) 3 flow predicted a good outcome, whereas recurrent ischemia in hospital, prior aspirin therapy and discharge creatinine predicted a poor outcome; age alone was not an adverse prognostic factor."3.76Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction. ( Attia, J; Baker, F; Collins, N; Hatton, R; Hiew, C; McElduff, P; Narasimhan, S; O'Connor, S; Williams, T, 2010)
"The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke."3.76Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010)
"The effect of biochemical aspirin resistance (BAR) on ischemic stroke has not been well established."3.76Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. ( Jeon, SB; Kang, DW; Kim, BJ; Kim, HJ; Kim, JS; Kwon, SU; Song, HS, 2010)
"Platelet deposition and thrombus formation caused by angioplasty appear to be important in the development of 2 complications: acute thrombotic occlusion and restenosis."3.76Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. ( Harker, LA, 1987)
"To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)."3.75Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009)
"Aspirin remains the most commonly used antithrombotic agent for the prevention of recurrent stroke among antithrombotic naive patients with a first-ever ischemic stroke in our institution."3.75The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke. ( Hseuh, IH; Lin, YJ; Po, HL, 2009)
"(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months."3.75Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009)
"In primary prevention, aspirin reduces the risk of stroke but not of myocardial infarction in women while in men only the risk of myocardial infarction but not stroke could be significantly reduced."3.75Antiplatelet agents in stroke prevention: acute and long-term treatment strategies. ( Diener, HC; Weber, R; Weimar, C, 2009)
"Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction."3.75Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009)
"The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period."3.74Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008)
"Gastric ulcers were induced with acetic acid in rats; aspirin was administrated by gavage from day 25 to day 54 after ulcer induction."3.74Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. ( Guo, CJ; Huang, GP; Jia, BB; Wang, GZ; Wang, JF; Xie, CG; Yin, GL; Zhou, G, 2007)
" With a treatment that included aspirin, heparin, and a nitric oxide donor, her third pregnancy ended with a healthy neonate at term."3.74Successful pregnancy with the use of nitric oxide donors and heparin after recurrent severe preeclampsia in a woman with scleroderma. ( Cabane, J; Carbonne, B; Cynober, E; Macé, G; Milliez, J, 2007)
"We conducted a retrospective study to determine the prevalence of Samter's triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003."3.74The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. ( Kim, JE; Kountakis, SE, 2007)
"Aspirin resistance is a well-documented laboratory finding, but the effects of clinical aspirin (ASA) failure on patients with acute coronary syndrome (ACS) have been debated."3.74Dual antiplatelet agent failure: a new syndrome or clinical nonentity? ( Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A, 2007)
"In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)."3.74[Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007)
" Hypertension, diabetes mellitus, transient ischemic attack (TIA), hyperlipemia and mural thrombus in left atrium were significantly correlated with the recurrence rate by univariate Cox proportional hazards regression analysis; but aspirin therapy, warfarin therapy and hypertension control were protective factors for the recurrence of ischemic stroke in patients with NVAF."3.74[A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation]. ( Cai, YY; Hu, Y; Luo, M; Quan, HB; Xie, RM, 2007)
"Aspirin is the standard therapy applied after coronary intervention, and statins are also prescribed to prevent secondary coronary heart disease."3.74Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. ( Akimoto, Y; Hiroyuki, D; Kajimoto, K; Kasai, T; Ken, Y; Kojima, T; Kubota, N; Miyauchi, K; Njaman, W; Takeshi, K, 2008)
"A literature search was conducted using EMBASE (1980-January 2008), PubMed (1966-January 2008), Google, and a manual search of the reference lists using the search terms gastrointestinal bleed, gastrointestinal hemorrhage, peptic ulcer hemorrhage, ASA, aspirin, Plavix, clopidogrel, and PPI."3.74Single antiplatelet therapy for patients with previous gastrointestinal bleeds. ( Ackman, ML; Gellatly, RM, 2008)
"Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease."3.74Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008)
"At a similar level of efficacy in inhibiting secondary thrombosis, triflusal seems to better preserve Cox-2 expression than aspirin and its metabolite HTB was able to protect endothelial prostacyclin production."3.74Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2. ( Badimon, L; Duran, X; Sánchez, S; Vilahur, G, 2008)
" The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel."3.73A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005)
"Six patients with a history of recurrent anaphylaxis associated with wheat ingestion were diagnosed as having WDEIA by the provocation test, which included wheat ingestion, exercise, aspirin intake and a combination of these challenges."3.73Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. ( Akaki, T; Hide, M; Kaneko, S; Kuroda, T; Kusatake, K; Matsuo, H; Morimoto, K; Morita, E; Niihara, H, 2005)
"Thrombotic events still occur in aspirin-treated patients with coronary artery disease."3.73Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. ( Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2006)
"Aspirin is the drug of choice in most patients with acute stroke, if thrombolysis is contraindicated."3.72[Anticoagulation and antiaggregation in neurological patients]. ( Arnold, M; Mattle, HP; Nedeltchev, K, 2003)
"Despite evidence-based guidelines, aspirin prescribing for the secondary prevention of stroke is sub-optimal."3.72Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement. ( Ashcroft, D; Bashford, J; Frischer, M; Short, D, 2003)
"During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited."3.72High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003)
"Aspirin is a common antiplatelet drug used in the prevention of ischemic stroke due to its inhibitory effect on platelet cyclooxygenase-1 (Cox-1)."3.72Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. ( Hillarp, A; Lethagen, S; Mattiasson, I; Palmqvist, B; Villoutreix, BO, 2003)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."3.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies."3.72Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004)
"Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered."3.71Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. ( Arquizan, C; Cabanes, L; Coste, J; Derumeaux, G; Lamy, C; Mas, JL; Zuber, M, 2001)
" Fever always occurred before their admission and aspirin (n = 12) or acetaminophen (n = 7) was prescribed."3.71[Severe Reye syndrome: report of 14 cases managed in a pediatric intensive care unit over 11 years]. ( Brivet, M; Chevret, L; Debray, D; Devictor, D; Durand, P; Fabre, M; Thabet, F, 2002)
"We studied 30 patients with postsurgical ulcer and aspirin abuse."3.70Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. ( Hirschowitz, BI; Lanas, A, 1998)
"To investigate the prevalence of aspirin use in older patients with prior myocardial infarction at the time of admission to a nursing home."3.70Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. ( Aronow, WS, 1998)
"To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome."3.70Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998)
"The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient."3.70Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998)
" All patients were contacted for ultrasonography and were interviewed for additional information on daily intake of aspirin, NSAIDs, cholesterol lowering medication, estrogen therapy, and biliary pain during follow-up."3.70Gallstone recurrence after successful shock wave therapy: the magnitude of the problem and the predictive factors. ( Afschrift, M; Cesmeli, E; De Buyzere, M; Elewaut, A; Elewaut, AE; Kerre, T, 1999)
"For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death."3.70Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? ( Goldberg, RJ; Gore, JM; Gurwitz, JH; Lessard, D; McCormick, D; Yarzebski, J, 1999)
"Aspirin-induced asthma (AIA) is frequently accompanied by nasal polyps."3.70Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient. ( Ogata, Y; Okinaka, Y; Takahashi, M, 1999)
"The clinical characteristics of idiopathic nasal polyposis in children (11 males and nine females; median: 12 years; range: 8-15 years) were very similar to those observed in adults (median: 50 years), in particular the relation to asthma (ten of 20 cases) and aspirin intolerance (two Fernand-Widal syndromes of 20 cases)."3.70[Does idiopathic naso-sinusal polyposis exist in children?]. ( Coffinet, L; Derelle, J; Jankowski, R; Pialoux, R, 1999)
"This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance."3.70[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999)
"Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease."3.70Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999)
"The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established."3.70Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000)
"The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke."3.70Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000)
"Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack."3.70Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000)
"Adding NTG to a thrombolytic regimen with rt-PA, aspirin and heparin increases the magnitude of restored flow and total patency duration following recanalization in a rabbit model of arterial thrombosis."3.69Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model. ( Battler, A; Chernine, A; Hasdai, D; Kornowski, R; Ovadia, Z, 1995)
"To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival."3.69Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1996)
" Those with acute myocardial infarction, radiolucent defects in coronary arteries suggestive of thrombus, and results that were not optimal after stent implantation were anticoagulated with warfarin and not Included in the study."3.69Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin. ( Aroney, CN; Bett, JH; McEniery, PT; Sankardas, MA, 1996)
"Weight-adjusted duteplase infusion, together with oral aspirin and intravenous heparin, in acute myocardial infarction resulted in patency of the infarct-related coronary artery and a safety profile comparable to those reported for the other form of tissue-type plasminogen activator, alteplase."3.69ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. ( Keltai, M; Malcolm, AD; Walsh, MJ, 1996)
"Asthmatic triad (AT) is a clinical syndrome incorporating bronchial asthma (BA), recurrent nasal and sinus polyps, intolerance of aspirin, derivatives of pirasolone and other nonsteroid antiinflammatory drugs."3.69[The in-vivo test of the inhibition of leukocyte natural migration with aspirin and analgin in the specific diagnosis of the asthmatic triad]. ( Kanchurina, NA; Poroshina, IuA; Prasolova, NI; Zemskov, VM, 1996)
"Treatment with warfarin was most effective in preventing recurrent arterial and venous thrombosis."3.69A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. ( Harris, EN; Krnic-Barrie, S; Looney, SW; O'Connor, CR; Pierangeli, SS, 1997)
" In 1982, it was suggested for the first time low doses of aspirin and prednisone for treatment of recurrent fetal death associated to this syndrome, heparin therapy was reported in 1984, recommended a doses of 15,000 U/day during first pregnancy trimester and 20,000 U/day posteriorly."3.69[Recurrent fetal death and antiphospholipid antibody syndrome. A case report]. ( Bustos López, HH; Hernández Andrade, E; Ramírez Peredo, J; Rojas-Poceros, G, 1997)
" Studies concerning the sensitivity, specificity and tolerance of the new intranasal provocation procedure using lysine-ASA were based primarily on cases of bronchial asthma and yielded differing results."3.68[Intranasal provocation with lysine acetylsalicylic acid]. ( Brasch, J; Cornelius, M; Mertens, J; Wellbrock, M, 1993)
"Recurrent chest pain with new ST-segment elevation was observed in 26 of 652 patients (4%) with myocardial infarction in a clinical trial of alteplase (recombinant tissue-type plasminogen activator; 100 mg) and aspirin with or without heparin."3.68Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. ( Arnout, J; Nÿssen, K; Simoons, ML; van den Brand, M; Verstraete, M, 1993)
"Low-dose aspirin is widely used in patients operated on for coronary disease as secondary prevention of coronary artery occlusion."3.68Gastric changes in coronary-operated patients with low-dose aspirin. ( Kivilaakso, E; Leivonen, M; Sipponen, P, 1992)
"One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin."3.68Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992)
"Patients with acute myocardial infarction (AMI) admitted between 1986 and 1989 were divided into aspirin (ASA) group (216 cases) and control group (211 cases)."3.68[A clinical trial of the secondary prevention of reinfarction with low dose aspirin]. ( Chen, Z, 1991)
"In conscious dogs with coronary thrombosis induced by electrical current, we assessed the impact on the rapidity of thrombolysis and the incidence of reocclusion of two types of adjunctive treatment given concomitantly with intravenous tissue-type plasminogen activator (t-PA): 1) inhibition of platelet function with a peptide mimetic antagonist of platelet glycoprotein IIb/IIIa receptors or with lysine acetylsalicylic acid (ASA) and 2) inhibition of thrombin activity with recombinant hirudin or with heparin."3.68Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. ( Abendschein, DR; Haskel, EJ; Prager, NA; Sobel, BE, 1991)
"Fifty-six patients who presented with non-steroidal anti-inflammatory drug-associated duodenal ulcers received maintenance treatment with ranitidine."3.67Ranitidine maintenance treatment of non-steroidal anti-inflammatory drug-induced duodenal ulceration. ( Penston, JG; Wormsley, KG, 1989)
"Aspirin has been reported to induce the adult respiratory distress syndrome (ARDS) in humans."3.67Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress syndrome. ( Krieger, BP; Suarez, M, 1986)
"Baseline white blood cell count (WCC) and haematocrit were examined in relation to recurrent coronary events and to all-cause mortality in 2026 persons enrolled in the first Persantin-Aspirin Reinfarction Study (PARIS-1) 2-60 months after myocardial infarction."3.67White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. ( Barton, BA; Forbes, CD; Krol, WF; Lowe, GD; Machado, SG, 1985)
" Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance."3.66Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982)
"Hydroxyurea has been rarely implicated as a cause of drug fever."3.66Fever caused by hydroxyurea. ( Bauernfeind, RA; Bauman, JL; Hartsough, N; Hasegawa, GR; Roden, R; Shulruff, S, 1981)
"We have studied seventy-five patients with recurrent urticaria and angio-oedema of more than 4 months duration and with positive provocation tests to aspirin, azo dyes, and/or benzoates."3.65A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes. ( Juhlin, L; Michaëlsson, G; Ros, AM, 1976)
" There were five chronic alcoholics, one aspirin abuser, one severely burned patient, and one patient with sepsis."3.65Gastric devascularization: an alternate approach to the surgical treatment of massive, diffuse hemorrhage from gastritis. ( Aust, JB; McFee, AS; Rittenhouse, M, 1976)
"Often used as an oral analgesic in the management of pain associated with traumatic hyphema, aspirin has an inhibitory effect on the blood clotting mechamism by its action on platelets."3.65The effect of aspirin on rebleeding in traumatic hyphema. ( Chan, W; Crawford, JS; Lewandowski, RL, 1975)
"A proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation."3.01Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. ( Bahit, MC; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Easton, JD; Granger, CB; Grauer, C; Kleine, E; Lopes, RD; Lyrer, P; Meyerhoff, J; Sacco, RL; Segura, T; Wachter, R, 2021)
"Patients with a recent embolic stroke of undetermined source were randomized to dabigatran (150 or 110 mg BID) or aspirin (100 mg QD)."3.01Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis. ( Brueckmann, M; Easton, JD; Grauer, C; Lee, BC; Liou, CW; Taniguchi, A; Toyoda, K; Uchiyama, S; Urano, Y; Wong, LKS, 2021)
"Patients with watershed infarction had higher risk of stroke recurrence than those without (17."2.94Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE. ( Atchaneeyasakul, K; Jing, J; Johnston, SC; Liebeskind, DS; Liu, L; Liu, X; Meng, X; Pan, Y; Pu, Y; Wang, A; Wang, Y; Zhao, X; Zou, X, 2020)
"The concept of embolic stroke of undetermined source (ESUS) unifies a subgroup of cryptogenic strokes based on neuroimaging, a defined minimum set of diagnostic tests, and exclusion of certain causes."2.94Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. ( Ameriso, SF; Arauz, A; Berkowitz, SD; Chamorro, Á; Connolly, SJ; Hankey, GJ; Hart, RG; Kasner, SE; Korompoki, E; Lindgren, A; Muir, KW; Mundl, H; Ozturk, S; Pearce, LA; Perera, K; Rudilosso, S; Sharma, M; Shoamanesh, A; Shuaib, A; Tatlisumak, T; Toni, D; Veltkamp, R, 2020)
"Major bleeding was the primary safety end point."2.90Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Röther, J; Wang, Y; Wong, KSL, 2019)
"Acute minor ischemic stroke (AMIS) or transient ischemic attack (TIA) is a common cerebrovascular event with a considerable high recurrence."2.87Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning. ( Feng, WW; Ji, XM; Li, SJ; Liu, SM; Meng, R; Ovbiagele, B; Ren, CH; Song, HQ; Zhao, WL, 2018)
"With unprovoked VTE, rates of recurrence in the 1173 patients given rivaroxaban, the 468 given aspirin, and the 243 given placebo were 2."2.87Risk of recurrent venous thromboembolism according to baseline risk factor profiles. ( Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Homering, M; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; Tamm, M; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS, 2018)
"Patients with lacunar stroke and CMBs likely harbor a more advanced form of cerebral small vessel disease in need of efficacious therapeutic strategies."2.84Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions. ( Anderson, DC; Bazan, C; Benavente, OR; Catanese, L; Hart, RG; Kase, CS; Marti-Fabregas, J; McClure, LA; Pearce, LA; Sharma, M; Shoamanesh, A, 2017)
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months."2.84SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017)
"Aspirin) was effective."2.82[Idiopathic recurrent pericarditis: review of the literature and the Geneva experience]. ( Dominati, A; Meyer, P; Seebach, JD, 2022)
"Secondary outcomes are ulcer recurrence, wound pain, quality of life and wellbeing, adherence to study medication, adherence to compression therapy, serum inflammatory markers, hospitalisations, and adverse events at 24 weeks."2.82Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial. ( Aldons, P; Barker, A; Dapiran, E; Darby, I; Haines, T; Loveland, P; Madan, JJ; McNeil, J; Sinha, S; Underwood, M; Vicaretti, M; Ward, S; Weller, CD; Wolfe, R; Woodward, M, 2016)
"The primary outcome is IS recurrence."2.80Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015)
"Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin."2.80Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial. ( Chang, HJ; Cho, IJ; Chung, N; Hong, GR; Jang, Y; Kim, KJ; Rah, YM; Shin, S, 2015)
"60."2.79Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014)
"Among 1244 patients with lacunar stroke (mean age, 63."2.79C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. ( Benavente, OR; Coffey, CS; Del Brutto, OH; Elkind, MS; Luna, JM; McClure, LA; Meyer, BC; Pettigrew, LC; Pretell, EJ; Roldan, A; Tapia, J; White, C; Zhang, Y, 2014)
"Rabeprazole was well tolerated at both doses."2.79Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. ( Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014)
"Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival."2.78Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013)
"Background stroke care was limited and none of the patients received thrombolytic therapy."2.76The International Stroke Trial database. ( Członkowska, A; Niewada, M; Sandercock, PA, 2011)
"Aspirin (ASA) is an effective antiplatelet drug that reduces the risk of myocardial infarction, stroke, or death by approximately 25% in patients who are at increased risk of cardiovascular events."2.75Factors responsible for "aspirin resistance" - can we identify them? ( Filipiak, KJ; Huczek, Z; Kosior, D; Opolski, G; Postuła, M; Serafin, A; Tarchalska-Kryńska, B, 2010)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."2.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"Myocardial infarction was more frequent in the early invasive strategy group (106 [18."2.73Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. ( Cornel, JH; de Winter, RJ; Hirsch, A; Tijssen, JG; Verheugt, FW; Windhausen, F, 2007)
"Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points of the trial."2.73Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM; Zee, RY, 2007)
"Women with a prior pregnancy affected by FGR have a 20% to 30% risk of recurrence, but effective preventive strategies are lacking."2.72Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. ( Blue, NR; Page, JM; Silver, RM, 2021)
""Pericarditis Acute pericarditis is a common disease, most often idiopathic or viral."2.72[Pericarditis]. ( Cacoub, P; Marques, C, 2021)
" There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO."2.71Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. ( DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004)
"Odds ratios (ORs) for adenoma recurrence were calculated using the lowest quartile of fiber intake as the reference."2.70Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial. ( Alberts, DS; Giuliano, AR; Guillén-Rodríguez, JM; Jacobs, ET; Martínez, ME; Roe, DJ, 2002)
"We analyzed the incidence and recurrence rate of early and late primary VF in 9,720 patients with a first acute MI, treated with thrombolytics, enrolled in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 trial."2.69Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. ( Cavalli, A; Negri, E; Santoro, L; Volpi, A, 1998)
"Dipyridamole was associated with a slight increase in headache, which resolved in most patients if therapy was continued."2.69Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. ( Forbes, CD, 1998)
"Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed."2.69Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. ( Alberts, MJ; Berdan, LG; Califf, RM; Deckers, J; Graffagnino, C; Granger, CB; Harrington, RA; Laskowitz, DT; Lincoff, AM; MacAulay, CM; Mahaffey, KW; Miller, JM; Simoons, ML; Sloan, MA; Topol, EJ, 1999)
"Danaparoid sodium appears to be an efficient and safe treatment in critically ill patients with HIT."2.69Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. ( Guyotat, D; Mahul, P; Mazet, E; Mismetti, P; Reynaud, J; Tardy, B; Tardy-Poncet, B, 1999)
" Sumatriptan is more effective, but resulted in more adverse events."2.69Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St ( Diener, HC, 1999)
"Cilostazol is a potent antiplatelet agent with less serious side effects."2.69Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999)
"Fifty-two patients had symptomatic intracranial atherosclerosis and fulfilled entry criteria."2.69Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. ( Albers, GW; Thijs, VN, 2000)
"Cilostazol is a potent antiplatelet agent with antiproliferative properties."2.69Effects of cilostazol on angiographic restenosis after coronary stent placement. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, NH; Nah, DY; Park, SJ; Park, SW, 2000)
"Piracetam was significantly superior to ASA in the secondary endpoint (P=0."2.69Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000)
"Acute idiopathic pericarditis is complicated by recurrence in 15 to 30% of cases."2.69[Efficacy of colchicine in recurrent acute idiopathic pericarditis]. ( Amoura, Z; Cacoub, P; Godeau, P; Piette, JC; Sbaï, A; Wechsler, B, 2000)
"Nonfatal myocardial infarction was present in seven patients in group A, four in group B and none in group C (group B vs."2.68Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. ( Cerdá, MA; Daroca, AM; Duronto, EA; García, CN; Gurfinkel, EP; Manos, EJ; Mautner, B; Mejaíl, RI, 1995)
"Aspirin was the most widely prescribed drug (79."2.68[Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study]. ( Boissel, JP; Gillet, J; Leizorovicz, A; Némoz, C, 1995)
"In the remainder symptomatic polyp recurrence was delayed compared with the previous experience while on intranasal steroids, with eight patients remaining symptom free at 15 months compared with an expected number of three (P = < 0."2.68Intranasal lysine aspirin in recurrent nasal polyposis. ( Darby, YC; Freedman, A; Hassab, M; Lund, VJ; Scadding, GK, 1995)
"Taprostene was administered to 19 patients as a continuous intravenous infusion from 2 hours before until 8 (n = 6) or 24 (n = 6) hours after angioplasty; 7 control patients were given a combination of 330 mg aspirin and 75 mg dipyridamole."2.68[The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty]. ( Heinz, M; Söhngen, M; Theiss, W; van de Flierdt, E, 1996)
"Aspirin was associated with a significant excess of 5 (SD 1) transfused or fatal extracranial bleeds per 1000; in the absence of heparin the excess was 2 (SD 1) and was not significant."2.68The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. ( , 1997)
"Aspirin (ASA) has become a well-documented therapeutic adjunct in patients with coronary heart disease."2.68Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) ( Aursnes, I; Kjekshus, J; Nguyen, KN, 1997)
"Restenosis was assessed by repeat angiography at 3 months and clinical symptoms up to 12 months."2.68The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty. ( Fligelstone, LJ; Horrocks, EH; Horrocks, M; Lane, IF; Murphy, P; Ruttley, MS; Watson, HR, 1997)
"Dipyridamole was applied in 550 interventions (455 interventions in men, 95 interventions in women, age = 59."2.68[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study]. ( Heidland, UE; Heintzen, MP; Kelm, M; Klimek, WJ; Leschke, M; Michel, CJ; Schwartzkopff, B; Strauer, BE; Vester, EG, 1997)
"Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients."2.67Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. ( , 1993)
"In the aspirin group the recurrence rate was 18."2.67Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy? ( Adamek, HE; Buttmann, A; Riemann, JF; Weber, J, 1994)
"Aspirin was effective only in complex and less severe lesions (< 90% stenosis)."2.67Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. ( de Swart, H; Lie, KI; Meyer, A; Michels, HR; van der Pol, JM; van Eenige, MJ; Veen, G; Verheugt, FW; Werter, CJ, 1993)
" Unfortunately, dosing strategies and monitoring have not kept pace with the rest of the field."2.67The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration. ( Becker, RC; Gore, JM, 1993)
"Ticlopidine has not been formally compared with aspirin in patients with a completed stroke."2.67Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. ( Harbison, JW, 1992)
"Heparin is an effective, widely used treatment for unstable angina."2.67Reactivation of unstable angina after the discontinuation of heparin. ( Juneau, M; Lam, J; McCans, J; Théroux, P; Waters, D, 1992)
"Aspirin-treated lesions (n = 163) had lost 16 +/- 22% (mean +/- standard deviation) of lumen and placebo-treated lesions 22 +/- 25% of lumen (n = 134) at angiography (p less than 0."2.67Effects of low-dose aspirin on restenosis after coronary angioplasty. ( Cope, GD; Cumpston, GN; Gibbons, FA; Luke, P; Mews, GC; Taylor, RR, 1991)
"Restenosis was assessed by percent area stenosis as determined by quantitative angiographic techniques before, immediately and 1 year after angioplasty."2.67Effects of diltiazem on complications and restenosis after coronary angioplasty. ( Giorgi, LV; Good, TH; Hartzler, GO; Ligon, RW; McCallister, BD; O'Keefe, JH; Webb, DL, 1991)
" These results demonstrate that high aspirin dosage does not reduce the restenosis rate more than low dosage."2.67[Effects of high and low doses of acetylsalicylic acid on the restenosis rate after initially successful coronary angioplasty]. ( Grimme, M; Kochsiek, K; Schanzenbächer, P; Walter, U, 1991)
" It cannot, however, be concluded from this study that 75 mg dipyridamole in combination with 100 mg ASA tid is more effective in preventing reocclusion after PTA than in combination with 330 mg ASA tid."2.67Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. ( Deichsel, G; Heiss, HW; Just, H; Middleton, D, 1990)
"These data indicate that migraine is mediated, at least in part, by the effects of platelets and suggest that low-dose aspirin should be considered for prophylaxis among those with a history of established migraine."2.67Low-dose aspirin for migraine prophylaxis. ( Buring, JE; Hennekens, CH; Peto, R, 1990)
"Pericarditis is the most common form of pericardial disease and may be associated with significant morbidity and mortality."2.66Managing acute and recurrent idiopathic pericarditis. ( Cornelio, CK; Epperson, TM; Schwier, NC, 2020)
"Main outcomes were stroke recurrence and major bleeding."2.66Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020)
"BACKGROUND Priapism is rarely reported as a complication in patients with essential thrombocythemia at presentation."2.66Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature. ( Jain, M; Kumar, N; Tripathi, AK; Verma, SP, 2020)
"Dabigatran was shown to be safer than vitamin K antagonists and similarly effective for the prevention of recurrent VTE."2.66Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. ( Imberti, D; Mastroiacovo, D; Pomero, F, 2020)
" Eight hours before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued."2.66Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. ( Aldridge, HE; Bonan, R; Bourassa, MG; David, PR; Henderson, M; Kazim, F; Lespérance, J; Salvatori, VA; Schwartz, L, 1988)
" A statistically significant superiority of the 30 mg aspirin dosage compared with the 1000 mg dosage was found in patients aged over 50 years, in male patients, in patients with angina pectoris in their anamnesis, in patients with ST-depression of greater than 0."2.66Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus. ( Förster, W; Hoffmann, W, 1988)
"Of the 5 cerebral infarcts, 4 occurred in the control group, 3 patients died."2.65[The treatment of transitory ischemic attacks with acetylsalicylic acid: results of a double-blind-study (author's transl)]. ( Dorndorf, W; Loew, D; Reuther, R, 1980)
"However, considering that most stroke recurrences occur i n the short term, a time limited double antiplatelet scheme could result in significant benefits to patients with acute ischemic stroke."2.61[Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group recommendation]. ( Bottaro, F; Caruso, D; Catalano, HN; Izcovich, A; Pollán, J; Saavedra, E; Tisi Baña, M, 2019)
"Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke."2.61Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019)
"Recurrent pericarditis is one of the most frequent pericardial diseases, affecting up to 30% of the patients who have experienced acute pericarditis."2.58Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. ( Brucato, A; Cantarini, L; Di Lenarda, A; Emmi, G; Gattorno, M; Imazio, M; Lopalco, G; Marcolongo, R; Martini, A; Prisco, D, 2018)
"All drug classes were found to favour migraine chronification."2.58Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients. ( D'Amico, D; Grazzi, L; Grignani, E; Raggi, A; Sansone, E, 2018)
"Stillbirth affects at least 2."2.58Care prior to and during subsequent pregnancies following stillbirth for improving outcomes. ( Ellwood, DA; Flenady, V; Heazell, AE; Lassi, ZS; Middleton, P; Murphy, MM; Shepherd, E; Silver, RM; Wilson, T; Wojcieszek, AM, 2018)
"Acute and recurrent pericarditis is the most common pericardial syndrome encountered in clinical practice either as an isolated process or as part of a systemic disease."2.55Acute and Recurrent Pericarditis. ( Gaita, F; Imazio, M, 2017)
" The combination of clopidogrel and aspirin is not recommended for long-term use (more than two to three years) because of increased bleeding risk."2.55Recurrent Ischemic Stroke: Strategies for Prevention. ( Garcellano, M; Oza, R; Rundell, K, 2017)
"Recurrent pericarditis is the most troublesome complication of pericarditis occurring in 15 to 30% of cases."2.55Recurrent pericarditis. ( Battaglia, A; Gaido, L; Gaita, F; Imazio, M, 2017)
"Recurrent pericarditis is one of the most common and troublesome complications after an episode of pericarditis, and affects 20-50% of patients treated for pericarditis."2.53Recurrent pericarditis: new and emerging therapeutic options. ( Brucato, A; Gaita, F; Imazio, M; Lazaros, G, 2016)
"Recurrent pericarditis is one of the most troublesome complications of pericarditis occurring in about one third of patients with a previous attack of pericarditis."2.53Recurrent Pericarditis: Modern Approach in 2016. ( Adler, Y; Charron, P; Imazio, M, 2016)
"Idiopathic (viral) pericarditis is the most common form of pericardial disease in the Western world."2.52Pharmacotherapy update of acute idiopathic pericarditis. ( Coons, JC; Rao, SK; Schwier, NC, 2015)
"Treatment of celecoxib with a proton pump inhibitor is safer than treatment with nonselective NSAID and a proton pump inhibitor in high risk gastrointestinal and cardiovascular patients who mostly also take acetylsalicylic acid."2.52[Gastrointestinal bleeding]. ( Lanas, Á, 2015)
"Recurrence is rare and occurs most commonly in children."2.50Recurrent Kawasaki disease in a child with retropharyngeal involvement: a case report and literature review. ( Aldemir-Kocabaş, B; Çiftçi, E; Fitöz, S; İnce, E; Kcal, MM; Ramoğlu, MG; Tutar, E, 2014)
"Recurrent pericarditis are common and their management remains a matter of debate."2.47[What's new in recurrent pericarditis in 2011?]. ( Cacoub, P; Geri, G, 2011)
"Bleeding is potentially the most significant antiplatelet-associated side effect."2.47Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011)
"Aspirin was given as well as percutaneous endovascular PFO closure was performed with no immediate complication."2.47Patent foramen ovale and recurrent transient neurological symptoms: a case report and review of literature. ( Anamnart, C; Poungvarin, N, 2011)
" If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended."2.46[Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010)
"Chronic rhinosinusitis is often associated with bronchial asthma."2.45[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options]. ( Jung, H, 2009)
"Women with a history of previous preeclampsia are at increased risk of preeclampsia and other adverse pregnancy outcomes in subsequent pregnancies."2.44Prediction and prevention of recurrent preeclampsia. ( Barton, JR; Sibai, BM, 2008)
"Ten patients with aneurysms and/or pseudoaneurysms and six patients with occlusive lesions have undergone surgical treatment."2.44Major arterial involvement and review of Behcet's disease. ( Alpagut, U; Dayioglu, E; Ugurlucan, M, 2007)
"Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system."2.44Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007)
"The antiphospholipid syndrome is an antibody mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events."2.44[The antiphospholipid syndrome, an update]. ( Alonso Santor, JE; Inglada Galiana, L; Pérez Paredes, G, 2007)
"Preventive treatment of preeclampsia consists essentially of low dose aspirin."2.44[Latest developments: management and treatment of preeclampsia]. ( Tsasaris, V; Winer, N, 2008)
"Aspirin non-response was more frequently associated with the use of "home-established" cut-offs or when closure time was only assessed after aspirin (rather than both before and after)."2.44Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. ( Cerletti, C; Crescente, M; de Gaetano, G; Di Castelnuovo, A; Iacoviello, L; Vermylen, J, 2008)
"The short-term risk of stroke after transient ischemic attack (TIA) is about 10% to 20% in the first 3 months, with much of the risk front-loaded in the first week."2.43Stroke prevention. MATCHing therapy to the patient with TIA. ( Buchan, AM; Demchuk, AM; Hill, MD; Weir, NU, 2005)
"Twenty-three children had varicella at age 1."2.43Post-varicella arteriopathy of childhood: natural history of vascular stenosis. ( Armstrong, D; deVeber, G; Domi, T; Lanthier, S, 2005)
"The antiphospholipid syndrome is currently best treated with anticoagulation."2.43Anticoagulation therapy in the antiphospholipid syndrome: recent advances. ( Crowther, MA; Ng, HJ, 2005)
"About 80% of strokes have ischemic origin."2.43[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005)
"The risk of TIA or stroke recurrence reaches 30-45%."2.42[Stenosis of the carotid arteries]. ( Kaźmierski, MK, 2003)
"The diagnosis of carotid stenosis is made after occurrence of a cerebral ischemic event or during an angiologic examination, mainly using Doppler/Duplex-sonography."2.42[Carotid stenosis: diagnosis, patient selection, therapy]. ( Barth, A, 2003)
"Nasal polyps are as common as adult onset asthma and unilateral polyps require histological examination."2.42Nasal polyps. ( Drake-Lee, AB, 2004)
"The treatment of migraine takes into consideration the intensity of the headache and the accompanying symptoms."2.42[Treatment and prophylaxis of an acute migraine attack]. ( Diener, HC; Gendolla, A, 2004)
"Since 1987 the antiphospholipid syndrome has been recognized as a major cause of acquired thrombophilia, whether it is associated with systemic lupus erythematosus or occurs as a free-standing syndrome (primary form)."2.41[Antiphospholipid syndrome]. ( Arvieux, J; Hachulla, E, 2002)
"The standard therapy in Crohn's disease and ulcerative colitis is based on corticosteroids and aminosalicylates."2.41[Therapy of chronic inflammatory bowel diseases]. ( Stange, EF, 2002)
"Arterial and venous thrombosis are the most common and clinically relevant events of the so-called antiphospholipid syndrome; they are reported in approximately one third of patients with the antiphospholipid (aPL) antibodies."2.41The epidemiology of the antiphospholipid syndrome: who is at risk? ( Finazzi, G, 2001)
"Colchicine treatment seems to be efficacious and can be used to stop steroid therapy."2.41[Is chronic or recurrent idiopathic pericarditis an autonomous inflammatory disease?]. ( Disdier, P; Ene, N; Granel, B; Habib, G; Mesana, T; Pache, X; Rey, J; Serratrice, J; Swiader, L; Weiller, PJ, 2001)
"Prevention of recurrence with antiarrhythmic drugs is somewhat problematic because of incomplete efficacy (30% recurrence at 1 year) and the potential for inducing other, life-threatening arrhythmias."2.40Management of atrial fibrillation: out-of-hospital approach. ( Folland, ED, 1999)
"6 studies with a placebo-controlled, double blind, randomized protocol on the effect of acetylsalicylic acid (ASA) in a dosage of higher than 100 mg/day have been published."2.39[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia]. ( Hartmann, A, 1995)
" There is disagreement over the optimal dosage to prevent a stroke: earlier studies considered > or = 975 mg ASS per day, sometimes in combination with other substances, while more recently, lower dosages of about 300 mg per day or even as low as < or = 100 mg per day have been proposed."2.39[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage]. ( Hennerici, MG; Meairs, S, 1995)
"Over 80% of recurrences are infrequent and can be treated when they occur n 20% of ulcer patients have 3 recurrences/yr, ulcer complications, or such poor health that recurrence might prove fatal."2.38Maintenance therapy for peptic ulcer--who needs it? ( McCarthy, DM, 1993)
"Aspirin has many uses in cardiovascular disease."2.38The use of aspirin in cardiovascular disease. ( Byers, JF, 1993)
"The role of Kawasaki disease (KD) as a contributor to early childhood cardiac morbidity in Adelaide was investigated by a review of hospital admission and case-note data from January 1979 to June 1990."2.38Kawasaki disease in Adelaide: a review. ( Goldwater, PN; Smith, PK, 1993)
"The risk of early recurrence of embolism in the first 30 days ranges from 8 to 15%."2.38[Embolic complications of chronic atrial fibrillation]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Théolade, R, 1992)
" Some of the newer NSAIDs seem at normal dosage to be far less damaging than traditional ASA or indomethacin."2.37Gastroduodenal damage due to drugs, alcohol and smoking. ( Domschke, S; Domschke, W, 1984)
"Epistaxis is the most common otolaryngological emergency and one-third of epistaxis patients regularly take low-dose acetylsalicylic acid (ASA) for the prevention of cardiovascular disease (CVD)."1.91The pattern of epistaxis recurrence in patients taking prophylactic acetylsalicylic acid (ASA) from a 10 year cohort. ( Hoch, S; Rudhart, S; Stanković, P; Stojković, S; Wilhelm, T, 2023)
"Acute pericarditis has a wide spectrum of clinical presentations largely depending on underlying aetiologies."1.62Age- and sex-based differences in patients with acute pericarditis. ( Antonopoulos, AS; Lazaros, G; Lazarou, E; Tousoulis, D; Vassilopoulos, D; Vlachopoulos, C; Vogiatzi, G, 2021)
"Following an acute ischemic stroke or transient ischemic attack, 2 rates of stroke recurrence are suggested by data from trials of acute secondary prevention treatments: a transient rapid rate followed by a persisting slower rate of stroke."1.62Two-State Kinetic Model of Rates of Stroke Recurrence in the POINT Study Population. ( Brorson, JR; Bulwa, ZB, 2021)
"The score was predictive of recurrence among most patient subgroups."1.62A risk score for pericarditis recurrence. ( Antonopoulos, AS; Imazio, M; Karavidas, A; Lazaros, G; Lazarou, E; Tousoulis, D; Toutouzas, K; Tsioufis, C; Vasileiou, P; Vassilopoulos, D; Vlachopoulos, C, 2021)
"Aspirin and warfarin were resumed at a median (IQR) of 5."1.56The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices. ( Asleh, R; Dawit, S; Freeman, WD; Li, Z; Matos, NL; O'Carroll, CB; Rabinstein, AA; Santos, CD, 2020)
"The majority presented with recurrent transient ischemic attacks/minor strokes within a single vascular territory over days to weeks."1.56Focal Cerebral Arteriopathy in Young Adult Patients With Stroke. ( Cronin, S; Fanning, N; McKenna, MC, 2020)
"No recurrences were registered in the polypill group, compared to 1 recurrence in the conventional treatment group."1.56Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. ( Alonso-Canovas, A; Chico-García, JL; Cruz-Culebras, A; de Felipe Mimbrera, A; García-Madrona, S; Gómez-López, A; Masjuan, J; Matute-Lozano, C; Natera-Villalba, E; Ros-Castelló, V; Sánchez-Sánchez, A; Vera-Lechuga, R, 2020)
"The PLA recurrence rate in patients taking aspirin daily for 30 or more days, from 90 days before to 90 days after the first PLA episode (aspirin users), and aspirin non-users was 42."1.51Aspirin use is associated with reduced risk for recurrence of pyogenic liver abscess: a propensity score analysis. ( Chang, CC; Chen, FJ; Chuah, SK; Lee, CH; Liu, JS; Tai, WC, 2019)
"Peripheral artery disease affects 1."1.51Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. ( Ademi, Z; Hird, TR; Liew, D; Owen, AJ; Reid, CM; Si, S; Tonkin, A; Zomer, E, 2019)
"Default of therapy for polycythemia is associated with a profound risk of recurrent strokes requiring patient education and support to prevent the devastating consequence of this modifiable but rare cause of stroke."1.51Recurrent Stroke in a Ghanaian Patient With Polycythemia. ( Berchie, PO; Opare-Sem, OK; Ovbiagele, B; Sarfo, FS, 2019)
"2."1.51Management of idiopathic recurrent pericarditis during pregnancy. ( Adler, Y; Brucato, A; Imazio, M; Lucianetti, M; Maestroni, S; Pluymaekers, N; Rampello, S; Tombetti, E; Valenti, A, 2019)
"A part of familial Hirschsprung disease has genetic factors in common with cerebrovascular disease."1.51A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease. ( Abe, K; Hishikawa, N; Ohta, Y; Sasaki, R; Sato, K; Takemoto, M; Yamashita, T, 2019)
" Direct oral anticoagulants (DOACs): For long-term secondary prevention, a reduced dosing regimen of DOACs was found to be effective with a low bleeding risk."1.48[Prolonged Secondary Prevention After Venous Thromboembolism]. ( Bauersachs, R, 2018)
"We report a patient who had recurrent deep vein thrombosis (DVT) as the presenting symptom of Behcet's Disease."1.48Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease. ( Chun, K; Lakha, S; Png, CYM; Ting, W, 2018)
"Chest pain recurrence was defined as the first revisit to the emergency room with angina."1.48Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018)
" Major adverse cardiac and cerebrovascular events (MACCE) [death, myocardial infarction (MI), stroke, and unplanned reintervention] and thrombolysis in myocardial infarction (TIMI) bleeding (major/minor) were registered during hospitalization and follow-up."1.48Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. ( Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T, 2018)
"Stroke recurrence and mortality rates in patients receiving aspirin (N=34 679) were compared with those receiving clopidogrel (N=7611) during a 12-month follow-up period."1.48Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data. ( Chang, WL; Chen, CH; Chi, NF; Hsu, CY; Hu, CJ; Jeng, JS; Li, JY; Lien, LM; Lin, CH; Liu, CH; Sun, Y; Wen, CP, 2018)
"The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations."1.46Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017)
"Aspirin use was updated at each clinic visit and considered as a time-varying covariate."1.46Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. ( Bavry, AA; Bhatt, DL; Elbez, Y; Elgendy, IY; Mahmoud, AN; Sorbets, E; Steg, PG, 2017)
"The cumulative recurrence rate at 1 year was 15%."1.46Analysis of risk factors for colonic diverticular bleeding and recurrence. ( Fukui, H; Miwa, H; Ohda, Y; Oshima, T; Taki, M; Taniguchi, Y; Tomita, T; Tozawa, K; Watari, J, 2017)
"Given the high risk of stroke recurrence, antiplatelets followed by anticoagulation for secondary prevention were initiated."1.46Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question. ( Abubakar, H; Hassan, AAI; Ibrahim, W; Subahi, A, 2017)
"The primary end point was recurrence of ACS or death >30days after the index event."1.46Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017)
"Age above 55 years was associated with recurrence of ACS in C2238/ANP-minor allele carriers (hazard ratio 1."1.43T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. ( Abbolito, S; Battistoni, A; Bianchi, F; Burocchi, S; Cangianiello, S; Caprinozzi, M; Comito, F; Cotugno, M; De Giusti, M; Di Castro, S; Dito, E; Farcomeni, A; Greco, ES; Marchitti, S; Pagliaro, B; Pierelli, G; Rubattu, S; Sciarretta, S; Stanzione, R; Volpe, M, 2016)
"The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented."1.43Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016)
"In conclusion, recurrence of CVEs occurred independently of HTPR and residual COX-1 activity."1.43Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. ( Abumiya, T; Furui, E; Hattori, A; Hosomi, N; Isshiki, T; Kada, A; Kaikita, K; Kario, K; Katayama, Y; Kawamura, A; Kimura, K; Kitagawa, K; Minematsu, K; Miyata, S; Miyata, T; Nagao, T; Nagatsuka, K; Nakagawara, J; Nakane, H; Nishikawa, M; Ogawa, H; Okada, H; Saito, K; Takiuchi, S; Tanaka, K; Taomoto, K; Uchiyama, S; Wada, H; Yamawaki, T; Yonemoto, N, 2016)
"Only one patient had a late recurrence almost 11 years after shunt implantation."1.43Subdural haematoma complicating shunting for normal pressure hydrocephalus in the setting of concomitant antiplatelet medication - a report of 11 cases. ( Birkeland, P; Lauritsen, J; Poulsen, FR, 2016)
"Six cases (6."1.43Complication of Stenting in Intracranial Arterial Stenosis. ( Liu, L; Zhang, F, 2016)
"Nineteen patients presented vascular recurrence after stroke, and 19 matched patients did not present vascular recurrence during the first year of follow-up."1.43PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. ( Bin Dukhyil, AA; Carrera, C; Cullell, N; Fernandez-Cadenas, I; Fontana, P; Gallego-Fabrega, C; Krupinski, J; Martí-Fàbregas, J; Montaner, J; Muiño, E; Pera, J; Pezzini, A; Reny, JL; Segura, T; Serrano-Heras, G; Slowik, A, 2016)
"The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage."1.43[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016)
"Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke."1.43High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016)
"Antiplatelet therapy in patients with chronic subdural hematoma (cSDH) presents significant neurosurgical challenges."1.43Does Early Resumption of Low-Dose Aspirin After Evacuation of Chronic Subdural Hematoma With Burr-Hole Drainage Lead to Higher Recurrence Rates? ( Fandino, J; Kamenova, M; Lutz, K; Mariani, L; Schaedelin, S; Soleman, J, 2016)
"The long-term recurrence of lower gastrointestinal bleeding (LGIB) and associated mortality have not been studied extensively."1.42Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding. ( Akiyama, J; Aoki, T; Kishida, Y; Mizokami, M; Nagata, N; Niikura, R; Sakurai, T; Sekine, K; Shimbo, T; Tanaka, S; Uemura, N; Watanabe, K; Yanase, M; Yokoi, C, 2015)
"An autoimmune disease was present in seven (29%) cases."1.42Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015)
"These results suggest that the recurrence of NSAID-induced small bowel injury was not frequent in the presence of conservative treatment."1.42Long-Term Outcomes of NSAID-Induced Small Intestinal Injury Assessed by Capsule Endoscopy in Korea: A Nationwide Multicenter Retrospective Study. ( Chang, DK; Cheon, JH; Choi, MG; Chun, HJ; Jang, BI; Jeen, YT; Jeon, SR; Jeon, SW; Kim, JH; Kim, JO; Kim, JS; Lee, KJ; Lim, YJ; Moon, JS; Park, CH; Shim, KN; Song, EM; Song, HJ; Ye, BD, 2015)
"Antiphospholipid syndrome is an autoimmune disorder characterized by the occurrence of venous and arterial thrombosis, as well as morbidity in pregnancy, in the presence of anti-phospholipid antibodies."1.42Elevated levels of antibodies against phosphatidylserine/prothrombin complex and/or cardiolipin associated with infection and recurrent purpura in a child: a forme fruste of antiphospholipid syndrome? ( Igarashi, T; Inaba, M; Katagiri, I; Kawana, S; Kinoshita, Y; Mayumi, N, 2015)
"Prior cases of APS associated with cardiac tamponade despite low volumes of effusion have been reported, albeit without good demonstration of hemodynamic findings."1.40Cardiac tamponade due to low-volume effusive constrictive pericarditis in a patient with uncontrolled type II autoimmune polyglandular syndrome. ( Blackshear, JL; Kurklinsky, A; Lane, G; Palmer, WC; Ussavarungsi, K, 2014)
"Twenty-two cases of childhood bacterial meningitis complicated by stroke were identified."1.40Antithrombotic therapy for secondary stroke prevention in bacterial meningitis in children. ( Askalan, R; Bjornson, B; Boelman, C; deVeber, G; MacGregor, D; Moharir, M; Richrdson, S; Shroff, M; Yau, I, 2014)
"Liver fibrosis was assessed by histological evaluation."1.40Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. ( Boëlle, PY; Chazouillères, O; Conti, F; Corpechot, C; Durand, F; Duvoux, C; Mackiewicz, V; Paradis, V; Poujol-Robert, A; Poupon, R; Wendum, D, 2014)
"Rebleeding was diagnosed when the previously treated lesion bled again within 30 days of the initial episode."1.40Rebleeding after initial endoscopic hemostasis in peptic ulcer disease. ( Hong, MJ; Jin, CJ; Kim, JH; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2014)
"We describe a case of recurrent Kawasaki disease (KD) in a non-Asian 6-year-old boy who had been diagnosed with typical KD without cardiac involvement at age 3 years."1.40Kawasaki shock syndrome complicating a recurrence of Kawasaki disease. ( Bœuf, B; Dauphin, C; Lang, M; Lusson, JR; Merlin, E; Tissandier, C, 2014)
"Routine follow-up has revealed no recurrence of symptoms."1.40The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis. ( BinBrek, AS; Mahmoud, WE; Murugesan, V; Rajani, AR, 2014)
"Recurrent epistaxis is a rare presentation of internal carotid artery C4/C5 segment pseudo-aneurysm rupture."1.40Endovascular treatment of internal carotid artery pseudo-aneurysm presenting with epistaxis. A case report. ( Bazina, A; Hucika, Z; Mišmaš, A; Pavliša, G; Poljaković, Z, 2014)
"In selected low TE risk patients undergoing ablation for AF, a short period of periprocedural therapeutic anticoagulation with LMWH together with aspirin is an effective and safe strategy to prevent TE events."1.39Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy. ( Acena, M; Berte, B; Bun, SS; De Meyer, G; Duytschaever, M; Tavernier, R; Van Heuverswyn, F; Vandekerckhove, Y, 2013)
"Recurrent Takotsubo cardiomyopathy is a relatively uncommon condition seen in patients with severe physical or emotional stress."1.39An unusual cause of recurrent chest pain in an adult woman: a case of recurrent stress-induced (Takotsubo) cardiomyopathy. ( Aryal, MR; Hope, EJ; Mainali, NR; Pradhan, R, 2013)
"Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality."1.39Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013)
"Within a regional STEMI system of care, half-dose fibrinolysis combined with immediate transfer for PCI may be a safe and effective option for STEMI patients with expected delays due to long-distance transfer."1.38Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. ( Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK, 2012)
"Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6."1.38The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. ( Buffon, A; Burzotta, F; Crea, F; De Caterina, AR; Leone, AM; Mazzari, MA; Mongiardo, R; Niccoli, G; Porto, I; Rebuzzi, AG; Sgueglia, GA; Trani, C, 2012)
"The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3."1.38Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012)
"An acute spontaneous spinal epidural hematoma (SSEH) is a rare spinal pathology."1.37Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel. ( Cho, YR; Hong, BY; Kim, HS; Kim, HW; Ko, YJ; Lee, JI; Lim, SH, 2011)
"The diagnosis of Kawasaki disease must be raised when predisposing factors are present in this group."1.37[Kawasaki disease in older children and young adults: 10 years of experience in Marseille, France]. ( Bonello, B; Bosdure, E; Bresson, V; Chabrol, B; Dubus, JC; Rousset-Rouvière, C; Serratrice, J, 2011)
"The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes."1.37Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011)
"Freedom from repeat intervention for re-recurrence was 89% in the CEA group and 95% in the CAS group (p=0."1.36Redo surgery or carotid stenting for restenosis after carotid endarterectomy: results of two different treatment strategies. ( Attigah, N; Böckler, D; Deyle, C; Geisbüsch, P; Hartmann, M; Külkens, S; Ringleb, P, 2010)
"Over all, he had 15 times of transient ischemic attack with no lasting deficit."1.36[Case of branch atheromatous disease presenting capsular warning syndrome]. ( Dougu, N; Nukui, T; Taguchi, Y; Takashima, S; Tanaka, K; Toyoda, S, 2010)
"These findings were compatible with systemic lupus erythematosus (SLE)."1.36[Sporadic hemiplegic migraine-like headache in a patient with systemic lupus erythematosus]. ( Doi, H; Isobe, N; Kira, J; Ohyagi, Y; Tateishi, T; Yamasaki, R, 2010)
" Moreover, dosage and duration of postoperative low-molecular-weight heparin (LMWH) administration were associated with a higher risk of reoperation (Mann-Whitney U-test, p<0."1.36The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. ( Forster, MT; Gerlach, R; Mathé, AK; Scharrer, I; Seifert, V; Senft, C, 2010)
"There were early recurrences (while in hospital) in 20 previously unaffected arteries (26."1.36Neurosonographic monitoring of 105 spontaneous cervical artery dissections: a prospective study. ( Ballotta, E; Baracchini, C; Meneghetti, G; Tonello, S, 2010)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."1.35Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"The lack of reported recurrences may lead to less cautious administration of antithrombotic therapy."1.35Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy. ( Fonville, S; Ramos, LM; Rinkel, GJ; van der Worp, HB, 2009)
"Aspirin resistance was determined by platelet aggregation (>20%) to one or more of the four agonists, namely arachidonic acid (1."1.35Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. ( Becker, PJ; Bernstein, PL; Connor, MD; Jacobson, BF, 2009)
"He was diagnosed as idiopathic cerebral infarction."1.35[Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs]. ( Ikegami, M; Matsuda, S; Miyashita, Y; Obara, S; Shimizu, M; Sugiyama, N; Takagi, S; Takizawa, S; Yokoyama, J, 2009)
"Histology showed typical wedge-shaped infarction in the affected organs with endothelial proliferation and occlusion by thrombus."1.35Degos' disease: a rare condition simulating rheumatic diseases. ( Chung, HY; Mok, MY; Trendell-Smith, NJ; Yeung, CK, 2009)
"In addition, the recurrence of atrial fibrillation increased 2."1.35[Factors influencing development of atrial fibrillation after implantation of cardiac pacemaker for sinus node dysfunction]. ( Aganauskiene, J; Aidietiene, S; Aidietis, A; Bagdonas, K; Barysiene, J; Jezovas, V; Jurkuvenas, P; Kaireviciūte, D; Laucevicius, A; Marinskis, G, 2009)
"We describe an infant who had recurrence of Kawasaki disease and responded to therapy with Intravenous Immune globulin (IVIG) and highlight the need for recognition of this vasculitis, which is being increasingly recognised in the Indian subcontinent."1.35Recurrent Kawasaki disease. ( Balasubramanian, S; Ganesh, R, 2009)
"Myopericarditis is relatively common and shows a benign evolution also in spontaneous cases not related to vaccination."1.35Myopericarditis versus viral or idiopathic acute pericarditis. ( Belli, R; Cecchi, E; Chinaglia, A; Demarie, D; Demichelis, B; Ghisio, A; Ierna, S; Imazio, M; Pomari, F; Trinchero, R, 2008)
"Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year."1.33Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006)
"The cumulative 10 year mortality and recurrence rate were 92."1.33Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. ( Manios, E; Peppes, V; Spengos, K; Tsivgoulis, G; Vemmos, K; Zakopoulos, N, 2005)
"Arteriosclerosis is the main cause of lacunar CVA and IOMP."1.33Clinical characteristics of patients with ischemic ocular nerve palsies and lacunar brain infarcts: a retrospective comparative study. ( Goldhammer, Y; Hartmann, B; Kessler, A; Pollak, L; Rabey, MJ, 2005)
"Aspirin treatment had no significant effect on the neointimal smooth muscle component, but partially inhibited macrophage infiltration, without inhibiting ICAM-1 expression."1.33S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. ( Berry, CL; Campbell, JH; Thomas, AC; Worth, NF, 2005)
"Symptom recurrence (angina and congestive heart failure), adverse cardiac events (myocardial infarction, coronary reintervention, and sudden cardiac death), and overall mortality were prospectively recorded."1.33Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. ( Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA, 2006)
"First, patients with quiescent Crohn's disease and ulcerative colitis received the non-NSAID analgesic acetaminophen (n = 26) and the conventional NSAIDs naproxen (n = 32), diclofenac (n = 29), and indomethacin (n = 22) for 4 weeks."1.33Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. ( Bjarnason, I; Bjornsson, E; Maiden, L; Premchand, P; Sherwood, R; Smale, S; Takeuchi, K; Thjodleifsson, B, 2006)
"The sequence and timing of taking migraine medications, whether prescription or over-the-counter, and the patient's response to their treatment, is unknown."1.33Acute migraine treatment: patterns of use and satisfaction in a clinical population. ( Hopkins, M; Malik, SN; Silberstein, SD; Young, WB, 2006)
"Cryptogenic stroke is part of the disease of stress-induced cerebrovascular disease."1.33A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk. ( Eggers, AE, 2006)
"Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion."1.33Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006)
"Stroke is a major health problem worldwide."1.33Effects of policosanol on patients with ischemic stroke: a pilot open study. ( Alvarez, E; Fernández, JC; Fernández, L; Gámez, R; Illnait, J; Más, R; Mendoza, S; Ortega, LL; Sánchez, J, 2006)
"Poststroke recurrence rate was low (7."1.32Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003)
"Two of the intracerebral hemorrhages occurred in the site where asymptomatic MBs were found at baseline."1.32Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. ( Fan, YH; Lam, WW; Mok, VC; Wong, KS; Zhang, L, 2003)
"During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients."1.32Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? ( Banerjee, S; Denniston, AK; Dodson, PM; Gibson, JM, 2004)
"Acute pericarditis has generally a brief and benign course after empiric treatment by non-steroidal anti-inflammatory drugs, and routine hospitalization of most patients may be unnecessary."1.32Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. ( Cecchi, E; Demarie, D; Demichelis, B; Gaschino, G; Ghisio, A; Giuggia, M; Imazio, M; Parrini, I; Trinchero, R, 2004)
"Strokes were subtyped according to inferred mechanism."1.32Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. ( Barzegar, S; Bauer, K; Costigan, T; Furie, KL; Kistler, JP; Mohr, JP; Rosenberg, R; Rosner, B; Sciacca, R; Thompson, JL; Thornell, B, 2004)
"Aspirin users were older on average than nonusers (59 years of age compared with 53 years; p = 0."1.32Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. ( Atkinson, JL; Friedman, JA; McClelland, RL; McIver, JI; Meyer, FB; Nichols, DA; Pichelmann, MA; Piepgras, DG; Toussaint, LG; Wijdicks, EF, 2004)
"During restenosis, an impairment of nitric oxide (NO)-dependent pathways may occur."1.31Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. ( Cirino, G; Condorelli, M; Del Soldato, P; Ignarro, LJ; Napoli, C; Pinto, A; Sica, V; Sorrentino, R, 2001)
"Severe bleeding was defined by the need for admission to hospital."1.31Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. ( Castellino, G; Cuadrado, MJ; Godfrey, T; Hughes, GR; Khamashta, MA, 2001)
" We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk."1.31Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001)
" After a transient response to pulse corticosteroids, his disease ultimately subsided with combination therapy with pulse and high dosage corticosteroids and cyclosporin A."1.31Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. ( Chatila, T; Kim, J; Raman, V; Sharkey, A, 2001)
"Patients with antiphospholipid syndrome are at high risk of pregnancy loss as well as maternal morbidity, especially thrombo-embolic disease."1.30Obstetric outcome in antiphospholipid syndrome. ( Farquharson, RG; Granger, KA, 1997)
"History of untreated hypertension prior to the initial stroke (RR = 1."1.30Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study. ( Baranska-Gieruszczak, M; Czlonkowska, A; Hier, DB; Lechowicz, W; Ryglewicz, D, 1997)
"A therapy-resistant angle closure glaucoma following displacement of the lens-iris diaphragm due to massive choroidal and subretinal hemorrhages has rarely been reported."1.30[Acute glaucoma caused by massive subretinal hemorrhage in age-related macular degeneration and disordered thrombocyte function]. ( Hesse, L; Poller, S, 1997)
"In 52 patients who presented with NAION between 1984 and 1997 adequate information was available regarding use of aspirin, presence of risk factors and second eye involvement."1.30Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. ( Huna-Baron, R; Kurtz, S; Salomon, O; Seligsohn, U; Steinberg, DM, 1999)
"We examined 159 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan."1.30Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan. ( Ihara, T; Kakisita, E; Minami, N; Mori, Y; Omine, M; Shiku, H; Tamaki, S; Wada, H, 1999)
"Six cases of acute myocardial infarction are reported with early disease reactivation following the abrupt discontinuation of heparin infusion three days after alteplase thrombolysis and concomitant aspirin therapy."1.29Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. ( Di Tano, G; Mazzù, A, 1995)
"The rate of recurrence of thrombosis was highest (1."1.29The management of thrombosis in the antiphospholipid-antibody syndrome. ( Cuadrado, MJ; Hughes, GR; Hunt, BJ; Khamashta, MA; Mujic, F; Taub, NA, 1995)
"Women with acute myocardial infarction have a worse prognosis than men but the excess risk is confined to the first 30 days and is only partly explained by age and other baseline variables."1.29Acute myocardial infarction in women: survival analysis in first six months. ( Laji, K; Parsons, L; Ranjadayalan, K; Timmis, AD; Wilkinson, P, 1994)
"The embolic risk and changes of thrombus location and size were investigated in 29 consecutive patients with echocardiographically proven thrombi in the left atrium."1.29[Transthoracic and transesophageal follow-up in patients with left atrial thrombosis]. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, R, 1994)
" Of the 52 with partial inhibition at initial testing, 35 achieved complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or fluctuation of response at the same dosage, but 8 of those 35 (22."1.29Development of aspirin resistance in persons with previous ischemic stroke. ( Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994)
"Acute myocardial infarctions were registered in group 1 in 25% (11."1.29[Emergency intracoronary stent implantation: complications and experiences with 124 patients]. ( Arens, R; Heuer, H; Krakau, I; Müller, T; Rissel, U; Schulze-Waltrup, N; Willgeroth, W, 1994)
"Aspirin was usually chosen after initial brain ischemia."1.29Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. ( Furlan, AJ; Hanna, JP; Sila, CA; Stewart, WJ; Sun, JP; Tan, M, 1994)
"Blood clots were produced in a femoral artery segment with endothelial damage and distal stenosis."1.29Does external ultrasound accelerate thrombolysis? Results from a rabbit model. ( Battler, A; Chernine, A; Kornowski, R; Meltzer, RS; Vered, Z, 1994)
"In patients with migraine, ECT may be expected to trigger a migraine attack, probably in the same way as spontaneous seizures."1.29Migraine after electroconvulsive therapy. ( Folkerts, H, 1995)
"Prevention of recurrence of fibrillation is unnecessary for many after a first episode, especially when idiopathic."1.28[Drug treatments of atrial fibrillation]. ( Brechenmacher, C; Chauvin, M; Koenig, A, 1992)
"Chronic subdural hematoma appears to be a suitable model for the evaluation of risk factors in the development of hemorrhage."1.28Aspirin as a risk factor for hemorrhage in patients with head injuries. ( Gratzl, O; Marbet, G; Radü, EW; Reymond, MA, 1992)
"Five warfarin-treated patients had five significant bleeding events (0."1.28Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. ( Brewer, PM; Rosove, MH, 1992)
" No effect on APTT was detectable in this dosage after 3 h infusion."1.28Reocclusion after thrombolysis: a problem solved by hirudin? ( Eschenfelder, V; Rübsamen, K, 1991)
"Fibrin monomers were threefold positive and D-dimer concentration was increased to 4 mg/l (elevated clotting activation)."1.28[Recurrent thromboembolism due to increased acetylsalicylic acid-resistant platelet aggregation]. ( Himmelreich, G; Riess, H, 1991)
" While steroid dosage was gradually decreased, administration of acetylsalicylic acid (for three months 100 mg daily, then three times daily 100 mg) brought about complete disappearance of the visual signs."1.28[The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities]. ( Berg, PA; Leo-Kottler, B; Weller, M; Wiethölter, H, 1991)
"Treatment with aspirin and a residual stenosis of 25-49% immediately after successful PTCA were the only variables associated with restenosis (P less than 0."1.28Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. ( Emanuelsson, H; Hjalmarson, A; Johansson, SR; Karlsson, T; Wiklund, O, 1991)
" Whereas the death rate was nearly the same in all three former dosage groups the total reinfarction rate was higher (22."1.28Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study. ( Förster, W; Handreg, W; Hoffmann, W; Kampe, W; Muche, J; Nitschke, M, 1991)
"The overall restenosis rate was 40%."1.28Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group. ( Bass, T; Cowley, M; Goldberg, SH; Henderson, MA; Hirshfeld, JW; Macdonald, RG; Margolis, JR; Taussig, A; Vetrovec, G; Whitworth, H, 1990)
" The risk of therapy with acetyl salicylic acid (ASS) in low dosage is significantly smaller."1.28[Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct]. ( Dahn, G; Kothe, K, 1990)
"The composition of an evolving arterial thrombus may be a determinant of how effectively pharmacologic agents prevent reocclusion after initially successful thrombolysis."1.28Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. ( Abendschein, DR; Adams, SP; Feigen, LP; Gorczynski, RJ; Haskel, EJ; Saffitz, JE; Sobel, BE, 1989)
" Platelet accumulation at the PTA site occurred with both doses of aspirin, with no differences between the two dosage groups."1.28Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries. ( Ahmadi, R; Dudczak, R; Ehringer, H; Jung, M; Koppensteiner, R; Leitha, T; Minar, E; Stümpflen, A, 1989)
"Thrombotic thrombocytopenic purpura is a severe multisystemic disorder of unknown origin."1.28Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura. ( Eldor, A; Ezra, Y; Mordel, N; Sadovsky, E; Schenker, JG, 1989)
"The frequency of a high-grade restenosis in patients with diabetes mellitus and coronary heart disease was not significantly increased, but supports the view that these are risk factors in the development of atherosclerotic changes in an operated carotid artery."1.28Late carotid restenosis: aetiologic factors for recurrent carotid artery stenosis during long-term follow-up. ( Haapanen, A; Harju, E; Jokela, H; Riekkinen, H; Salenius, JP, 1989)
"The reported recurrence rate is lower than comparable figures in published reports."1.27[Incidence of recurrence after successful transluminal coronary angioplasty]. ( Kaltenbach, M; Kober, G; Scherer, D; Schmidt-Moritz, A, 1983)
"The mean degree of stenosis was reduced from 77 +/- 12% to 29 +/- 15% and the mean systolic pressure gradient from 78 +/- 18 to 25 +/- 9 mmHg."1.27Role of percutaneous transluminal coronary angioplasty in patients with variant angina and coexistent coronary stenosis refractory to maximal medical therapy. ( Brücke, P; Herbinger, W; Leisch, F, 1984)
"A clinical diagnosis of systemic lupus erythematosus (SLE) was made in four women."1.27Lupus anticoagulant in pregnancy. ( Butler, WS; Liggins, GC; Lubbe, WF; Palmer, SJ, 1984)
" Dose-response platelet aggregometry detected no differences between groups in the sensitivity of platelets to adenosine diphosphate (ADP), collagen, and epinephrine."1.27Etiologic factors for recurrent carotid artery stenosis. ( Clagett, GP; Hutton, JE; McDonald, PT; Olson, DW; Rich, NM; Salander, JM; Youkey, JR, 1983)
"01)."1.27Analgesic ingestion and other factors preceding relapse in ulcerative colitis. ( McNeil, NI; Rampton, DS; Sarner, M, 1983)
"A higher recurrence rate after angioplasty is seen in the presence of a wall thrombus."1.27[Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis]. ( Lorenz, RL; Schramm, W; Theisen, K; Weber, MA, 1986)
"Therapy that will reduce acute platelet-thrombus deposition appears to be an important factor for reduction of restenosis."1.27Restenosis after arterial angioplasty: a hemorrheologic response to injury. ( Badimon, L; Chesebro, JH; Fuster, V; Lam, JY, 1987)
"This is a reangiography rate of 94%."1.27The Frankfurt experience in restenosis after coronary angioplasty. ( Bussmann, WD; Kaltenbach, M; Kober, G; Vallbracht, C, 1987)
"The observed restenosis rate is less than 50% of that reported by the PTCA registry of the NHLBI."1.27Recurrence rate after successful coronary angioplasty. ( Kaltenbach, M; Kober, G; Scherer, D; Vallbracht, C, 1985)
"An 18-month-old child with Kawasaki syndrome twice developed severe recurrence of symptoms when the acetylsalicylic acid (Aspirin) dosage was decreased from 80 mg/kg/day."1.27Relapsing Kawasaki's disease. ( Brady, S; Feild, C; Lowe, B, 1987)
"The hypotension was found to be refractory to intravenous fluids, dopamine, and antihistamines, but was immediately reversed by intravenous epinephrine."1.26Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. ( Oates, JA; Roberts, LJ; Turk, JW, 1982)
"Eight patients with transient ischemic attacks, and three with partial nonprogressive strokes associated with mitral valve prolapse, are reported."1.26TIA, stroke, and mitral valve prolapse. ( Watson, RT, 1979)
"Growing pains are recurrent limb pains peculiar to children."1.26Growing pains: fact or fiction? ( Calabro, JJ; Holgerson, WB; Repice, MM; Wachtel, AE, 1976)
"The factors that determine the recurrence rate of chronic gastric ulcer were studied in 105 patients."1.25Factors relevant to the prognosis of chronic gastric ulcer. ( Coupland, GA; Greig, M; Hobbin, E; Piper, DW; Shinners, J, 1975)

Research

Studies (1,237)

TimeframeStudies, this research(%)All Research%
pre-1990204 (16.49)18.7374
1990's336 (27.16)18.2507
2000's313 (25.30)29.6817
2010's308 (24.90)24.3611
2020's76 (6.14)2.80

Authors

AuthorsStudies
Bahit, MC1
Sacco, RL9
Easton, JD9
Meyerhoff, J2
Cronin, L3
Kleine, E2
Grauer, C4
Brueckmann, M4
Diener, HC15
Lopes, RD2
Brainin, M2
Lyrer, P2
Wachter, R1
Segura, T2
Granger, CB8
Dai, L2
Xu, J3
Yan, H1
Chen, Z4
Pan, Y7
Meng, X12
Li, H9
Wang, Y38
Merkler, AE1
Pearce, LA8
Kasner, SE8
Shoamanesh, A6
Birnbaum, LA1
Kamel, H2
Sheth, KN2
Sharma, R2
Lun, R1
Dhaliwal, S1
Zitikyte, G1
Roy, DC1
Hutton, B1
Dowlatshahi, D1
Santana-Mateos, M1
Medina-Gil, JM2
Saavedra-Santana, P1
Martínez-Quintana, E2
Rodríguez-González, F2
Tugores, A2
Mac Grory, B2
Piccini, JP1
Yaghi, S3
Poli, S2
De Havenon, A3
Rostanski, SK1
Weiss, M1
Xian, Y3
Johnston, SC14
Feng, W2
Chen, S1
Cai, D1
Lai, Y1
He, J1
Wu, Q1
Huang, P1
Zhou, L2
Sun, H2
Dominati, A1
Meyer, P1
Seebach, JD1
Ezquer, F2
Quintanilla, ME2
Morales, P2
Santapau, D2
Munita, JM1
Moya-Flores, F1
Ezquer, M2
Herrera-Marschitz, M2
Israel, Y2
Zhang, X1
Jing, J6
Zhao, X15
Liu, L17
Wang, A11
Wang, D7
Stanković, P1
Hoch, S1
Rudhart, S1
Stojković, S1
Wilhelm, T1
Akao, K1
Izumida, T1
Imamura, T1
Liu, JS2
Lee, CH1
Chuah, SK2
Tai, WC2
Chang, CC2
Chen, FJ1
Hankey, GJ8
Izcovich, A1
Caruso, D1
Tisi Baña, M1
Bottaro, F1
Pollán, J1
Saavedra, E1
Catalano, HN1
Santos, CD1
Matos, NL1
Asleh, R1
Dawit, S1
Rabinstein, AA1
O'Carroll, CB1
Li, Z3
Freeman, WD1
Kim, SM1
Jung, JM1
Kim, BJ3
Lee, JS4
Kwon, SU3
Vanassche, T1
Verhamme, P3
Anand, SS2
Shestakovska, O1
Fox, KA7
Bhatt, DL12
Avezum, A1
Alings, M1
Aboyans, V1
Maggioni, AP2
Widimsky, P3
Berkowitz, SD6
Yusuf, S5
Connolly, SJ6
Eikelboom, JW5
Bosch, J1
Wang, IK1
Yen, TH1
Guo, YC1
Sun, Y2
Lien, LM2
Chang, WL2
Chen, PL1
Yang, YC1
Sung, FC1
Hsu, CY2
Kwon, HS1
Lee, D1
Lee, MH1
Yu, S2
Lim, JS1
Yu, KH2
Oh, MS1
Hong, KS3
Lee, EJ1
Kang, DW2
Berríos-Cárcamo, P1
Olivares, B1
Yang, M1
Li, J8
Zhang, N3
Garg, S1
Chichareon, P1
Kogame, N1
Takahashi, K1
Modolo, R1
Tomaniak, M1
Fath-Ordoubadi, F1
Anderson, R1
Oldroyd, KG1
Stables, RH1
Kukreja, N1
Chowdhary, S1
Galasko, G1
Hoole, S1
Zaman, A1
Hamm, CW2
Steg, PG9
Jüni, P1
Valgimigli, M2
Windecker, S4
Onuma, Y1
Serruys, PW2
D'Ascenzo, F2
Gili, S2
Bertaina, M2
Iannaccone, M1
Cammann, VL1
Di Vece, D1
Kato, K1
Saglietto, A1
Szawan, KA1
Frangieh, AH1
Boffini, B1
Annaratone, M1
Sarcon, A1
Levinson, RA1
Franke, J1
Napp, LC1
Jaguszewski, M1
Noutsias, M1
Münzel, T1
Knorr, M1
Heiner, S1
Katus, HA2
Burgdorf, C1
Schunkert, H1
Thiele, H2
Bauersachs, J1
Tschöpe, C1
Pieske, BM1
Rajan, L1
Michels, G1
Pfister, R1
Cuneo, A1
Jacobshagen, C1
Hasenfuß, G1
Karakas, M1
Koenig, W1
Rottbauer, W1
Said, SM1
Braun-Dullaeus, RC2
Banning, A1
Cuculi, F1
Kobza, R1
Fischer, TA1
Vasankari, T1
Airaksinen, KEJ1
Opolski, G3
Dworakowski, R1
MacCarthy, P1
Kaiser, C1
Osswald, S1
Galiuto, L1
Crea, F3
Dichtl, W1
Franz, WM1
Empen, K1
Felix, SB1
Delmas, C1
Lairez, O1
El-Battrawy, I1
Akin, I1
Borggrefe, M2
Horowitz, JD1
Kozel, M1
Tousek, P1
Gilyarova, E1
Shilova, A1
Gilyarov, M1
Biondi-Zoccai, G1
Winchester, DE1
Ukena, C1
Neuhaus, M1
Bax, JJ1
Prasad, A1
Di Mario, C2
Böhm, M1
Gasparini, M1
Ruschitzka, F1
Bossone, E1
Citro, R1
Rinaldi, M2
De Ferrari, GM1
Lüscher, T1
Ghadri, JR1
Templin, C3
Paciaroni, M1
Ince, B1
Hu, B1
Jeng, JS2
Kutluk, K1
Lou, M1
Parfenov, V1
Wong, KSL3
Zamani, B1
Paek, D1
Min Han, J1
Del Aguila, M1
Girotra, S1
Liu, X4
Qiu, Y1
Yu, ED1
Xiang, S1
Meng, R2
Niu, KF1
Zhu, H1
Cacoub, P4
Schwier, NC3
Cornelio, CK1
Epperson, TM1
Schneider, DJ1
McMahon, SR1
Ehle, GL1
Chava, S1
Taatjes-Sommer, HS1
Meagher, S1
Platt, B1
Belarski, E1
Manaloor, J1
Ofner, S1
Carroll, AE1
John, CC1
Wood, JB1
García-Ropero, Á1
Vargas-Delgado, AP1
Santos-Gallego, CG1
Badimon, JJ1
Faggioni, M1
Redfors, B1
Crowley, A1
Claessen, BE1
Farhan, S1
Mastoris, I1
Witzenbichler, B1
Maehara, A1
Weisz, G1
Généreux, P1
Ben-Yehuda, O1
Mehran, R3
Kirtane, AJ1
Stone, GW3
Kwon, S1
Chan, AT1
Zuo, Z1
Lin, J7
You, J1
Guo, W1
Gao, L1
Geng, L1
Wang, X5
Wan, Q1
Zhang, Q3
Pu, Y2
Zou, X2
Atchaneeyasakul, K1
Liebeskind, DS1
Guo, J1
Wang, J2
Guo, Y2
Feng, J1
Randall, B1
Andersen, G1
Iversen, HK1
Roine, RO1
Sjostrand, C1
Rhodes, JF1
Søndergaard, L1
Cucchiara, B1
Elm, J1
Coutts, SB3
Willey, JZ1
Biros, MH1
Ross, MA1
Zhang, C3
Kleindorfer, DO1
Levitan, EB1
Howard, VJ1
Howard, G1
Soliman, EZ1
Richards, A1
Jackson, NJ1
Cheng, EM1
Bryg, RJ1
Brown, A1
Towfighi, A1
Sanossian, N1
Barry, F1
Li, N1
Vickrey, BG1
Egan, RA1
Arnold, AC1
Lee, AG1
Van Stavern, GP1
McKenna, MC1
Fanning, N1
Cronin, S1
Alexander, JH1
Wojdyla, D1
Vora, AN1
Thomas, L1
Goodman, SG2
Aronson, R1
Romoli, M1
Giannandrea, D1
Eusebi, P1
Cupini, LM1
Ricci, S2
Calabresi, P1
Gencer, B1
Li, XS1
Gurmu, Y2
Bonaca, MP3
Morrow, DA2
Cohen, M10
Storey, RF4
Johanson, P3
Wang, Z3
Hazen, SL1
Sabatine, MS3
Bar, M1
Bernstein, RA2
Donnan, G2
Gdovinová, Z1
Kleinig, TJ1
Martins, S1
Milling, T1
Pfeilschifter, W1
Reif, M1
Rose, DZ1
Šaňák, D1
Schäbitz, WR1
Mill, J1
Olivares, AL1
Arzamendi, D1
Agudelo, V1
Regueiro, A1
Camara, O1
Freixa, X1
Furtado, RHM1
Venkateswaran, RV1
Nicolau, JC1
Magnani, G2
Goto, S1
Dellborg, M3
Kamensky, G2
Isaza, D1
Aylward, P1
Weitz, JI5
Angiolillo, DJ2
Geisler, T1
Heitmeier, S1
Veltkamp, R3
Korompoki, E1
Sharma, M4
Toni, D5
Ameriso, SF4
Mundl, H5
Tatlisumak, T1
Lindgren, A2
Arauz, A4
Ozturk, S1
Muir, KW2
Chamorro, Á2
Perera, K2
Shuaib, A3
Rudilosso, S1
Hart, RG10
Verdoia, M1
Nardin, M1
Gioscia, R1
Negro, F1
Marcolongo, M1
Suryapranata, H1
Kedhi, E1
De Luca, G1
Amarenco, P3
Perera, KS2
Ntaios, G5
Lang, W1
Bereczki, D1
Uchiyama, S10
Yoon, BW1
Lavados, P1
Firstenfeld, A1
Mikulik, R3
Povedano, GP2
Ferrari, J1
Verma, SP1
Kumar, N1
Jain, M1
Tripathi, AK1
Lazaros, G3
Antonopoulos, AS2
Lazarou, E2
Vlachopoulos, C2
Vogiatzi, G1
Vassilopoulos, D2
Tousoulis, D2
Conway, J1
Friedman, BW1
Cameli, P1
D'Alessandro, M1
Bergantini, L1
Silvestri, E1
Romaldi, A1
Emmi, G2
Parronchi, P1
Bargagli, E1
Bulwa, Z1
Saleh Velez, FG1
Brorson, JR2
Pinto, CB1
Smith, EE1
Martí-Fàbregas, J4
Liu, YY1
O'Donnell, MJ1
Field, TS4
Santo, GC1
Olavarria, V1
Lutsep, H2
You, SC1
Rho, Y1
Bikdeli, B1
Kim, J2
Siapos, A1
Weaver, J1
Londhe, A1
Cho, J1
Park, J1
Schuemie, M1
Suchard, MA1
Madigan, D1
Hripcsak, G1
Gupta, A1
Reich, CG1
Ryan, PB1
Park, RW1
Krumholz, HM2
Ros-Castelló, V1
Natera-Villalba, E1
Gómez-López, A1
Sánchez-Sánchez, A1
Chico-García, JL1
García-Madrona, S1
Vera-Lechuga, R1
Matute-Lozano, C1
de Felipe Mimbrera, A1
Cruz-Culebras, A2
Alonso-Canovas, A1
Masjuan, J3
Lee, HL2
Kim, JT1
Park, MS1
Choi, KH1
Cho, KH2
Park, JM1
Kang, K1
Lee, SJ1
Kim, JG1
Cha, JK1
Kim, DH1
Park, TH1
Park, SS1
Lee, KB1
Lee, J3
Cho, YJ1
Park, HK2
Lee, BC3
Sun Oh, M1
Kim, DE1
Ryu, WS1
Choi, JC1
Kwon, JH2
Kim, WJ1
Shin, DI1
Sohn, SI1
Hong, JH1
Bae, HJ1
Aoki, J1
Iguchi, Y1
Urabe, T1
Yamagami, H1
Todo, K1
Fujimoto, S1
Idomari, K1
Kaneko, N1
Iwanaga, T1
Terasaki, T1
Tanaka, R1
Yamamoto, N1
Tsujino, A1
Nomura, K1
Abe, K2
Uno, M1
Okada, Y3
Matsuoka, H1
Yamagata, S1
Yamamoto, Y2
Yonehara, T1
Inoue, T1
Yagita, Y1
Kimura, K4
Espersen, J1
Weber, U1
Römer-Franz, A1
Lenarz, T1
Stolle, SRO1
Warnecke, A1
Wong, YS1
Tsai, CF1
Hsu, YH1
Ong, CT1
Lin, MP1
Meschia, JF1
Gopal, N1
Barrett, KM1
Ross, OA1
Ertekin-Taner, N1
Brott, TG1
Singh, S1
de Ronde, MWJ1
Creemers, EE1
Van der Made, I1
Meijering, R1
Chan, MY1
Hwee Tan, S1
Tang Chin, C1
Mark Richards, A1
Troughton, RW1
Yean Yip Fong, A1
Yan, BP1
Pinto-Sietsma, SJ1
Song, CG1
Bi, LJ1
Zhao, JJ1
Li, W2
Yang, F2
Jiang, W2
Toyoda, K3
Liou, CW2
Wong, LKS1
Taniguchi, A1
Urano, Y1
Bulwa, ZB1
Witte, KK1
Tsivgoulis, G2
Reynolds, MR1
Tsintzos, SI1
Eggington, S1
Ismyrloglou, E1
Lyon, J1
Huynh, M1
Egea, M1
de Brouwer, B1
Ziegler, PD1
Franco, N1
Joglekar, R1
Rosemas, SC1
Liu, S1
Thijs, V1
Sheriff, F1
Inam, ME1
Thanh Truong, VT1
Lopez-Rivera, V1
Lekka, E1
Kermali, K1
Sheth, S1
Maud, A1
Gupta, V1
Rodriguez, G1
Pedroza, C1
Chen, PR1
Rostanski, S1
Kvernland, A1
Furie, KL2
Kim, AS2
Henninger, N1
Blue, NR1
Page, JM1
Silver, RM2
Imazio, M11
Vasileiou, P1
Karavidas, A1
Toutouzas, K1
Tsioufis, C1
Lansberg, M1
Tirschwell, D1
Mistry, E1
Marques, C1
Hilkens, NA1
Algra, A7
Bath, PM5
Csiba, L1
Hacke, W3
Kappelle, LJ3
Koudstaal, PJ5
Leys, D2
Mas, JL4
Greving, JP1
Huynh, K1
Rao, Z2
Zheng, H2
Wang, F2
Dong, K3
Cao, Y3
Chan, FKL1
Ching, JYL1
Tse, YK3
Lam, K2
Wong, GLH1
Ng, SC3
Lee, V2
Au, KWL1
Cheong, PK2
Suen, BY1
Chan, H2
Kee, KM1
Lo, A2
Wong, VWS1
Wu, JCY1
Kyaw, MH1
Tolcher, MC1
Chu, DM1
Hollier, LM1
Mastrobattista, JM1
Racusin, DA1
Ramin, SM1
Sangi-Haghpeykar, H1
Aagaard, KM1
Majidi, S1
Leon Guerrero, CR1
Gandhy, S1
Burger, KM1
Sigounas, D1
Pareek, M1
Ten Berg, JM2
Kristensen, SD1
Grove, EL2
Bavry, AA1
Elgendy, IY1
Elbez, Y1
Mahmoud, AN1
Sorbets, E1
Shavadia, J1
Welsh, R1
Gershlick, A1
Zheng, Y1
Huber, K2
Halvorsen, S1
Van de Werf, F3
Armstrong, PW1
Kern, A1
Gil, RJ1
Bojko, K1
Sienkiewicz, E1
Januszko-Giergielewicz, B1
Górny, J1
Bil, J1
Çetin, İİ1
Ekici, F1
Kocabaş, A1
Çevik, BŞ1
Eminoğlu, S1
Azak, E1
Kibar, AE1
Arı, ME1
Sürücü, M1
Orgun, A1
Dunn, A1
Bazan, C2
Catanese, L1
McClure, LA4
Anderson, DC2
Kase, CS1
Benavente, OR7
Lee, M2
Saver, JL3
Rao, NM2
Wu, YL2
Ovbiagele, B6
Visser, L1
de Boer, MA1
de Groot, CJM1
Nijman, TAJ1
Hemels, MAC1
Bloemenkamp, KWM1
Bosmans, JE1
Kok, M1
van Laar, JO1
Sueters, M1
Scheepers, H1
van Drongelen, J1
Franssen, MTM1
Sikkema, JM1
Duvekot, HJJ1
Bekker, MN1
van der Post, JAM1
Naaktgeboren, C1
Mol, BWJ1
Oudijk, MA1
Ramotowski, B1
Żuk, A1
Budaj, A3
Albers, GW4
Denison, H2
Evans, SR2
Held, P2
Hill, MD2
Jonasson, J1
Ladenvall, P2
Minematsu, K5
Molina, CA3
Yelnik, CM1
Urbanski, G1
Drumez, E1
Caron, C1
Maillard, H1
Morell-Dubois, S1
Dubucquoi, S1
Launay, D1
Hachulla, E4
Hatron, PY2
Duhamel, A1
Lambert, M1
Galyfos, G1
Kerasidis, S1
Kastrisios, G1
Giannakakis, S1
Sachmpazidis, I1
Anastasiadou, C1
Geropapas, G1
Papapetrou, A1
Papacharalampous, G1
Maltezos, C1
Milionis, H1
Papavasileiou, V1
Spengos, K2
Manios, E2
Elisaf, M1
Vemmos, K2
Zhang, J3
Ming, T1
Cong, Y1
Li, F1
Taki, M1
Oshima, T1
Tozawa, K1
Taniguchi, Y1
Tomita, T1
Ohda, Y1
Fukui, H1
Watari, J1
Miwa, H1
Ielasi, A1
Campo, G1
Rapetto, C1
Varricchio, A1
Cortese, B1
Brugaletta, S1
Geraci, S1
Vicinelli, P1
Scotto di Uccio, F1
Secco, GG1
Poli, A1
Nicolini, E1
Ishida, K1
Latib, A1
Tespili, M1
Ahn, S1
Min, SK1
Ha, J1
Min, SI1
Kim, SY1
Cho, MJ1
Cho, S1
Gaita, F4
Subahi, A1
Hassan, AAI1
Abubakar, H1
Ibrahim, W1
Oza, R1
Rundell, K1
Garcellano, M1
Ahmadi, M1
Abdolmohammadi-Vahid, S1
Ghaebi, M1
Aghebati-Maleki, L1
Dolati, S1
Farzadi, L1
Ghasemzadeh, A1
Hamdi, K1
Younesi, V1
Nouri, M1
Yousefi, M1
Kim, JB1
Choi, BG1
Rha, SW1
Seo, HS1
Choi, SY1
Byun, JK1
Na, JO1
Choi, CU1
Kim, EJ1
Park, CG1
Oh, DJ1
Kawai, T1
Oda, K1
Funao, N1
Nishimura, A1
Matsumoto, Y1
Mizokami, Y1
Ashida, K1
Sugano, K1
Mager, A1
Talmor, Y1
Chezar Azzerad, C1
Iakobishvili, Z1
Porter, A1
Kornowski, R4
Hasdai, D2
Aoki, T2
Yamada, A1
Hirata, Y1
Suzuki, H2
Nakada, A1
Niikura, R2
Seto, M1
Okamoto, M1
Koike, K1
Robertson, L1
Yeoh, SE1
Ramli, A1
Woodhouse, LJ1
Appleton, JP1
Beridze, M1
Christensen, H1
Dineen, RA1
Duley, L1
England, TJ1
Flaherty, K1
Havard, D1
Heptinstall, S1
James, M1
Krishnan, K1
Markus, HS3
Montgomery, AA1
Pocock, SJ2
Randall, M1
Ranta, A1
Robinson, TG1
Scutt, P1
Venables, GS2
Sprigg, N1
Antigüedad-Muñoz, J1
de la Riva, P1
Arenaza Choperena, G1
Muñoz Lopetegi, A1
Andrés Marín, N1
Fernández-Eulate, G1
Moreno Valladares, M1
Martínez Zabaleta, M1
Liu, SM1
Zhao, WL1
Song, HQ1
Li, SJ1
Ren, CH1
Ji, XM1
Feng, WW1
Bauersachs, R3
Lakha, S1
Png, CYM1
Chun, K1
Ting, W1
Tanaskovic, S1
Radak, D1
Aleksic, N1
Calija, B1
Maravic-Stojkovic, V1
Nenezic, D1
Ilijevski, N1
Popov, P1
Vucurevic, G1
Babic, S1
Matic, P1
Gajin, P1
Vasic, D1
Rancic, Z1
Wangqin, R1
Grimaldi-Bensouda, L1
Danchin, N4
Dallongeville, J1
Falissard, B1
Furber, A1
Cottin, Y1
Bonello, L2
Morel, O1
Leclercq, F1
Puymirat, E1
Ghanem, F1
Delarche, N1
Benichou, J1
Abenhaim, L1
Moll, F1
Baumgartner, I2
Jaff, M1
Nwachuku, C1
Tangelder, M1
Ansel, G1
Adams, G1
Zeller, T3
Rundback, J1
Grosso, M1
Lin, M1
Mercur, MF1
Minar, E5
Prins, MH1
Lensing, AWA1
Prandoni, P4
Wells, PS3
Beyer-Westendorf, J2
Bounameaux, H4
Brighton, TA3
Cohen, AT2
Davidson, BL2
Decousus, H1
Kakkar, AK1
van Bellen, B2
Pap, AF1
Homering, M1
Tamm, M1
Brucato, A3
Cantarini, L1
Di Lenarda, A1
Gattorno, M1
Lopalco, G1
Marcolongo, R2
Martini, A1
Prisco, D1
Belcaro, G3
Dugall, M3
Hu, S3
Feragalli, B3
Cotellese, R2
Ledda, A2
Corsi, M2
Ricci, A2
Ippolito, E2
Errichi, BM1
Cornelli, U2
Cesarone, MR2
Hosoi, M3
Kalantzi, KI1
Ntalas, IV1
Chantzichristos, VG1
Tsoumani, ME1
Adamopoulos, D1
Asimakopoulos, C1
Bourdakis, A1
Darmanis, P1
Dimitriadou, A1
Gkiokas, S1
Ipeirotis, K1
Kitikidou, K1
Klonaris, I1
Kostaki, A1
Logothetis, D1
Mainas, K1
Mais, T1
Maragiannis, A1
Martiadou, K1
Mavronasos, K1
Michelongonas, I1
Mitropoulos, D1
Papadimitriou, G1
Papadopoulos, A1
Papaioakeim, M1
Sofillas, K1
Stabola, S1
Stefanakis, E1
Stergiou, D1
Thoma, M1
Zenetos, A1
Zisekas, S1
Goudevenos, JA1
Panagiotakos, DB1
Tselepis, AD1
Lee, Y1
Park, HC1
Shin, J1
De Stefano, V1
Finazzi, G3
Barbui, T2
Dimitroulis, D1
Golabkesh, M1
Naguib, D1
Knoop, B1
Dannenberg, L1
Helten, C1
Pöhl, M1
Jung, C1
Kelm, M2
Zeus, T1
Polzin, A1
Khan, SU1
Talluri, S1
Rahman, H1
Lekkala, M1
Khan, MS1
Riaz, H1
Shah, H3
Kaluski, E1
Sattur, S1
Chen, G1
Ma, C1
Li, X1
Wang, Q1
Xu, Q1
Lv, Q1
Can, A1
Rudy, RF1
Castro, VM1
Dligach, D1
Finan, S1
Gainer, V1
Shadick, NA1
Savova, G1
Murphy, S1
Cai, T1
Weiss, ST1
Du, R1
Grazzi, L1
Grignani, E1
D'Amico, D1
Sansone, E1
Raggi, A1
Palareti, G1
Poli, D1
Malinova, LI1
Furman, NV1
Dolotovskaya, PV1
Chernousova, LA1
Denisova, TP1
Chi, NF1
Wen, CP1
Liu, CH1
Li, JY1
Chen, CH1
Lin, CH1
Hu, CJ1
Murphy, SJX1
Naylor, AR2
Ricco, JB1
Sillesen, H1
Kakkos, S1
Halliday, A1
de Borst, GJ1
Vega de Ceniga, M1
Hamilton, G1
McCabe, DJH1
Kheiri, B1
Osman, M1
Abdalla, A1
Haykal, T1
Swaid, B1
Ahmed, S1
Chahine, A1
Hassan, M1
Bachuwa, G1
Al Qasmi, M1
Zomer, E1
Si, S1
Hird, TR1
Liew, D1
Owen, AJ1
Tonkin, A1
Reid, CM1
Ademi, Z1
Wojcieszek, AM1
Shepherd, E1
Middleton, P1
Lassi, ZS1
Wilson, T1
Murphy, MM1
Heazell, AE1
Ellwood, DA1
Flenady, V1
Hao, Q2
Tampi, M1
O'Donnell, M2
Foroutan, F1
Siemieniuk, RA1
Guyatt, G2
Prasad, K1
Siemieniuk, R1
Lytvyn, L1
Heen, AF1
Agoritsas, T1
Vandvik, PO1
Gorthi, SP1
Fisch, L1
Jusufovic, M1
Muller, J1
Booth, B1
Horton, E1
Fraiz, A1
Siemieniuk, J1
Fobuzi, AC1
Katragunta, N1
Rochwerg, B1
Salido, L1
DeFelipe, A1
Hernández-Antolín, R1
Fernández-Golfín, C1
Matute, C1
Vera, R1
Pérez-Torre, P1
Zamorano, JL1
Berchie, PO1
Sarfo, FS1
Opare-Sem, OK1
Kamenova, M3
Mueller, C1
Coslovsky, M1
Guzman, R1
Mariani, L3
Soleman, J3
Coppens, M1
Eikelboom, JWA1
Chen, W2
Simon, T1
Wutzler, A1
Krogias, C1
Grau, A1
Heuschmann, PU1
Haeusler, KG2
Pluymaekers, N1
Tombetti, E1
Rampello, S1
Maestroni, S1
Lucianetti, M1
Valenti, A1
Adler, Y2
Knutsson, M1
Röther, J1
Melis, M1
Levi, C1
King, A1
Madigan, J1
Norris, J1
Chan, NC1
Fioravanti, F1
Bongiovanni, F1
Raposeiras-Roubin, S1
Abu-Assi, E1
Kinnaird, T1
Ariza-Solé, A1
Manzano-Fernández, S1
Velicki, L1
Xanthopoulou, I1
Cerrato, E1
Rognoni, A1
Boccuzzi, G1
Omedè, P1
Montabone, A1
Taha, S1
Durante, A1
Autelli, M1
Grosso, A1
Blanco, PF1
Garay, A1
Quadri, G1
Varbella, F1
Queija, BC1
Paz, RC1
Fernández, MC1
Pousa, IM1
Gallo, D1
Morbiducci, U1
Dominguez-Rodriguez, A1
Valdés, M1
Cequier, A1
Alexopoulos, D1
Iñiguez-Romo, A1
Lüscher, TF1
Ma, Y1
Liu, Y3
Du, F1
Healey, JS1
Gladstone, DJ1
Swaminathan, B1
Eckstein, J1
Epstein, AE1
Pagola, J1
Yang, X3
Endres, M1
Karlinski, M1
Czlonkowska, A3
Santo, G1
Bradford, HD1
Gizzi, C2
Rodriguez, P2
Xie, X1
Laskowitz, DT2
Miao, Z1
Kong, T1
Chen, J2
Sun, K1
Zhang, W2
Song, L1
Hui, R1
Kreuzer, J1
Cotton, D3
Chernyatina, M1
Ferro, JM1
Grond, M1
Kallmünzer, B1
Krupinski, J2
Lemmens, R1
Odinak, M1
Schellinger, PD1
Sato, K1
Sasaki, R1
Ohta, Y1
Takemoto, M1
Hishikawa, N1
Yamashita, T1
Veltkamp, RC1
Sheridan, P1
Bangdiwala, SI1
Gagliardi, RJ1
Peters, G1
Imberti, D1
Pomero, F1
Mastroiacovo, D1
Im, KA1
Oude Ophuis, T1
Hamm, C2
Spinar, J1
Kiss, RG1
Lopez-Sendon, J1
Ardissino, D1
Kontny, F1
Montalescot, G2
Bengtsson, O1
Himmelmann, A1
Braunwald, E4
Wester, A1
Attar, R1
Mohammad, MA1
Andell, P1
Hofmann, R1
Jensen, J1
Szummer, K1
Erlinge, D1
Koul, S1
Ringelstein, A1
Schlamann, M1
Goericke, SL1
Mönninghoff, C1
Sandalcioglu, IE1
El Hindy, N1
Forsting, M2
Wanke, I1
Fruth, K1
Pogorzelski, B1
Schmidtmann, I1
Springer, J1
Fennan, N1
Fraessdorf, N1
Boessert, A1
Schaefer, D1
Gosepath, J2
Mann, WJ2
Duytschaever, M1
Berte, B1
Acena, M1
De Meyer, G1
Bun, SS1
Van Heuverswyn, F1
Vandekerckhove, Y1
Tavernier, R1
Lilly, LS1
Kim, SJ1
Bang, OY1
Iida, O1
Yokoi, H1
Soga, Y1
Inoue, N1
Suzuki, K3
Yokoi, Y1
Kawasaki, D1
Zen, K2
Urasawa, K1
Shintani, Y1
Miyamoto, A1
Hirano, K1
Miyashita, Y2
Tsuchiya, T1
Shinozaki, N1
Nakamura, M1
Isshiki, T2
Hamasaki, T1
Nanto, S1
Mainali, NR1
Aryal, MR1
Pradhan, R1
Hope, EJ1
Pullicino, PM2
Thompson, JL3
Sanford, AR1
Qian, M2
Teerlink, JR2
Haddad, H1
Diek, M1
Freudenberger, RS1
Labovitz, AJ2
Di Tullio, MR4
Lok, DJ2
Ponikowski, P2
Anker, SD2
Graham, S2
Mann, DL1
Mohr, JP6
Homma, S5
Castellucci, LA1
Cameron, C1
Le Gal, G1
Rodger, MA1
Coyle, D1
Clifford, T1
Gandara, E1
Wells, G1
Carrier, M1
Pourrat, O1
Neau, JP1
Pouget-Abadie, JF1
Pierre, F1
Strobl, FF1
Brechtel, K1
Schmehl, J1
Reiser, MF1
Claussen, CD1
Tepe, G1
Varenhorst, C1
Jensevik, K1
Jernberg, T1
Sundström, A1
Hasvold, P1
Held, C1
Lagerqvist, B1
James, S1
Castilla-Guerra, L1
Navas-Alcántara, MS1
Fernández-Moreno, MC1
Nosul, M1
Kolb, GF1
Pergolini, A1
Pino, PG1
Zampi, G1
Polizzi, V1
Musumeci, F1
Butterfield, JH1
Weiler, CR1
Arruti, M1
Aldazabal, M1
Blanco, A1
Piñeiro, L1
Zapico, MS1
González, F1
López de Munain, A1
Diez-Ewald, M1
Rotondano, G1
Cipolletta, L1
Koch, M2
Bianco, MA1
Grossi, E1
Marmo, R1
Pumar, JM1
Banguero, A1
Arias-Rivas, S1
Blanco, M2
Rodríguez-Yáñez, M1
Sucasas, P1
Castiñeira-Mourenza, JA1
Vázquez-Herrero, F1
Tai, WA1
Alvarez-Sabín, J1
Quintana, M1
Santamarina, E1
Maisterra, O1
Garay-Sánchez, P1
Limiñana, JM1
Saavedra, P1
Elkind, MS1
Luna, JM1
Zhang, Y2
Coffey, CS2
Roldan, A1
Del Brutto, OH1
Pretell, EJ1
Pettigrew, LC1
Meyer, BC1
Tapia, J2
White, C1
Palmer, WC1
Kurklinsky, A1
Lane, G1
Ussavarungsi, K1
Blackshear, JL1
Abu Daya, H1
Eloubeidi, M1
Tamim, H1
Halawi, H1
Malli, AH1
Rockey, DC1
Barada, K1
Chen, CY1
Lee, KT1
Lee, CT1
Lai, WT1
Huang, YB1
Yi, X2
Wang, C7
Zhang, B1
Chi, W1
Vranckx, P1
Leonardi, S2
Tebaldi, M1
Biscaglia, S1
Parrinello, G1
Rao, SV1
Lai, YS1
Yang, LT1
Kao Yang, YH1
Liu, PY1
Censori, B1
Nagata, N1
Shimbo, T1
Tanaka, S2
Sekine, K1
Kishida, Y1
Watanabe, K1
Sakurai, T1
Yokoi, C1
Akiyama, J1
Yanase, M1
Mizokami, M1
Uemura, N1
Blake, DM1
Vazquez, A2
Tomovic, S1
Jyung, RW1
Mekinian, A1
Costedoat-Chalumeau, N1
Masseau, A1
Botta, A1
Chudzinski, A1
Theulin, A1
Emmanuelli, V1
De Carolis, S1
Revaux, A1
Nicaise, P1
Cornelis, F1
Subtil, D1
Montestruc, F1
Bucourt, M1
Chollet-Martin, S1
Carbillon, L1
Fain, O1
Davidai, G1
Gorelick, P1
Lipton, RB1
Sacco, R1
Boelman, C1
Shroff, M1
Yau, I1
Bjornson, B1
Richrdson, S1
deVeber, G2
MacGregor, D1
Moharir, M1
Askalan, R1
Iwakiri, R1
Higuchi, K2
Kato, M1
Fujishiro, M1
Kinoshita, Y3
Watanabe, T2
Takeuchi, T2
Yamauchi, M1
Sanomura, M1
Nakagawa, H1
Sugisaki, N1
Ogawa, H2
Arakawa, T2
Fujimoto, K2
Poujol-Robert, A1
Boëlle, PY1
Conti, F1
Durand, F1
Duvoux, C1
Wendum, D1
Paradis, V1
Mackiewicz, V1
Chazouillères, O1
Corpechot, C1
Poupon, R1
Simes, J1
Becattini, C1
Agnelli, G1
Kirby, AC1
Mister, R1
Alabed, S1
Cabello, JB1
Irving, GJ1
Qintar, M1
Burls, A1
Undas, A1
Brummel-Ziedins, K1
Mann, KG1
Rubattu, S1
De Giusti, M1
Farcomeni, A1
Abbolito, S1
Comito, F1
Cangianiello, S1
Greco, ES1
Dito, E1
Pagliaro, B1
Cotugno, M1
Stanzione, R1
Marchitti, S1
Bianchi, F1
Di Castro, S1
Battistoni, A1
Burocchi, S1
Caprinozzi, M1
Pierelli, G1
Sciarretta, S1
Volpe, M1
Mutlu, I1
Mutlu, MF1
Biri, A1
Bulut, B1
Erdem, M1
Erdem, A1
Freudenberger, R1
Mann, D1
Lip, GY2
Estol, CJ1
Levin, B1
Hong, MJ1
Lee, SY1
Kim, JH4
Sung, IK1
Park, HS1
Shim, CS1
Jin, CJ1
Tissandier, C1
Lang, M1
Lusson, JR1
Bœuf, B1
Merlin, E1
Dauphin, C1
Rajani, AR1
Mahmoud, WE1
Murugesan, V1
BinBrek, AS1
Lee, HC1
Lee, JD1
Chang, KC1
Wu, CY1
Lee, TH1
Wang, HH1
Shim, KN1
Song, EM1
Jeen, YT1
Kim, JO1
Jeon, SR1
Chang, DK1
Song, HJ1
Lim, YJ1
Kim, JS2
Ye, BD1
Park, CH1
Jeon, SW2
Cheon, JH1
Lee, KJ1
Jang, BI1
Moon, JS1
Chun, HJ1
Choi, MG1
Hoshino, H1
Origasa, H1
Naritomi, H1
Yamaguchi, T1
Wu, C2
Alotaibi, GS1
Alsaleh, K1
Linkins, LA1
McMurtry, MS1
Bazina, A1
Mišmaš, A1
Hucika, Z1
Pavliša, G1
Poljaković, Z1
Zheng, YM1
Xie, CH1
Gong, FQ1
Aldemir-Kocabaş, B1
Kcal, MM1
Ramoğlu, MG1
Tutar, E1
Fitöz, S1
Çiftçi, E1
İnce, E1
Zheng, M1
Li, Y2
Zhang, L2
Shang, X1
Yan, C1
Coons, JC1
Rao, SK1
Kwok, CS1
Copley, HC1
Myint, PK1
Loke, YK1
Boonyawat, K1
Crowther, MA2
Abdel-Rahman, I1
Murphy, C1
Shore, S1
Jones, PG1
Maddox, TM1
Bradley, SM1
Stolker, JM1
Arnold, SV1
Parashar, S1
Peterson, P1
Spertus, J1
Ho, PM1
Chen, T1
Xu, G1
Tan, D1
Asinger, RW2
Smyth, NG1
De, SK1
Lefaucheur, R1
Bourre, B1
Ozkul-Wermester, O1
Maltête, D1
Wallon, D1
Telaku, S1
Kraja, B1
Qirjako, G1
Prifti, S1
Fejza, H1
Valenzuela, A1
Aizman, A1
Luzzi, R1
Holberg, G1
Kakkar, A1
Lensing, AW1
Prins, M1
Haskell, L1
Wei, YQ1
Wang, DG1
Yang, H1
Cao, H1
Gary, T1
Prüller, F1
Raggam, R1
Mahla, E1
Eller, P1
Hafner, F1
Brodmann, M1
Satoh, K1
Tanabe, H1
Ichiishi, E1
Ando, K1
Chung, WC1
Jeon, EJ1
Kim, DB1
Sung, HJ1
Kim, YJ1
Lim, ES1
Kim, MA1
Oh, JH1
Alnæs, MS1
Mardal, KA1
Bakke, S1
Sorteberg, A1
Shin, S1
Kim, KJ1
Cho, IJ1
Hong, GR1
Jang, Y2
Chung, N1
Rah, YM1
Chang, HJ2
Batchelder, A1
Hunter, J1
Cairns, V1
Sandford, R1
Munshi, A1
Kim, SH1
Jung, JT1
Kwon, JG1
Kim, EY1
Lee, DW1
Park, KS1
Lee, SH4
Park, JB1
Ha, CY1
Park, YS2
Wong, KS3
Leng, X1
Soo, Y1
Li-Sha, G1
Peng, C1
Yue-Chun, L1
Vergallo, R1
Aguirre, AD1
Abtahian, F1
Minami, Y1
Soeda, T1
Chatzizisis, YS1
Croce, K1
Jang, IK2
Mayumi, N1
Inaba, M1
Igarashi, T1
Katagiri, I1
Kawana, S1
Bai, Y1
Han, J1
Zhang, G1
Zhao, G1
Kim, YS1
Lee, SR1
Lanas, Á2
Christiansen, CB1
Pallisgaard, J1
Gerds, TA1
Olesen, JB2
Jørgensen, ME1
Numé, AK1
Carlson, N1
Kristensen, SL1
Gislason, G1
Torp-Pedersen, C3
Odden, MC1
Sawaya, BP1
White, CL1
Peralta, CA1
Pergola, PE1
Marik, PE1
Cavallazzi, R1
Yu, LH1
Wang, DX1
Li, YH1
Lu, QA1
Zong, SJ1
Wang, XC1
Lee, JY1
Moon, IT1
Lee, HY1
Han, DS1
Park, TK1
Song, YB1
Ahn, J1
Carriere, KC1
Hahn, JY1
Yang, JH1
Choi, SH1
Choi, JH1
Gwon, HC1
Shahidi, S1
Owen-Falkenberg, A1
Gottschalksen, B1
Ellemann, K1
van Hoorn, ME1
Hague, WM1
van Pampus, MG1
Bezemer, D1
de Vries, JI2
Radovanovic, D1
Maurer, L1
Bertel, O1
Witassek, F1
Urban, P2
Stauffer, JC1
Pedrazzini, G1
Erne, P1
Murphy, SJ1
Coughlan, CA1
Tobin, O1
Kinsella, J1
Lonergan, R1
Gutkin, M1
McCabe, DJ1
Yang, C2
Qian, J1
Tang, X2
Gao, P2
Hu, Y2
Parker, WA1
Beato, J1
Fígueira, L1
Penas, S1
Santos-Silva, R1
Falcão, M1
Carneiro, Â1
Reis, FF1
Wilson, LK1
Dake, MD1
Ansel, GM1
Jaff, MR1
Ohki, T1
Saxon, RR1
Smouse, HB1
Machan, LS1
Snyder, SA1
O'Leary, EE1
Ragheb, AO1
Ge, F1
Lin, H1
Li, M1
Guo, R1
Ruan, Z1
Chang, T1
Ayub, A1
Parkash, O1
Naeem, B1
Murtaza, D1
Khan, AH1
Jafri, W1
Hamid, S1
Bernlochner, I1
Jaitner, J1
Fries, V1
Dommasch, M1
Mayer, K1
Ott, I1
Langwieser, N1
Fusaro, M1
Laugwitz, KL1
Kastrati, A3
Ibrahim, T1
Weller, CD1
Barker, A1
Darby, I1
Haines, T1
Underwood, M1
Ward, S1
Aldons, P1
Dapiran, E1
Madan, JJ1
Loveland, P1
Sinha, S1
Vicaretti, M1
Wolfe, R1
Woodward, M1
McNeil, J1
Nagatsuka, K1
Miyata, S1
Kada, A1
Kawamura, A1
Nakagawara, J1
Furui, E1
Takiuchi, S1
Taomoto, K1
Kario, K1
Saito, K2
Nagao, T1
Kitagawa, K1
Hosomi, N1
Tanaka, K2
Kaikita, K1
Katayama, Y1
Abumiya, T1
Nakane, H1
Wada, H2
Hattori, A2
Nishikawa, M1
Yamawaki, T1
Yonemoto, N1
Okada, H1
Miyata, T1
Birkeland, P1
Lauritsen, J1
Poulsen, FR1
Charron, P1
Holzgreve, H1
Chan, FK3
Leung Ki, EL1
Wong, GL1
Ching, JY3
Au, KW1
Wu, JC3
Zhang, F1
Rothwell, PM3
Norrving, B2
Mehta, Z1
Kamal, S1
Khan, MA1
Altorok, N1
Gallego-Fabrega, C1
Carrera, C1
Reny, JL3
Fontana, P3
Slowik, A1
Pera, J1
Pezzini, A1
Serrano-Heras, G1
Bin Dukhyil, AA1
Muiño, E1
Cullell, N1
Montaner, J1
Fernandez-Cadenas, I1
Zhang, YQ1
Wei, CL1
Hu, YH1
Kraszewska-Głomba, B1
Kuchar, E1
Szenborn, L1
Savino, K1
Maiello, M1
Pelliccia, F1
Ambrosio, G1
Palmiero, P1
Deng, QQ1
Tang, J1
Chen, C3
Markus, H1
Huang, YN1
Zhao, H1
Ratanakorn, D1
Fu, JH1
Packard, KA1
Hilleman, DE1
Lutz, K2
Schaedelin, S1
Fandino, J2
Godley, RW1
Hernandez-Vila, E1
Liang, CM1
Hsu, CN1
Yang, SC1
Wu, CK1
Shih, CW1
Ku, MK1
Yuan, LT1
Wang, JW1
Tseng, KL1
Sun, WC1
Hung, TH1
Nguang, SH1
Hsu, PI1
Wu, DC1
He, Y1
Kyaw, M1
Tanigawa, T1
Naito, Y1
Lui, R1
Tang, RS1
Sakata, Y1
Handa, O1
Nebiki, H1
Abe, T1
Mishiro, T1
Cosmi, B1
Rosenberg, K1
Ferri, LA1
Morici, N1
Grosseto, D1
Tortorella, G1
Bossi, I1
Sganzerla, P1
Cacucci, M1
Sibilio, G1
Tondi, S1
Toso, A1
Ferrario, M1
Gandolfo, N1
Ravera, A1
Mariani, M1
Corrada, E1
Di Ascenzo, L1
Petronio, AS2
Cavallini, C1
Moffa, N1
De Servi, S1
Savonitto, S1
Kang, X1
Wang, T1
He, L1
Xu, H1
Liu, Z1
Zhao, A1
Bank, S1
Maiti, S1
Guha, S1
Sinha, AK1
Zhang, T1
Jin, SS1
Yang, RL1
Wang, XD1
Jiang, N1
Gan, YH1
Kou, XX1
Zhou, YH1
Hauguel-Moreau, M1
Boccara, F2
Boyd, A1
Salem, JE1
Brugier, D1
Curjol, A1
Hulot, JS1
Kerneis, M1
Galier, S1
Cohen, A2
Collet, JP1
Silvain, J1
Song, H1
Hou, C1
Cao, Q1
Huang, X1
Wang, M1
Ji, X1
Nevzati, E1
Dolp, A1
Battaglia, A1
Gaido, L1
Skeith, L1
Rodger, M1
Sheikh Rezaei, S1
Geroldinger, A1
Heinze, G1
Reichardt, B1
Wolzt, M1
Li, XG1
Ma, N1
Sun, SS1
Xu, Z1
Wang, YJ1
Miao, ZR1
Zhao, ZG1
Lin, Y1
Ou, L1
Crescente, M2
Di Castelnuovo, A2
Iacoviello, L2
de Gaetano, G2
Cerletti, C2
Stern, S1
Cohen, MJ1
Gilon, D2
Leshno, M1
Brezis, M1
Diener, C1
Kauffman, AB1
Delate, T1
Olson, KL1
Cymbala, AA1
Hutka, KA1
Kasten, SL1
Rasmussen, JR1
Ibrahim, K1
Hass, N1
Kolschmann, S1
Strasser, RH1
Barton, JR1
Sibai, BM1
Mateen, FJ1
Mohr, DN1
Hoover, PL1
Mold, JW1
Rozsasi, A1
Polzehl, D1
Deutschle, T1
Smith, E1
Wiesmiller, K1
Riechelmann, H1
Keck, T1
Suri, MF1
Hussein, HM1
Abdelmoula, MM1
Divani, AA1
Qureshi, AI1
Stammler, F1
Grau, C1
Eckstein, HH1
Jackevicius, CA1
Tu, JV1
Demers, V1
Melo, M1
Cox, J1
Rinfret, S1
Kalavrouziotis, D1
Johansen, H1
Behlouli, H1
Newman, A1
Pilote, L1
van der Worp, HB1
Fonville, S1
Ramos, LM1
Rinkel, GJ1
Bernstein, PL1
Jacobson, BF1
Connor, MD1
Becker, PJ1
Mehta, SR1
Bassand, JP1
Chrolavicius, S1
Diaz, R1
Jolly, S1
Rupprecht, HJ2
Suryadevara, S1
Capranzano, P1
Zenni, MZ1
Guzman, LA1
Bass, TA3
Turan, TN1
Maidan, L1
Cotsonis, G1
Lynn, MJ2
Romano, JG1
Levine, SR1
Chimowitz, MI2
Hanhart, J1
Koskas, P1
Obadia, M1
Le Mer, Y1
Sahel, JA1
Paques, M1
Cartwright, MS1
White, DL1
Miller, LM1
Roach, ES1
Bevilacqua, S1
Alkodami, AA1
Volpi, E1
Cerillo, AG1
Berti, S1
Glauber, M1
Gianetti, J2
Sugiyama, N1
Matsuda, S1
Shimizu, M1
Obara, S1
Ikegami, M1
Yokoyama, J1
Takizawa, S1
Takagi, S1
De Labriolle, A1
Lemesle, G2
Steinberg, DH1
Roy, P1
Torguson, R1
Suddath, WO1
Satler, LF2
Kent, KM5
Pichard, AD2
Waksman, R2
van den Bergh, PJ1
Kievit, PC2
Brouwer, MA2
Aengevaeren, WR1
Veen, G3
Verheugt, FW8
Butera, G1
Gaio, G1
Carminati, M1
Chung, HY1
Trendell-Smith, NJ1
Yeung, CK1
Mok, MY1
Georgiadis, D2
Arnold, M3
von Buedingen, HC1
Valko, P1
Sarikaya, H1
Rousson, V1
Mattle, HP3
Bousser, MG2
Baumgartner, RW3
Laalou, FZ1
Kuntzmann, H1
Mahoudeau, G1
Kremer, S1
Pain, L1
Aidietis, A1
Barysiene, J1
Marinskis, G1
Aidietiene, S1
Kaireviciūte, D1
Jurkuvenas, P1
Aganauskiene, J1
Bagdonas, K1
Jezovas, V1
Laucevicius, A1
Famakin, BM1
Stern, BJ1
George, MG1
Rocher, F1
Brunschwig, C1
Lebrun, C1
Bischoff, A1
Chiu, PW2
Ng, EK1
Beales, IL1
Yamasaki, H1
Matsubara, S2
Sasaki, I1
Nagahiro, S1
Balasubramanian, S1
Ganesh, R1
Szczeklik, A1
Shetty, S1
Ghosh, K1
Mega, JL1
Mohanavelu, S1
Burton, P1
Poulter, R1
Misselwitz, F1
Hricak, V1
Barnathan, ES1
Bordes, P1
Witkowski, A2
Markov, V1
Oppenheimer, L1
Gibson, CM1
Bonvini, RF1
Barazer, I1
Berdagué, P1
de Moerloose, P1
Schved, JF1
Gris, JC1
Najafi, L1
Noohi, AH1
Renard, E1
Chiquet, C1
Bouillet, L1
Romanet, JP1
Po, HL2
Lin, YJ1
Hseuh, IH1
Heestermans, AA1
Van Werkum, JW1
Dill, T1
Gosselink, AT1
De Boer, MJ2
Van Houwelingen, G1
Hoorntje, JC1
Koopmans, PC1
Van 't Hof, AW1
Kurosawa, H1
Okuya, M1
Matsushita, T1
Kubota, T1
Endoh, K1
Kuwashima, S1
Hagisawa, S1
Sato, Y1
Fukushima, K1
Sugita, K1
Park, MJ1
Hayashi, Y1
Arisaka, O1
Attigah, N1
Külkens, S1
Deyle, C1
Ringleb, P1
Hartmann, M1
Geisbüsch, P1
Böckler, D1
Cheung, J1
Rajala, J1
Moroz, D1
Zhu, Q1
Stamm, M1
Sandha, GS1
Weber, R2
Weimar, C1
Lee, CW3
Park, DW1
Kim, YH1
Hong, MK4
Kim, JJ4
Park, SW3
Yun, SC1
Seong, IW1
Lee, JH1
Lee, NH2
Cho, YH1
Cheong, SS1
Lim, DS1
Yang, JY1
Lee, SG1
Kim, KS1
Yoon, J1
Jeong, MH3
Seung, KB1
Hong, TJ1
Park, SJ3
Jung, H1
Papi, C1
Aratari, A1
Moretti, A1
Mangone, M1
Margagnoni, G1
Capurso, L1
Barkun, AN2
Bardou, M1
Sung, JJ1
Lau, JY1
Lee, YT1
Leung, VK1
Wong, VW1
Sharma, RK1
Reddy, HK1
Singh, VN2
Voelker, DJ1
Bhatt, G1
Sørensen, R1
Hansen, ML1
Abildstrom, SZ1
Hvelplund, A1
Andersson, C1
Jørgensen, C1
Madsen, JK2
Hansen, PR2
Køber, L2
Gislason, GH2
Juhász, M1
Herszényi, L1
Tulassay, Z1
Le May, MR1
Wells, GA1
Glover, CA1
So, DY1
Froeschl, M1
Marquis, JF1
O'Brien, ER1
Turek, M1
Thomas, A1
Kass, M1
Jadhav, S1
Labinaz, M1
Kim, SS1
Kim, HK1
Kim, MC1
Lee, MG2
Ko, JS2
Park, KH2
Sim, DS2
Yoon, NS2
Yoon, HJ2
Park, HW2
Hong, YJ2
Ahn, YK1
Cho, JG2
Park, JC2
Kang, JC2
Cross, KP1
Randell, KA1
Herr, SM1
Schwalm, JD1
Ahmad, M1
Salehian, O1
Natarajan, MK1
Sallustio, F1
Di Legge, S1
Rossi, C1
Stanzione, P1
Burke, JP1
Sander, S1
Zarotsky, V1
Henk, H1
Nannucci, S1
Pescini, F1
Valenti, R1
Ciolli, L1
Bianchi, S1
Dotti, MT1
Inzitari, D1
Pantoni, L1
Kralinger, MT1
Stolba, U1
Velikay, M1
Egger, S1
Binder, S1
Wedrich, A1
Haas, A1
Parel, JM1
Kieselbach, GF1
Postuła, M1
Tarchalska-Kryńska, B1
Filipiak, KJ2
Kosior, D1
Serafin, A1
Huczek, Z2
Dato, I1
Niccoli, G2
Bacà, M1
Pontecorvo, ML1
Hiew, C1
Williams, T1
Hatton, R1
Narasimhan, S1
O'Connor, S1
Baker, F1
McElduff, P1
Attia, J1
Collins, N1
Geraghty, OC1
Paul, NL1
Chandratheva, A1
Taguchi, Y1
Takashima, S1
Nukui, T1
Dougu, N1
Toyoda, S1
Doi, H1
Tateishi, T1
Isobe, N1
Yamasaki, R1
Ohyagi, Y1
Kira, J1
Forster, MT1
Mathé, AK1
Senft, C1
Scharrer, I1
Seifert, V1
Gerlach, R1
Jeon, SB1
Song, HS1
Kim, HJ1
Alberts, MJ2
Emery, J1
Oliveira, DC1
Silva, RF1
Silva, DJ1
Lima, VC1
Baracchini, C1
Tonello, S1
Meneghetti, G1
Ballotta, E1
Kim, N1
Lee, BH1
Kang, JM1
Seo, P1
Lim, MK2
Song, BJ1
Lee, JW1
Hwang, JH1
Kim, JW1
Jeong, SH1
Lee, DH2
Jung, HC1
Song, IS1
Gizewski, ER1
Venerito, M1
Kandulski, A1
Malfertheiner, P1
Kim, KH1
Ahn, Y1
Barison, A1
de Carlo, M1
Bellini, F1
Capozza, PF1
Lunardini, A1
Lim, SH1
Hong, BY1
Cho, YR1
Kim, HS4
Lee, JI1
Kim, HW1
Ko, YJ1
Farina, A1
Spinazzola, A1
Abbiati, G1
Arpini, MT1
Bergamaschi, L1
Riva, A1
Berticelli, P1
Geri, G1
Sandercock, PA2
Niewada, M1
Członkowska, A1
Guthrie, R1
Oldgren, J1
Khder, Y1
Roberts, J1
Siegbahn, A2
Tijssen, JG2
Wallentin, L3
Charlot, M1
Ahlehoff, O1
Selmer, C1
Lindhardsen, J1
Bresson, V1
Bonello, B1
Rousset-Rouvière, C1
Serratrice, J2
Chabrol, B1
Dubus, JC1
Bosdure, E1
Tchan, M1
Sillence, D1
McEvoy, JW1
Blaha, MJ1
Nasir, K1
Yoon, YE1
Choi, EK1
Cho, IS1
Chun, EJ1
Choi, SI1
Rivera, JJ1
Blumenthal, RS2
Vidal-Jordana, A1
Barroeta-Espar, I1
Sáinz Pelayo, MP1
Mateo, J1
Delgado-Mederos, R1
Pujol Lereis, VA1
Ameriso, S1
Anamnart, C1
Poungvarin, N1
Mono, ML2
Geister, L1
Galimanis, A1
Jung, S1
Praz, F1
Fischer, U1
Wolff, S1
Findling, O1
Wahl, A2
Meier, B7
Nedeltchev, K4
Hsiao, FY1
Mullins, CD1
Wen, YW1
Huang, WF1
Chen, PF1
Tsai, YW1
Cuisset, T1
Quilici, J1
Grosdidier, C1
Fourcade, L1
Gaborit, B1
Pankert, M1
Molines, L1
Morange, PE1
Bonnet, JL1
Alessi, MC1
Larson, DM1
Duval, S1
Sharkey, SW1
Garberich, RF1
Madison, JD1
Stokman, PJ1
Dirks, TG1
Westin, RK1
Harris, JL1
Henry, TD1
Leone, AM1
Sgueglia, GA1
Porto, I1
Burzotta, F1
Trani, C1
De Caterina, AR1
Buffon, A1
Mazzari, MA1
Mongiardo, R1
Rebuzzi, AG1
Roa, LF1
Hernandez, B1
Merlos, M1
Marquez, JM1
Artigas, C1
Perez, A1
Cantu-Brito, C1
Barinagarrementeria, F1
Delhaye, C1
Martin, RH1
Vinisko, R1
Donnan, GA1
Tricoci, P1
Mahaffey, KW3
Chong, BH1
Chan, KH1
Pong, V1
Lau, KK1
Chan, YH1
Zuo, ML1
Lui, WM1
Leung, GK1
Lau, CP1
Tse, HF1
Pu, JK1
Siu, CW1
Geeganage, CM1
Topol, EJ5
Dengler, R1
Bath, MW1
Elgin, U1
Sen, E1
Teke, MY1
Tirhis, H1
Ozturk, F1
Renard, D1
Larue, A1
Taieb, G1
Jeanjean, L1
Labauge, P1
del Río Solá, ML1
Antonio, J1
Fajardo, G1
Vaquero Puerta, C1
Havel, M1
Ertl, L1
Braunschweig, F1
Markmann, S1
Leunig, A1
Gamarra, F1
Kramer, MF1
Gokce, M1
Altan, I1
Unal, S1
Kuskonmaz, B1
Aytac, S1
Cetin, M1
Tuncer, M1
Gumruk, F1
Gurgey, A1
Smith, PK2
Goodnough, LT1
Levy, JH1
Poston, RS1
Short, MA1
Weerakkody, GJ1
Lenarz, LA1
Fischer-Betz, R1
Specker, C1
Brinks, R1
Schneider, M1
Barraclough, K1
Mallen, CD1
Helliwell, T1
Hider, SL1
Dasgupta, B1
Milan, M1
Noventa, F2
Ghirarduzzi, A1
Pengo, V1
Vedovetto, V1
Filippi, L1
Campello, E1
Szychowski, JM1
Zhang, Z1
Jian, X1
Liu, H1
Zhou, Q2
Fang, YB1
Li, Q1
Yang, PF1
Huang, QH1
Zhao, WY1
Xu, Y2
Hong, B1
Liu, JM1
El-Mitwalli, A1
Azzam, H1
Abu-Hegazy, M1
Gomaa, M1
Wasel, Y1
Barry, EL1
Poole, EM1
Baron, JA2
Makar, KW1
Mott, LA2
Sandler, RS2
Ahnen, DJ1
Bresalier, RS1
McKeown-Eyssen, GE2
Ulrich, CM1
Burrows, AM1
Zipfel, G1
Lanzino, G1
Kiesz, RS1
Wiernek, SL1
Wiernek, BK1
Radvany, MG1
Buszman, PP1
Szymanski, R1
Konkolewska, MD1
Martin, JL1
Buszman, PE1
Mulukutla, SR1
Marroquin, OC1
Vlachos, HA1
Selzer, F1
Toma, C1
Kip, KE1
Abbott, JD1
Holper, E1
Khandhar, S1
Kutcher, M1
Kelsey, S1
Smith, C1
Faxon, D1
Williams, DO2
Chi, L1
Li, L1
Han, JL1
Li, HY1
Qiao, R1
Yu, HY1
Zeng, H1
Gao, W1
Neogi, T1
Chaisson, C1
Hunter, DJ1
Choi, H1
Kahn, JE1
Veyssier-Belot, C1
Renier, JL1
de Mazancourt, P1
Peltier, JY1
de Raucourt, E1
Lopez-Yunez, AM1
Cuadrado, MJ3
Shah, PB1
Lilly, CM1
Turpie, AG3
Hiller, E2
Kao, A1
Dlugos, D1
Hunter, JV1
Mamula, P1
Thorarensen, O1
Fliri, M1
Jacobs, ET1
Giuliano, AR1
Roe, DJ1
Guillén-Rodríguez, JM1
Alberts, DS2
Martínez, ME2
Kübler, W2
Arvieux, J1
Hoppe, UC1
Musolino, R1
La Spina, P1
Granata, A1
Gallitto, G1
Leggiadro, N1
Carerj, S1
Manganaro, A1
Tripodi, F1
Epifanio, A1
Gangemi, S1
Di Perri, R1
Schölmerich, J1
Stange, EF1
Ornato, JP1
Maillard, L1
Michiels, JJ2
Berneman, Z1
Schroyens, W1
van Urk, H1
Gerschutz, GP1
Bergstrand, L1
Fellenius, C2
Lindahl, B1
Lins, LE1
Nilsson, T1
Pehrsson, K1
Swahn, E1
Trespalacios, FC1
Taylor, AJ1
Agodoa, LY1
Bakris, GL1
Abbott, KC1
Gorelick, PB2
Richardson, D1
Kelly, M1
Ruland, S1
Hung, E1
Harris, Y1
Kittner, S1
Leurgans, S1
O'Brien, TG1
Fultz, KE1
Babbar, N1
Yerushalmi, H1
Qu, N1
Boorman, D1
Einspahr, J1
Gerner, EW1
Comunale, ME1
Maslow, A1
Robertson, LK1
Haering, JM1
Mashikian, JS1
Lowenstein, E1
Reikvam, A1
Madsen, S1
Landmark, K1
Short, D1
Frischer, M1
Bashford, J1
Ashcroft, D1
James, MW1
Hawkey, CJ2
Limmer, S1
Ittel, TH1
Wietholtz, H1
Ng, FH1
Wong, SY1
Chang, CM1
Chen, WH1
Kng, C1
Lanas, AI1
Wong, BC2
Nanda, S1
Agarwal, U1
Sangwan, K1
Fan, YH1
Lam, WW1
Mok, VC1
Petri, M1
Mahé, I1
Grenard, AS1
Caulin, C1
Bergmann, JF1
Ito, E2
Takahashi, A1
Yamamoto, H1
Kuzuhara, S1
Nakajima, M2
Kaźmierski, MK1
Leschke, M2
Klimek, W1
Gensini, GF3
Maritz, F1
Gurfinkel, EP5
Timerman, A1
Krzeminska-Pakula, M1
White, HD5
Santopinto, J1
Bigonzi, F3
Hecquet, C1
Vittori, L1
Haberl, R1
Barth, A1
Bonnefoy, E1
Chabaud, S1
Lapostolle, F1
Dubien, PY1
Cristofini, P1
Leizorovicz, A4
Touboul, P1
Werner, GS1
Emig, U1
Mutschke, O1
Schwarz, G1
Bahrmann, P1
Figulla, HR1
Füessl, HS1
Takada, T1
Tanaka, M1
Hunt, RH2
Bazzoli, F1
Giugliano, RP1
Murphy, SA1
Demopoulos, LA1
DiBattiste, PM1
Weintraub, WS1
McCabe, CH1
Antman, EM1
Cannon, CP1
Bruno, A3
McConnell, JP1
Cohen, SN1
Tietjen, GE1
Wallis, RA1
Bang, NU2
Bellelli, G1
Trabucchi, M1
Herlitz, J1
Holm, J2
Peterson, M1
Karlson, BW1
Haglid Evander, M1
Erhardt, L2
Banerjee, S1
Denniston, AK1
Gibson, JM1
Dodson, PM1
Faraday, N1
Braunstein, JB1
Heldman, AW1
Bolton, ED1
Chiles, KA1
Gerstenblith, G1
Schulman, SP1
Grau, AJ1
Boddy, AW1
Dukovic, DA1
Buggle, F1
Lichy, C1
Brandt, T1
Demichelis, B2
Parrini, I1
Giuggia, M1
Cecchi, E3
Gaschino, G1
Demarie, D3
Ghisio, A3
Trinchero, R3
Hillarp, A2
Palmqvist, B1
Lethagen, S1
Villoutreix, BO1
Mattiasson, I1
McKevitt, FM1
Macdonald, S1
Cleveland, TJ1
Gaines, PA1
Sciacca, RR2
Schuepbach, RA1
Meili, EO1
Schneider, E2
Peter, U1
Bachli, EB1
Freeman, AF1
Shulman, ST1
Bats, AS1
Lejeune, V1
Cynober, E2
Safar, E1
Gonzales, M1
Milliez, J2
Carbonne, B2
Drake-Lee, AB1
Santa-Cruz, RA1
Steinhubl, SR1
Matetzky, S1
Shenkman, B1
Guetta, V1
Shechter, M1
Beinart, R1
Bienart, R1
Goldenberg, I1
Novikov, I1
Pres, H1
Savion, N1
Varon, D1
Hod, H2
Wienbergen, H1
Gitt, AK1
Schiele, R1
Juenger, C1
Heer, T1
Vogel, C1
Gottwik, M1
Senges, J1
DiTullio, MR1
Locker, C1
Mohr, R1
Lev-Ran, O1
Uretzky, G1
Frimerman, A1
Shaham, Y1
Shapira, I1
Matsui, M1
Tomimoto, H1
Sano, K1
Hashikawa, K1
Fukuyama, H1
Shibasaki, H1
Senna, G1
Bilò, MB1
Antonicelli, L1
Schiappoli, M1
Crivellaro, MA1
Bonadonna, P1
Dama, AR1
Rosenberg, R1
Bauer, K1
Rosner, B1
Sciacca, R1
Barzegar, S1
Thornell, B1
Costigan, T1
Kistler, JP1
Kassem-Moussa, H1
Graffagnino, C2
Tasissa, G1
Sila, CA2
Simes, RJ1
Califf, RM7
Bhapkar, MV1
Newby, LK1
Reissmann, A1
Bischoff, SC1
Fleig, W1
Bogousslavsky, J1
Hirsh, J1
Stejskal, D1
Prosková, J1
Lacnák, B1
Horalík, D1
Hamplová, A1
Oral, I1
Hrabovská, I1
Ochmanová, R1
Adamovská, S1
Juráková, R1
Ozanová, G1
Juchelka, J1
Kulísková, O1
Pĕnkavová, H1
Karreman, AJ1
Gendolla, A1
Zakopoulos, N1
Peppes, V1
Toussaint, LG1
Friedman, JA1
Wijdicks, EF1
Piepgras, DG1
Pichelmann, MA1
McIver, JI1
McClelland, RL1
Nichols, DA1
Meyer, FB1
Atkinson, JL1
Gallino, A1
Do, DD1
Alerci, M1
Cozzi, L1
Segatto, JM1
Bernier, J1
Tutta, P1
Kellner, F1
Triller, J1
Amann-Vesti, B1
Studer, G1
Jäger, K1
Aschwanden, M1
Canevascini, R1
Jacob, AL1
Kann, R1
Greiner, R1
Mahler, F1
Claeys, MJ1
Van der Planken, MG1
Bosmans, JM1
Vertessen, F1
Van Der Goten, P1
Wuyts, FL1
Vrints, CJ1
Arkkila, PE1
Seppälä, K1
Kosunen, TU1
Sipponen, P2
Mäkinen, J1
Rautelin, H1
Färkkilä, M1
Weir, NU1
Demchuk, AM1
Buchan, AM1
Kumana, CR1
Cheung, G1
Lauder, IJ1
Cheung, BM1
Kiechl, S1
Schleinitz, MD1
Heidenreich, PA1
Lanthier, S1
Armstrong, D1
Domi, T1
Gassaye, D1
Atipo Ibara, BI1
Ndolo-Mpika, AB1
Ibara, JR1
Okouo, M1
Ossendza, RA1
Ngoma-Mambouana, P1
Itoua-Ngaporo, A1
Pollak, L1
Kessler, A1
Rabey, MJ1
Hartmann, B1
Goldhammer, Y1
Matsuo, H1
Morimoto, K1
Akaki, T1
Kaneko, S1
Kusatake, K1
Kuroda, T1
Niihara, H1
Hide, M1
Morita, E1
Khamashta, MA4
Hunt, BJ2
Marchioli, R2
Brancaccio, V1
Schinco, P1
Wisloff, F1
Musial, J1
Baudo, F1
Berrettini, M1
Testa, S1
D'Angelo, A1
Tognoni, G2
Nakashima, S1
Arai, S1
Mizuno, Y1
Yoshino, K1
Ando, S1
Nakamura, Y1
Sugawara, K1
Koike, M1
Saito, E1
Naito, M1
Nakao, M1
Ito, H1
Hamaoka, K1
Rai, F1
Asakura, Y1
Akamatu, M1
Fujimori, K1
Inao, M1
Imai, Y1
Ota, S1
Fujiwara, K1
Shiibashi, M1
Worth, NF1
Berry, CL1
Thomas, AC1
Campbell, JH1
Asero, R1
Sick, PB1
Brosteanu, O1
Ulrich, M1
Niebauer, J2
Busch, I1
Schuler, G2
Koga, T1
Oshita, Y1
Kamimura, T1
Koga, H1
Aizawa, H1
Yip, HK1
Chang, HW1
Lan, MY1
Chen, MC1
Meier, JM1
Delabays, A1
Girod, G1
Eeckhout, E1
Ng, HJ1
Bobbio, M1
Pomari, F2
Moratti, M1
Belli, R2
Jamieson, DG1
Parekh, A1
Ezekowitz, MD1
Woodside, DB1
Colton, P1
Staab, R1
Schreiber, M1
Sutandar-Pinnock, K1
Poynter, B1
Sacevich, T1
Ederhy, S1
Meuleman, C1
Hammoudi, N1
Janower, S1
Szapáry, L1
Brogan, GX1
Peterson, ED1
Mulgund, J1
Ohman, EM2
Gibler, WB1
Pollack, CV1
Farkouh, ME1
Roe, MT1
Gurbuz, AT1
Zia, AA1
Vuran, AC1
Cui, H1
Aytac, A1
Takeuchi, K3
Smale, S1
Premchand, P1
Maiden, L1
Sherwood, R1
Thjodleifsson, B1
Bjornsson, E1
Bjarnason, I1
Schneider, CA1
Schaefer, A1
Stumme, B1
Drexler, H1
von Depka, M1
Malik, SN1
Hopkins, M1
Young, WB1
Silberstein, SD1
Halkes, PH1
van Gijn, J3
van Wijk, I1
Casella, G1
Greco, C1
Perugini, E1
Pallotti, MG1
Pavesi, PC1
Di Pasquale, G1
Frelinger, AL1
Furman, MI1
Linden, MD1
Fox, ML1
Barnard, MR1
Michelson, AD1
Freedman, JE1
Eggers, AE1
Spoor, MT1
Geltz, A1
Bolling, SF1
Stiefelhagen, P1
Palumbo, A1
Rus, C1
Zeldis, JB1
Rodeghiero, F1
Boccadoro, M1
Onizuka, M1
Kazekawa, K1
Nagata, S1
Tsutsumi, M1
Aikawa, H1
Tomokiyo, M1
Iko, M1
Kodama, T1
Nii, K1
Tanaka, A1
Albucher, JF1
Martel, P1
Cordonnier, C1
Fuchs, I1
Frossard, M1
Spiel, A1
Riedmüller, E1
Laggner, AN1
Jilma, B1
Ortega, LL1
Sánchez, J1
Más, R1
Fernández, L1
Mendoza, S1
Gámez, R1
Fernández, JC1
Illnait, J1
Alvarez, E1
Boos, CJ1
Harrison, P1
Keeling, D1
Johansen, M1
Derendorf, H1
Kim, S1
Burke, CA1
Church, TR1
Cole, BF1
Haile, RW1
Sharifkazemi, MB1
Zamirian, M1
Aslani, A1
O'Donoghue, M1
Wiviott, SD1
Yilmaz, S1
Bayan, K1
Dursun, M1
Canoruç, F1
Kilinç, N1
Tüzün, Y1
Daniş, R1
Ertem, M1
Spencer, FA1
Lessard, D2
Doubeni, C1
Yarzebski, J2
Gore, JM4
Goldberg, RJ2
Kozieradzka, A1
Kamiński, KA1
Pepiński, W1
Janica, J1
Korecki, J1
Skolimowski, K1
Frankowska, E1
Kralisz, P1
Bonda, TA1
Dobrzycki, S1
Musiał, WJ1
Małek, ŁA1
Spiewak, M1
Grabowski, M1
Szpotańska, M1
Rosiak, M1
Główczyńska, R1
Imiela, T1
Alpagut, U1
Ugurlucan, M1
Dayioglu, E1
Hirsch, A1
Windhausen, F1
Cornel, JH1
de Winter, RJ1
Liao, JK1
Kikano, GE1
Brown, MT1
Luxembourg, B1
Mani, H1
Toennes, SW1
Strubel, G1
Klaeffling, C1
Daemgen-von Brevern, G1
Geisen, C1
Lindhoff-Last, E1
Chinaglia, A1
Ierna, S1
Wang, GZ1
Huang, GP1
Yin, GL1
Zhou, G1
Guo, CJ1
Xie, CG1
Jia, BB1
Wang, JF1
Macé, G1
Cabane, J1
Kim, JE1
Kountakis, SE1
Okajima, K1
Abe, Y1
Salameh, MJ1
Jin, Z1
Glynn, RJ1
Ridker, PM1
Goldhaber, SZ1
Zee, RY1
Buring, JE4
Barnes, GD1
Kline-Rogers, E1
Vedre, A1
Armstrong, DF1
Froehlich, JB1
Eagle, KA1
Gurm, HS1
Alonso Santor, JE1
Inglada Galiana, L1
Pérez Paredes, G1
Hsia, J2
Domenig, CM1
Aspalter, M1
Umathum, M1
Holzenbein, TJ1
Overgaard, K1
Poulsen, TS1
Husted, SE1
Lorenzen, ND1
Eldrup, N1
Laustsen, J1
Sztriha, LK1
Sas, K1
Seres, E1
Boda, K1
Lenti, L1
Csifcsak, G1
Kovacs, N1
Vecsei, L1
Luo, M1
Xie, RM1
Quan, HB1
Cai, YY1
Winer, N1
Tsasaris, V1
Vermylen, J1
Smout, J1
Cleanthis, M1
Stansby, G1
Gengo, FM1
Rainka, M1
Robson, M1
Gengo, MF1
Forrest, A1
Hourihane, M1
Bates, V1
Sofi, F1
Marcucci, R1
Gori, AM1
Abbate, R1
Kubota, N1
Kasai, T1
Miyauchi, K1
Njaman, W1
Kajimoto, K1
Akimoto, Y1
Kojima, T1
Ken, Y1
Takeshi, K1
Hiroyuki, D1
Dalen, JE1
Levi, M1
Nagarakanti, R1
Sodhi, S1
Lee, R1
Ezekowitz, M1
Gellatly, RM1
Ackman, ML1
Mikkelsson, J1
Eskola, M1
Nikus, K1
Karhunen, PJ1
Niemela, K1
Tseng, GY1
Lin, HJ1
Duran, X1
Sánchez, S1
Vilahur, G1
Badimon, L2
Schubert, TT2
Boissel, JP3
Faucomprez, C1
McNicol, GP1
Schröder, R1
Kallio, V1
Mitchell, JR2
Friedewald, WT1
Schoenberger, JA1
Toshima, H1
Adachi, K1
Chabali, R1
Haynes, RE1
Spann, JF1
Offerhaus, L1
Burkart, F2
Gorlin, R1
Fuster, V4
Kornitzer, M1
Il'in, VN1
Stepanov, NV1
Ikhaev, ZA1
Sharonin, GV1
Bogdanets, LI1
Buckler, P1
Douglas, AS1
Kirchhof, B1
Haustein, UF1
Rytter, M1
Kaltenbach, M3
Kober, G3
Schmidt-Moritz, A1
Scherer, D2
Thornton, MA1
Gruentzig, AR1
Hollman, J2
King, SB4
Douglas, JS2
Faxon, DP3
Sanborn, TA2
Haudenschild, CC1
Ryan, TJ2
Hillis, LD1
Leisch, F1
Herbinger, W1
Brücke, P1
Elwood, PC4
Wüthrich, B1
Ramirez-Lassepas, M1
Domschke, S1
Domschke, W1
Weber, M1
von Schacky, C1
Lorenz, R1
Meister, W1
Kotzur, J1
Reichart, B1
Theisen, K2
Weber, PC1
Breddin, K5
Markiewicz, M1
Rymar, B1
Florkiewicz, H1
Wysokiński, A1
Volger, E1
Theiss, W2
Lubbe, WF1
Butler, WS1
Palmer, SJ1
Liggins, GC1
Lucas, MA1
Ganley, JP1
Geiger, JM1
Clement, JR1
Rigby, PG1
Levy, GJ1
Mannucci, PM1
Romano, P1
Van Aken, WG1
Verdecchia, P1
Reuther, R1
Dorndorf, W1
Loew, D4
Lechner, K2
Oberla, K1
Walter, E4
Rentrop, P1
Blanke, H1
Karsch, KR1
Guiraud-Chaumeil, B1
Rascol, A1
David, J1
Boneu, B2
Clanet, M1
Bierme, R2
Clagett, GP1
Rich, NM1
McDonald, PT1
Salander, JM1
Youkey, JR1
Olson, DW1
Hutton, JE1
Rampton, DS1
McNeil, NI1
Sarner, M1
Jones, RJ1
Lundh, B1
Fagher, B1
Weber, E2
Loeliger, EA1
Robertson, RM1
Robertson, D1
Roberts, LJ2
Maas, RL1
FitzGerald, GA1
Friesinger, GC1
Oates, JA2
Straub, PW1
Kraska, T1
Malanowicz, W1
Skarzyńska, M1
Tymińska, K1
Kent, S1
van de Loo, J1
Castaldi, PA1
Schbath, J1
Destors, JM1
Gillet, J2
Halawa, B1
Mazurek, W1
Sherry, DD1
Patterson, MW1
Petty, RE1
Turk, JW1
Horwitz, DL1
Settipane, RA1
Constantine, HP1
Settipane, GA1
Klimt, CR2
Faergeman, O1
Bauman, JL1
Shulruff, S1
Hasegawa, GR1
Roden, R1
Hartsough, N1
Bauernfeind, RA1
Maruyama, S1
Tohgi, H2
Hirai, S1
Ikeda, Y1
Shinohara, Y1
Matsuda, T1
Fujishima, M1
Kameyama, M1
Larsson, H1
Areskog, M1
Areskog, NH1
Jonasson, T1
Ringqvist, I1
Poole-Wilson, PA1
Langford, EJ1
Brown, AS1
Wainwright, RJ1
de Belder, AJ1
Thomas, MR1
Smith, RE1
Radomski, MW1
Martin, JF1
Moncada, S1
Di Tano, G1
Mazzù, A1
Isogaya, M1
Yamada, N1
Koike, H1
Ueno, Y1
Kumagai, H1
Ochi, Y1
Okazaki, S1
Nishio, S1
Savage, MP2
Goldberg, S3
Bove, AA2
Deutsch, E2
Vetrovec, G3
Macdonald, RG3
Bass, T2
Margolis, JR3
Whitworth, HB2
Taussig, A2
Schmitt, C2
Karch, M1
Plewan, A1
Montero, M1
Schömig, A5
Russo, R1
Laveder, F1
Agostini, C1
Manos, EJ1
Mejaíl, RI1
Cerdá, MA1
Duronto, EA1
García, CN1
Daroca, AM1
Mautner, B1
Förster, W7
Frölich, JC2
van Latum, JC1
van Swieten, JC1
Channer, KS1
Lasry, JL1
Boyer, JC1
Bories, H1
Kadouch, R1
Lagneau, P1
Schrör, K2
Ahmadi, A1
Koppensteiner, R4
Maca, T1
Stümpflen, A3
Ugurluoglu, A1
Ehringer, H4
Chernine, A2
Ovadia, Z1
Battler, A2
Moulin, C1
Bosson, JL1
Rolachon, A1
Li, V1
Cohard, M1
Girard, M1
Hostein, J1
Mehan, VK2
Salzmann, C1
Kaufmann, U1
French, JK2
Hamer, AW1
Brown, MA2
Williams, BF2
Ormiston, JA1
Cross, DB1
Pickard, JD1
Walker, V1
Brandt, L1
Zygmunt, S1
Smythe, J1
Wielgosz, AT1
Valentín Segura, V1
Valls Grima, F1
Broch Porcar, MJ1
Miralles Serrano, L1
Olivares Toledo, D1
Alvarez Cebrián, F1
Matchar, DB1
McCrory, DC1
Barnett, HJ1
Feussner, JR1
Mujic, F1
Taub, NA1
Hughes, GR2
Eriksson, SE1
Whitford, DL1
Southern, AJ1
Fitch, LL1
Buchwald, H1
Matts, JP1
Johnson, JW1
Campos, CT1
Long, JM1
Xiong, J2
Parry, G2
Adams, PC3
Chamberlain, D2
Wieczorek, I2
McBride, R1
Chesebro, JH4
Laupacis, A1
Flaker, GC1
Singer, DE1
Pfeffer, MA1
Braunvald, Iu1
Moĭe, LA1
Basta, L1
Kaddi, TE1
Dévis, BR1
Geltman, EM1
Goldman, S1
Fleĭker, GS1
Bonnier, JJ1
Post, D1
Wilkinson, P2
Laji, K1
Ranjadayalan, K2
Parsons, L1
Timmis, AD2
Vlachoyiannopoulos, PG1
Tsiakou, E1
Chalevelakis, G1
Raptis, SA1
Moutsopoulos, HM1
Zotz, R1
Pinnau, U1
Genth, S1
Erbel, R3
Meyer, J3
Averkov, OV1
Zateĭshchikov, DA1
Gratsianskiĭ, NA1
Logutov, IuA1
Iavelov, IS1
Ianus, Vm1
Helgason, CM1
Bolin, KM1
Hoff, JA1
Winkler, SR1
Mangat, A1
Tortorice, KL1
Brace, LD1
Anaya Ordóñez, S1
Matas Hoces, A1
Britton, M1
Michel, PL1
Chiba, K1
Takahashi, H1
Tamura, K1
Sasaki, K1
Yao, SK2
Ober, JC2
Ferguson, JJ2
Maffrand, JP2
Anderson, HV2
Buja, LM2
Willerson, JT3
Shahar, E1
McGovern, PG1
Sprafka, JM1
Adamek, HE1
Buttmann, A1
Weber, J1
Riemann, JF1
Rissel, U1
Müller, T1
Schulze-Waltrup, N1
Krakau, I1
Arens, R1
Willgeroth, W1
Heuer, H1
Theilmann, L1
Sauer, P1
Roeren, T1
Otto, G1
Arnold, JC1
Noeldge, G1
Richter, G1
Stiehl, A1
McCarthy, DM1
Heller, RF2
Knapp, JC1
Valenti, LA1
Dobson, AJ2
Byers, JF1
Juillière, Y1
Kettani, C1
Buffet, P1
Anconina, J1
Cuillière, M1
Cherrier, F1
Wellbrock, M1
Mertens, J1
Cornelius, M1
Brasch, J1
Hoberg, E1
Dietz, R1
Frees, U1
Rauch, B1
Schwarz, F1
Tillmanns, H1
Weichert, W1
Meents, H1
Abt, K1
Lieb, H1
Hach, W1
Krzywanek, HJ1
Breddin, HK2
Hanna, JP1
Sun, JP1
Furlan, AJ1
Stewart, WJ1
Tan, M1
Chaturvedi, S1
Ansell, J1
Recht, L1
Heigl, F1
Heigl, B1
Kampfhammer, HP1
Steinbeck, G1
Grotemeyer, KH3
Scharafinski, HW2
Husstedt, IW3
Meyer, A1
Werter, CJ2
de Swart, H1
Lie, KI2
van der Pol, JM2
Michels, HR1
van Eenige, MJ2
Becker, RC1
Meltzer, RS1
Vered, Z1
Desmet, W1
Vrolix, M1
De Scheerder, I1
Van Lierde, J1
Willems, JL1
Piessens, J1
Strain, J1
Keller, C1
Gull, S1
Prentice, A1
Wehmeier, A1
Bischof, G1
Pratschner, T1
Kail, M1
Mittlböck, M1
Turkof, E1
Puig, S1
Polterauer, P1
Kretschmer, G2
Hansen, F1
Lindblad, B1
Persson, NH1
Bergqvist, D1
Zeitler, E1
Beyer-Enke, S1
Rompel, O1
Stevenson, R1
Roberts, R4
Kaaja, R1
Julkunen, H1
Ammälä, P1
Palosuo, T1
Kurki, P1
Langer, A3
Green, D1
Miller, V1
Simoons, ML5
Arnout, J1
van den Brand, M1
Nÿssen, K1
Verstraete, M2
Sivenius, J1
Riekkinen, PJ1
Laakso, M1
Smets, P1
Lowenthal, A2
Sarin, S1
Shami, SK1
Cheatle, TR1
Bearn, P1
Scurr, JH1
Coleridge Smith, PD1
Saito, T1
Saitoh, S1
Asakura, T1
Kanke, M1
Owada, K1
Maruyama, Y1
Bologna, SD1
Nensey, Y1
Schubert, AB1
Mascha, EJ1
Ma, CK1
Goldwater, PN1
Meijer, A1
Prager, NA2
Torr-Brown, SR1
Sobel, BE3
Abendschein, DR3
Lodder, J1
Boiten, J1
Fernández-Avilés, F1
Alonso, JJ1
Durán, JM1
Gimeno, F1
Muñoz, JC1
de la Fuente, L1
San Román, JA1
Némoz, C1
Folkerts, H1
Caruzzo, E1
Caruzzo, C1
Graf, WD1
Riback, PS1
Radford, MJ1
Ellerbeck, EF1
Hennen, J1
Meehan, TP1
Petrillo, M1
Jencks, SF1
Andersson, R1
Ezra, Y2
Rose, M1
Eldor, A2
Altman, R1
Rouvier, J1
Gurfinkel, E1
Haddad, B1
Uzan, M1
Bréart, G2
Uzan, S3
Hartmann, A1
Hennerici, MG1
Meairs, S1
Scadding, GK1
Hassab, M1
Darby, YC1
Lund, VJ1
Freedman, A1
Cottier, C1
Elikowski, W1
Psuja, P1
Lewandowski, K1
Przybył, M1
Wendland, M1
Wróblewski, D1
Jazienicki, B1
Przybył, L1
Zawilska, K1
Eisenberg, MJ1
Topal, EJ1
Rodgers, A1
MacMahon, S2
Gamble, G1
Slattery, J1
Sandercock, P5
Warlow, C3
Bowker, TJ1
Clayton, TC1
Ingham, J1
McLennan, NR1
Hobson, HL1
Pyke, SD1
Schofield, B1
Wood, DA1
Sankardas, MA1
McEniery, PT1
Aroney, CN1
Bett, JH1
Chen, LY1
Nichols, WW1
Mattsson, C1
Teger-Nilson, AC1
Wallin, R1
Saldeen, TG1
Mehta, JL1
Stroobandt, G1
Fransen, P1
Thauvoy, C1
Menard, E1
Saito, S1
Hosokawa, FG1
Kim, K1
Miyake, S1
Norris, RM1
Hart, HH1
Oler, A1
Whooley, MA1
Oler, J1
Grady, D1
Mark, DB1
Talley, JD1
Bowman, L1
Lam, LC1
Anderson, KM2
Jollis, JG1
Cleman, MW2
Lee, KL1
Aversano, T1
Untereker, WJ1
Davidson-Ray, L1
Diethrich, EB1
Ndiaye, M1
Reid, DB1
Collins, R4
Flather, M1
Baigent, C1
Remvig, L1
Mortensen, S1
Appleby, P1
Godwin, J1
Peto, R5
Heinz, M1
van de Flierdt, E1
Söhngen, M1
van den Brand, MJ1
van Miltenburg, A1
van der Wieken, LR1
de Feyter, PJ1
Rapaport, E1
Gheorghiade, M1
Malcolm, AD1
Keltai, M1
Walsh, MJ1
Umemura, K1
Nishiyama, H1
Kikuchi, S1
Kondo, K1
Nakashima, M1
Julian, DG1
Chamberlain, DA1
Enserink, M1
Neumann, FJ1
Walter, H2
Schühlen, H3
Hadamitzky, M2
Zitzmann-Roth, EM1
Dirschinger, J2
Hausleiter, J1
Blasini, R1
Alt, E1
Santiago, T1
Chasuk, R1
Lenkovsky, F1
Neirinck, LG1
Glezer, SV1
Klein, LW1
Wahid, F1
VandenBerg, BJ1
Parrillo, JE1
Calvin, JE1
Gregorini, L1
Marco, J1
de Lorgeril, M1
Salen, P1
Caillat-Vallet, E1
Hanauer, MT1
Barthelemy, JC1
Mamelle, N1
Kanchurina, NA1
Poroshina, IuA1
Prasolova, NI1
Zemskov, VM1
Baim, DS3
Carrozza, JP1
Galassi, AR1
Tamburino, C1
Grassi, R1
Monaco, A1
Russo, G1
Ierna, SM1
Calvi, V1
Giuffrida, G1
Ishikawa, K2
Kanamasa, K1
Hama, J1
Ogawa, I1
Takenaka, T1
Naito, T1
Yamamoto, T1
Nakai, S1
Oyaizu, M1
Kimura, A1
Yamamoto, K1
Katori, R1
Seaton, TL1
Hull, MA1
Knifton, A1
Filipowicz, B1
Brough, JL1
Vautier, G1
Kher, A1
Samama, MM1
Barragan, P1
Pietri, P1
Villain, P1
Silvestri, M1
Roquebert, PO1
Dippel, DW2
Nichols, FT1
Ulm, K1
Hennekens, CH3
Wilber, DJ1
Gunnar, RM1
Nguyen, KN1
Aursnes, I1
Kjekshus, J1
Stiegler, H1
Schädlich, PK1
Brecht, JG1
Moussa, I1
Moses, J1
Reimers, B1
Di Francesco, L1
Martini, G1
Tobis, J1
Colombo, A2
Laperche, T1
Laurian, C1
Roudaut, R1
Demers, C2
Fromell, GJ3
Goodman, S2
Premmereur, J2
Granger, KA1
Farquharson, RG1
Horrocks, M1
Horrocks, EH1
Murphy, P1
Lane, IF2
Ruttley, MS1
Fligelstone, LJ1
Watson, HR1
Lee, TK2
Chan, KW1
Huang, ZS1
Ng, SK1
Lin, RT1
Yuan, RY1
Lai, ML1
Chang, TW1
Yan, SH1
Deng, JC1
Liu, LH1
Lee, KY2
Lie, SK1
Sung, SM1
Hu, HH2
Ryglewicz, D1
Baranska-Gieruszczak, M1
Lechowicz, W1
Hier, DB1
Robinson, J1
Poller, S1
Hesse, L1
Aylward, PE1
Frey, MJ1
Adgey, AA1
Nair, R1
Hillis, WS1
Shalev, Y1
Maraganore, J1
Adelman, B1
Leadley, RJ1
Kasiewski, CJ1
Bostwick, JS1
Bentley, R1
McVey, MJ1
White, FJ1
Perrone, MH1
Dunwiddie, CT1
Anzuini, A2
Rosanio, S2
Legrand, V2
Tocchi, M2
Coppi, R2
Marazzi, G1
Vicedomini, G1
Pagnotta, P1
Montorfano, M1
Bonnier, H2
Sheiban, I2
Kulbertus, HE2
Chierchia, SL2
Krnic-Barrie, S1
O'Connor, CR1
Looney, SW1
Pierangeli, SS1
Harris, EN2
Rojas-Poceros, G1
Ramírez Peredo, J1
Hernández Andrade, E1
Bustos López, HH1
Bruna, C1
Rossetti, G1
Vado, A1
Racca, E1
Steffenino, G2
Dellavalle, A1
Ribichini, F1
Ferrero, V1
Menardi, E1
Uslenghi, E1
Heintzen, MP1
Heidland, UE1
Klimek, WJ1
Michel, CJ1
Schwartzkopff, B1
Vester, EG1
Strauer, BE1
Rossi, G1
Karádi, I1
Kárpáti, S1
Romics, L1
Venketasubramanian, N1
Singh, J1
Hui, F1
Stoupel, E1
Hirschowitz, BI1
Sullivan, MH1
Clark, NA1
de Swiet, M1
Nelson-Piercy, C1
Elder, MG1
Calvey, TA1
Gough, MJ1
Aronow, WS1
Oemrawsingh, PV2
Tuinenburg, JC1
Schalij, MJ2
Jukema, JW1
Reiber, JH1
Bruschke, AV2
Pizzulli, L1
Lüderitz, B1
Kleiman, NS1
Lincoff, AM3
Kereiakes, DJ1
Miller, DP1
Aguirre, FV1
Weisman, HF1
Raza, K1
Karokis, D1
Kitas, GD1
Udayachalerm, W1
van der Wall, EE1
Martínez Elbal, L1
López Mínguez, JR1
Alonso, M1
Calvo, I1
Insa, L1
Lezaun, R1
Colman, T1
Esplugas, E1
Vázquez, N1
Picó, F1
Amaro, A1
Kurz, X1
Annemans, L1
Dresse, A1
Volpi, A1
Cavalli, A1
Santoro, L1
Negri, E1
Riyazi, N1
Leeda, M1
Huijgens, PC1
van Geijn, HP1
Dekker, GA1
Klootwijk, P1
Meij, S1
Melkert, R1
Lenderink, T1
Pepine, CJ1
Bystedt, J1
Asplund, K1
Higgins, RM1
Connolly, JO1
Hendry, BM1
Forbes, CD2
Popma, JJ2
Weitz, J1
Bittl, JA1
Kuntz, RE1
Lansky, AJ1
Saucedo, J1
Greenberg, A1
Leon, MB1
Maizels, M1
Nordt, TK1
Moser, M1
Kohler, B1
Ruef, J1
Peter, K1
Bode, C1
Gensini, G1
De Caterina, R1
Calver, AL1
Dawkins, KD1
Gray, HH1
Haywood, GA1
Morgan, JM1
Simpson, IA1
Cesmeli, E1
Elewaut, AE1
Kerre, T1
De Buyzere, M1
Afschrift, M1
Elewaut, A1
McCormick, D1
Gurwitz, JH1
Maresta, A1
Balducelli, M1
Cantini, L1
Casari, A1
Chioin, R1
Fontanelli, A1
Monici Preti, PA1
Repetto, S1
Raffaghello, S1
Morice, MC1
García-Dorado, D2
Permanyer-Miralda, G1
Brotons, C1
Calvo, F1
Campreciós, M1
Oliveras, J1
Santos, MT1
Moral, I1
Soler-Soler, J1
Catherwood, E1
Fitzpatrick, WD1
Greenberg, ML1
Holzberger, PT1
Malenka, DJ1
Gerling, BR1
Birkmeyer, JD1
Ogata, Y1
Okinaka, Y1
Takahashi, M1
Pialoux, R1
Coffinet, L1
Derelle, J1
Jankowski, R1
Harrington, RA1
Miller, JM1
Sloan, MA1
Berdan, LG1
MacAulay, CM1
Deckers, J1
Gorter, JW1
De Schryver, EL1
Folland, ED1
Tardy-Poncet, B1
Tardy, B1
Reynaud, J1
Mahul, P1
Mismetti, P1
Mazet, E1
Guyotat, D1
Tsuchikane, E1
Fukuhara, A1
Kobayashi, T2
Kirino, M1
Yamasaki, K1
Izumi, M1
Otsuji, S1
Tateyama, H1
Sakurai, M1
Awata, N1
Atamuradov, MA1
Garaev, TA1
Boysen, G1
Lee, HJ1
Kaldenbach, T1
Schäfer, D1
Bittinger, F1
Klimek, L1
Jauhar, R1
Bergman, G1
Savino, S1
Shaknovich, A1
Parikh, M1
Danenberg, HD1
Hasin, Y1
Gavaghan, BJ1
Kittleson, MD1
McAloose, D1
Steiner, M1
Escolar, G2
Revilla, M1
Obach, V1
Vila, N1
Reverter, JC1
Ordinas, A1
Berntorp, E1
Yoon, Y1
Shim, WH1
Pyun, WB1
Kim, IJ1
Cho, SY1
Robbins, MA1
Marso, SP1
Wolski, K1
Peterson, J1
Brener, S1
Salomon, O1
Huna-Baron, R1
Steinberg, DM1
Kurtz, S1
Seligsohn, U1
Caro, JJ1
Migliaccio-Walle, K1
Le Roux, A1
Rothbart, RM1
McAnulty, JH1
Halperin, JL1
Cruz-Fernández, JM1
López-Bescós, L1
López García-Aranda, V1
Cabadés, A1
Martín-Jadraque, L1
Velasco, JA1
Castro-Beiras, A1
Torres, F1
Marfil, F1
Navarro, E1
Nakai, K1
Tajima, K1
Kishimoto, Y1
Katsura, K1
Kawamura, M1
Hanada, M1
Amakawa, R1
Fujimoto, M1
Fukuhara, S1
Mori, Y1
Tamaki, S1
Minami, N1
Shiku, H1
Ihara, T1
Omine, M1
Kakisita, E1
Hemphill, JC1
Crassard, I1
Niclot, P1
Piette, AM1
Blétry, O1
Berge, E2
Abdelnoor, M1
Nakstad, PH1
Sandset, PM2
Van Langenhove, G1
Vermeersch, P1
Serrano, P1
Kutryk, MJ1
Stockman, D1
Convens, C1
Van den Branden, F1
Vanagt, E1
Albertal, M1
Van den Heuvel, P1
Zeymer, U1
Neuhaus, KL1
Franke, A1
Stinnett, SS1
Weatherley, BD1
Cohen, N1
Almoznino-Sarafian, D1
Alon, I1
Gorelik, O1
Koopfer, M1
Chachashvily, S1
Shteinshnaider, M1
Litvinjuk, V1
Modai, D1
Chen, ZM1
Pan, HC1
Counsell, C1
Liu, LS1
Xie, JX1
Ruzyłło, W1
Gil, R1
Górecka, B1
Purzycki, Z1
Kośmider, M1
Poloński, L1
Lekston, A1
Gasior, M1
Zmudka, K1
Pieniazek, P1
Buszman, P1
Drzewiecki, J1
Ciećwierz, D1
Sadowski, Z1
Thijs, VN1
Gondek, K1
Nucera, E2
Schiavino, D2
Milani, A1
Del Ninno, M1
Misuraca, C1
Buonomo, A1
D'Ambrosio, C1
Paludetti, G1
Patriarca, G2
Nah, DY1
Sarasin, FP2
Gaspoz, JM1
Qasim, A1
Chauhan, A1
More, RS1
Silber, S1
Krischke, I1
Prohaska, M1
Evers, S1
Fischer, M2
Siegel, AM1
Sandor, P1
Kollias, SS1
Borja, J1
Olivella, P1
Modrzyński, M1
Wróbel, B1
Zawisza, E1
Grochowski, P1
Pache, J1
Gaziano, JM1
Skerrett, PJ1
Backues, KA1
Hoover, JP1
Bahr, RJ1
Confer, AW1
Chalman, JA1
Larry, ML1
Schütt, M1
Klüter, H1
Wiedemann, GJ1
Richardt, G1
Sbaï, A1
Wechsler, B1
Amoura, Z1
Godeau, P1
Piette, JC1
Napoli, C1
Cirino, G1
Del Soldato, P1
Sorrentino, R1
Sica, V1
Condorelli, M1
Pinto, A1
Ignarro, LJ1
Farquhar, D1
Hurlen, M1
Hole, T1
Seljeflot, I1
Arnesen, H1
Naber, CK1
Kaiser, CA1
Rahman, YA1
Haude, M1
Baumgart, D1
Chorzempa, A1
Tabloski, P1
Scrutinio, D1
Cimminiello, C1
Marubini, E1
Pitzalis, MV1
Di Biase, M1
Rizzon, P1
Castellino, G1
Godfrey, T1
Branch, DW1
Porter, TF1
Rittenhouse, L1
Caritis, S1
Sibai, B1
Hogg, B1
Lindheimer, MD1
Klebanoff, M1
MacPherson, C1
VanDorsten, JP1
Landon, M1
Paul, R1
Miodovnik, M1
Meis, P1
Thurnau, G1
Kuroda, Y1
Hara, K1
Nakajima, H1
Ikari, Y1
Deva, R1
Ciccoli, R1
Kock, L1
Nigam, S1
Kollum, M1
Bhargava, B1
Mintz, GS1
Kolodgie, FD1
Virmani, R1
Kipp, A1
Allen, JK1
Margolis, S1
Young, DR1
Tanabe, Y1
Nakagawa, I1
Walenga, JM1
Hoppensteadt, D1
Pifarré, R1
Fox, NL1
Forman, S1
Hunninghake, DB1
Campeau, L1
Herd, JA1
Hoogwerf, BJ1
Hickey, A1
Probstfield, JL1
Terrin, ML1
Mukherjee, D1
Chew, DP1
Robbins, M1
Yadav, JS1
Raymond, RE1
Moliterno, DJ1
Raman, V1
Sharkey, A1
Chatila, T1
Walters, MR1
Lees, KR1
Ogasawara, MS1
Iinuma, Y1
Aoki, K1
Katano, K1
Ozaki, Y1
Suzumori, K1
Darius, H2
Bertrand-Hardy, JM1
Humphreys, M1
Yagi, K1
Nakamura, A1
Sekine, A1
Watanabe, H1
Liistro, F1
Grundmann, T1
Töpfner, M1
Sträter, R1
Kurnik, K1
Heller, C1
Schobess, R1
Luigs, P1
Nowak-Göttl, U1
Gottlieb, S1
Arquizan, C1
Lamy, C1
Zuber, M3
Cabanes, L1
Derumeaux, G1
Coste, J1
Rollins, G1
Empson, M1
Lassere, M1
Craig, JC1
Scott, JR1
Granel, B1
Rey, J1
Pache, X1
Swiader, L1
Habib, G1
Mesana, T1
Ene, N1
Disdier, P1
Weiller, PJ1
Morais, J1
Du, ZD1
Cao, QL1
Joseph, A1
Koenig, P1
Heischmidt, M1
Waight, DJ1
Rhodes, J1
Brorson, J1
Hijazi, ZM1
Schweiger, C1
Tavazzi, L1
Valagussa, F1
Goertler, M1
Blaser, T1
Krueger, S1
Hofmann, K1
Baeumer, M1
Wallesch, CW1
Poerner, TC1
Kralev, S1
Voelker, W1
Sueselbeck, T1
Latsch, A1
Pfleger, S1
Schumacher, B1
Haase, KK1
Darbà, J1
Izquierdo, I1
Pontes, C1
Navas, C1
Rovira, J1
Proia, A1
Paesano, R1
Torcia, F1
Annino, L1
Capria, S1
Ferrari, A1
Ferrazza, G1
Pacifici, E1
Pantalissi, A1
Meloni, G1
Baron, D1
Bombardier, C1
Bursey, FR1
Marshall, JR1
Morgan, DG1
Paré, P1
Thomson, AB1
Whittaker, JS1
Lai, KC1
Lam, SK1
Chu, KM1
Hui, WM1
Hu, WH1
Lau, GK1
Wong, WM1
Yuen, MF1
Chan, AO1
Lai, CL1
Wong, J1
Rote, NS1
Thabet, F1
Durand, P1
Chevret, L1
Fabre, M1
Debray, D1
Brivet, M1
Devictor, D1
de Jong, MC1
Monnens, LA1
Goodlin, RC1
Haesslein, HO1
Fleming, J1
Vogel, G1
Fischer, C1
Huyke, R1
Williams, WO1
Gorn, RA1
Elliott, J1
Uberla, K2
McDowell, FH1
Wayoff, M1
Simon, C1
Gazel, P1
Watson, RT1
Fisherman, EW2
Cohen, GN2
Okabe, S2
Takagi, K2
Umeda, N1
Mit'kin, AF1
Hess, H1
Müller-Fassbender, H1
Ingrisch, H1
Mietaschk, A1
Bucher, HJ1
Jacobs, JC1
Hui, RM1
Illig, L1
Crawford, JS2
Ros, AM1
Juhlin, L1
Michaëlsson, G1
Honda, K1
Shaper, AG1
Rittenhouse, M1
McFee, AS1
Aust, JB1
Heuchel, G1
Hässler, W1
Kalendovsky, Z1
Austin, J1
Steele, P1
Lewandowski, RL1
Chan, W1
Piper, DW1
Greig, M1
Coupland, GA1
Hobbin, E1
Shinners, J1
Colin, P1
Noir, A1
Menget, A1
Schirrer, J1
Estavoyer, JM1
Raffi, A1
Calabro, JJ1
Wachtel, AE1
Holgerson, WB1
Repice, MM1
Wu, KK1
Barnes, RW1
Hoak, JC1
Dabrowski, M1
Sleight, P1
Rubowitz, AH1
Porath, A1
Chauvin, M2
Koenig, A2
Brechenmacher, C2
Terres, W1
Ruchelka, A1
Weilepp, A1
Kupper, W1
Hatzis, J1
Noutsis, K1
Hatzidakis, E1
Bassioukas, K1
Perissios, A1
Fouchard, J1
Le, F1
Py, A1
Guérin, F1
Balelli, LA1
Sandborn, T1
Haudenschild, C1
Valeri, R1
Kimata, S1
Harbison, JW1
Arslan, Z1
Tezic, T1
Akinci, A1
Gur, I1
Haspolat, E1
Karademir, S1
Leivonen, M1
Kivilaakso, E1
López Bescós, L1
Ranke, C2
Creutzig, A2
Hecker, H2
Alexander, K3
Luska, G1
Wagner, HH1
Galanski, M1
Avenarius, HJ1
Sankarkumar, T1
Panda, A1
Angra, SK1
Roux, S1
Christeller, S1
Lüdin, E1
Juliard, JM1
Himbert, D1
Sherry, S1
Marder, VJ1
Cherng, WJ1
Chiang, CW1
Kuo, CT1
Lee, CP1
Lee, YS1
Harker, LA2
Bernstein, EF1
Dilley, RB1
Scala, TE1
Sise, MJ1
Hye, RJ1
Otis, SM1
Roberts, RS1
Gent, M1
Théolade, R1
Reymond, MA1
Marbet, G1
Radü, EW1
Gratzl, O1
Green, BK1
Gordon, GD1
Horak, AR1
Millar, RN1
Commerford, PJ1
Presbitero, P1
Rabajoli, F1
Paolillo, V1
Kleiman, N1
Aguirre, F1
Chaitman, BR1
Ross, AM1
Théroux, P1
Waters, D1
Lam, J1
Juneau, M1
McCans, J1
van Oppen, J1
van Ommen, V1
Bär, FW1
de Swart, JB1
van der Veen, FH1
Wellens, HJ1
Alexander, HM1
Steele, PL1
Malcolm, JA1
Rosove, MH1
Brewer, PM1
Lange, J1
Alter, M1
Lai, SM1
Friday, GH1
Sobel, E1
Toedter, LJ1
Beaufils, M2
Bazin, B2
Capitant, C1
Paris, J1
Papa, G1
Schinco, G1
Fais, G1
Dunbabin, D1
Gibson, RS2
Franzosi, MG1
Malacrida, R1
Rübsamen, K1
Eschenfelder, V1
Beisiegel, B1
Hafner, G1
Pop, T1
Treese, N1
Thomassin, JM1
Korchia, D1
Yu, Q1
Kou, W1
Lu, Z1
Yao, K1
Gao, R1
Jia, Y1
Duan, B1
Bulbena, O1
Bravo, ML1
Navarro, C1
de Bono, DP2
Hoffman, W1
Schanzenbächer, P2
Pilger, E1
Lammer, J1
Bertuch, H1
Stark, G1
Decrinis, M1
Pfeiffer, KP1
Krejs, GJ1
Hershey, LA1
Rutsch, W1
Heyndrickx, GR1
Mast, EG1
Wijns, W1
Rensing, BJ1
Vos, J1
Stibbe, J1
Mase, K1
Yasunaga, K1
Taussig, AS1
Cowley, M3
Ahmadi, R3
Altmann, E1
Spranger, C1
Schweizer, J1
Hoffmann, A1
Schmidt, PK1
Bourassa, MG3
Lespérance, J3
Eastwood, C2
Schwartz, L3
Côté, G1
Kazim, F3
Hudon, G1
Himmelreich, G1
Riess, H1
Mohler, ER1
Stark, KS1
Haskel, EJ2
Rogers, WJ1
Babb, JD1
Frederick, M1
Passamani, ER1
Pfisterer, M1
Wenzel, R1
Petch, MC1
Domoto, DT1
Bauman, JE1
Joist, JH1
Taylor, RR1
Gibbons, FA1
Cope, GD1
Cumpston, GN1
Mews, GC1
Luke, P1
Weller, M1
Leo-Kottler, B1
Berg, PA1
Wiethölter, H1
Johansson, SR1
Wiklund, O1
Karlsson, T1
Hjalmarson, A1
Emanuelsson, H1
Neri Serneri, GG1
Poggesi, L1
Trotta, F1
Modesti, PA1
Boddi, M1
Ieri, A1
Margheri, M1
Casolo, GC1
Bini, M1
Lien, IN1
Ryu, SJ1
Tchen, PH1
Chen, CJ1
Wu, SC1
Chen, YC1
Schatz, RA1
Leon, M1
Ellis, SG1
Hirshfeld, JW2
Cabin, HS1
Walker, C1
Stagg, J1
O'Keefe, JH1
Giorgi, LV1
Hartzler, GO1
Good, TH1
Ligon, RW1
Webb, DL1
McCallister, BD1
Grimme, M1
Walter, U1
Kochsiek, K1
Hoffmann, W3
Nitschke, M1
Muche, J1
Kampe, W1
Handreg, W1
Prentice, CR1
Knudtson, ML1
Flintoft, VF1
Roth, DL1
Hansen, JL1
Duff, HJ1
Reece, EA1
Gabrielli, S1
Cullen, MT1
Zheng, XZ1
Hobbins, JC1
Yasuda, T1
Gold, HK1
Yaoita, H1
Leinbach, RC1
Guerrero, JL1
Holt, R1
Fallon, JT1
Collen, D1
Heiss, HW1
Just, H1
Middleton, D1
Deichsel, G1
Schmidt, T1
Tebbe, U1
Schrader, J1
Brune, S1
Kreuzer, H1
van der Laarse, A1
Funke-Küpper, AJ1
Sterkman, LG1
Galema, TW2
Roos, JP2
Henderson, MA1
Goldberg, SH1
Whitworth, H1
Nye, ER1
Ablett, MB1
Robertson, MC1
Ilsley, CD1
Sutherland, WH1
Sigwart, U1
Hawkins, L1
Bach, M1
Dahn, G1
Kothe, K1
Schlake, HP1
Vlot, AJ1
Hené, RJ1
Sixma, JJ1
Ricou, F1
Nukta, E1
Holman, RA1
Davis, M1
Gough, KR1
Gartell, P1
Britton, DC1
Smith, RB1
Wille, B1
Klein, W1
Luha, H1
Eber, B1
Dusleag, J1
Brussee, H1
Rotman, B1
Arafah, M1
Ganassin, L1
Vinazzer, H1
Cox, JL1
Gotlieb, AI1
Barbash, GI1
Rath, S1
Miller, HI1
Roth, A1
Har-Zahav, Y1
Modan, M1
Rotstein, Z1
Batler, A1
Zivelin, A1
Adams, SP1
Feigen, LP1
Saffitz, JE1
Gorczynski, RJ1
Penston, JG1
Wormsley, KG1
Dudczak, R2
Leitha, T1
Jung, M2
Mordel, N1
Sadovsky, E1
Schenker, JG1
Chrobocek, J1
Zichner, R1
Weihrauch, TR1
Biller, J1
Adams, HP1
Godersky, JC1
Loftus, CM1
Mitchell, VL1
Banwart, KJ1
Jones, MP1
Danays, T1
Leor, Y1
Feldman, S1
Rabinowitz, B1
Wilhelm, OG1
Clayman, MD1
Castaigne, A1
Duval-Moulin, AM1
Dutoit, C1
Schlant, RC1
Johnson, MW1
Flynn, HW1
Gass, JD1
Salenius, JP1
Haapanen, A1
Harju, E1
Jokela, H1
Riekkinen, H1
Schreiber, TL1
Macina, G1
McNulty, A1
Bunnell, P1
Kikel, M1
Miller, DH1
Devereux, RB1
Tenney, R1
Zola, B1
Dehmer, GJ1
van den Berg, EK1
Eichhorn, EJ1
Prewitt, JB1
Campbell, WB1
Jennings, L1
Schmitz, JM1
Borhani, NO1
Caneschi, S1
Bonaventi, C1
Finzi, F1
Knatterud, GL1
Stamler, J1
Meier, P1
Bamford, J1
Starkey, I1
Evans, AE1
Follath, F1
Arnold, AE1
Betriu, A1
Col, J1
Dougherty, FC1
von Essen, R1
Lambertz, H1
Lubsen, J1
Davenport, J1
Whittaker, K1
Cohen, LS1
Hood, K1
Gleeson, D1
Ruppin, DC1
Dowling, RH1
Schöfl, R1
Lockshin, MD1
Druzin, ML1
Qamar, T1
Goldberg, RK1
Levine, S1
Fenster, PE1
Weber, MA1
Lorenz, RL1
Schramm, W1
Lam, JY1
Roubin, GS1
Bussmann, WD1
Vallbracht, C2
Austin, GE1
Lynn, M1
Aldridge, HE1
Salvatori, VA1
Henderson, M1
Bonan, R1
David, PR1
Vahanian, A1
Wilhelmsen, L1
Pion, PD1
Shimizu, Y1
Tanaka, T1
Takayama, Y1
Hayashi, T1
Ito, Y1
Abe, M1
Matsuda, M1
Ida, T1
Sakakibara, T1
Obunai, Y1
Tomaru, T1
Uchida, Y1
Sonoki, H1
Sugimoto, T1
Meek, AC1
Chidlow, A1
Greenhalgh, RM1
McCollum, CN1
Romano, PE1
Küpper, AJ1
Marcus, M1
Biedner, B1
Lifshitz, T1
Yassur, Y1
Spławińska, B1
Spławiński, J1
Wallenburg, HC1
Rotmans, N1
Rumore, MM1
Goldstein, GS1
Matthewson, K1
Pugh, S1
Northfield, TC1
Hays, LJ1
Beller, GA1
Moore, CA1
Burwell, LR1
Craddock, GB1
Gascho, JA1
Smucker, ML1
Tedesco, C1
Nygaard, TW1
Meikle, D1
De Martiis, M1
Parenzi, A1
Barlattani, A1
De Martiis, A1
Phillips, BM1
David, TJ1
West, CD1
Głab-Kordecka, E1
Khalfen, ESh1
Ivanova, IA1
Feild, C1
Brady, S1
Lowe, B1
Wohns, RN1
Dupont, C1
Suarez, M1
Krieger, BP1
Long, JB1
Lynch, TG1
Karanfilian, RG1
Hobson, RW1
Herskovits, E1
Famulari, A1
Tamaroff, L1
Gonzalez, AM1
Dominguez, R1
Fraiman, H1
Vila, J1
Collins-Williams, C1
Shekelle, RB1
Gale, M1
Norusis, M1
Rühle, H1
Bunt, TJ1
Haynes, JL1
Rubin, JR1
Goldstone, J1
Bollinger, A1
Brunner, U1
Witteman, GJ1
Brubaker, SJ1
Johnson, M1
Marks, RG1
Gorichkina, LA1
Frolova, MK1
Kuria, VF1
Lowe, GD1
Machado, SG1
Krol, WF1
Barton, BA1
Harrison, MJ1
Marshall, J1
Meadows, JC1
Russell, RW1
Guiraud, B1
Pris, J1
Sheffer, AL1
Miller, GC1
Witham, AC1
Bock, OA2
Timaffy, M1
Búzás, J1
Chrisman, OD1
Snook, GA1
Wilson, TC1
Cochrane, AL1
Burr, ML1
Sweetnam, PM1
Williams, G1
Welsby, E1
Hughes, SJ1
Renton, R1
Mirić, V1
Tomasević, M1
Rybkin, LI1

Clinical Trials (115)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol[NCT02239120]Phase 35,390 participants (Actual)Interventional2014-11-27Completed
Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909]Phase 37,213 participants (Actual)Interventional2014-12-23Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed)
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]Phase 34,881 participants (Actual)Interventional2010-05-28Terminated (stopped due to The trial was halted by the DSMB.)
Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589]Phase 35,100 participants (Actual)Interventional2009-12-31Completed
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]Phase 327,395 participants (Actual)Interventional2013-02-28Completed
International Multicenter Registry on Takotsubo Cardiomyopathy[NCT01947621]4,000 participants (Anticipated)Observational2011-01-31Recruiting
Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613]Phase 3900 participants (Actual)Interventional2022-10-01Completed
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial[NCT06120725]Phase 3580 participants (Actual)Interventional2021-09-01Completed
Novel Biomarkers of Thrombotic Risk[NCT02505217]200 participants (Actual)Observational2015-07-31Completed
"RCT of an Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to Stay Within the Guidelines (SUSTAIN)"[NCT00861081]410 participants (Actual)Interventional2010-01-31Completed
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400]Phase 44,614 participants (Actual)Interventional2015-06-04Completed
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562]Phase 321,379 participants (Actual)Interventional2010-10-31Completed
Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy[NCT06013020]Phase 4374 participants (Anticipated)Interventional2023-08-28Recruiting
Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds[NCT05032053]3,000 participants (Anticipated)Observational [Patient Registry]2022-03-01Recruiting
CRYptogenic STroke And underLying AF Trial[NCT00924638]Phase 4447 participants (Actual)Interventional2009-06-30Completed
A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429]Phase 311,016 participants (Actual)Interventional2018-01-22Completed
A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)[NCT00153660]Phase 3514 participants (Actual)Interventional2005-06-30Completed
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]Phase 31,899 participants (Actual)Interventional2008-03-01Completed
Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864]Phase 4400 participants (Anticipated)Interventional2020-10-01Recruiting
A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720]Phase 313,307 participants (Actual)Interventional2014-01-07Completed
A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: the BVS STEMI STRATEGY-IT Registry[NCT02601781]Phase 4500 participants (Actual)Interventional2015-10-31Active, not recruiting
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606]Phase 4272 participants (Anticipated)Interventional2016-12-31Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452763]Phase 3621 participants (Actual)Interventional2011-10-31Completed
A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456247]Phase 3439 participants (Actual)Interventional2012-03-31Completed
Feasibility of Applying Remote Ischemic Conditioning in Secondary Prevention in Patients With Minor Ischemic Stroke or Transient Ischemic Attack -A Single-arm Futility Study[NCT03004820]167 participants (Actual)Interventional2016-12-06Completed
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775]Phase 2203 participants (Actual)Interventional2013-02-06Completed
Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497]Phase 41,220 participants (Actual)Interventional2015-09-30Completed
Impact of Perioperative Maintenance or Interruption of Low-dose Aspirin on Recurrence Rate and Thrombotic Events After Burr-hole Drainage of Chronic Subdural Hematoma: a Randomized, Placebo Controlled, Double Blinded Study[NCT03120182]142 participants (Anticipated)Interventional2018-02-19Recruiting
The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke[NCT05636748]120 participants (Anticipated)Observational2023-02-28Recruiting
Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform[NCT02311231]Phase 46,012 participants (Actual)Interventional2014-06-30Completed
Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488]Phase 211 participants (Actual)Interventional2018-09-05Completed
Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756]Phase 4200 participants (Anticipated)Interventional2009-03-31Recruiting
Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study[NCT00163267]Phase 2/Phase 380 participants (Actual)Interventional2005-09-30Completed
A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700]78,000 participants (Actual)Observational2006-01-31Active, not recruiting
Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306]Phase 33,020 participants (Actual)Interventional2003-02-28Completed
Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623]Phase 3128 participants (Anticipated)Interventional2020-07-31Not yet recruiting
Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895]Phase 3204 participants (Anticipated)Interventional2021-04-01Not yet recruiting
Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370]Phase 41,884 participants (Actual)Interventional2013-12-13Completed
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism[NCT02064439]Phase 33,365 participants (Actual)Interventional2014-03-05Completed
Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke[NCT01923818]Phase 2/Phase 33,700 participants (Anticipated)Interventional2013-09-30Not yet recruiting
Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046]120 participants (Anticipated)Observational2020-03-11Recruiting
A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System(G-stream) in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359]280 participants (Anticipated)Interventional2022-05-27Recruiting
Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406]474 participants (Actual)Interventional2005-03-31Completed
A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura[NCT05568147]Phase 2/Phase 3100 participants (Anticipated)Interventional2022-10-01Not yet recruiting
Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)[NCT01408186]Phase 3264 participants (Actual)Interventional2011-01-31Completed
Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503]Phase 42,000 participants (Anticipated)Interventional2012-11-30Recruiting
The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872]2,000 participants (Anticipated)Observational2013-05-31Enrolling by invitation
The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases[NCT01867281]Phase 432 participants (Actual)Interventional2013-06-30Completed
Challenge Test for Acetylsalicylic Acid Hypersensitivity[NCT01681615]50 participants (Anticipated)Interventional2012-09-30Not yet recruiting
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452]Phase 325,086 participants (Actual)Interventional2006-06-30Completed
Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China[NCT05316311]194 participants (Anticipated)Interventional2022-05-24Recruiting
The Predictive Value of Retinal Vascular Signs for Patients With Intracranial Artery Stenosis: A Prospective, Continuity Study, Cross-sectional Study[NCT05270746]1,000 participants (Anticipated)Observational2022-02-27Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coron[NCT00402597]Phase 23,490 participants (Actual)Interventional2006-11-30Completed
[NCT00153725]156 participants Interventional2003-02-28Completed
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171]Phase 2/Phase 3150 participants (Anticipated)Interventional2018-08-01Active, not recruiting
Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293]Phase 3140 participants (Anticipated)Interventional2018-06-19Recruiting
To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation - a Prospective, Randomized, Controlled Trial[NCT01624545]368 participants (Actual)Interventional2012-06-01Completed
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445]Phase 4160 participants (Actual)Interventional2019-05-01Completed
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]Phase 420,332 participants (Actual)Interventional2003-08-31Completed
"PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314]142 participants (Actual)Interventional2019-11-20Completed
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591]Phase 313,619 participants (Actual)Interventional2004-11-30Completed
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]228 participants (Actual)Interventional2012-01-31Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]Phase 420 participants (Actual)Interventional2016-06-26Completed
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301]100 participants (Anticipated)Observational2015-09-30Not yet recruiting
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428]159 participants (Actual)Interventional2006-05-31Completed
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044]Phase 330 participants (Anticipated)Interventional2009-04-30Recruiting
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]889 participants (Actual)Interventional2013-06-30Terminated (stopped due to Ethics Committe decision)
Patent Foramen Ovale in Cryptogenic Stroke Study[NCT00697151]Phase 4630 participants (Actual)Interventional1993-06-30Completed
Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial[NCT05907694]714 participants (Anticipated)Interventional2023-12-01Active, not recruiting
European Registry on the Management of Helicobacter Pylori Infection[NCT02328131]10,000 participants (Anticipated)Observational2013-06-30Recruiting
Focal Cerebral Arteriopathy Steroid Trial[NCT06040255]Phase 480 participants (Anticipated)Interventional2023-10-01Not yet recruiting
[NCT00000614]Phase 30 participants Interventional1998-09-30Completed
Retrospective Review on Patients With Recurrent Asthmatic Attacks Requiring Hospitalizations[NCT04479501]2,280 participants (Actual)Observational2017-12-01Completed
A 3 Year Longitudinal Study of the Level of Asthma Control and Treatment of Asthma Patients in Hong Kong[NCT03239431]400 participants (Anticipated)Observational [Patient Registry]2017-09-15Recruiting
Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263]133 participants (Anticipated)Observational2023-11-01Not yet recruiting
Outcomes of Low-dose Colchicine in Patients With Myocardial Infarction: A Randomized Controlled Trial[NCT04218786]Phase 20 participants (Actual)Interventional2025-12-31Withdrawn (stopped due to Due to the pandemic, there were logistical issues in continuing the study.)
Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993]25 participants (Actual)Observational2012-11-30Completed
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]Phase 3105 participants (Anticipated)Interventional2014-04-30Recruiting
Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms[NCT05945563]208 participants (Anticipated)Observational [Patient Registry]2023-01-17Recruiting
Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin[NCT01931852]312 participants (Actual)Interventional2013-09-30Completed
[NCT00000491]Phase 30 participants Interventional1974-10-31Completed
Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414]12 participants Observational2000-10-31Completed
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600]Phase 4400 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475]Phase 448 participants (Actual)Interventional2014-12-10Completed
[NCT00000490]Phase 30 participants Interventional1973-06-30Completed
Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233]400 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073]Phase 1/Phase 295 participants (Actual)Interventional2005-03-31Completed
The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612]7,057 participants (Actual)Observational [Patient Registry]2009-05-31Completed
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261]Phase 41,001 participants (Actual)Interventional2003-04-30Completed
Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591]300 participants Interventional2001-04-30Active, not recruiting
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796]Phase 31,473 participants (Actual)Interventional2006-12-31Active, not recruiting
Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty[NCT00597974]108 participants (Actual)Observational2003-09-30Completed
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655]500 participants (Anticipated)Interventional2017-01-31Completed
Phase II Dose-finding Open Study of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Injection Administered Within 3 Hours After Onset of Hyperacute Ischemic Stroke[NCT04676659]Phase 2240 participants (Actual)Interventional2018-05-12Completed
Thrombolysis Treated by TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Control and Non-inferior Phase Ⅲ Trial, 3T Stroke-Ⅲ[NCT05745259]Phase 31,630 participants (Anticipated)Interventional2022-10-26Recruiting
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Controlled Phase II Trial[NCT05281549]Phase 2225 participants (Anticipated)Interventional2021-05-02Active, not recruiting
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]11,976 participants (Actual)Interventional2016-03-23Completed
French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022]300 participants (Anticipated)Observational [Patient Registry]2022-06-15Recruiting
Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809]Phase 4240 participants (Actual)Interventional2006-08-31Completed
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287]Phase 280 participants (Anticipated)Interventional2014-01-31Recruiting
[NCT00005196]0 participants Observational1986-12-31Completed
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment[NCT04037397]Phase 3120 participants (Anticipated)Interventional2019-09-24Active, not recruiting
Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)[NCT02893215]1,622 participants (Anticipated)Observational [Patient Registry]2016-11-30Recruiting
Laryngeal Manifestations of Connective Tissue Diseases[NCT04582292]50 participants (Anticipated)Observational [Patient Registry]2020-11-01Not yet recruiting
[NCT00000527]Phase 20 participants Interventional1986-08-31Completed
[NCT00000505]Phase 30 participants Interventional1983-04-30Completed
[NCT00000500]Phase 30 participants Interventional1981-09-30Completed
A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311]Phase 470 participants (Actual)Interventional2006-10-31Completed
A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337]Phase 437 participants (Actual)Interventional2006-10-31Completed
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268]Phase 472 participants (Actual)Interventional2019-04-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death

Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)4.80
Acetylsalicylic Acid, Aspirin (ASA) 100 mg5.40

Adjudicated Fatal Bleed

Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated. (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.00
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.05

Adjudicated Intracranial Hemorrhage

"Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.67
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.63

Adjudicated Ischaemic Stroke

Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)3.97
Acetylsalicylic Acid, Aspirin (ASA) 100 mg4.71

Adjudicated Life-threatening Bleed

"Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.76
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.91

Adjudicated Recurrent Stroke

Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, approximately 43 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)4.09
Acetylsalicylic Acid, Aspirin (ASA) 100 mg4.80

All-cause Death

All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)1.24
Acetylsalicylic Acid, Aspirin (ASA) 100 mg1.28

Any Bleed (Investigator-reported)

"This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)15.21
Acetylsalicylic Acid, Aspirin (ASA) 100 mg11.64

Disabling Stroke

Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.55
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.93

First Major Bleed (Adjudicated)

"First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows:~Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or,~Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or,~Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)1.84
Acetylsalicylic Acid, Aspirin (ASA) 100 mg1.33

Incidence Rate of a Major Bleeding Event According to the International Society on Thrombosis and Haemostasis (ISTH) Criteria (Adjudicated)

Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.82
Acetylsalicylic Acid 100 mg OD0.67

Incidence Rate of All-Cause Mortality

All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.88
Acetylsalicylic Acid 100 mg OD1.50

Incidence Rate of Any of the Following: Cardiovascular Death, Recurrent Stroke, Systemic Embolism and Myocardial Infarction

Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD6.20
Acetylsalicylic Acid 100 mg OD5.85

Incidence Rate of Clinically Relevant Non-Major Bleeding Events

Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD3.52
Acetylsalicylic Acid 100 mg OD2.32

Incidence Rate of Intracranial Hemorrhage

Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD0.70
Acetylsalicylic Acid 100 mg OD0.35

Incidence Rate of Life-Threatening Bleeding Events

Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.02
Acetylsalicylic Acid 100 mg OD0.43

Incidence Rate of the Composite Efficacy Outcome (Adjudicated)

Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD5.14
Acetylsalicylic Acid 100 mg OD4.78

Incidence Rate of the Following: Stroke, Ischemic Stroke, Disabling Stroke, Cardiovascular (CV) Death, Myocardial Infarction

"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

,
Interventionevent/100 participant-years (Number)
StrokeIschemic strokeDisabling strokeCV death(includes death due to hemorrhage)Myocardial infarction
Acetylsalicylic Acid 100 mg OD4.714.560.840.660.67
Rivaroxaban 15 mg OD5.114.711.200.990.49

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel141
Placebo167

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel121
Placebo160

Death From Any Cause

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel18
Placebo12

Death From Ischemic Vascular Causes

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel6
Placebo4

Hemorrhagic Stroke

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel5
Placebo3

Ischemic or Hemorrhagic Stroke

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel116
Placebo156

Ischemic Stroke

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel112
Placebo155

Major Hemorrhage

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel23
Placebo10

Major Hemorrhage Other Than Intracranial Hemorrhage

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel17
Placebo7

Minor Hemorrhage

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel40
Placebo13

Myocardial Infarction

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel10
Placebo7

Other Symptomatic Intracranial Hemorrhage

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo0

Symptomatic Intracerebral Hemorrhage

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo2

All-cause Mortality

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg313
Rivaroxaban 5mg + Aspirin Placebo366
Rivaroxaban Placebo + Aspirin 100mg378

All-cause Mortality in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg282

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg389
Rivaroxaban 5mg + Aspirin Placebo453
Rivaroxaban Placebo + Aspirin 100mg516

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg329
Rivaroxaban 5mg + Aspirin Placebo397
Rivaroxaban Placebo + Aspirin 100mg450

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg379
Rivaroxaban 5mg + Aspirin Placebo448
Rivaroxaban Placebo + Aspirin 100mg496

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg353

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg288
Rivaroxaban 5mg + Aspirin Placebo255
Rivaroxaban Placebo + Aspirin 100mg170

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg138

Bleeding

number of participants with the occurrence of a bleeding event leading the participant to seek medical attention (NCT02505217)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
High FcγRIIa Expression6
Low FcγRIIa Expression6

Cardiovascular Event - Myocardial Infarction, Stroke, Death

number of participants with myocardial infarction, stroke, and/or death (NCT02505217)
Timeframe: average duration of follow-up 19 months

InterventionParticipants (Count of Participants)
High FcγRIIa Expression17
Low FcγRIIa Expression6

Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA

"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban24.66
Vitamin K Antagonist35.79

The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin

"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet15.28
Placebo Matching Acetylsalicylic Acid Film Coated Tablet17.73

The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA

"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban57.24
Vitamin K Antagonist69.19

The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin

"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet65.72
Placebo Matching Acetylsalicylic Acid Film Coated Tablet60.56

The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period

"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban24.66
Vitamin K Antagonist35.79

The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period

"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet40.51
Placebo Matching Acetylsalicylic Acid Film Coated Tablet21.03

The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA

"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban15.85
Vitamin K Antagonist17.17

Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization

Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg5.1
Ticagrelor 60 mg4.7
Placebo5.2

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients

A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg2.6
Ticagrelor 60 mg2.3
Placebo1.1

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization

Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg2.9
Ticagrelor 60 mg2.9
Placebo3.4

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization

Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg7.8
Ticagrelor 60 mg7.8
Placebo9.0

AF Detection Rate Within 12 Months

Percentage of subjects with AF detected within 12 months of follow-up (NCT00924638)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Continuous Monitoring12.4
Control Arm2.0

AF Detection Rate Within 6 Months

Percentage of subjects with AF detected within 6 months of follow-up (NCT00924638)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Continuous Monitoring8.9
Control Arm1.4

Clinical Disease Burden and Care Pathway

Incidence of cardiovascular (CV) or stroke/TIA related hospitalizations within 12 months (NCT00924638)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Continuous Monitoring10.5
Control Arm7.2

Health Outcome as Evaluated by EQ-5D Questionnaire

EQ-5D VAS (visual analog scale) quality of life score, which is a continuous measure of quality of life ranging from 0 (worst) to 100 (perfect health). (NCT00924638)
Timeframe: 12 months

Interventionunits on a scale of 0 to 100 (Mean)
Continuous Monitoring78.9
Control Arm76.3

Incidence of Recurrent Stroke or TIA (Transient Ischemic Attack)

Percentage of subjects with recurrent stroke or TIA within 12 months of follow-up (NCT00924638)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Continuous Monitoring7.1
Control Arm9.1

Use of Antiarrhythmic Drugs

Percentage of subjects who were using antiarrhythmic drugs at the 12 months follow-up visit (NCT00924638)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Continuous Monitoring2.0
Control Arm1.6

Use of Oral Anticoagulation (OAC) Drugs

Percentage of subjects who were using OAC drugs at the 12 months follow-up visit (NCT00924638)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Continuous Monitoring14.7
Control Arm6.0

Impact of Patient Assistant Use on AF Diagnosis

AF detection lag (days from AF occurrence to AF diagnosis) characterized by patient assistant (PA) use frequency (NCT00924638)
Timeframe: Follow-up closure

Interventiondays from AF occurrence to AF diagnosis (Mean)
PA used everydayPA used most of the time (5-6 days/week)PA used sometimes (3-4 days/week)PA used rarely (1-2 days/week)PA never usedPA use frequency not reported
Continuous Monitoring14.025.0174.815.392.020.0

Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Moderate/Severe

Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR36
PLACEBO11

Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Severe

Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR28
PLACEBO7

Composite of Subsequent Stroke or Death

Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR303
PLACEBO362

ICH or Fatal Bleeding Event

Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR22
PLACEBO6

Ischaemic Stroke

Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR276
PLACEBO345

Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3

The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR1282
PLACEBO1284

Premature Permanent Discontinuation of IP Due to Bleeding

Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR152
PLACEBO32

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)50
Primary PCI (Group B)43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)59
Primary PCI (Group B)73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)100
Primary PCI (Group B)123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)117
Primary PCI (Group B)135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)77
Primary PCI (Group B)85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)43
Primary PCI (Group B)42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)116
Primary PCI (Group B)135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)31
Primary PCI (Group B)32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)41
Primary PCI (Group B)56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)57
Primary PCI (Group B)72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)9
Primary PCI (Group B)2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)6
Primary PCI (Group B)3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)61
Primary PCI (Group B)45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)206
Primary PCI (Group B)191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)23
Primary PCI (Group B)21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)45
Primary PCI (Group B)41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)19
Primary PCI (Group B)11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)1
Primary PCI (Group B)2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)32
Primary PCI (Group B)38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)10
Primary PCI (Group B)29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)2
Primary PCI (Group B)0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)7
Primary PCI (Group B)4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)8
Primary PCI (Group B)1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)267
Primary PCI (Group B)236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)15
Primary PCI (Group B)5

EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit

"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)

InterventionIndex score (Mean)
Ticagrelor 90 mg0.85
ASA 100 mg0.84

EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit

"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)

InterventionIndex score (Mean)
Ticagrelor 90 mg0.72
ASA 100 mg0.68

EQ-5D at Visit 1 (Enrolment)

"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)

InterventionIndex score (Mean)
Ticagrelor 90 mg0.70
ASA 100 mg0.70

EQ-5D at Visit 2 (Day 7+-2d)

"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)

InterventionIndex score (Mean)
Ticagrelor 90 mg0.80
ASA 100 mg0.79

Net Clinical Outcome

Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg457
ASA 100 mg508

Number of Participants by Severity of Stroke and Overall Disability

"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg1107
ASA 100 mg1194

Number of Participants With All-Cause Death

Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg68
ASA 100 mg58

Number of Participants With Composite of Ischaemic Stroke, MI and CV Death

Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg423
ASA 100 mg475

Number of Participants With Composite of Stroke/MI/Death

Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg442
ASA 100 mg497

Number of Participants With CV Death

Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg41
ASA 100 mg35

Number of Participants With Disabling Stroke

Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg277
ASA 100 mg307

Number of Participants With Fatal Stroke

Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg18
ASA 100 mg17

Number of Participants With Ischaemic Stroke

Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg385
ASA 100 mg441

Number of Participants With MI

Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg25
ASA 100 mg21

Number of Participants With PLATO Major Bleeding Event

"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg31
ASA 100 mg38

Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event

Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study

InterventionParticipants (Number)
Ticagrelor 90 mg82
ASA 100 mg37

Number of Participants With Stroke

Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days

InterventionParticipants (Number)
Ticagrelor 90 mg390
ASA 100 mg450

Change in NIHSS

"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days

,
InterventionParticipants (Number)
<=-5-4-3-2-1012345>5Missing
ASA 100 mg1274388101073113168379311611614450
Ticagrelor 90 mg1324037791088109968167281813610474

Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period

Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel1
Edoxaban3

Number of Participants With Amputations

Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel3
Edoxaban1

Percentage of Participants With First Re-stenosis / Re-occlusion

Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months

Interventionpercentage of participants (Number)
Clopidogrel34.7
Edoxaban30.9

Safety Assessments

"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel30
Edoxaban31

Percentage of Participants With Clinically Relevant Bleeding During Treatment

Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months

,
Interventionpercentage of participants (Number)
Including Access Site Bleeding (IASB)Excluding Access Site Bleed (EASB)
Clopidogrel86
Edoxaban116

Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment

The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months

,
Interventionpercentage of participants (Number)
IASB : Major BleedingIASB: CRNM BleedingIASB: Minor BleedingEASB : Major BleedingEASB : CRNM BleedingEASB : Minor Bleeding
Clopidogrel5420.84317.8
Edoxaban110201519

Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days

The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months

Interventionparticipants (Number)
Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD12
Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD17
Acetylsalicylic (ASA) 100 mg, OD12

Number of Participants With First Treatment-emergent Major Bleeding

"The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months

,,
Interventionparticipants (Number)
Any major bleedingFatal bleedingNon-fatal critical organ bleedNon-fatal non-critical organ bleeding
Acetylsalicylic (ASA) 100 mg, OD3111
Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD5023
Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD6141

Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism

"The primary efficacy outcomes (i.e., recurrent venous thromboembolism [VTE] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism [PE] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months

,,
Interventionparticipants (Number)
CompositeSymptomatic recurrent Deep vein thrombosis (DVT)Symptomatic recurrent PEDeath (PE)Death (unexplained and PE cannot be ruled out)
Acetylsalicylic (ASA) 100 mg, OD50291911
Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD138500
Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD179602

Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism

The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months

,,
Interventionparticipants (Number)
CompositeIschemic strokeNon-CNS systemic embolismMyocardial infarctionSymptomatic recurrent DVTSymptomatic recurrent PEDeath (PE)Death (unexplained and PE cannot be ruled out)Death (cardiovascular: myocardial infarction)Death (cardiovascular: ischemic stroke)
Acetylsalicylic (ASA) 100 mg, OD5621429181100
Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD18410850000
Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD19201960100

Event-free Survival Rate

"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months

InterventionPercentage of participants (Number)
Zilver PTX90.4
PTA (Control)83.9

Primary Patency

Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months

InterventionPercentage of participants (Number)
Zilver PTX82.7
PTA (Control)32.7

First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level

(NCT00335452)
Timeframe: 30 days

Interventionparticipants (Number)
Clopidogrel 300/75/75 mg + ASA Low Dose267
Clopidogrel 300/75/75 mg + ASA High Dose290
Clopidogrel 600/150/75 mg + ASA Low Dose282
Clopidogrel 600/150/75 mg + ASA High Dose240

First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel + ASA High Dose52721125165
Clopidogrel + ASA Low Dose54623126055

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA55722227461
Clopidogrel 600/150/75 mg + ASA52222623759

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA39213222535
Clopidogrel 600/150/75 mg + ASA33013017228

Occurrence of Major Bleeding - ASA Dose Level Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel + ASA High Dose28221673
Clopidogrel + ASA Low Dose28521574

Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel 300/75/75 mg + ASA25519565
Clopidogrel 600/150/75 mg + ASA31323683

Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison

This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Stent trombosis- Definite- Probable
Clopidogrel 300/75/75 mg + ASA20011189
Clopidogrel 600/150/75 mg + ASA1355877

The Composite Endpoint of All Cause Death, Myocardial Infarction (MI) (Including Repeat MI), Stroke (Ischemic, Hemorrhagic or Unknown), or Severe Recurrent Ischemia Requiring Revascularization (Primary Efficacy)

The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210

InterventionPatients (Number)
Placebo83
Riva 5 mg Total Daily Dose (TDD)23
Riva 10 mg TDD55
Riva 15 mg TDD27
Riva 20 mg TDD36

The Composite Endpoint of Cardiovascular Death, Myocardial Infarction (MI), or Stroke

The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210

InterventionPatients (Number)
Placebo63
Riva 5 mg Total Daily Dose (TDD)18
Riva 10 mg TDD40
Riva 15 mg TDD21
Riva 20 mg TDD21

The Composite Endpoint of Death (All Cause), MI (or reMI), Stroke, Severe Recurrent Ischemia Requiring Revascularization, or Thrombolysis in Myocardial Infarction (TIMI) (Major or Minor Bleeding) to Assess the Net Clinical Benefit

The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban. (NCT00402597)
Timeframe: Day 1 to Day 210

InterventionPatients (Number)
Placebo88
Riva 5 mg Total Daily Dose (TDD)24
Riva 10 mg TDD71
Riva 15 mg TDD35
Riva 20 mg TDD48

The Composite Endpoint of Death (All Cause), Myocardial Infarction (MI) (or Repeat MI), or Stroke

The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210

InterventionPatients (Number)
Placebo66
Riva 5 mg Total Daily Dose (TDD)18
Riva 10 mg TDD40
Riva 15 mg TDD21
Riva 20 mg TDD22

The Number of Deaths (All Cause)

The number of patients who died due to any cause from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210

InterventionPatients (Number)
Placebo18
Riva 5 mg Total Daily Dose (TDD)11
Riva 10 mg TDD9
Riva 15 mg TDD4
Riva 20 mg TDD9

Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety)

The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention. (NCT00402597)
Timeframe: Day 1 to Day 210

InterventionPatients (Number)
Placebo36
Riva 5 mg Total Daily Dose (TDD)17
Riva 10 mg TDD109
Riva 15 mg TDD43
Riva 20 mg TDD89

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole1333
Clopidogrel1333

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan1367
Placebo1463

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole916
Clopidogrel898

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan880
Placebo934

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: Randomization to final patient contact

InterventionParticipants (Number)
Telmisartan125
Placebo151

Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel692
Clopidogrel822

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events

The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel797
Clopidogrel938

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel502573
Prasugrel389462

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months

,
InterventionParticipants (Number)
UA/NSTEMI (n=5044, n=5030)STEMI (n=1769, n=1765)All ACS (n=6813, n=6795)
Clopidogrel565216781
Prasugrel469174643

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)

The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel504588
Prasugrel399472

Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events

TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)

,
InterventionParticipants (Number)
TIMI Major or Minor BleedingTIMI Major BleedingTIMI Major Bleeding - Life-threatening (LT)LT - FatalLT - Symptomatic intracranial hemorrage (ICH)LT - Requiring inotropesLT - Requiring surgical interventionLT - Requiring transfusion (>=4 units)TIMI Minor Bleeding
Clopidogrel2311115651781930125
Prasugrel303146852119211945164

Number of Participants With Healed Peptic Ulcer

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Interventionparticipants (Number)
Histamine-2 Receptor Antagonist Group106
Placebo Group101

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm189
Placebo Arm230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm1078
Placebo Arm1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm78
Placebo Arm101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm303
Placebo Arm353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm134
Placebo Arm152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm141
Placebo Arm166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm42
Placebo Arm30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

InterventionParticipants (Count of Participants)
Intervention Arm352
Placebo Arm325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm264
Placebo Arm309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm668
Placebo Arm754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm1506
Placebo Arm1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm214
Placebo Arm246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm26
Placebo Arm25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm54
Placebo Arm43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm9
Placebo Arm12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm23
Placebo Arm30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

InterventionParticipants (Count of Participants)
Intervention Arm290
Placebo Arm333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm8
Placebo Arm21

Change in Nitric Oxide Formation From Baseline to 3 Months

Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)

Interventionng/mL (Mean)
Arm 1 of 5 Randomized Treatment Arms27.6
Arm 2 of 5 Randomized Treatment Arms27.0
Arm 3 of 5 Randomized Treatment Arms31.4
Arm 4 of 5 Randomized Treatment Arms25.7
Arm 5 of 5 Randomized Treatment Arms28.3

Change in Nitric Oxide Formation From Baseline to 3 Months.

Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)

Interventionng/mL (Mean)
1 of 5 Randomized Treatment Arms10.0
2 of 5 Randomized Treatment Arms11.2
3 of 5 Randomized Treatment Arms10.0
4 of 5 Randomized Treatment Arms11.0
5 of 5 Randomized Treatment Arms9.6

Reviews

234 reviews available for aspirin and Recrudescence

ArticleYear
Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.
    JAMA neurology, 2022, 02-01, Volume: 79, Issue:2

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Ischemic Attack

2022
[Idiopathic recurrent pericarditis: review of the literature and the Geneva experience].
    Revue medicale suisse, 2022, Apr-06, Volume: 18, Issue:776

    Topics: Aspirin; Chronic Disease; Colchicine; Humans; Pericarditis; Recurrence

2022
[Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group recommendation].
    Medicina, 2019, Volume: 79, Issue:4

    Topics: Aspirin; Benzodiazepines; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient

2019
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
    Stroke, 2019, Volume: 50, Issue:12

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis.
    American journal of reproductive immunology (New York, N.Y. : 1989), 2020, Volume: 83, Issue:4

    Topics: Abortion, Spontaneous; Animals; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-W

2020
Managing acute and recurrent idiopathic pericarditis.
    JAAPA : official journal of the American Academy of Physician Assistants, 2020, Volume: 33, Issue:1

    Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathiopri

2020
Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?
    Journal of cardiovascular pharmacology, 2020, Volume: 75, Issue:4

    Topics: Administration, Oral; Animals; Aspirin; Blood Coagulation; Coronary Artery Disease; Coronary Thrombo

2020
Should Aspirin Be Prescribed to Prevent Recurrence in Nonarteritic Anterior Ischemic Optic Neuropathy?
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2020, Volume: 40, Issue:3

    Topics: Aspirin; Humans; Optic Neuropathy, Ischemic; Platelet Aggregation Inhibitors; Prescription Drugs; Re

2020
Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:10

    Topics: Anticoagulants; Aspirin; Foramen Ovale, Patent; Humans; Ischemic Stroke; Middle Aged; Randomized Con

2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:8

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug;

2020
Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature.
    The American journal of case reports, 2020, Jul-28, Volume: 21

    Topics: Adult; Antineoplastic Agents; Aspirin; Cytoreduction Surgical Procedures; Humans; Hydroxyurea; Male;

2020
Aspirin after Acute Ischemic Stroke.
    American family physician, 2020, 09-01, Volume: 102, Issue:5

    Topics: Aspirin; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mortality; Odds Ratio; Plate

2020
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2021, Volume: 30, Issue:3

    Topics: Aged; Anti-Inflammatory Agents; Aspirin; Cilostazol; Female; Humans; Intracranial Hemorrhages; Ische

2021
Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies.
    Obstetrics and gynecology clinics of North America, 2021, Volume: 48, Issue:2

    Topics: Adult; Anticoagulants; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Gestational A

2021
[Pericarditis].
    La Revue du praticien, 2021, Volume: 71, Issue:1

    Topics: Aspirin; Colchicine; Humans; Interleukin 1 Receptor Antagonist Protein; Pericarditis; Prospective St

2021
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2017
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
    Stroke, 2017, Volume: 48, Issue:9

    Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Plat

2017
Acute and Recurrent Pericarditis.
    Cardiology clinics, 2017, Volume: 35, Issue:4

    Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chest Pain

2017
Recurrent Ischemic Stroke: Strategies for Prevention.
    American family physician, 2017, Oct-01, Volume: 96, Issue:7

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; P

2017
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    The Cochrane database of systematic reviews, 2017, 12-15, Volume: 12

    Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized

2017
Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism.
    Internal and emergency medicine, 2018, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Biomarker

2018
Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting.
    European journal of preventive cardiology, 2019, Volume: 26, Issue:2

    Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Thrombosis; Dual Anti-Platelet Therapy; Female; Graf

2019
Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients.
    Current pain and headache reports, 2018, Aug-27, Volume: 22, Issue:11

    Topics: Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspiri

2018
The prevention of venous thromboembolism recurrence in the elderly: a still open issue.
    Expert review of hematology, 2018, Volume: 11, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Inc

2018
Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2019, Volume: 57, Issue:2

    Topics: Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, Combinati

2019
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
    Journal of thrombosis and thrombolysis, 2019, Volume: 47, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemor

2019
Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.
    The Cochrane database of systematic reviews, 2018, 12-17, Volume: 12

    Topics: Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Parent

2018
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
    BMJ (Clinical research ed.), 2018, Dec-18, Volume: 363

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack

2018
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials.
    Thrombosis and haemostasis, 2019, Volume: 119, Issue:5

    Topics: Anticoagulants; Aspirin; Canada; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Rea

2019
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
    Blood transfusion = Trasfusione del sangue, 2020, Volume: 18, Issue:1

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Hum

2020
Treatment of acute and recurrent idiopathic pericarditis.
    Circulation, 2013, Apr-23, Volume: 127, Issue:16

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Colchicine; Dis

2013
Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
    Contributions to nephrology, 2013, Volume: 179

    Topics: Aspirin; Cerebrovascular Circulation; Cohort Studies; Endothelium, Vascular; Female; Hemorrhage; Hum

2013
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
    BMJ (Clinical research ed.), 2013, Aug-30, Volume: 347

    Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines;

2013
[Acute herpes simplex virus type 1 retinal necrosis three years after herpes simplex encephalitis].
    Revista de neurologia, 2014, Jan-01, Volume: 58, Issue:1

    Topics: Acyclovir; Antiviral Agents; Aspirin; Cataract Extraction; Causality; Drug Therapy, Combination; Enc

2014
Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.
    Expert review of neurotherapeutics, 2014, Volume: 14, Issue:7

    Topics: Animals; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopid

2014
Colchicine for pericarditis.
    The Cochrane database of systematic reviews, 2014, Aug-28, Issue:8

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colchicine; Humans; Ibuprofen; Indo

2014
Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:11

    Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Fibrin; Fibrinolytic Agents; Humans; Platelet

2014
Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options.
    Expert review of clinical immunology, 2014, Volume: 10, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Colchicine; Drug Therapy, Co

2014
Recurrent Kawasaki disease in a child with retropharyngeal involvement: a case report and literature review.
    Medicine, 2014, Volume: 93, Issue:29

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Humans; Immunoglobulins, Intravenous; Male;

2014
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
    Cerebrovascular diseases (Basel, Switzerland), 2015, Volume: 39, Issue:1

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla

2015
Pharmacotherapy update of acute idiopathic pericarditis.
    Pharmacotherapy, 2015, Volume: 35, Issue:1

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Clinical Trials

2015
Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials.
    Stroke, 2015, Volume: 46, Issue:4

    Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Placebos; Platelet Aggr

2015
Aspirin in secondary prevention of recurrent venous thromboembolism.
    Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:3

    Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence;

2015
Does aspirin reduce recurrence after completing anticoagulant treatment for an idiopathic thromboembolic event?
    Medwave, 2015, Apr-09, Volume: 15, Issue:3

    Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled

2015
Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015, Volume: 15, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colchicine; Dose-Response Relationship, Drug; Drug

2015
Recurrent pericarditis: new and emerging therapeutic options.
    Nature reviews. Cardiology, 2016, Volume: 13, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Azathioprine; Colchicine; Gl

2016
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
    BMC cardiovascular disorders, 2015, Sep-18, Volume: 15

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut

2015
[Gastrointestinal bleeding].
    Gastroenterologia y hepatologia, 2015, Volume: 38 Suppl 1

    Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Transfusion; Celecox

2015
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Anticoagulants; Aspirin; Data Collection; Drug Administration Schedule; Female; Hemorrhage; Humans;

2015
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
    Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2015, Volume: 36, Issue:12

    Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At

2015
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Heart (British Cardiac Society), 2016, 05-15, Volume: 102, Issue:10

    Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage

2016
Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
    European journal of neurology, 2016, Volume: 23, Issue:6

    Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc

2016
Recurrent Pericarditis: Modern Approach in 2016.
    Current cardiology reports, 2016, Volume: 18, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathioprine; Colchicine; Drug Therapy, Combinatio

2016
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
    Lancet (London, England), 2016, Jul-23, Volume: 388, Issue:10042

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Random

2016
Patent foramen ovale and cryptogenic stroke: from studies to clinical practice: Position paper of the Italian Chapter, International Society Cardiovascular Ultrasound.
    International journal of clinical practice, 2016, Volume: 70, Issue:8

    Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Echocardiography; Embolism, Paradoxical; Foramen O

2016
Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:6

    Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Medication Adherence; Recurrence; R

2016
Management of idiopathic venous thromboembolism.
    Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:12

    Topics: Anticoagulants; Aspirin; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Hu

2016
Recurrent pericarditis.
    La Revue de medecine interne, 2017, Volume: 38, Issue:5

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Pericarditis; Pro

2017
Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: Is it time to put the needles away?
    Thrombosis research, 2017, Volume: 151 Suppl 1

    Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Placent

2017
PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Odds Ratio; Platelet Aggregation; Platele

2008
Prediction and prevention of recurrent preeclampsia.
    Obstetrics and gynecology, 2008, Volume: 112, Issue:2 Pt 1

    Topics: Adult; Antihypertensive Agents; Aspirin; Calcium, Dietary; Female; Fetal Growth Retardation; Heparin

2008
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jan-01, Volume: 73, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Drug

2009
Predicting poor outcome from acute upper gastrointestinal hemorrhage.
    Gastroenterology clinics of North America, 2009, Volume: 38, Issue:2

    Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Esophageal and

2009
Anti-phospholipid antibodies and other immunological causes of recurrent foetal loss--a review of literature of various therapeutic protocols.
    American journal of reproductive immunology (New York, N.Y. : 1989), 2009, Volume: 62, Issue:1

    Topics: Abortion, Spontaneous; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Aspirin; Clinical Tri

2009
[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options].
    Praxis, 2009, Nov-18, Volume: 98, Issue:23

    Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypers

2009
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
    Vascular health and risk management, 2009, Volume: 5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Huma

2009
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
    Digestion, 2010, Volume: 81, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr

2010
Aspirin resistance: fact or fiction?
    Arquivos brasileiros de cardiologia, 2010, Volume: 95, Issue:3

    Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio

2010
[Actual review of diagnostics and endovascular therapy of intracranial arterial stenoses].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2011, Volume: 183, Issue:2

    Topics: Angiography, Digital Subtraction; Angioplasty; Aspirin; Brain Infarction; Brain Ischemia; Cerebral A

2011
[Dilemma between gastroprotection and cardiovascular prevention].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:44

    Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases;

2010
[What's new in recurrent pericarditis in 2011?].
    La Revue de medecine interne, 2011, Volume: 32, Issue:12

    Topics: Acute Disease; Algorithms; Aspirin; Colchicine; Disease Progression; Humans; Pericarditis; Recurrenc

2011
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
    Advances in therapy, 2011, Volume: 28, Issue:6

    Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi

2011
Patent foramen ovale and recurrent transient neurological symptoms: a case report and review of literature.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2011, Volume: 94 Suppl 1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Surgical Procedures; Echocardiography, Tra

2011
[Decreasing incidence of stent thrombosis].
    Annales de cardiologie et d'angeiologie, 2011, Volume: 60, Issue:6

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap

2011
Promises of PAR-1 inhibition in acute coronary syndrome.
    Current cardiology reports, 2012, Volume: 14, Issue:1

    Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Imines; Lactones; Male; Myocardial Ischemia; Plate

2012
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
    Stroke, 2012, Volume: 43, Issue:4

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab

2012
[Patent foramen ovale and stroke].
    Fortschritte der Neurologie-Psychiatrie, 2012, Volume: 80, Issue:5

    Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Platelet Aggregation In

2012
The management of stroke patients by neurologists: common questions and new observations.
    Seminars in neurology, 2002, Volume: 22, Issue:1

    Topics: Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Case Management; Cl

2002
Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome).
    Current rheumatology reports, 2002, Volume: 4, Issue:5

    Topics: Acute Disease; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Monitoring; Heparin, Low-Mol

2002
Interventional therapy for coronary artery disease.
    American journal of respiratory and critical care medicine, 2002, Sep-15, Volume: 166, Issue:6

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy, Coronary; B

2002
State of the art--a journey through the world of antithrombotic therapy.
    Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3

    Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A

2002
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
    Zeitschrift fur Kardiologie, 2002, Volume: 91 Suppl 2

    Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon

2002
[Antiphospholipid syndrome].
    Annales de cardiologie et d'angeiologie, 2002, Volume: 51, Issue:3

    Topics: Adult; Aged; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Femal

2002
[Antithrombotic therapy for ischemic cerebrovascular accident].
    Archives des maladies du coeur et des vaisseaux, 2002, Volume: 95 Spec No 7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Fibrinolytic Agents; Humans; Recurrenc

2002
[Etiology and pathogenesis of inflammatory bowel diseases].
    Praxis, 2002, Nov-20, Volume: 91, Issue:47

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Co

2002
[Therapy of chronic inflammatory bowel diseases].
    Praxis, 2002, Nov-20, Volume: 91, Issue:47

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2002
[The best of thrombosis in 2002].
    Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96 Spec No 1

    Topics: Abciximab; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ster

2003
[Secondary prevention after ischemic stroke].
    Praxis, 2003, Jan-29, Volume: 92, Issue:5

    Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorv

2003
[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2003, Jun-26, Volume: 123, Issue:13-14

    Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Thrombosis; Drug Therapy, Combination; Fi

2003
Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
    British journal of clinical pharmacology, 2003, Volume: 56, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc

2003
[Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Zeitschrift fur Gastroenterologie, 2003, Volume: 41, Issue:8

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Gastrointestinal

2003
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome.
    Current rheumatology reports, 2003, Volume: 5, Issue:5

    Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Evidence-Based Medicine; Humans; International N

2003
[Which antithrombotic treatment should be used in the treatment of an elderly patient with chronic atrial fibrillation?].
    Presse medicale (Paris, France : 1983), 2003, Jul-26, Volume: 32, Issue:25

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibril

2003
[Stenosis of the carotid arteries].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2003, Volume: 56, Issue:5-6

    Topics: Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy; Humans; Recurrence;

2003
[Lacunar infarcts].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:9

    Topics: Adult; Aged; Aspirin; Autopsy; Brain; Carotid Stenosis; Cerebral Infarction; Dementia; Female; Fibri

2003
[Cryptogenic stroke and patent foramen ovale].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:9

    Topics: Administration, Oral; Adult; Anticoagulants; Aspirin; Echocardiography, Transesophageal; Follow-Up S

2003
[Carotid stenosis: diagnosis, patient selection, therapy].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:9

    Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Carotid St

2003
Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing.
    Alimentary pharmacology & therapeutics, 2004, Volume: 19 Suppl 1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Helicobacter pylori; Huma

2004
Refractory Kawasaki disease.
    The Pediatric infectious disease journal, 2004, Volume: 23, Issue:5

    Topics: Anti-Inflammatory Agents; Aspirin; Cyclosporine; Drug Therapy, Combination; Fever; Humans; Immunoglo

2004
Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy.
    European journal of obstetrics, gynecology, and reproductive biology, 2004, Jun-15, Volume: 114, Issue:2

    Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Arteries; Aspirin; Female; Fetal Deat

2004
Nasal polyps.
    Hospital medicine (London, England : 1998), 2004, Volume: 65, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bacterial Infections; Drug Hypersensitivit

2004
Clopidogrel: how good is it and how does it work?
    Current cardiology reports, 2004, Volume: 6, Issue:4

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination;

2004
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:2

    Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspir

2004
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
    Archives of internal medicine, 2004, Oct-25, Volume: 164, Issue:19

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia

2004
[Treatment and prophylaxis of an acute migraine attack].
    MMW Fortschritte der Medizin, 2004, Sep-02, Volume: 146, Issue:35-36

    Topics: Acupuncture Therapy; Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Analgesics; A

2004
Stroke prevention. MATCHing therapy to the patient with TIA.
    Postgraduate medicine, 2005, Volume: 117, Issue:1

    Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc

2005
Post-varicella arteriopathy of childhood: natural history of vascular stenosis.
    Neurology, 2005, Feb-22, Volume: 64, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiog

2005
[Digestive bleeding and anti-inflammatory drugs at the teaching hospital of Brazzaville].
    Bulletin de la Societe de pathologie exotique (1990), 2004, Volume: 97, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Congo; Femal

2004
[Patent foramen ovale and stroke].
    Archives des maladies du coeur et des vaisseaux, 2004, Volume: 97, Issue:10

    Topics: Adult; Age of Onset; Aspirin; Heart Septal Defects, Atrial; Humans; Middle Aged; Platelet Aggregatio

2004
Anticoagulation therapy in the antiphospholipid syndrome: recent advances.
    Current opinion in pulmonary medicine, 2005, Volume: 11, Issue:5

    Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Kidney Transplantation; Pregnanc

2005
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Journal of cardiovascular pharmacology and therapeutics, 2005, Volume: 10, Issue:3

    Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates

2005
[Preventing cerebrovascular accidents during atrial fibrillation].
    Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18

    Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver

2005
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
    Orvosi hetilap, 2005, Oct-09, Volume: 146, Issue:41

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel;

2005
[Atheromatosis of the thoracic aorta and risk of stroke].
    Giornale italiano di cardiologia (2006), 2006, Volume: 7, Issue:5

    Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Clopidogrel; Controlled

2006
Major arterial involvement and review of Behcet's disease.
    Annals of vascular surgery, 2007, Volume: 21, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Aneurysm, False; Anticoagulants; Aortic Aneurysm, Abdominal; Arteria

2007
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
    Circulation, 2007, Mar-27, Volume: 115, Issue:12

    Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr

2007
[Aspirin].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Oct-28, Volume: 64 Suppl 7

    Topics: Aspirin; Humans; Recurrence; Stroke

2006
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:5

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial

2007
Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
    Neurology, 2007, Aug-07, Volume: 69, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Case-Control Studies; Cohort Stu

2007
[The antiphospholipid syndrome, an update].
    Anales de medicina interna (Madrid, Spain : 1984), 2007, Volume: 24, Issue:5

    Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphosph

2007
PRO: Should aspirin be used in all women older than 65 years to prevent stroke?
    Preventive cardiology, 2007,Fall, Volume: 10 Suppl 4

    Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cost of Illness; Evidence-Based Practice; Femal

2007
[Antiplatelet and anticoagulant treatment after percutaneous transluminal angioplasty for peripheral arteriosclerosis. Survey of a Cochrane review].
    Ugeskrift for laeger, 2007, Sep-24, Volume: 169, Issue:39

    Topics: Angioplasty, Balloon; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Evidence-Based Medici

2007
[Latest developments: management and treatment of preeclampsia].
    Journal de gynecologie, obstetrique et biologie de la reproduction, 2008, Volume: 37, Issue:1

    Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Aspirin; Calcium; Calcium Channel Blockers; Female

2008
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:1

    Topics: Adult; Aged; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Tolerance; E

2008
Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis.
    International journal of cardiology, 2008, Aug-18, Volume: 128, Issue:2

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Drug Resistance; Humans; Platel

2008
Chronic antithrombotic therapy in post-myocardial infarction patients.
    Cardiology clinics, 2008, Volume: 26, Issue:2

    Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip

2008
Update in treatment of peptic ulcer disease.
    Missouri medicine, 1984, Volume: 81, Issue:11

    Topics: Adult; Aged; Alcohol Drinking; Aluminum; Antacids; Anti-Ulcer Agents; Aspirin; Bismuth; Cimetidine;

1984
Cardiac death prevention in post-myocardial infarction patients: a review.
    Acta cardiologica. Supplementum, 1980, Issue:25

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu

1980
[Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics].
    Deutsche medizinische Wochenschrift (1946), 1981, Apr-24, Volume: 106, Issue:17

    Topics: Adrenergic beta-Antagonists; Alprenolol; Anti-Arrhythmia Agents; Aspirin; Dipyridamole; Female; Fibr

1981
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
    British medical journal (Clinical research ed.), 1982, Oct-23, Volume: 285, Issue:6349

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe

1982
[Prevention of myocardial infarction by chemotherapy].
    Nihon rinsho. Japanese journal of clinical medicine, 1982, Volume: 40, Issue:11

    Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Blood Platelets

1982
Cardiovascular involvement in Kawasaki syndrome.
    Southern medical journal, 1983, Volume: 76, Issue:3

    Topics: Adrenal Cortex Hormones; Age Factors; Arrhythmias, Cardiac; Arteritis; Aspirin; Cardiovascular Disea

1983
Changing concepts of pathophysiology, prognosis, and therapy in acute myocardial infarction.
    The American journal of medicine, 1983, Volume: 74, Issue:5

    Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Coronary Vasospasm; Death, Sudden; Dipyridam

1983
Percutaneous transluminal coronary angioplasty.
    The American journal of the medical sciences, 1984, Volume: 288, Issue:2

    Topics: Angina, Unstable; Angioplasty, Balloon; Animals; Aspirin; Calcium Channel Blockers; Coronary Artery

1984
[Allergic and pseudoallergic skin reactions to drugs and food additives].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1983, May-17, Volume: 72, Issue:20

    Topics: Aspirin; Chronic Disease; Dermatitis, Contact; Drug Hypersensitivity; Drug Tolerance; Female; Food A

1983
Platelet inhibitors for TIAs. A review of prospective drug trial results.
    Postgraduate medicine, 1984, Volume: 75, Issue:5

    Topics: Aged; Aspirin; Clofibrate; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemic Attack,

1984
Gastroduodenal damage due to drugs, alcohol and smoking.
    Clinics in gastroenterology, 1984, Volume: 13, Issue:2

    Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Aspirin; Ethanol; Gastric Mucosa; Gastrointestinal

1984
[Primary thrombocyte reactions in hemostasis and thrombogenesis and the possibilities of influencing them by drugs].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1984, May-15, Volume: 39, Issue:10

    Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation;

1984
[Treatment of thrombosis and prevention of recurrence].
    Lakartidningen, 1980, Jun-04, Volume: 77, Issue:23

    Topics: Aspirin; Heparin; Humans; Prognosis; Recurrence; Thrombosis

1980
[Interference in platelet-fibrinogen system for prevention and therapy of myocardial infarct].
    Deutsche medizinische Wochenschrift (1946), 1982, Jan-15, Volume: 107, Issue:2

    Topics: Angina Pectoris; Anticoagulants; Aspirin; Fibrinolysis; Humans; Myocardial Infarction; Recurrence

1982
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1981, Oct-01, Volume: 34, Issue:19

    Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial

1981
Some issues concerning treatment in patients after myocardial infarction.
    Archives des maladies du coeur et des vaisseaux, 1995, Volume: 88 Spec No 3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Myocardial Infarction; Recurrence; Time F

1995
[Radiofrequency ablation in permanent ectopic left atrial tachycardia].
    Deutsche medizinische Wochenschrift (1946), 1995, Nov-10, Volume: 120, Issue:45

    Topics: Adult; Aspirin; Catheter Ablation; Chemotherapy, Adjuvant; Electrocardiography; Female; Follow-Up St

1995
[Prevention of reinfarction with 100 mg or 30 mg ASS daily?].
    Zeitschrift fur Kardiologie, 1995, Volume: 84, Issue:5

    Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Pla

1995
What do we really know about secondary prevention after myocardial infarction?
    The Canadian journal of cardiology, 1995, Volume: 11 Suppl A

    Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Competence; Humans; Life Style; Myocardial Infarction

1995
Medical treatment for stroke prevention.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Prevention of myocardial reinfarction. Recommendations based on results of drug trials.
    Postgraduate medicine, 1993, Nov-01, Volume: 94, Issue:6

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic

1993
[Coronary disease: benefits of aspirin. What dose for which disease?].
    Annales de cardiologie et d'angeiologie, 1994, Volume: 43, Issue:4

    Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female;

1994
Maintenance therapy for peptic ulcer--who needs it?
    Gastroenterologia Japonica, 1993, Volume: 28 Suppl 5

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Helicobacter Infections; Heli

1993
The use of aspirin in cardiovascular disease.
    The Journal of cardiovascular nursing, 1993, Volume: 8, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Posto

1993
The role of dipyridamole in the therapy of vascular disease.
    Geriatrics, 1993, Volume: 48, Issue:1

    Topics: Animals; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Survival; Heart Valve Prosthesis; Huma

1993
When do vascular surgeons prescribe antiplatelet therapy? Current attitudes.
    European journal of vascular surgery, 1993, Volume: 7, Issue:1

    Topics: Angioplasty, Balloon; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vascular; Humans; Is

1993
Kawasaki disease in Adelaide: a review.
    Journal of paediatrics and child health, 1993, Volume: 29, Issue:2

    Topics: Adolescent; Anti-Bacterial Agents; Aspirin; Cardiovascular Diseases; Child; Child, Preschool; Female

1993
Incidence, natural history, and risk factors in lacunar infarction.
    Advances in neurology, 1993, Volume: 62

    Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cerebral Infarction; Diabetic Angiopathies; Fem

1993
[Secondary prevention of ischemic cardiopathy].
    Cardiologia (Rome, Italy), 1995, Volume: 40, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents;

1995
Pharmacologic treatment of recurrent pediatric headache.
    Pediatric annals, 1995, Volume: 24, Issue:9

    Topics: Acetaminophen; Adolescent; Adrenal Cortex Hormones; Analgesics; Aspirin; Child; Child, Preschool; Er

1995
Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies.
    American journal of hematology, 1996, Volume: 51, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Aspirin; Combined Modality Therapy; Diagnostic Errors; Dipyridamole;

1996
Oral anticoagulant treatment with and without aspirin.
    Thrombosis and haemostasis, 1995, Volume: 74, Issue:1

    Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridam

1995
[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia].
    Der Nervenarzt, 1995, Volume: 66, Issue:12

    Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ischemi

1995
[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage].
    Der Nervenarzt, 1995, Volume: 66, Issue:12

    Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra

1995
Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction.
    Archives of internal medicine, 1996, Jul-22, Volume: 156, Issue:14

    Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Hospitalization; Humans; Myocardial In

1996
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
    JAMA, 1996, Sep-11, Volume: 276, Issue:10

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Hemorrhage; He

1996
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
    BMJ (Clinical research ed.), 1996, Sep-14, Volume: 313, Issue:7058

    Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Myoc

1996
Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins?
    Thrombosis research, 1996, Volume: 81, Issue:2 Suppl

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Disease

1996
Pharmacologic therapies after myocardial infarction.
    The American journal of medicine, 1996, Oct-08, Volume: 101, Issue:4A

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic

1996
[The use of acetylsalicylic acid in IHD].
    Terapevticheskii arkhiv, 1996, Volume: 68, Issue:8

    Topics: Angina, Unstable; Aspirin; Coronary Vessels; Cyclooxygenase Inhibitors; Dose-Response Relationship,

1996
Stent thrombosis. Closing in on the best preventive treatment.
    Circulation, 1997, Mar-04, Volume: 95, Issue:5

    Topics: Aspirin; Atherectomy; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Recurrence; Stents;

1997
[Low molecular weight heparin in unstable angina].
    Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl

    Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap

1996
[Antiplatelet therapy during coronary endoprosthesis placement].
    Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combin

1996
Recent advances in stroke management.
    Journal of the Medical Association of Georgia, 1997, Volume: 86, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Female; Fibrinolytic Agents; Humans; In

1997
Aspirin in the treatment and prevention of cardiovascular disease.
    Annual review of public health, 1997, Volume: 18

    Topics: Aged; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Middle Aged

1997
Antiplatelet agents prevent cardiac events in patients with coronary artery disease.
    Internal medicine (Tokyo, Japan), 1998, Volume: 37, Issue:2

    Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Europe; Humans; Japan; Myocardial Infarction; P

1998
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
    Nederlands tijdschrift voor geneeskunde, 1998, Feb-07, Volume: 142, Issue:6

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel

1998
Alkalinization and hemodialysis in severe salicylate poisoning: comparison of elimination techniques in the same patient.
    Clinical nephrology, 1998, Volume: 50, Issue:3

    Topics: Acute Disease; Adult; Alcoholic Intoxication; Aspirin; Bipolar Disorder; Drug Overdose; Epilepsy, To

1998
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
    Thrombosis research, 1998, Sep-15, Volume: 92, Issue:1 Suppl 1

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I

1998
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome.
    Lupus, 1998, Volume: 7 Suppl 2

    Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin

1998
Antithrombotic therapy in patients undergoing coronary angioplasty.
    Chest, 1998, Volume: 114, Issue:5 Suppl

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Coronary

1998
Clinical profile of saruplase: angiographic findings.
    International journal of clinical practice. Supplement, 1998, Volume: 99

    Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Fibrinolytic Agents; Heparin; Humans; Myoca

1998
Management of atrial fibrillation: out-of-hospital approach.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; Heart

1999
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
    Journal of internal medicine, 1999, Volume: 246, Issue:3

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors

1999
[Acute pericarditis: etiology, diagnosis, course, complications and treatment].
    La Revue du praticien, 1999, Nov-15, Volume: 49, Issue:18

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Tamponade; Diagnosis, Diffe

1999
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
    The Medical clinics of North America, 2000, Volume: 84, Issue:1

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr

2000
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
    Geriatrics, 2000, Volume: 55, Issue:3

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Brai

2000
[Aspirin and cerebral ischemic accidents].
    La Revue de medecine interne, 2000, Volume: 21 Suppl 1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Infarction; Clinica

2000
[Aspirin and antiphospholipid syndrome].
    La Revue de medecine interne, 2000, Volume: 21 Suppl 1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Arteriosc

2000
Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
    Zeitschrift fur Kardiologie, 2000, Volume: 89 Suppl 4

    Topics: Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Cerebral Hemorrhage; Clinical Trials, Phase

2000
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha

2000
Failed thrombolysis in myocardial infarction.
    International journal of cardiology, 2000, Volume: 75, Issue:1

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As

2000
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
    Medicina clinica, 2000, Nov-04, Volume: 115, Issue:15

    Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari

2000
Aspirin in the treatment and prevention of cardiovascular disease.
    Haemostasis, 2000, Volume: 30 Suppl 3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie

2000
Stroke prevention: antiplatelet and antithrombolytic therapy.
    Haemostasis, 2000, Volume: 30 Suppl 3

    Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog

2000
Post myocardial infarction treatment in the older adult.
    The Nurse practitioner, 2001, Volume: 26, Issue:3

    Topics: Adrenergic beta-Antagonists; Aftercare; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors;

2001
The epidemiology of the antiphospholipid syndrome: who is at risk?
    Current rheumatology reports, 2001, Volume: 3, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Animals; Antibodies, Anticardiolipin; Antibodies, Antiphosphol

2001
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.
    Obstetrics and gynecology, 2002, Volume: 99, Issue:1

    Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Th

2002
[Is chronic or recurrent idiopathic pericarditis an autonomous inflammatory disease?].
    La Revue de medecine interne, 2001, Volume: 22, Issue:12

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; As

2001
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Cerebrovascular diseases (Basel, Switzerland), 2002, Volume: 13 Suppl 1

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art

2002
[Heparin or aspirin in the treatment of acute cerebral infarction?].
    La Revue du praticien, 2001, Dec-01, Volume: 51, Issue:19

    Topics: Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Fibrinolytic Agents; Heparin; Humans; Patient Sel

2001
Thrombotic thrombocytopenic purpura and pregnancy: a case report and a review of the literature.
    Annals of hematology, 2002, Volume: 81, Issue:4

    Topics: Adult; Aspirin; Disease Management; Female; Heparin; Humans; Practice Guidelines as Topic; Pregnancy

2002
Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2002, Volume: 16, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Dose

2002
[Anticoagulation therapy in myocardial infarction (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1975, Apr-08, Volume: 64, Issue:14

    Topics: Anticoagulants; Aspirin; Coumarins; Dipyridamole; Fibrinolysis; Heparin; Humans; Leg; Myocardial Inf

1975
[Prevention of complications and the methods of increasing the safety of percutaneous transluminal coronary angioplasty (PTCA)].
    Kardiologia polska, 1992, Volume: 37, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Catheterization; Coronary Disease; Extracorporeal Circulati

1992
The secondary prevention of myocardial infarction by drug treatment; excluding lipid lowering agents.
    Clinical and experimental hypertension. Part A, Theory and practice, 1992, Volume: 14, Issue:1-2

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Humans; Hypert

1992
[Isolated atrial fibrillation. The risk of embolism and its prevention].
    Presse medicale (Paris, France : 1983), 1992, Jun-27, Volume: 21, Issue:24

    Topics: 4-Hydroxycoumarins; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Aspirin; Atrial Fibr

1992
[Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction].
    Revista espanola de cardiologia, 1992, Volume: 45 Suppl 2

    Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans;

1992
Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis.
    Journal of the American College of Cardiology, 1992, Mar-01, Volume: 19, Issue:3

    Topics: Angina Pectoris; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Female; Humans; Male; Meta-An

1992
[Can coronary "restenosis" after percutaneous angioplasty be prevented?].
    Presse medicale (Paris, France : 1983), 1992, Feb-01, Volume: 21, Issue:4

    Topics: Adrenal Cortex Hormones; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Coronary

1992
[Embolic complications of chronic atrial fibrillation].
    Archives des maladies du coeur et des vaisseaux, 1992, Volume: 85, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Heart Valve Diseases; Humans; Primary Prevention; Pro

1992
[Angioplasty in unstable angina].
    Cardiologia (Rome, Italy), 1992, Volume: 37, Issue:2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Combined Modali

1992
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
    Drugs, 1991, Volume: 42 Suppl 2

    Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele

1991
Perspectives on therapeutic interventions in patients with acute myocardial infarction: viewpoints after the GISSI-2 results.
    Clinical cardiology, 1991, Volume: 14, Issue:7

    Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Recurrence; Streptokinas

1991
[Nasosinusal polyposis. Indications. Results. Apropos of 222 ethmoidectomies].
    Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 1991, Volume: 108, Issue:8

    Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Ethmoid Sinus; Female; Humans; Male; Middle Age

1991
What is the role of invasive intervention after coronary thrombolysis?
    European heart journal, 1991, Volume: 12 Suppl G

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Heparin; Humans; Myocardial Infa

1991
Stroke prevention in women: role of aspirin versus ticlopidine.
    The American journal of medicine, 1991, Volume: 91, Issue:3

    Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Meta-Analysis as Topic; Recurrence; Sex Factors;

1991
A review of secondary coronary prevention with dipyridamole and aspirin.
    Thrombosis research. Supplement, 1990, Volume: 12

    Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infar

1990
Recurrent adverse pregnancy outcome and antiphospholipid antibodies.
    American journal of obstetrics and gynecology, 1990, Volume: 163, Issue:1 Pt 1

    Topics: Adrenal Cortex Hormones; Antibodies; Aspirin; Blood Coagulation Factors; Cardiolipins; Female; Human

1990
Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty.
    The Canadian journal of cardiology, 1988, Volume: 4, Issue:4

    Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Cyclooxygenase Inhibitors

1988
Management of acute non-Q-wave myocardial infarction: role of prophylactic pharmacotherapy and indications for predischarge coronary arteriography.
    Clinical cardiology, 1989, Volume: 12, Issue:7 Suppl 3

    Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Electrocardiog

1989
[Optimal dosage of acetylsalicylic acid. I: Use in primary and secondary prevention of myocardial infarct and following aortocoronary bypass operation].
    Medizinische Klinik (Munich, Germany : 1983), 1989, Jan-15, Volume: 84, Issue:1

    Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Po

1989
[Aspirin in coronary heart disease].
    Harefuah, 1989, Jan-01, Volume: 116, Issue:1

    Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence

1989
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
    Circulation, 1989, Volume: 80, Issue:4

    Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar

1989
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
    Circulation, 1989, Volume: 80, Issue:4

    Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar

1989
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
    Circulation, 1989, Volume: 80, Issue:4

    Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar

1989
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
    Circulation, 1989, Volume: 80, Issue:4

    Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar

1989
After coronary thrombolysis and reperfusion, what next?
    Journal of the American College of Cardiology, 1989, Volume: 14, Issue:4

    Topics: Animals; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myoca

1989
[Platelet antiaggregants and coronary pathology].
    La Revue du praticien, 1989, Nov-01, Volume: 39, Issue:25

    Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence

1989
Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty.
    Circulation, 1989, Volume: 80, Issue:6 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Coronar

1989
Prevention of restenosis after coronary angioplasty: a pharmacological approach.
    European heart journal, 1989, Volume: 10 Suppl G

    Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical

1989
Secondary prevention in elderly survivors of heart attacks.
    American family physician, 1988, Volume: 38, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cholesterol; Female; Humans; Hypertension; Male; Myocard

1988
Medical prophylaxis for the post myocardial infarct patient.
    Cardiology clinics, 1988, Volume: 6, Issue:1

    Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T

1988
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
    The American journal of cardiology, 1987, Jul-31, Volume: 60, Issue:3

    Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Aspirin; Clinical Trials as Topic; Dipyr

1987
Influence of the methodology of percutaneous transluminal coronary angioplasty on restenosis.
    The American journal of cardiology, 1987, Jul-31, Volume: 60, Issue:3

    Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Coronary Thrombosis; Huma

1987
[Pharmacological prevention of coronary thrombosis].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1987, Jun-29, Volume: 42, Issue:26

    Topics: Aspirin; Blood Coagulation; Coronary Disease; Coronary Thrombosis; Humans; Recurrence

1987
Prevention of recurrent myocardial infarction and sudden death with aspirin therapy.
    Drug intelligence & clinical pharmacy, 1987, Volume: 21, Issue:12

    Topics: Aspirin; Death, Sudden; Humans; Myocardial Infarction; Prognosis; Recurrence

1987
Pathogenesis and management of arthropathy in cystic fibrosis.
    Journal of the Royal Society of Medicine, 1986, Volume: 79 Suppl 12

    Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Joint Diseases

1986
Asymptomatic carotid disease.
    Surgery, gynecology & obstetrics, 1985, Volume: 160, Issue:1

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor

1985
Clinical spectrum of adverse reactions to tartrazine.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1985, Volume: 22, Issue:3

    Topics: Angioedema; Aspirin; Asthma; Azo Compounds; Child; Child, Preschool; Dermatitis, Contact; Diet; Food

1985

Trials

340 trials available for aspirin and Recrudescence

ArticleYear
Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
    Circulation, 2021, 11-30, Volume: 144, Issue:22

    Topics: Administration, Oral; Age Factors; Aged; Aspirin; Atrial Fibrillation; Body Mass Index; Dabigatran;

2021
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2021, 12-01, Volume: 78, Issue:12

    Topics: Adult; Aged; Aspirin; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Humans; Mal

2021
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
    Clinical neurology and neurosurgery, 2022, Volume: 215

    Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence

2022
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
    European journal of preventive cardiology, 2020, Volume: 27, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug T

2020
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
    Journal of neurology, 2020, Volume: 267, Issue:3

    Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle

2020
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2020, Volume: 96, Issue:7

    Topics: Aged; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female

2020
Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
    Arteriosclerosis, thrombosis, and vascular biology, 2020, Volume: 40, Issue:3

    Topics: Aged; Aspirin; Biomarkers; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal

2020
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2020, Volume: 95 Suppl 1

    Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substi

2020
Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE.
    European journal of neurology, 2020, Volume: 27, Issue:5

    Topics: Aspirin; Drug Therapy, Combination; Female; Humans; Infarction; Male; Middle Aged; Platelet Aggregat

2020
Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Foramen Ov

2020
Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack: Secondary Analysis of the POINT Randomized Clinical Trial.
    JAMA neurology, 2020, 05-01, Volume: 77, Issue:5

    Topics: Aged; Aspirin; Black or African American; Clopidogrel; Female; Humans; Ischemic Attack, Transient; I

2020
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
    Stroke, 2020, Volume: 51, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Dabigatran; Double-Blind Method; Female; Fibrinolytic Agents; Huma

2020
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
    Journal of the American Heart Association, 2020, 05-18, Volume: 9, Issue:10

    Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female

2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
    JAMA neurology, 2020, 10-01, Volume: 77, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Hu

2020
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:8

    Topics: Aged; Aspirin; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intra

2020
Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:11

    Topics: Aged; Aspirin; Carotid Artery Diseases; Clopidogrel; Comorbidity; Double-Blind Method; Dual Anti-Pla

2020
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2021, 01-01, Volume: 78, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum

2021
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2021, 01-01, Volume: 78, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum

2021
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2021, 01-01, Volume: 78, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum

2021
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2021, 01-01, Volume: 78, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum

2021
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
    Stroke, 2021, Volume: 52, Issue:3

    Topics: Asia, Eastern; Asian People; Aspirin; Cohort Studies; Dabigatran; Double-Blind Method; Embolic Strok

2021
Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial.
    Stroke, 2021, Volume: 52, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dual Anti-Platelet

2021
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
    Lancet (London, England), 2017, Jun-17, Volume: 389, Issue:10087

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular

2017
Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions.
    Annals of neurology, 2017, Volume: 82, Issue:2

    Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Double-Blind Method; Female; Humans; Magnetic Resonance I

2017
Low dose aspirin in the prevention of recurrent spontaneous preterm labour - the APRIL study: a multicenter randomized placebo controlled trial.
    BMC pregnancy and childbirth, 2017, Jul-14, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aspirin; Cost-Benefit Analysis; Double-Blind Method; Female; Gestational Age; Hum

2017
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
    Stroke, 2017, Volume: 48, Issue:9

    Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac

2017
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
    Trials, 2017, Sep-22, Volume: 18, Issue:1

    Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con

2017
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
    Gut, 2018, Volume: 67, Issue:6

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double

2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
    Gut, 2018, Volume: 67, Issue:6

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double

2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
    Gut, 2018, Volume: 67, Issue:6

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double

2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
    Gut, 2018, Volume: 67, Issue:6

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double

2018
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
    Lancet (London, England), 2018, 03-03, Volume: 391, Issue:10123

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb

2018
Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning.
    Chinese medical journal, 2018, Feb-05, Volume: 131, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Ther

2018
Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial.
    Stroke and vascular neurology, 2017, Volume: 2, Issue:4

    Topics: Aged; Aspirin; China; Clopidogrel; Double-Blind Method; Dual Anti-Platelet Therapy; Female; Humans;

2017
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2018, Volume: 25, Issue:2

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Europe; Factor Xa In

2018
Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adult; Aged; Aspirin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Midd

2018
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
    Current vascular pharmacology, 2019, Volume: 17, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H

2019
Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA.
    Neurology, 2018, 09-04, Volume: 91, Issue:10

    Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Clopidogrel; Double-Blind Method; Female; Follow-Up

2018
Low-dose aspirin and burr-hole drainage of chronic subdural hematoma: study protocol for a randomized controlled study.
    Trials, 2019, Jan-21, Volume: 20, Issue:1

    Topics: Aspirin; Confidentiality; Data Interpretation, Statistical; Double-Blind Method; Drainage; Hematoma,

2019
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Circulation research, 2019, Volume: 124, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona

2019
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
    Stroke, 2019, Volume: 50, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attac

2019
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
    JAMA neurology, 2019, 06-01, Volume: 76, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal, Disse

2019
The influence of mean arterial pressure on the efficacy and safety of dual antiplatelet therapy in minor stroke or transient ischemic attack patients.
    Journal of clinical hypertension (Greenwich, Conn.), 2019, Volume: 21, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arterial Pressure; Aspirin; Blood Pressure; Case-Cont

2019
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2019, 07-01, Volume: 76, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Intracr

2019
Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time.
    European journal of neurology, 2019, Volume: 26, Issue:9

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle

2019
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20

    Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence

2019
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20

    Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence

2019
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20

    Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence

2019
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20

    Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence

2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:8

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Female; Hu

2019
Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.
    Allergy, 2013, Volume: 68, Issue:5

    Topics: Adult; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Follow-Up Studies; Huma

2013
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
    Circulation, 2013, Jun-11, Volume: 127, Issue:23

    Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric

2013
Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2013, Volume: 20, Issue:5

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Clopidogrel; Double-Blind Method; Drug Thera

2013
[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].
    Zeitschrift fur Gerontologie und Geriatrie, 2014, Volume: 47, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibit

2014
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
    Cerebrovascular diseases (Basel, Switzerland), 2014, Volume: 37, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence;

2014
C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.
    Stroke, 2014, Volume: 45, Issue:3

    Topics: Aged; Antihypertensive Agents; Aspirin; Biomarkers; Blood Pressure; C-Reactive Protein; Clopidogrel;

2014
A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:7

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Intra

2014
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
    European heart journal, 2014, Oct-01, Volume: 35, Issue:37

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans;

2014
Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:7

    Topics: Aged; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duodenal Ulcer; Female; Fibrinolytic Agents;

2014
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
    Circulation, 2014, Sep-23, Volume: 130, Issue:13

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H

2014
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
    Circulation, 2014, Sep-23, Volume: 130, Issue:13

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H

2014
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
    Circulation, 2014, Sep-23, Volume: 130, Issue:13

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H

2014
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
    Circulation, 2014, Sep-23, Volume: 130, Issue:13

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H

2014
Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
    Cerebrovascular diseases (Basel, Switzerland), 2014, Volume: 38, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heart Failure; Humans; Male; Middle Aged

2014
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
    BMJ open, 2014, Dec-02, Volume: 4, Issue:12

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Stud

2014
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke.
    Neurology, 2015, Mar-31, Volume: 84, Issue:13

    Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Glyc

2015
Left Ventricular Geometry on Transthoracic Echocardiogram and Prognosis after Lacunar Stroke: The SPS3 Trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Echocardiography; Female; Heart Ventricles; Humans; Magnetic Resonance I

2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
    Thrombosis and haemostasis, 2015, Aug-31, Volume: 114, Issue:3

    Topics: Aspirin; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Fibrinolytic Agents;

2015
Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.
    Yonsei medical journal, 2015, Volume: 56, Issue:5

    Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Female; Humans; In

2015
Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
    Neurology, 2015, Sep-29, Volume: 85, Issue:13

    Topics: Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug Therapy, Combination

2015
Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.
    BMC neurology, 2015, Oct-12, Volume: 15

    Topics: Adult; Aspirin; Clinical Protocols; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient

2015
Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial.
    Hypertension (Dallas, Tex. : 1979), 2016, Volume: 67, Issue:1

    Topics: Aspirin; Blood Pressure; Blood Pressure Determination; Clopidogrel; Drug Therapy, Combination; Femal

2016
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.
    European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 197

    Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co

2016
Morphological classification of penetrating artery pontine infarcts and association with risk factors and prognosis: The SPS3 trial.
    International journal of stroke : official journal of the International Stroke Society, 2016, Volume: 11, Issue:4

    Topics: Antihypertensive Agents; Aspirin; Cerebral Infarction; Clopidogrel; Constriction, Pathologic; Double

2016
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
    Journal of the American Heart Association, 2016, Mar-21, Volume: 5, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method

2016
Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial.
    Trials, 2016, Apr-11, Volume: 17

    Topics: Aspirin; Australia; Clinical Protocols; Combined Modality Therapy; Cyclooxygenase Inhibitors; Double

2016
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
    Journal of the neurological sciences, 2016, Aug-15, Volume: 367

    Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co

2016
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
    Neurology, 2016, Oct-11, Volume: 87, Issue:15

    Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth

2016
Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
    Gastroenterology, 2017, Volume: 152, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Famotidine; Female; Hemoglobins; Histamine H2

2017
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    American heart journal, 2016, Volume: 181

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy

2016
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
    Stroke, 2017, Volume: 48, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Glycated Serum Al

2017
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
    Allergy, 2008, Volume: 63, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization,

2008
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
    Allergy, 2008, Volume: 63, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization,

2008
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
    Allergy, 2008, Volume: 63, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization,

2008
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
    Allergy, 2008, Volume: 63, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization,

2008
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
    Medical science monitor : international medical journal of experimental and clinical research, 2008, Volume: 14, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A

2008
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
    American heart journal, 2008, Volume: 156, Issue:6

    Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi

2008
Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis.
    Stroke, 2009, Volume: 40, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Constriction, Pathologic; Double-Blind Met

2009
Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome.
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Coronary Occlusion; Coumarins; Hemorrhage; Humans; International Norm

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug

2009
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis

2009
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    The American journal of cardiology, 2009, Nov-15, Volume: 104, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C

2009
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
    Annals of internal medicine, 2010, Jan-05, Volume: 152, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster

2010
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
    Circulation. Cardiovascular interventions, 2009, Volume: 2, Issue:4

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp

2009
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
    Journal of thrombosis and thrombolysis, 2010, Volume: 30, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies

2010
Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2010, Volume: 248, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Austria; Double-Blind Method; Drainage; Drug Combinations;

2010
Factors responsible for "aspirin resistance" - can we identify them?
    Kardiologia polska, 2010, Volume: 68, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Ag

2010
The International Stroke Trial database.
    Trials, 2011, Apr-21, Volume: 12

    Topics: Access to Information; Activities of Daily Living; Aged, 80 and over; Anticoagulants; Asia; Aspirin;

2011
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
    European heart journal, 2011, Volume: 32, Issue:22

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-

2011
Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency.
    Annals of vascular surgery, 2012, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Bandages, Hydrocolloid; Cardiovascular Agents; Chi-Square D

2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
    Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause

2012
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
    The New England journal of medicine, 2012, Aug-30, Volume: 367, Issue:9

    Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem

2012
CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
    Cancer causes & control : CCC, 2013, Volume: 24, Issue:1

    Topics: Adenoma; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Chemoprevention; Colorectal Neoplasms; Cytoch

2013
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
    The American journal of cardiology, 2013, Feb-15, Volume: 111, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Rela

2013
Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events.
    International journal of stroke : official journal of the International Stroke Society, 2013, Volume: 8, Issue:7

    Topics: Aged; Asian People; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Myocard

2013
Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial.
    Journal of the National Cancer Institute, 2002, Nov-06, Volume: 94, Issue:21

    Topics: Adenoma; Aged; Aspirin; Colorectal Neoplasms; Dietary Fiber; Educational Status; Exercise; Female; F

2002
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
    American heart journal, 2003, Volume: 145, Issue:4

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure

2003
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
    European heart journal, 2003, Volume: 24, Issue:10

    Topics: Abciximab; Administration, Cutaneous; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood F

2003
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.
    JAMA, 2003, Jun-11, Volume: 289, Issue:22

    Topics: Aged; Aspirin; Black or African American; Double-Blind Method; Female; Humans; Male; Middle Aged; Pl

2003
Effect of site of venous protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction.
    Journal of cardiothoracic and vascular anesthesia, 2003, Volume: 17, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiopulmonary Bypass; Constriction, Pathol

2003
Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke.
    Internal medicine (Tokyo, Japan), 2003, Volume: 42, Issue:9

    Topics: Adult; Aged; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic Attac

2003
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
    Journal of the American College of Cardiology, 2003, Oct-15, Volume: 42, Issue:8

    Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography;

2003
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
    Circulation, 2003, Dec-09, Volume: 108, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Emergency Medic

2003
Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction.
    Stroke, 2004, Volume: 35, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Cerebral Infarction; Dose-Response R

2004
Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.
    European heart journal, 2004, Volume: 25, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female;

2004
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
    Platelets, 2004, Volume: 15, Issue:1

    Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspiri

2004
Leukocyte count as an independent predictor of recurrent ischemic events.
    Stroke, 2004, Volume: 35, Issue:5

    Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk

2004
Effect of aspirin and warfarin therapy in stroke patients with valvular strands.
    Stroke, 2004, Volume: 35, Issue:6

    Topics: Adult; Aged; Aortic Valve; Aspirin; Echocardiography, Transesophageal; Endpoint Determination; Fibri

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    European annals of allergy and clinical immunology, 2004, Volume: 36, Issue:6

    Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celec

2004
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
    American heart journal, 2004, Volume: 148, Issue:3

    Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypa

2004
High-grade infarct-related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction.
    American heart journal, 2004, Volume: 148, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary S

2004
Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2004, Volume: 11, Issue:6

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon; Arterial Occlusive Diseases; As

2004
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    European heart journal, 2005, Volume: 26, Issue:6

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Diseas

2005
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
    European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent

2005
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:5

    Topics: Administration, Oral; Adult; Algorithms; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholip

2005
Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005, Volume: 35, Issue:6

    Topics: Acetaminophen; Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anal

2005
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
    American heart journal, 2005, Volume: 149, Issue:4

    Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl

2005
Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial.
    Archives of internal medicine, 2005, Sep-26, Volume: 165, Issue:17

    Topics: Adult; Aged; Anti-Inflammatory Agents; Aspirin; Colchicine; Female; Humans; Male; Middle Aged; Peric

2005
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A

2007
Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study.
    Lancet (London, England), 2007, Mar-10, Volume: 369, Issue:9564

    Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Biomarkers; Cardiac Catheterization; C

2007
Impact of valvular thickness on stroke recurrence in medically treated patients with stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 24, Issue:4

    Topics: Adult; Aged; Aortic Valve; Aspirin; Brain Ischemia; Double-Blind Method; Echocardiography, Transesop

2007
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study.
    Circulation, 2007, Sep-25, Volume: 116, Issue:13

    Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Aspirin; Double-Blind Method; Drug A

2007
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:3

    Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel

2008
Cardiac death prevention in post-myocardial infarction patients: a review.
    Acta cardiologica. Supplementum, 1980, Issue:25

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu

1980
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
    British medical journal (Clinical research ed.), 1982, Oct-23, Volume: 285, Issue:6349

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe

1982
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
    Nederlands tijdschrift voor geneeskunde, 1983, Apr-16, Volume: 127, Issue:16

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Top

1983
The role of pharmacotherapy in secondary prevention of myocardial infarction and death.
    The Mount Sinai journal of medicine, New York, 1984, Volume: 51, Issue:3

    Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Fem

1984
Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study.
    Circulation, 1984, Volume: 69, Issue:4

    Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Aspirin; Coumarins; Follow-Up Studies; Humans; M

1984
British studies of aspirin and myocardial infarction.
    The American journal of medicine, 1983, Jun-14, Volume: 74, Issue:6A

    Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarction; P

1983
[Low-dose acetylsalicylic acid (100 mg/day) following aortocoronary bypass operation].
    Klinische Wochenschrift, 1984, May-15, Volume: 62, Issue:10

    Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Circulatio

1984
[Results of ambulatory follow-up of patients after myocardial infarction treated with platelet aggregation inhibitors and antithrombotic drugs].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1983, Nov-28, Volume: 38, Issue:48

    Topics: Acenocoumarol; Adult; Ambulatory Care; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyrida

1983
Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs. conventional antiaggregants: a six-month randomized follow-up study.
    Angiology, 1984, Volume: 35, Issue:7

    Topics: Aged; Aspirin; Dipyridamole; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; P

1984
[Secondary prevention of ischemic cardiopathy with anti-platelet aggregates in the post-infarct patient. Review].
    Giornale italiano di cardiologia, 1982, Volume: 12, Issue:8

    Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation

1982
[The treatment of transitory ischemic attacks with acetylsalicylic acid: results of a double-blind-study (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1980, May-23, Volume: 122, Issue:21

    Topics: Aspirin; Cerebral Infarction; Humans; Ischemic Attack, Transient; Placebos; Recurrence; Vertebrobasi

1980
The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.
    Circulation, 1980, Volume: 62, Issue:6 Pt 2

    Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Aspirin; Austria; Clinical Trials as Topic; Death, Sudden;

1980
[Persantin and aspirin in coronary heart disease. The persantin-aspirin reinfarction study group (PARIS)].
    MMW, Munchener medizinische Wochenschrift, 1980, Dec-05, Volume: 122, Issue:49

    Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Combin

1980
[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial].
    Revue neurologique, 1982, Volume: 138, Issue:5

    Topics: Aspirin; Clinical Trials as Topic; Dihydroergotoxine; Dipyridamole; Humans; Ischemic Attack, Transie

1982
A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.
    JAMA, 1980, Feb-15, Volume: 243, Issue:7

    Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarc

1980
Aspirin and recurrent myocardial infarction.
    JAMA, 1980, Aug-15, Volume: 244, Issue:7

    Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial Infar

1980
Secondary prevention of myocardial infarction--the present state of the ART.
    British medical journal, 1980, May-03, Volume: 280, Issue:6223

    Topics: Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial

1980
Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials.
    The New England journal of medicine, 1981, Apr-23, Volume: 304, Issue:17

    Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Arteries; Aspirin; Clinical Trials as Topic; Coron

1981
[The platelet inhibitor problem].
    Schweizerische medizinische Wochenschrift, 1981, Apr-04, Volume: 111, Issue:14

    Topics: Aspirin; Blood Transfusion; Brain Ischemia; Clinical Trials as Topic; Female; Humans; Male; Myocardi

1981
[Results of prevention of second myocardial infarct with syncumar or aspirin].
    Kardiologia polska, 1981, Volume: 24, Issue:9

    Topics: Acenocoumarol; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Middle Aged; Myoc

1981
Can aspirin prevent recurrence of heart attacks and strokes?
    Geriatrics, 1982, Volume: 37, Issue:1

    Topics: Adult; Aged; Antithrombins; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Hu

1982
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
    Australian and New Zealand journal of medicine, 1981, Volume: 11, Issue:6

    Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo

1981
E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures.
    Scandinavian journal of haematology. Supplementum, 1981, Volume: 38

    Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Data Collectio

1981
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1981, Oct-01, Volume: 34, Issue:19

    Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial

1981
A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction.
    The New England journal of medicine, 1982, 09-16, Volume: 307, Issue:12

    Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Death, Sudden;

1982
[Long term prophylaxis of re-infarct. Results of the persantin-acetylsalicylic acid re-infarct study].
    Fortschritte der Medizin, 1980, Aug-28, Volume: 98, Issue:32

    Topics: Adult; Aged; Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Female; Humans;

1980
A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group.
    Angiology, 1995, Volume: 46, Issue:11

    Topics: Aged; Aspirin; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Humans; Incidence; Ischemi

1995
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
    European heart journal, 1995, Volume: 16, Issue:7

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Angina, Unstable; Aspirin; Coronary Disease; Dos

1995
Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty.
    Lancet (London, England), 1994, Nov-26, Volume: 344, Issue:8935

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Glutathione; Heparin; Human

1994
Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)
    Circulation, 1995, Dec-01, Volume: 92, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method

1995
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
    Journal of the American College of Cardiology, 1995, Volume: 26, Issue:2

    Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Drug Therapy, Combination; Female;

1995
Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group.
    Journal of neurology, neurosurgery, and psychiatry, 1995, Volume: 59, Issue:2

    Topics: Aged; Aspirin; Atenolol; Cerebral Arteries; Cerebrovascular Disorders; Double-Blind Method; Female;

1995
Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty.
    Circulation, 1995, Apr-15, Volume: 91, Issue:8

    Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Re

1995
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
    Journal of the American College of Cardiology, 1995, Volume: 25, Issue:1

    Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Dipyridamole; Double-Blind Method

1995
Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty
    Journal of the American College of Cardiology, 1995, Volume: 25, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilazapril; Coronary Angiography; Coronary Disease; Double-

1995
Audit of secondary prophylaxis after myocardial infarction.
    BMJ (Clinical research ed.), 1994, Nov-12, Volume: 309, Issue:6964

    Topics: Adrenergic beta-Antagonists; Aftercare; Aspirin; Community Health Services; England; Hospitalization

1994
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
    American heart journal, 1995, Volume: 129, Issue:4

    Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero

1995
Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
    Journal of the American College of Cardiology, 1993, Nov-01, Volume: 22, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug Therapy

1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
[Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
    Kardiologiia, 1993, Volume: 33, Issue:12

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Captopril; Cardiac Output, Low

1993
[Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study)].
    Kardiologiia, 1993, Volume: 33, Issue:5

    Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Follow-Up

1993
[Sumatriptan in the treatment of acute migraine: its role in primary health care].
    Atencion primaria, 1994, Apr-30, Volume: 13, Issue:7

    Topics: Acute Disease; Administration, Oral; Algorithms; Aspirin; Caffeine; Double-Blind Method; Drug Therap

1994
The role of autopsy findings in multicenter treatment evaluations as exemplified by two aspirin trials.
    Quality assurance in health care : the official journal of the International Society for Quality Assurance in Health Care, 1993, Volume: 5, Issue:4

    Topics: Aspirin; Autopsy; Cause of Death; Cerebral Infarction; Death, Sudden, Cardiac; Diagnostic Errors; Do

1993
Comparison of symptomatic and asymptomatic reinfarctions after small subcortical stroke.
    European neurology, 1994, Volume: 34, Issue:3

    Topics: Aged; Aspirin; Cerebral Angiography; Cerebral Infarction; Cholesterol, HDL; Female; Fibrinogen; Foll

1994
Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy?
    Scandinavian journal of gastroenterology, 1994, Volume: 29, Issue:4

    Topics: Adult; Aged; Aspirin; Cholelithiasis; Female; Follow-Up Studies; Humans; Life Tables; Lithotripsy; M

1994
Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal-systemic stent shunts: a controlled study.
    Hepatology (Baltimore, Md.), 1994, Volume: 20, Issue:3

    Topics: Aged; Aspirin; Constriction, Pathologic; Female; Follow-Up Studies; Humans; Liver; Liver Transplanta

1994
Secondary prevention after acute myocardial infarction.
    The American journal of cardiology, 1993, Oct-01, Volume: 72, Issue:11

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cholesterol; Exercise; Female; Humans; Male; Midd

1993
Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty.
    American heart journal, 1994, Volume: 127, Issue:3

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis;

1994
Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.
    British heart journal, 1994, Volume: 71, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Dipyridamole;

1994
Acetylsalicylic acid--reocclusion--prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease.
    VASA. Zeitschrift fur Gefasskrankheiten, 1994, Volume: 23, Issue:1

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Response

1994
Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis.
    Journal of the American College of Cardiology, 1993, Volume: 22, Issue:7

    Topics: Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Multivariate

1993
The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration.
    Cardiology, 1993, Volume: 83, Issue:1-2

    Topics: Administration, Oral; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Com

1993
Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
    Circulation, 1994, Volume: 89, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method

1994
Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
    Circulation, 1994, Volume: 89, Issue:1

    Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agen

1994
Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Study group on pharmacological treatment after PTA.
    European journal of vascular surgery, 1994, Volume: 8, Issue:1

    Topics: Aged; Angiography; Angioplasty, Balloon; Aspirin; Dipyridamole; Double-Blind Method; Drug Combinatio

1994
Can recurrent stenosis after carotid endarterectomy be prevented by low-dose acetylsalicylic acid? A double-blind, randomised and placebo-controlled study.
    European journal of vascular surgery, 1993, Volume: 7, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Dose-Response R

1993
European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly.
    Acta neurologica Scandinavica, 1993, Volume: 87, Issue:2

    Topics: Actuarial Analysis; Aged; Aspirin; Cause of Death; Cerebral Infarction; Cerebrovascular Disorders; D

1993
Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study.
    Circulation, 1993, Volume: 87, Issue:5

    Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Male;

1993
Influence on early outcome and restenosis of urokinase before elective coronary angioplasty.
    The American journal of cardiology, 1993, Jul-01, Volume: 72, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary

1993
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.
    Journal of the American College of Cardiology, 1996, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Aspirin; Coronary Angiography;

1996
[Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study].
    Archives des maladies du coeur et des vaisseaux, 1995, Volume: 88, Issue:9

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Drug Prescr

1995
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet (London, England), 1996, Mar-02, Volume: 347, Issue:9001

    Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa

1996
Intranasal lysine aspirin in recurrent nasal polyposis.
    Clinical otolaryngology and allied sciences, 1995, Volume: 20, Issue:6

    Topics: Administration, Intranasal; Adult; Aspirin; Drug Combinations; Humans; Lysine; Male; Middle Aged; Na

1995
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
    Polskie Archiwum Medycyny Wewnetrznej, 1996, Volume: 95, Issue:1

    Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male

1996
Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group.
    BMJ (Clinical research ed.), 1996, Jul-20, Volume: 313, Issue:7050

    Topics: Aspirin; Cerebrovascular Disorders; Diastole; Female; Humans; Hypertension; Male; Middle Aged; Recur

1996
Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression.
    The New Zealand medical journal, 1996, Jul-26, Volume: 109, Issue:1026

    Topics: Aged; Aspirin; Biphenyl Compounds; Coronary Care Units; Double-Blind Method; Electrocardiography; Fe

1996
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
    Circulation, 1996, Aug-15, Volume: 94, Issue:4

    Topics: Abciximab; Aged; Angioplasty; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Transfusion; Co

1996
Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study.
    Journal of neurology, neurosurgery, and psychiatry, 1996, Volume: 60, Issue:4

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Feasibility

1996
[The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty].
    VASA. Zeitschrift fur Gefasskrankheiten, 1996, Volume: 25, Issue:1

    Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Cardi

1996
Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
    European heart journal, 1995, Volume: 16 Suppl L

    Topics: Abciximab; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As

1995
A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial.
    BMJ (Clinical research ed.), 1996, Dec-07, Volume: 313, Issue:7070

    Topics: Anistreplase; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Female; Heparin; Humans; Male; Myocar

1996
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
    Journal of the American College of Cardiology, 1997, Volume: 29, Issue:1

    Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin;

1997
Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris.
    The American journal of cardiology, 1997, Feb-01, Volume: 79, Issue:3

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Coronary Angi

1997
Control of bias in dietary trial to prevent coronary recurrences: The Lyon Diet Heart Study.
    European journal of clinical nutrition, 1997, Volume: 51, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Anti

1997
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group.
    Japanese circulation journal, 1997, Volume: 61, Issue:1

    Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mid

1997
Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration.
    Gut, 1997, Volume: 40, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cimetidine; Cross-Over S

1997
We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
    Stroke, 1997, Volume: 28, Issue:4

    Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug;

1997
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
    Circulation, 1997, Apr-15, Volume: 95, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality

1997
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.
    Lancet (London, England), 1997, May-31, Volume: 349, Issue:9065

    Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet (London, England), 1997, Jun-07, Volume: 349, Issue:9066

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul

1997
Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
    The American journal of cardiology, 1997, Jan-15, Volume: 79, Issue:2

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    The New England journal of medicine, 1997, Aug-14, Volume: 337, Issue:7

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female;

1997
The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty.
    International angiology : a journal of the International Union of Angiology, 1997, Volume: 16, Issue:2

    Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Constriction, Pathologic; Female;

1997
Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan.
    Thrombosis research, 1997, Jul-15, Volume: 87, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggr

1997
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
    Circulation, 1997, Oct-07, Volume: 96, Issue:7

    Topics: Analysis of Variance; Antithrombins; Aspirin; Cardiac Catheterization; Double-Blind Method; Drug Adm

1997
[Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
    Giornale italiano di cardiologia, 1997, Volume: 27, Issue:9

    Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Coro

1997
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
    Journal of the American College of Cardiology, 1998, Volume: 31, Issue:2

    Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri

1998
PAMI (Primary Angioplasty in Myocardial Infarction) Stent Pilot Trial.
    Clinical cardiology, 1998, Volume: 21, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myoca

1998
Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
    Giornale italiano di cardiologia, 1998, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Co

1998
[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
    Zeitschrift fur Kardiologie, 1997, Volume: 86, Issue:12

    Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coro

1997
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Circulation, 1998, May-19, Volume: 97, Issue:19

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy; Blood Coagu

1998
Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database.
    The American journal of cardiology, 1998, Aug-01, Volume: 82, Issue:3

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atenolol; Drug Administration Routes; Electrocardio

1998
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    The American journal of cardiology, 1998, Sep-10, Volume: 82, Issue:5B

    Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Double-Blind Method; Drug Administration Routes; D

1998
Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
    Circulation, 1998, Oct-06, Volume: 98, Issue:14

    Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin;

1998
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
    Thrombosis research, 1998, Sep-15, Volume: 92, Issue:1 Suppl 1

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I

1998
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
    Thrombosis research, 1998, Sep-15, Volume: 92, Issue:1 Suppl 1

    Topics: Aged; Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Disease-Free Su

1998
The trapidil restenosis trial (STARC study): background, methods and clinical characteristics of the patient population.
    Clinical trials and meta-analysis, 1994, Volume: 29, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Cohort Studies; Coronary D

1994
Advances in post stenting medication protocol.
    The Journal of invasive cardiology, 1995, Volume: 7 Suppl A

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination

1995
Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates.
    Clinical cardiology, 1999, Volume: 22, Issue:4

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Calcium Channel Blo

1999
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
    Circulation, 1999, May-11, Volume: 99, Issue:18

    Topics: Acute Disease; Age Factors; Aged; Angina, Unstable; Aspirin; Brain Damage, Chronic; Cerebral Hemorrh

1999
Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study. The STEPS Investigators. Significance of Transesophageal Echocardiography in the Prevention of Recurrent Stroke.
    American heart journal, 1999, Volume: 137, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Echocardiography

1999
[Secondary prevention after ischemic cerebral infarct. The ESPRIT Study: low dose anticoagulation, combined therapy with acetylsalicylic acid/dipyridamole or monotherapy with acetylsalicylic acid?].
    Der Nervenarzt, 1999, Volume: 70, Issue:4

    Topics: Anticoagulants; Aspirin; Australia; Cerebral Infarction; Dipyridamole; Dose-Response Relationship, D

1999
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Chest, 1999, Volume: 115, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation Factors; Chondroitin Sulf

1999
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Circulation, 1999, Jul-06, Volume: 100, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium; Cell Division; Cilostazol; Combined Modality

1999
Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St
    Cephalalgia : an international journal of headache, 1999, Volume: 19, Issue:6

    Topics: Adult; Analgesics; Aspirin; Double-Blind Method; Female; Humans; Infusions, Intravenous; Injections,

1999
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
    The American journal of cardiology, 1999, Sep-01, Volume: 84, Issue:5

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo

1999
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
    The American journal of cardiology, 1999, Sep-02, Volume: 84, Issue:5A

    Topics: Adult; Angina, Unstable; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Double-Blind Method; Drug

1999
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
    The American journal of cardiology, 1999, Sep-02, Volume: 84, Issue:5A

    Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose

1999
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
    Nutrition reviews, 1999, Volume: 57, Issue:10

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H

1999
Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study.
    Journal of the neurological sciences, 1999, Dec-15, Volume: 171, Issue:2

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Aspirin; Dose-Response Rel

1999
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
    Thrombosis research, 1999, Nov-01, Volume: 96, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca

1999
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
    The American journal of cardiology, 1999, Dec-15, Volume: 84, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp

1999
Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])].
    The American journal of cardiology, 1999, Dec-01, Volume: 84, Issue:11

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chest Pain; Corona

1999
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.
    Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Cohort Studies; Dose-Re

2000
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coron
    Lancet (London, England), 2000, Jan-29, Volume: 355, Issue:9201

    Topics: Administration, Oral; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Humans; Male; Mi

2000
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
    European heart journal, 2000, Volume: 21, Issue:6

    Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; My

2000
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
    Lancet (London, England), 2000, Apr-08, Volume: 355, Issue:9211

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation;

2000
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
    American heart journal, 2000, Volume: 139, Issue:6

    Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardi

2000
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha

2000
A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators.
    American heart journal, 2000, Volume: 140, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary D

2000
Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy.
    Neurology, 2000, Aug-22, Volume: 55, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; F

2000
Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies.
    Thorax, 2000, Volume: 55 Suppl 2

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin;

2000
Effects of cilostazol on angiographic restenosis after coronary stent placement.
    The American journal of cardiology, 2000, Sep-01, Volume: 86, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Disease

2000
Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study.
    Journal of the neurological sciences, 2000, Dec-01, Volume: 181, Issue:1-2

    Topics: Aspirin; Blood Platelets; Demography; Double-Blind Method; Endpoint Determination; Female; Follow-Up

2000
Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen.
    The American journal of cardiology, 2001, Feb-15, Volume: 87, Issue:4

    Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy,

2001
[Efficacy of colchicine in recurrent acute idiopathic pericarditis].
    Archives des maladies du coeur et des vaisseaux, 2000, Volume: 93, Issue:12

    Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Colchicin

2000
Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction.
    European journal of heart failure, 2001, Volume: 3, Issue:2

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dose-Response Relationship, Drug; Dr

2001
Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
    Journal of the American College of Cardiology, 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Aspirin; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Humans; Male;

2001
The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.
    Journal of thrombosis and thrombolysis, 2001, Volume: 11, Issue:2

    Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relati

2001
[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
    Zeitschrift fur Kardiologie, 2001, Volume: 90, Issue:5

    Topics: Administration, Oral; Angina Pectoris; Aspirin; Cause of Death; Cerebral Infarction; Delayed-Action

2001
Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study.
    Stroke, 2001, Volume: 32, Issue:11

    Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Fibrinolytic Agents; Follow-Up Studies

2001
Insights from CURE: using clopidogrel on top of standard therapy.
    Cerebrovascular diseases (Basel, Switzerland), 2002, Volume: 13 Suppl 1

    Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari

2002
Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
    Lipids, 2001, Volume: 36 Suppl

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi

2001
Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke.
    Journal of neurology, neurosurgery, and psychiatry, 2002, Volume: 72, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Emb

2002
Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
    PharmacoEconomics, 2002, Volume: 20, Issue:3

    Topics: Acute Disease; Aspirin; Double-Blind Method; Drug Costs; Humans; Myocardial Infarction; Platelet Agg

2002
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Thrombosis and haemostasis, 2002, Volume: 87, Issue:4

    Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal

2002
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
    The New England journal of medicine, 2002, Jun-27, Volume: 346, Issue:26

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A

2002
[Prevention of reinfarction with acetylsalicylic acid].
    Folia haematologica (Leipzig, Germany : 1928), 1979, Volume: 106, Issue:5-6

    Topics: Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Prospectiv

1979
[Course control of platelet function and blood lipid levels during a 2 years prospective study on the prevention of reinfarction with acetylsalicylic acid, phenprocoumon and placebo].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1978, Issue:84

    Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Humans; Lipids; Longitudinal Studies; M

1978
A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction.
    The Journal of the Royal College of General Practitioners, 1979, Volume: 29, Issue:204

    Topics: Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardial Infarction; Random Allocation; R

1979
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.
    Thrombosis and haemostasis, 1979, Feb-28, Volume: 41, Issue:1

    Topics: 4-Hydroxycoumarins; Aged; Aspirin; Austria; Blood Platelets; Double-Blind Method; Evaluation Studies

1979
[Prevention of re-occlusion after recanalisation of occluded arteries by the catheter method (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1978, Dec-15, Volume: 103, Issue:50

    Topics: Arterial Occlusive Diseases; Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination;

1978
Editorial: aspirin and myocardial infarction: a new national cooperative trial.
    JAMA, 1975, Jun-30, Volume: 232, Issue:13

    Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Informed Consent; Male; Middle Aged;

1975
A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.
    European neurology, 1992, Volume: 32, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combinati

1992
Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
    Stroke, 1992, Volume: 23, Issue:12

    Topics: Adult; Aspirin; Cerebrovascular Disorders; Diarrhea; Double-Blind Method; Female; Humans; Male; Midd

1992
[Dose-dependent inhibition of plaque growth in the carotid artery by acetylsalicylic acid].
    VASA. Supplementum, 1992, Volume: 35

    Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Dose-Response Relationship, Drug; Double-Blind Meth

1992
[Comparison of 50 mg and 900 mg/day acetylsalicylic acid for prevention of recurrence after percutaneous transluminal angioplasty of the lower extremities: results of the LARA study].
    VASA. Supplementum, 1992, Volume: 35

    Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Re

1992
A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction.
    American heart journal, 1992, Volume: 123, Issue:4 Pt 1

    Topics: Aspirin; Cardiac Catheterization; Drug Therapy, Combination; Electrocardiography; Heparin; Humans; I

1992
Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy.
    Annals of internal medicine, 1992, May-01, Volume: 116, Issue:9

    Topics: Aged; Aspirin; Carotid Stenosis; Combined Modality Therapy; Dipyridamole; Drug Therapy, Combination;

1992
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Journal of the American College of Cardiology, 1992, Volume: 20, Issue:1

    Topics: Aspirin; Coronary Angiography; Coronary Vessels; Hemorrhage; Heparin; Humans; Myocardial Infarction;

1992
Reactivation of unstable angina after the discontinuation of heparin.
    The New England journal of medicine, 1992, Jul-16, Volume: 327, Issue:3

    Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; He

1992
[More about aspirin in cardiology].
    Kardiologia polska, 1992, Volume: 36, Issue:4

    Topics: Anticoagulants; Aspirin; Blood Coagulation; Humans; International Cooperation; Myocardial Infarction

1992
Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial.
    Lancet (London, England), 1991, Jun-15, Volume: 337, Issue:8755

    Topics: Adult; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Administration Schedule; Drug

1991
Prevention of relapse in nasal polyposis.
    Lancet (London, England), 1991, Jun-15, Volume: 337, Issue:8755

    Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Evaluat

1991
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
    Drugs, 1991, Volume: 42 Suppl 2

    Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele

1991
[Modification of thrombocyte function in diagnostic and therapeutic interventions in cardiology].
    Zeitschrift fur Kardiologie, 1991, Volume: 80 Suppl 5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-

1991
Secondary prevention of myocardial reinfarction with low dose aspirin.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 1991, Volume: 6, Issue:3

    Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Plate

1991
Ticlopidine, a new anti-thrombotic drug.
    Journal of neurology, neurosurgery, and psychiatry, 1991, Volume: 54, Issue:10

    Topics: Aspirin; Dipyridamole; Humans; Intracranial Embolism and Thrombosis; Long-Term Care; Recurrence; Tic

1991
Two year Cottbus reinfarction study with 30 mg aspirin per day.
    Prostaglandins, leukotrienes, and essential fatty acids, 1991, Volume: 44, Issue:3

    Topics: Aged; Aspirin; Dinoprost; Follow-Up Studies; Gastrointestinal Diseases; Germany; Hospitals, District

1991
Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results.
    Circulation, 1991, Volume: 83, Issue:1

    Topics: Aged; Angioplasty, Balloon; Angioplasty, Laser; Arterial Occlusive Diseases; Aspirin; Dipyridamole;

1991
Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARP
    Circulation, 1991, Volume: 84, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Biphenyl Compounds; Constriction, Pathologic; Coronary Dise

1991
Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty.
    American heart journal, 1991, Volume: 122, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method

1991
[Randomized comparative study of the recurrence rate following femoro-popliteal PTA: high (1.0 g/die) vs low (0.1 g/die) acetylsalicylic acid dose].
    VASA. Supplementum, 1991, Volume: 33

    Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Femoral

1991
Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty.
    Journal of the American College of Cardiology, 1991, Volume: 18, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Double-Blind Method; Female

1991
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators.
    Journal of the American College of Cardiology, 1991, Volume: 17, Issue:5

    Topics: Aged; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Co

1991
Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge?
    European heart journal, 1991, Volume: 12, Issue:2

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery Byp

1991
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis.
    Thrombosis research, 1991, Jun-15, Volume: 62, Issue:6

    Topics: Aspirin; Blood Coagulation Tests; Blood Platelets; Catheters, Indwelling; Drug Evaluation; Drug Ther

1991
Effects of low-dose aspirin on restenosis after coronary angioplasty.
    The American journal of cardiology, 1991, Oct-01, Volume: 68, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; Coronary Angiography; Coron

1991
Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.
    Lancet (London, England), 1990, Mar-17, Volume: 335, Issue:8690

    Topics: Administration, Oral; Aged; Analysis of Variance; Angina Pectoris; Angina, Unstable; Aspirin; Double

1990
Secondary prevention of ischemic stroke with low dose acetylsalicylic acid.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 1990, Volume: 89, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Humans; Male; Middle Ag

1990
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.
    Circulation, 1991, Volume: 83, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Equipment Design; Female; F

1991
Effects of diltiazem on complications and restenosis after coronary angioplasty.
    The American journal of cardiology, 1991, Feb-15, Volume: 67, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; Coronary Angiography; Coronary Di

1991
[Effects of high and low doses of acetylsalicylic acid on the restenosis rate after initially successful coronary angioplasty].
    Deutsche medizinische Wochenschrift (1946), 1991, Mar-29, Volume: 116, Issue:13

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged;

1991
Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty.
    Journal of the American College of Cardiology, 1990, Mar-01, Volume: 15, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro

1990
Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA.
    Angiology, 1990, Volume: 41, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriosclerosis Obliterans; Aspirin; Dipyrida

1990
Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction.
    The American journal of cardiology, 1990, Aug-01, Volume: 66, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Follow-Up Studies; Hu

1990
European Stroke Prevention Study. ESPS Group.
    Stroke, 1990, Volume: 21, Issue:8

    Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T

1990
Low-dose aspirin for migraine prophylaxis.
    JAMA, 1990, Oct-03, Volume: 264, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Double-Blind Method; Drug Administ

1990
Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty.
    Australian and New Zealand journal of medicine, 1990, Volume: 20, Issue:4

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Dipyridamole; Drug Th

1990
Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).
    The American journal of cardiology, 1990, Dec-01, Volume: 66, Issue:19

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery

1990
Acetylsalicylic acid vs. metoprolol in migraine prophylaxis--a double-blind cross-over study.
    Headache, 1990, Volume: 30, Issue:10

    Topics: Adult; Aspirin; Double-Blind Method; Female; Humans; Male; Metoprolol; Migraine Disorders; Recurrenc

1990
The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.
    American heart journal, 1990, Volume: 119, Issue:2 Pt 1

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Double-Blind Method;

1990
[Prevention of recurrence of cerebrovascular thromboses. A randomized comparative study of acetylsalicylic acid and sodium pentosan polysulfate].
    Fortschritte der Medizin, 1987, Feb-20, Volume: 105, Issue:5

    Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Intracranial Embolism and Thrombosis; Ische

1987
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
    The New England journal of medicine, 1989, 03-09, Volume: 320, Issue:10

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali

1989
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
    The New England journal of medicine, 1989, 03-09, Volume: 320, Issue:10

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali

1989
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
    The New England journal of medicine, 1989, 03-09, Volume: 320, Issue:10

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali

1989
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
    The New England journal of medicine, 1989, 03-09, Volume: 320, Issue:10

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali

1989
A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study.
    Stroke, 1989, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cerebral Infarction; Clinical Trials as Topic;

1989
Idiopathic recurrent fetal growth retardation and aspirin-dipyridamole therapy.
    American journal of obstetrics and gynecology, 1989, Volume: 160, Issue:3

    Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Fetal Growth Ret

1989
Aspirin for prevention of myocardial infarction and stroke.
    The Medical letter on drugs and therapeutics, 1989, Aug-25, Volume: 31, Issue:799

    Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Att

1989
Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty.
    Circulation, 1989, Volume: 80, Issue:6 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Coronar

1989
Prevention of restenosis after coronary angioplasty: a pharmacological approach.
    European heart journal, 1989, Volume: 10 Suppl G

    Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical

1989
Superior prevention of reinfarction by 30 mg per day aspirin compared with 1000 mg: results of a two years follow-up study in Cottbus.
    Progress in clinical and biological research, 1989, Volume: 301

    Topics: Aged; Aspirin; Female; Follow-Up Studies; Germany, East; Humans; Male; Middle Aged; Myocardial Infar

1989
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
    The American journal of cardiology, 1989, Oct-15, Volume: 64, Issue:14

    Topics: Angina Pectoris; Angina, Unstable; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electro

1989
Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids.
    The New England journal of medicine, 1988, Sep-22, Volume: 319, Issue:12

    Topics: Angioplasty, Balloon; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Angiography; Coro

1988
Prevention of coronary heart disease in practice. Implications of the results of recent clinical trials.
    JAMA, 1985, Jul-12, Volume: 254, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Blood Platelets; Cholesterol; C

1985
Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.
    Journal of the American College of Cardiology, 1986, Volume: 7, Issue:2

    Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Dig

1986
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
    Lancet (London, England), 1988, Jan-30, Volume: 1, Issue:8579

    Topics: Adult; Aged; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Cor

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet (London, England), 1988, Aug-13, Volume: 2, Issue:8607

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica

1988
Medical prophylaxis for the post myocardial infarct patient.
    Cardiology clinics, 1988, Volume: 6, Issue:1

    Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T

1988
Prevention of gallstone recurrence by non-steroidal anti-inflammatory drugs.
    Lancet (London, England), 1988, Nov-26, Volume: 2, Issue:8622

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cholelithiasis; Dr

1988
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
    The American journal of cardiology, 1987, Jul-31, Volume: 60, Issue:3

    Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Aspirin; Clinical Trials as Topic; Dipyr

1987
Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    The New England journal of medicine, 1988, Jun-30, Volume: 318, Issue:26

    Topics: Administration, Oral; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Coronary Angiography;

1988
[Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
    Archives des maladies du coeur et des vaisseaux, 1988, Volume: 81 Spec No

    Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heparin; Hu

1988
[ISIS-2--a study of patients with myocardial infarction. A combination of streptokinase and acetylsalicylic acid diminishes mortality risk, reinfarction and stroke].
    Lakartidningen, 1988, Aug-31, Volume: 85, Issue:35

    Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myo

1988
Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus.
    Biomedica biochimica acta, 1988, Volume: 47, Issue:10-11

    Topics: Aged; Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Middle Aged; Myoc

1988
Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction.
    The American journal of cardiology, 1988, Apr-15, Volume: 61, Issue:11

    Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Double-Blind

1988
Aspirin and secondary bleeding after traumatic hyphema.
    Annals of ophthalmology, 1988, Volume: 20, Issue:4

    Topics: Adult; Aspirin; Clinical Trials as Topic; Eye Injuries; Hemorrhage; Humans; Hyphema; Recurrence; Wou

1988
Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole.
    American journal of obstetrics and gynecology, 1987, Volume: 157, Issue:5

    Topics: Adult; Aspirin; Birth Weight; Clinical Trials as Topic; Dipyridamole; Epoprostenol; Female; Fetal Gr

1987
Aspirin to prevent myocardial infarction and death.
    The Medical letter on drugs and therapeutics, 1986, Mar-14, Volume: 28, Issue:709

    Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardi

1986
[Randomized clinical study of the efficacy of buflomedil in the prevention of recurrence of cerebral ischemia in comparison with anti-platelet aggregation agents].
    La Clinica terapeutica, 1986, Mar-15, Volume: 116, Issue:5

    Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Ischemic Attack, Transient; Pyrrolidines; R

1986
[Secondary prevention of ischemic heart disease. Evaluation of platelet function in patients treated with anticoagulants and cod liver oil].
    Polskie Archiwum Medycyny Wewnetrznej, 1986, Volume: 75, Issue:1

    Topics: Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Cod Liver Oil; Coronary Disease; Dip

1986
[Prevention of recurrent myocardial infarcts by long-term aspirin therapy].
    Kardiologiia, 1986, Volume: 26, Issue:9

    Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Death, Sudden; Female; Follow-Up Studies; Humans; Ma

1986
Asymptomatic carotid disease.
    Surgery, gynecology & obstetrics, 1985, Volume: 160, Issue:1

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor

1985
Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants.
    European neurology, 1985, Volume: 24, Issue:1

    Topics: Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Female; Humans; Ischemic A

1985
Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study.
    The American journal of cardiology, 1985, Aug-01, Volume: 56, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Aspirin; Clinical Trials as Topic; Coronary Disease; Double-Blind

1985
[Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct].
    Zeitschrift fur arztliche Fortbildung, 1985, Volume: 79, Issue:11

    Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Fibrinolytic A

1985
The protective effect of aspirin against degeneration of human articular cartilage.
    Clinical orthopaedics and related research, 1972, Volume: 84

    Topics: Aspirin; Cartilage Diseases; Cartilage, Articular; Clinical Trials as Topic; Humans; Joint Dislocati

1972
A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.
    British medical journal, 1974, Mar-09, Volume: 1, Issue:5905

    Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; Middle Aged;

1974
[Follow-up of a course of intermittent rheumatism].
    Medicinski arhiv, 1974, Volume: 28, Issue:0

    Topics: Adult; Aspirin; Chloroquine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Hydrarthro

1974

Other Studies

674 other studies available for aspirin and Recrudescence

ArticleYear
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
    Stroke, 2022, Volume: 53, Issue:2

    Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-45

2022
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy

2022
Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.
    Journal of the American Heart Association, 2022, Volume: 11, Issue:3

    Topics: Aspirin; Blood Glucose; Clopidogrel; Humans; Hyperglycemia; Ischemic Attack, Transient; Ischemic Str

2022
A dual treatment blocks alcohol binge-drinking relapse: Microbiota as a new player.
    Drug and alcohol dependence, 2022, 07-01, Volume: 236

    Topics: Acetylcysteine; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Animals; Aspirin; Chronic D

2022
No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke.
    Neurological research, 2022, Volume: 44, Issue:11

    Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Humans; Ischemic Attack,

2022
The pattern of epistaxis recurrence in patients taking prophylactic acetylsalicylic acid (ASA) from a 10 year cohort.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2023, Volume: 280, Issue:4

    Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Epistaxis; Humans; Recurrence; Retrospective Studi

2023
How to prevent recurrence of acute pericarditis.
    Journal of cardiology, 2024, Volume: 83, Issue:1

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Pericarditis; Recurrence

2024
Aspirin use is associated with reduced risk for recurrence of pyogenic liver abscess: a propensity score analysis.
    Scientific reports, 2019, 08-08, Volume: 9, Issue:1

    Topics: Adult; Aged; Aspirin; Cohort Studies; Female; Humans; Liver Abscess, Pyogenic; Male; Middle Aged; Re

2019
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE.
    Annals of internal medicine, 2019, 08-20, Volume: 171, Issue:4

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib

2019
The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices.
    Neurocritical care, 2020, Volume: 32, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Deprescriptions; Female; Fibrinolytic Agents; Heart Failure; Heart-As

2020
Antiplatelet agents for the secondary prevention of ischaemic stroke in patients with or without renal dysfunction.
    European journal of neurology, 2020, Volume: 27, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Glomerular Filtrat

2020
Aspirin and N-acetylcysteine co-administration markedly inhibit chronic ethanol intake and block relapse binge drinking: Role of neuroinflammation-oxidative stress self-perpetuation.
    Addiction biology, 2021, Volume: 26, Issue:1

    Topics: Acetylcysteine; Alcohol Drinking; Alcoholism; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2021
Lp-PLA
    Neurology, 2020, 01-14, Volume: 94, Issue:2

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Aspirin; Cerebrovascular Disorders; Clopidogre

2020
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
    Stroke, 2020, Volume: 51, Issue:2

    Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag

2020
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry.
    European journal of heart failure, 2020, Volume: 22, Issue:2

    Topics: Aspirin; Heart Failure; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregat

2020
[Recurrent pericarditis: New treatment].
    La Revue de medecine interne, 2020, Volume: 41, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Colchicine;

2020
Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.
    The American journal of cardiology, 2020, 03-01, Volume: 125, Issue:5

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Flow C

2020
Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    JAMA network open, 2020, 01-03, Volume: 3, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Arte

2020
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
    The American journal of cardiology, 2020, 03-01, Volume: 125, Issue:5

    Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi

2020
Extracting the benefits of berberine for colorectal cancer.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:3

    Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro

2020
Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction.
    Brain and behavior, 2020, Volume: 10, Issue:3

    Topics: Aged; Aldehydes; Aspirin; Cerebral Infarction; Drug Resistance; Female; Humans; Male; Middle Aged; P

2020
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
    Stroke, 2020, Volume: 51, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial

2020
Derivation and Application of a Tool to Estimate Benefits From Multiple Therapies That Reduce Recurrent Stroke Risk.
    Stroke, 2020, Volume: 51, Issue:5

    Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aspirin; Diet Therapy; Exer

2020
Focal Cerebral Arteriopathy in Young Adult Patients With Stroke.
    Stroke, 2020, Volume: 51, Issue:5

    Topics: Acyclovir; Adult; Antibodies, Viral; Antiviral Agents; Aspirin; Carotid Artery, Internal; Carotid St

2020
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Circulation, 2020, 05-19, Volume: 141, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fa

2020
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
    Journal of the American Heart Association, 2020, 05-18, Volume: 9, Issue:10

    Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal

2020
Impact of Flow Dynamics on Device-Related Thrombosis After Left Atrial Appendage Occlusion.
    The Canadian journal of cardiology, 2020, Volume: 36, Issue:6

    Topics: Aged; Antithrombins; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Comput

2020
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
    Vascular pharmacology, 2020, Volume: 132

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Dual Anti-Platelet Therapy; Female; Human

2020
Age- and sex-based differences in patients with acute pericarditis.
    European journal of clinical investigation, 2021, Volume: 51, Issue:3

    Topics: Acute Disease; Adult; Age Distribution; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammato

2021
A multicenter approach to evaluate omalizumab effectiveness in Samter's triad.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Aug-06, Volume: 90, Issue:3

    Topics: Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma

2020
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    JAMA, 2020, 10-27, Volume: 324, Issue:16

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies;

2020
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
    Cerebrovascular diseases extra, 2020, Volume: 10, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; At

2020
Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent
    Circulation. Cardiovascular quality and outcomes, 2020, Volume: 13, Issue:11

    Topics: Aged; Aspirin; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; Dual Anti-Platel

2020
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2021, Volume: 30, Issue:2

    Topics: Aged; Aspirin; Cilostazol; Disease Progression; Dual Anti-Platelet Therapy; Female; Humans; Japan; M

2021
Level of sex hormones and their association with acetylsalicylic acid intolerance and nasal polyposis.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Cone-Beam Computed Tomography; Drug Hypers

2020
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged

2020
Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome.
    Journal of the American Heart Association, 2021, 01-19, Volume: 10, Issue:2

    Topics: Acute Coronary Syndrome; Asia; Aspirin; Biomarkers; Blood Platelets; Drug Resistance; Female; Gene E

2021
The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study.
    International journal of medical sciences, 2021, Volume: 18, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Embolic Stroke; Female; Follow-Up Studies; Hirud

2021
Two-State Kinetic Model of Rates of Stroke Recurrence in the POINT Study Population.
    Stroke, 2021, Volume: 52, Issue:4

    Topics: Aspirin; Double-Blind Method; Fibrinolytic Agents; Humans; Ischemic Stroke; Kinetics; Nonlinear Dyna

2021
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
    BMC cardiovascular disorders, 2021, 03-31, Volume: 21, Issue:1

    Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabi

2021
Dual Antiplatelet Therapy Duration After Venous Sinus Stenting for Idiopathic Intracranial Hypertension and Stent Survival-Is Longer Necessarily Better? A Meta-Regression.
    World neurosurgery, 2021, Volume: 151

    Topics: Adult; Aspirin; Central Venous Pressure; Clopidogrel; Drug Therapy, Combination; Female; Graft Occlu

2021
A risk score for pericarditis recurrence.
    European journal of clinical investigation, 2021, Volume: 51, Issue:11

    Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chest Pain; Colchicine;

2021
Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial.
    JAMA network open, 2021, 06-01, Volume: 4, Issue:6

    Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Cohort Studies; Dual Anti-Platelet Therapy; Female; Huma

2021
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
    Stroke, 2021, Volume: 52, Issue:10

    Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc

2021
Venous thromboembolism: Risk of recurrence lower with rivaroxaban than aspirin.
    Nature reviews. Cardiology, 2017, Volume: 14, Issue:5

    Topics: Anticoagulants; Aspirin; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism

2017
The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
    Neurological research, 2017, Volume: 39, Issue:8

    Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischem

2017
Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia.
    American journal of obstetrics and gynecology, 2017, Volume: 217, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Diabetes Mellitus, Type 2;

2017
Numerous Fusiform and Saccular Cerebral Aneurysms in Central Nervous System Lupus Presenting with Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:7

    Topics: Adult; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Angiography; Diffusion Magnetic Re

2017
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.
    Clinical cardiology, 2017, Volume: 40, Issue:9

    Topics: Aged; Aspirin; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Male; Middle Aged;

2017
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
    Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

    Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F

2016
Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
    European journal of clinical investigation, 2017, Volume: 47, Issue:7

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; H

2017
The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen.
    The Turkish journal of pediatrics, 2016, Volume: 58, Issue:5

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Female; Follow-Up Studies; Huma

2016
In VTE, extending anticoagulation with rivaroxaban vs aspirin reduced recurrence without increasing bleeding.
    Annals of internal medicine, 2017, 06-20, Volume: 166, Issue:12

    Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism

2017
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
    Kardiologia polska, 2017, Volume: 75, Issue:6

    Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged;

2017
Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study.
    Lupus, 2018, Volume: 27, Issue:3

    Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagu

2018
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:10

    Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi

2017
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
    VASA. Zeitschrift fur Gefasskrankheiten, 2017, Volume: 46, Issue:6

    Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula

2017
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel

2017
Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
    International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:10

    Topics: Alleles; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; F

2017
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke.
    Brain research bulletin, 2017, Volume: 134

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Logistic Models;

2017
Analysis of risk factors for colonic diverticular bleeding and recurrence.
    Medicine, 2017, Volume: 96, Issue:38

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ca

2017
A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
    JACC. Cardiovascular interventions, 2017, 09-25, Volume: 10, Issue:18

    Topics: Absorbable Implants; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis;

2017
Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question.
    BMJ case reports, 2017, Oct-13, Volume: 2017

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Humans; Isolated Noncompaction

2017
Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment.
    Systems biology in reproductive medicine, 2017, Volume: 63, Issue:6

    Topics: Adult; Aspirin; Cytokines; Embryo Implantation; Embryo Transfer; Female; Fertilization in Vitro; Gen

2017
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
    Coronary artery disease, 2018, Volume: 29, Issue:1

    Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Dise

2018
Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids?
    Journal of cardiology, 2018, Volume: 71, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal;

2018
Etiology and long-term rebleeding of endoscopic ulcerative lesions in the small bowel in patients with obscure gastrointestinal bleeding: A multicenter cohort study.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:7

    Topics: Aged; Aspirin; Capsule Endoscopy; Cohort Studies; Endoscopy, Gastrointestinal; Female; Follow-Up Stu

2018
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:5

    Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases

2018
[Prolonged Secondary Prevention After Venous Thromboembolism].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:3

    Topics: Administration, Oral; Anticoagulants; Aspirin; Humans; Recurrence; Risk Factors; Secondary Preventio

2018
Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease.
    Annals of vascular surgery, 2018, Volume: 49

    Topics: Aspirin; Behcet Syndrome; Endovascular Procedures; Factor Xa Inhibitors; Femoral Vein; Humans; Iliac

2018
Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers.
    Journal of vascular surgery, 2018, Volume: 68, Issue:1

    Topics: Aged; Algorithms; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Carotid Stenosis;

2018
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
    Heart (British Cardiac Society), 2018, Volume: 104, Issue:19

    Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; Fr

2018
Prevention of recurrent venous thrombosis and post-thrombotic syndrome.
    Minerva cardioangiologica, 2018, Volume: 66, Issue:3

    Topics: Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Hum

2018
Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome.
    The international journal of cardiovascular imaging, 2018, Volume: 34, Issue:11

    Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Coronary Vasospasm; Coronary Vessels;

2018
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
    Blood cancer journal, 2018, 06-26, Volume: 8, Issue:7

    Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myeloproliferative Disorders; Recurre

2018
Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
    Journal of cardiovascular pharmacology, 2018, Volume: 72, Issue:4

    Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Pe

2018
Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.
    Basic & clinical pharmacology & toxicology, 2019, Volume: 124, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Aspirin; Biotransformation; Clopidogrel; Cyto

2019
Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: A case-control study.
    Neurology, 2018, 09-18, Volume: 91, Issue:12

    Topics: Aneurysm; Aneurysm, Ruptured; Aspirin; Case-Control Studies; Dose-Response Relationship, Drug; Femal

2018
[ADP-Induced Recalcified Blood Clotting Time as a Marker of Rethrombosis Risk and Effectiveness of Antiplatelet Therapy in Acute Coronary Syndrome].
    Kardiologiia, 2018, Volume: 58, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Humans; Male; Platelet A

2018
Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data.
    Journal of the American Heart Association, 2018, 10-02, Volume: 7, Issue:19

    Topics: Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Incidence; Male; Platelet Aggregation

2018
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    European journal of preventive cardiology, 2019, Volume: 26, Issue:8

    Topics: Aged; Aspirin; Australia; Carotid Artery Diseases; Cost-Benefit Analysis; Decision Support Technique

2019
Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.
    BMJ (Clinical research ed.), 2018, Dec-18, Volume: 363

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib

2018
Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke.
    European journal of neurology, 2019, Volume: 26, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Cardiac Surgical Procedures; Ech

2019
Recurrent Stroke in a Ghanaian Patient With Polycythemia.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:3

    Topics: Aphasia, Broca; Aspirin; Clopidogrel; Ghana; Humans; Hydroxyurea; Infarction, Middle Cerebral Artery

2019
Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    The Medical letter on drugs and therapeutics, 2018, Dec-03, Volume: 60, Issue:1561

    Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; F

2018
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
    JAMA neurology, 2019, 05-01, Volume: 76, Issue:5

    Topics: Aged; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19;

2019
Stroke prevention in patients with acute ischemic stroke and atrial fibrillation in Germany - a cross sectional survey.
    BMC neurology, 2019, Feb-12, Volume: 19, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Germany; Humans

2019
Management of idiopathic recurrent pericarditis during pregnancy.
    International journal of cardiology, 2019, 05-01, Volume: 282

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Disease Management; Female;

2019
Optimal stroke prevention in patients with PFO.
    The Lancet. Neurology, 2019, Volume: 18, Issue:3

    Topics: Aspirin; Foramen Ovale, Patent; Humans; Recurrence; Rivaroxaban; Stroke

2019
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    European journal of preventive cardiology, 2020, Volume: 27, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Eu

2020
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.
    Minerva cardioangiologica, 2019, Volume: 67, Issue:2

    Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Humans; Incidence; Male

2019
Aspirin reduced recurrent stroke risk in patients with lacunar stroke.
    Acta neurologica Scandinavica, 2019, Volume: 140, Issue:1

    Topics: Adult; Aged; Aspirin; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Plat

2019
A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:8

    Topics: Adult; Aspirin; Cerebral Angiography; Cerebral Infarction; Cilostazol; Diffusion Magnetic Resonance

2019
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
    European heart journal. Cardiovascular pharmacotherapy, 2019, 10-01, Volume: 5, Issue:4

    Topics: Aged; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Europe; Female; Hemorrhage;

2019
Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial.
    Journal of the American Heart Association, 2019, 08-20, Volume: 8, Issue:16

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Aspirin; Case-Control Studies; Dual Anti-P

2019
[3-year follow-up after endovascular aneurysm treatment with Silk® flow diverter].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2013, Volume: 185, Issue:4

    Topics: Adult; Aged; Aspirin; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Equipment Design

2013
Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy.
    Journal of cardiovascular electrophysiology, 2013, Volume: 24, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Echocardiography, Transesophageal;

2013
An unusual cause of recurrent chest pain in an adult woman: a case of recurrent stress-induced (Takotsubo) cardiomyopathy.
    BMJ case reports, 2013, May-24, Volume: 2013

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chest Pain; D

2013
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:1

    Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; Heart Failure;

2013
[Thrombosis risk during pregnancy after history of cerebral venous thrombosis].
    La Revue de medecine interne, 2015, Volume: 36, Issue:1

    Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Family Health; Female; Humans; Intracranial Thrombo

2015
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
    European heart journal, 2014, Volume: 35, Issue:15

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents;

2014
Aspirin resistant patients with recent ischemic stroke.
    Revista clinica espanola, 2014, Volume: 214, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Platelet Aggregation Inhibitors; Rec

2014
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
    Journal of cardiac surgery, 2014, Volume: 29, Issue:2

    Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc

2014
Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker.
    International archives of allergy and immunology, 2014, Volume: 163, Issue:2

    Topics: Acetates; Aged, 80 and over; Aspirin; Cromolyn Sodium; Cyclopropanes; Death, Sudden, Cardiac; Drug T

2014
[From apixaban to aspirin in the prevention of recurrent venous thromboembolism].
    Investigacion clinica, 2013, Volume: 54, Issue:3

    Topics: Anticoagulants; Antithrombins; Aspirin; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low

2013
Predictors of favourable outcome in non-variceal upper gastrointestinal bleeding: implications for early discharge?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Transfusion; Endoscopy, Digestive System; Esoph

2014
[Rescue treatment in acute thrombosis of intracranial stents].
    Revista de neurologia, 2014, Feb-01, Volume: 58, Issue:3

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Basilar Artery; Capillary Permeability; Cerebral Angiogr

2014
Secondary prevention of atherothrombotic or cryptogenic stroke.
    Circulation, 2014, Jan-28, Volume: 129, Issue:4

    Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Th

2014
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:8

    Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona

2014
Cardiac tamponade due to low-volume effusive constrictive pericarditis in a patient with uncontrolled type II autoimmune polyglandular syndrome.
    Acute cardiac care, 2014, Volume: 16, Issue:1

    Topics: Aspirin; Cardiac Tamponade; Cardiotonic Agents; Colchicine; Combined Modality Therapy; Glucocorticoi

2014
Opposing effects of aspirin and anticoagulants on morbidity and mortality in patients with upper gastrointestinal bleeding.
    Journal of digestive diseases, 2014, Volume: 15, Issue:6

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Female; H

2014
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
    International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate

2014
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:10

    Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma

2015
Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Fema

2015
Otologic manifestation of Samter triad.
    Ear, nose, & throat journal, 2014, Volume: 93, Issue:7

    Topics: Aspirin; Asthma, Aspirin-Induced; Female; Hearing Loss; Humans; Middle Aged; Nasal Polyps; Otitis Me

2014
Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.
    Autoimmunity, 2015, Volume: 48, Issue:1

    Topics: Abortion, Habitual; Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Cell Movement; Chorionic Vi

2015
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
    European journal of neurology, 2014, Volume: 21, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination;

2014
Antithrombotic therapy for secondary stroke prevention in bacterial meningitis in children.
    The Journal of pediatrics, 2014, Volume: 165, Issue:4

    Topics: Adolescent; Aspirin; Brain; Child; Child, Preschool; Diagnostic Imaging; Female; Fibrinolytic Agents

2014
Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.
    Clinics and research in hepatology and gastroenterology, 2014, Volume: 38, Issue:5

    Topics: Aspirin; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplan

2014
T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2016, Volume: 17, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aspirin; Atrial Natriuretic Factor; Female

2016
Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:3

    Topics: Abortion, Habitual; Anticoagulants; Apgar Score; Aspirin; Birth Weight; Blood Coagulation Factors; D

2015
Rebleeding after initial endoscopic hemostasis in peptic ulcer disease.
    Journal of Korean medical science, 2014, Volume: 29, Issue:10

    Topics: Antithrombins; Aspirin; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hemostasis, Endoscopic; Hum

2014
Kawasaki shock syndrome complicating a recurrence of Kawasaki disease.
    Pediatrics, 2014, Volume: 134, Issue:6

    Topics: Aspirin; Child; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug

2014
The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis.
    BMJ case reports, 2014, Nov-24, Volume: 2014

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Coronary Thrombosis; Diagnosis, Differential; Electrocardio

2014
Long-Term Outcomes of NSAID-Induced Small Intestinal Injury Assessed by Capsule Endoscopy in Korea: A Nationwide Multicenter Retrospective Study.
    Gut and liver, 2015, Nov-23, Volume: 9, Issue:6

    Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Capsule Endoscopy; Female; Huma

2015
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Thrombosis research, 2015, Volume: 135, Issue:2

    Topics: Administration, Oral; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Mortal

2015
Endovascular treatment of internal carotid artery pseudo-aneurysm presenting with epistaxis. A case report.
    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2014, Volume: 20, Issue:6

    Topics: Angiography, Digital Subtraction; Aspirin; Carotid Artery Injuries; Carotid Artery, Internal; Clopid

2014
Moyamoya disease associated with aortic coarctation.
    World journal of pediatrics : WJP, 2014, Volume: 10, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Coarctation; Aspirin; Calcium Channel Blocker

2014
Recurrent ischaemic stroke unveils polycythaemia vera.
    BMJ case reports, 2015, Mar-09, Volume: 2015

    Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutar

2015
Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Heart (British Cardiac Society), 2015, May-15, Volume: 101, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers

2015
Effects of platelet infusion, anticoagulant and other risk factors on the rehaemorrhagia after surgery of hypertensive cerebral hemorrhage.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Female; Hematoma; Humans; Intracranial Hemorrha

2015
Stroke mimicking relapse in a patient with CLIPPERS syndrome.
    Acta neurologica Belgica, 2015, Volume: 115, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Brain Stem; Encephalomye

2015
Clinical outcomes of nonvariceal upper gastrointestinal bleeding in Kosova.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2014, Volume: 25 Suppl 1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An

2014
Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study.
    Panminerva medica, 2015, Volume: 57, Issue:3

    Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Flavonoids; Humans; Incidence; Italy; Male; Middle Aged

2015
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel

2015
High Residual Collagen-Induced Platelet Reactivity Predicts Development of Restenosis in the Superficial Femoral Artery After Percutaneous Transluminal Angioplasty in Claudicant Patients.
    Cardiovascular and interventional radiology, 2016, Volume: 39, Issue:2

    Topics: Aged; Angiography; Angioplasty; Aspirin; Blood Platelets; Collagen; Female; Femoral Artery; Hemodyna

2016
[Diagnosis and treatment of aspirin--and NSAID-induced peptic ulcers].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastric Mucosa; Humans; Peptic Ulcer; Practice Gui

2015
Clinical characteristics of Helicobacter pylori-negative drug-negative peptic ulcer bleeding.
    World journal of gastroenterology, 2015, Jul-28, Volume: 21, Issue:28

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Breath Tests; Endoscopy, Gast

2015
Computational fluid dynamics evaluation of flow reversal treatment of giant basilar tip aneurysm.
    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2015, Volume: 21, Issue:5

    Topics: Aspirin; Basilar Artery; Blood Flow Velocity; Computer Simulation; Contraindications; Endovascular P

2015
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Drug A

2015
[Comparison between Endoscopic Therapy and Medical Therapy in Peptic Ulcer Patients with Adherent Clot: A Multicenter Prospective Observational Cohort Study].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 66, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; H

2015
Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:2

    Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Angiography; Coronary Artery Disease; H

2016
Elevated levels of antibodies against phosphatidylserine/prothrombin complex and/or cardiolipin associated with infection and recurrent purpura in a child: a forme fruste of antiphospholipid syndrome?
    Dermatology online journal, 2015, Jul-15, Volume: 21, Issue:7

    Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Bacterial Infection

2015
A Patient Guide: Managing Diverticulitis.
    Gastroenterology, 2015, Volume: 149, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonosco

2015
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
    Texas Heart Institute journal, 2015, Volume: 42, Issue:5

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resis

2015
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
    BMC neurology, 2015, Nov-02, Volume: 15

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies;

2015
[Recurrence of Cerebral Infarction Associated Aspirin Resistance or Chinese Medical Constitutions: a Correlation Study].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2015, Volume: 35, Issue:10

    Topics: Aspirin; Body Constitution; Cerebral Infarction; Drug Resistance; Humans; Medicine, Chinese Traditio

2015
Successful Management of Recurrent Colon Ulcer in Hemodialysis Patient after Conversion to Peritoneal Dialysis.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 66, Issue:6

    Topics: Aspirin; Colon; Colonic Diseases; Colonoscopy; Drug Therapy, Combination; Gastrointestinal Hemorrhag

2015
Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
    Circulation. Cardiovascular interventions, 2016, Volume: 9, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; I

2016
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
    International journal of stroke : official journal of the International Stroke Society, 2016, Volume: 11, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C

2016
Treatment and outcomes of patients with recurrent myocardial infarction: A prospective observational cohort study.
    Journal of cardiology, 2016, Volume: 68, Issue:6

    Topics: Age Factors; Aged; Aspirin; Cohort Studies; Comorbidity; Drug Utilization; Female; Guideline Adheren

2016
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
    Journal of the neurological sciences, 2016, Feb-15, Volume: 361

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr

2016
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
    European journal of ophthalmology, 2016, Aug-04, Volume: 26, Issue:5

    Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination;

2016
Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2016, Volume: 35, Issue:2

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Combinations; Female; Foll

2016
High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
    VASA. Zeitschrift fur Gefasskrankheiten, 2016, Volume: 45, Issue:2

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Therapy,

2016
Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients.
    Thrombosis and haemostasis, 2016, 08-01, Volume: 116, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; C

2016
Subdural haematoma complicating shunting for normal pressure hydrocephalus in the setting of concomitant antiplatelet medication - a report of 11 cases.
    British journal of neurosurgery, 2016, Volume: 30, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Female; Hematoma, Subdural, Chronic; Humans; Hydrocephalus, Normal

2016
[After the first stroke, acetylsalicylic acid is no longer enough].
    MMW Fortschritte der Medizin, 2016, Feb-18, Volume: 158, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Humans; Recurrence; Stroke

2016
Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage.
    Gastroenterology, 2016, Volume: 151, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Gastrointes

2016
Complication of Stenting in Intracranial Arterial Stenosis.
    Archives of Iranian medicine, 2016, Volume: 19, Issue:5

    Topics: Age Factors; Aged; Angioplasty; Aspirin; China; Clopidogrel; Computed Tomography Angiography; Constr

2016
Recurrent Kawasaki Disease: Mind the Age, But It Does Not Matter.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2016, Volume: 22, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Immunoglobulins, Intravenous; Male; Mucocu

2016
PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients.
    Stroke, 2016, Volume: 47, Issue:7

    Topics: Aspirin; Brain Ischemia; CpG Islands; DNA Methylation; Follow-Up Studies; Genetic Association Studie

2016
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2016, Jun-18, Volume: 48, Issue:3

    Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction;

2016
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.
    Stroke, 2016, Volume: 47, Issue:8

    Topics: Aged; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence

2016
Three episodes of Kawasaki disease including one after the Pneumo 23 vaccine in a child with a family history of Kawasaki disease.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2016, Volume: 115, Issue:10

    Topics: Aspirin; Child, Preschool; Family Health; Humans; Immunoglobulins, Intravenous; Male; Mucocutaneous

2016
Does Early Resumption of Low-Dose Aspirin After Evacuation of Chronic Subdural Hematoma With Burr-Hole Drainage Lead to Higher Recurrence Rates?
    Neurosurgery, 2016, Volume: 79, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Craniotomy; Drainage; Female; Hematoma, S

2016
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
    Texas Heart Institute journal, 2016, Volume: 43, Issue:4

    Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Mid

2016
Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study.
    Medicine, 2016, Volume: 95, Issue:36

    Topics: Adult; Age Factors; Aged; Aspirin; Female; Hemostasis, Endoscopic; Hospital Costs; Humans; Intubatio

2016
Aspirin is Key to Reducing Risk of Early Stroke Recurrence.
    The American journal of nursing, 2016, Volume: 116, Issue:11

    Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Recurrence; Risk Reduction Behavior; Stroke

2016
Effect of Low-Dose Aspirin on Midluteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss.
    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2016, Volume: 35, Issue:12

    Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Flow Velocity;

2016
TRIAD system catalase, insulin, and low dose aspirin neutralize the effect of dermcidin isoform-2 and prevent cell death in acute myocardial infarction and recurrence of the disease.
    Cardiology journal, 2016, Volume: 23, Issue:6

    Topics: Aspirin; Catalase; Cell Death; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Peptides

2016
Aspirin Blocks Orthodontic Relapse via Inhibition of CD4
    Journal of dental research, 2017, Volume: 96, Issue:5

    Topics: Animals; Aspirin; CD4-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Int

2017
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
    European heart journal, 2017, Jun-01, Volume: 38, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Se

2017
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
    Journal of the neurological sciences, 2017, Feb-15, Volume: 373

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat

2017
Burr-Hole Drainage for Chronic Subdural Hematoma Under Low-Dose Acetylsalicylic Acid: A Comparative Risk Analysis Study.
    World neurosurgery, 2017, Volume: 100

    Topics: Aged; Aspirin; Cardiovascular Diseases; Decompressive Craniectomy; Dose-Response Relationship, Drug;

2017
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
    International journal of cardiology, 2017, May-15, Volume: 235

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination;

2017
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
    Postgraduate medical journal, 2017, Volume: 93, Issue:1103

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia

2017
Cryptogenic stroke in a patient with a PFO: a decision analysis.
    The American journal of the medical sciences, 2008, Volume: 335, Issue:6

    Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Decision Trees; Foramen Ovale, Patent; Humans; Int

2008
[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
    MMW Fortschritte der Medizin, 2008, May-22, Volume: 150, Issue:21

    Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Germany; Humans; Multicenter Studies

2008
Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study.
    Clinical drug investigation, 2008, Volume: 28, Issue:8

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascula

2008
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
    Clinical research in cardiology : official journal of the German Cardiac Society, 2008, Volume: 97, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R

2008
45-year-old woman with recurrent headache and photophobia.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:8

    Topics: Acyclovir; Anti-Bacterial Agents; Antiviral Agents; Aspirin; Diagnosis, Differential; Female; Headac

2008
Does Aggrenox (aspirin/dipyridamole) reduce the risk of recurrent stroke to a greater degree than aspirin alone?
    The Journal of the Oklahoma State Medical Association, 2008, Volume: 101, Issue:5

    Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet A

2008
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    International journal of stroke : official journal of the International Stroke Society, 2006, Volume: 1, Issue:1

    Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi

2006
[Digital ischemia in a gardener: is rose cutting a vascular risk factor?].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:42

    Topics: Alprostadil; Aneurysm; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Finger Injuries; Fi

2008
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
    The New England journal of medicine, 2008, Oct-23, Volume: 359, Issue:17

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co

2008
Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy.
    Neurocritical care, 2009, Volume: 10, Issue:2

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Cerebral Angiography; Fatal Outcome; Female; Hepar

2009
Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events.
    Journal of the neurological sciences, 2009, Feb-15, Volume: 277, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Resistance; Female; Humans; Intracranial Thrombosis; M

2009
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
    Journal francais d'ophtalmologie, 2008, Volume: 31, Issue:8

    Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary B

2008
Recurrent stroke in a child with incontinentia pigmenti.
    Journal of child neurology, 2009, Volume: 24, Issue:5

    Topics: Aspirin; Brain; Female; Humans; Incontinentia Pigmenti; Infant, Newborn; Magnetic Resonance Imaging;

2009
Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function.
    The Annals of thoracic surgery, 2009, Volume: 87, Issue:2

    Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Coronary Stenosis; Dose-Response Relationship

2009
[Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs].
    No to hattatsu = Brain and development, 2009, Volume: 41, Issue:1

    Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation Tests; Cerebral Infarction; Child, Preschool; Cilo

2009
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jun-01, Volume: 73, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2009
Is steroid therapy enough to reverse complete atrioventricular block after percutaneous perimembranous ventricular septal defect closure?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2009, Volume: 10, Issue:5

    Topics: Anti-Inflammatory Agents; Aspirin; Atrioventricular Block; Cardiac Catheterization; Cardiac Pacing,

2009
Degos' disease: a rare condition simulating rheumatic diseases.
    Clinical rheumatology, 2009, Volume: 28, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Fatal Outcome; Fem

2009
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
    Neurology, 2009, May-26, Volume: 72, Issue:21

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu

2009
[Postoperative ischemic acute stroke and thrombolytic therapy].
    Annales francaises d'anesthesie et de reanimation, 2009, Volume: 28, Issue:4

    Topics: Acute Disease; Aged; Anticoagulants; Aphasia, Broca; Aspirin; Cholesteatoma; Ear Diseases; Ear, Exte

2009
[Factors influencing development of atrial fibrillation after implantation of cardiac pacemaker for sinus node dysfunction].
    Medicina (Kaunas, Lithuania), 2009, Volume: 45, Issue:3

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Data

2009
Recurrent pericarditis due to natalizumab treatment.
    Neurology, 2009, May-05, Volume: 72, Issue:18

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Chest Pain; Colchicine; D

2009
[Therapy of atrial fibrillation. Heart rate or rhythm control, marcumar or acetylsalicylic acid?].
    MMW Fortschritte der Medizin, 2009, Feb-26, Volume: 151, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Humans; Patient Education as Topic;

2009
Acknowledging a failed strategy.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jun-01, Volume: 73, Issue:7

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr

2009
Clopidogrel. Patients with peptic ulcers.
    BMJ (Clinical research ed.), 2009, May-20, Volume: 338

    Topics: Aspirin; Clopidogrel; Histamine H2 Antagonists; Humans; Peptic Ulcer Hemorrhage; Platelet Aggregatio

2009
Retinal artery embolization during carotid angioplasty and carotid artery stenting: case report.
    Neurologia medico-chirurgica, 2009, Volume: 49, Issue:5

    Topics: Aged; Angioplasty, Balloon; Anticoagulants; Antipyrine; Aspirin; Carotid Artery, External; Carotid S

2009
Recurrent Kawasaki disease.
    Indian journal of pediatrics, 2009, Volume: 76, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Humans; Immunoglobulins,

2009
Anti-interleukin-5 therapy and severe asthma.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma; Eosinophilia; Humans; In

2009
[The concept of aspirin "resistance": mechanisms and clinical relevance].
    La Revue de medecine interne, 2009, Volume: 30, Issue:12

    Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Huma

2009
Recurrent hematospermia due to aspirin.
    Indian journal of medical sciences, 2009, Volume: 63, Issue:6

    Topics: Adult; Aspirin; Hemospermia; Humans; Male; Platelet Aggregation Inhibitors; Recurrence

2009
[Frosted-branch angiitis revealing Behçet's disease].
    Journal francais d'ophtalmologie, 2009, Volume: 32, Issue:9

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Behcet Syndrome;

2009
The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke.
    Acta neurologica Taiwanica, 2009, Volume: 18, Issue:2

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Drug Utilization; Female; Fibrinolytic Agents; Humans; Male; M

2009
JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:9

    Topics: Aspirin; Child; Clone Cells; Cytotoxins; Diagnosis, Differential; Female; Headache; Humans; Hydroxyu

2009
Redo surgery or carotid stenting for restenosis after carotid endarterectomy: results of two different treatment strategies.
    Annals of vascular surgery, 2010, Volume: 24, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Feasibilit

2010
Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2009, Volume: 23, Issue:9

    Topics: Aged; Aspirin; Blood Transfusion; Endoscopy, Digestive System; Female; Gastrointestinal Hemorrhage;

2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr

2009
Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.
    Hamostaseologie, 2009, Volume: 29, Issue:4

    Topics: Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Pr

2009
Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aspirin; Beclomethasone; Cohort Studies; Colitis, Ulc

2010
Aspirin withdrawal in acute peptic ulcer bleeding: are we harming patients?
    Annals of internal medicine, 2010, Jan-05, Volume: 152, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; Pe

2010
Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
    Annals of internal medicine, 2010, Jan-05, Volume: 152, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster

2010
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Long-term clinical course of patients with isolated myocardial bridge.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:3

    Topics: Aged; Angina Pectoris; Aspirin; Coronary Angiography; Coronary Vasospasm; Female; Follow-Up Studies;

2010
A 19-month-old boy with recurrent respiratory distress.
    Pediatric emergency care, 2010, Volume: 26, Issue:2

    Topics: Acid-Base Equilibrium; Albuterol; Alkalosis, Respiratory; Aspirin; Asthma; Bicarbonates; Bites, Huma

2010
Ultrasound evaluation of early changes in arterial dissection.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2010, Volume: 19, Issue:2

    Topics: Aspirin; Blood Proteins; Carotid Artery, Internal; Carotid Artery, Internal, Dissection; Cerebrovasc

2010
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
    Current medical research and opinion, 2010, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema

2010
Stroke recurrence in an elderly CADASIL patient on aspirin discontinuation due to severe auto-immune thrombocytopenia.
    Aging clinical and experimental research, 2010, Volume: 22, Issue:1

    Topics: Aged, 80 and over; Aspirin; Autoimmune Diseases; CADASIL; Exons; Humans; Male; Receptor, Notch3; Rec

2010
Spontaneous coronary dissection as cause of recurring myocardial infarction.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:3

    Topics: Anticoagulants; Aortic Dissection; Aspirin; Coronary Aneurysm; Coronary Angiography; Drug Therapy, C

2011
Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction.
    The Journal of invasive cardiology, 2010, Volume: 22, Issue:6

    Topics: Age Distribution; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary

2010
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.
    Neurology, 2010, Jun-08, Volume: 74, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic A

2010
[Case of branch atheromatous disease presenting capsular warning syndrome].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:5

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Atorvastatin; Dextrans; Diffusion Magnetic Resonance Imagi

2010
[Sporadic hemiplegic migraine-like headache in a patient with systemic lupus erythematosus].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:5

    Topics: 1-Naphthylamine; Adult; Aspirin; Calcium Channel Blockers; Diagnosis, Differential; Female; Hemipleg

2010
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female

2010
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female

2010
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female

2010
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female

2010
Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke.
    European neurology, 2010, Volume: 64, Issue:1

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diffusion Magnetic Resonance Imaging;

2010
Platelet function testing for aspirin resistance is reasonable to do: yes!
    Stroke, 2010, Volume: 41, Issue:10

    Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Stroke

2010
The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against.
    Stroke, 2010, Volume: 41, Issue:10

    Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Stroke

2010
Neurosonographic monitoring of 105 spontaneous cervical artery dissections: a prospective study.
    Neurology, 2010, Nov-23, Volume: 75, Issue:21

    Topics: Administration, Oral; Adult; Anticoagulants; Aspirin; Carotid Artery, Internal, Dissection; Drug Adm

2010
[Risk factors for development and recurrence of peptic ulcer disease].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Female;

2010
Ischaemic stroke--prevention is better than cure.
    The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:1

    Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo

2010
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
    Journal of cardiology, 2011, Volume: 57, Issue:1

    Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie

2011
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
    Acute cardiac care, 2011, Volume: 13, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug

2011
Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011, Volume: 32, Issue:4

    Topics: Aspirin; Clopidogrel; Hematoma, Epidural, Spinal; Humans; Magnetic Resonance Imaging; Male; Middle A

2011
[Beyond coronary artery disease: interventional approach to carotid occlusive disease].
    Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:10 Suppl 1

    Topics: Aged; Aged, 80 and over; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Arte

2010
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
    BMJ (Clinical research ed.), 2011, May-11, Volume: 342

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Denmark; Drug Interactions; Humans; Kaplan-Meier Esti

2011
[Kawasaki disease in older children and young adults: 10 years of experience in Marseille, France].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2011, Volume: 18, Issue:7

    Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, No

2011
Fabry disease and Factor V Leiden: a potent vascular risk combination.
    Internal medicine journal, 2011, Volume: 41, Issue:5

    Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defib

2011
Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population.
    Archives of internal medicine, 2011, Jul-25, Volume: 171, Issue:14

    Topics: Acute Disease; Adult; Aged; Aspirin; Baltimore; Cardiovascular Agents; Case-Control Studies; Confoun

2011
[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].
    Neurologia (Barcelona, Spain), 2012, Volume: 27, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Female; Follow-Up Studies; Humans;

2012
Ischemic stroke in patients receiving aspirin.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis

2012
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
    Stroke, 2011, Volume: 42, Issue:10

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent;

2011
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Pharmacoepidemiology and drug safety, 2011, Volume: 20, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop

2011
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    The American journal of cardiology, 2011, Nov-15, Volume: 108, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B

2011
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers.
    European heart journal, 2012, Volume: 33, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Emergency T

2012
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2012, Volume: 13, Issue:12

    Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatibl

2012
[Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome].
    Revista de neurologia, 2011, Nov-16, Volume: 53, Issue:10

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cerebral Infarction; Female; Follow-Up St

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Use of aspirin in Chinese after recovery from primary intracranial haemorrhage.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:2

    Topics: Age Factors; Aspirin; Female; Follow-Up Studies; Humans; Intracranial Hemorrhages; Male; Middle Aged

2012
Microtrauma-induced recurrent hyphema and secondary glaucoma associated with chronic acetylsalicylic acid use.
    International ophthalmology, 2012, Volume: 32, Issue:1

    Topics: Administration, Oral; Adult; Angina Pectoris; Antihypertensive Agents; Aspirin; Diagnosis, Different

2012
Recurrent cerebral infarction in Klippel-Trenaunay-Weber syndrome.
    Clinical neurology and neurosurgery, 2012, Volume: 114, Issue:7

    Topics: Aspirin; Cerebral Angiography; Cerebral Infarction; Dysarthria; Female; Fibromuscular Dysplasia; Gai

2012
Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2013, Volume: 270, Issue:2

    Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Drug Hypersensitivity; Endosc

2013
Recurrent pediatric thrombosis: the effect of underlying and/or coexisting factors.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2012, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Anticoagulants; Aspirin; Child; Child, Preschool; Chronic Disease; Factor VIII; F

2012
Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study.
    Lupus, 2012, Volume: 21, Issue:11

    Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ische

2012
Diagnosis and management of giant cell arteritis.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2012, Volume: 62, Issue:599

    Topics: Administration, Oral; Anti-Inflammatory Agents; Aspirin; Biopsy; Giant Cell Arteritis; Glucocorticoi

2012
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosclerosis; Female; Fibrinolytic Agents; Huma

2012
Recurrent aortic aneurysm due to Behcet's disease: a case report from China.
    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2013, Volume: 19, Issue:2

    Topics: Adult; Anticoagulants; Aortic Aneurysm; Aortography; Aspirin; Behcet Syndrome; China; Glucocorticoid

2013
Treatment of blood blister-like aneurysms of the internal carotid artery with stent-assisted coil embolization.
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:7

    Topics: Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embol

2013
Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia.
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:7

    Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Brain Ischemia; Drug Resistance; Female; Hum

2013
Treatment of a pediatric recurrent fusiform middle cerebral artery (MCA) aneurysm with a flow diverter.
    BMJ case reports, 2012, Nov-15, Volume: 2012

    Topics: Adolescent; Aspirin; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Humans; Intracran

2012
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Sep-01, Volume: 82, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc

2013
[Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction].
    Zhonghua yi xue za zhi, 2012, Oct-16, Volume: 92, Issue:38

    Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle Aged;

2012
Low-dose aspirin use and recurrent gout attacks.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Cross-Over Stu

2014
Recurrent thromboembolism in a patient with beta-thalassemia major associated with double heterozygosity for factor V R506Q and prothrombin G20210A mutations.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:5

    Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; beta-Thalas

2002
[Long-term anticoagulation after bypass operation].
    Der Internist, 2002, Volume: 43, Issue:8

    Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Humans; Long-Term Care; Platelet Aggregation Inhi

2002
Anticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in children.
    Journal of child neurology, 2002, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Aspirin; Child; Colitis, Ulcerative;

2002
[Platelet aggregation inhibitor in general practice. Every 3rd infarct prevented--reinfarction rate cut in half].
    MMW Fortschritte der Medizin, 2002, Aug-22, Volume: 144, Issue:33-34

    Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Survival Rate;

2002
How to keep chest pain from cramping your style. If you are one of the millions of Americans for whom chest pain is part of daily life, here are some ABCs for getting it under control.
    Harvard heart letter : from Harvard Medical School, 2002, Volume: 13, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Aspirin; Chest Pain; Diet; Exercise; Fema

2002
[Embolism prevention in atrial fibrillation with heparin?].
    Deutsche medizinische Wochenschrift (1946), 2002, Dec-13, Volume: 127, Issue:50

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Heparin; Heparin, Low-Molecul

2002
Ischaemic stroke in young people: a prospective and long-term follow-up study.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 15, Issue:1-2

    Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec

2003
Aspirin or warfarin: what's best after a heart attack? Risk of bleeding counters warfarin's edge in efficacy.
    Health news (Waltham, Mass.), 2002, Volume: 8, Issue:11

    Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors;

2002
Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
    Annals of hematology, 2003, Volume: 82, Issue:3

    Topics: Aged; Aspirin; Busulfan; Erythromelalgia; Female; Fingers; Hematocrit; Humans; Male; Middle Aged; Pl

2003
[Anticoagulation and antiaggregation in neurological patients].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopid

2003
Heart failure as a cause for hospitalization in chronic dialysis patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular

2003
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
    Proceedings of the National Academy of Sciences of the United States of America, 2003, Jun-24, Volume: 100, Issue:13

    Topics: Adenoma; Adult; Aged; Aged, 80 and over; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin;

2003
Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement.
    BMC family practice, 2003, Jul-18, Volume: 4

    Topics: Aspirin; Attitude of Health Personnel; Drug Prescriptions; Humans; Patient Compliance; Physicians, F

2003
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
    Alimentary pharmacology & therapeutics, 2003, Aug-15, Volume: 18, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage;

2003
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
    Alimentary pharmacology & therapeutics, 2003, Aug-15, Volume: 18, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage;

2003
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
    Alimentary pharmacology & therapeutics, 2003, Aug-15, Volume: 18, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage;

2003
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
    Alimentary pharmacology & therapeutics, 2003, Aug-15, Volume: 18, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage;

2003
Successful perinatal outcome following recurrent idiopathic cerebrovascular strokes in pregnancy: a case report.
    Archives of gynecology and obstetrics, 2003, Volume: 268, Issue:3

    Topics: Adult; Aspirin; Cerebral Infarction; Delivery, Obstetric; Diagnosis, Differential; Drug Therapy, Com

2003
Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.
    Stroke, 2003, Volume: 34, Issue:10

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cohort Stu

2003
[How should anticoagulants be used in recurrent, ischemic and hemorrhagic brain infarctions?].
    Deutsche medizinische Wochenschrift (1946), 2003, Oct-17, Volume: 128, Issue:42

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemo

2003
[PRoFESS study presented. Change in secondary prevention].
    MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida

2003
[ASS and dipyridamole combination. A decisive contribution to secondary prevention after stroke].
    MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2

    Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio

2003
[Secondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?].
    MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2

    Topics: Aspirin; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ische

2003
Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings.
    Circulation, 2003, Dec-09, Volume: 108, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Collateral Circulation;

2003
[Heartburn without esophagitis. Symptoms more important than the finding?].
    MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39

    Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul

2003
A case of frequently recurring amaurosis fugax with atherothrombotic ophthalmic artery occlusion.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1

    Topics: Amaurosis Fugax; Angiography, Digital Subtraction; Arterial Occlusive Diseases; Arteriosclerosis; As

2004
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
    Circulation, 2004, Feb-24, Volume: 109, Issue:7

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbid

2004
The specificity of prescription patterns in secondary stroke prevention.
    Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:3

    Topics: Accidental Falls; Anticoagulants; Aspirin; Cognition Disorders; Geriatric Assessment; Humans; Patien

2004
Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
    Eye (London, England), 2004, Volume: 18, Issue:8

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascula

2004
Aspirin resistance.
    BMJ (Clinical research ed.), 2004, Feb-28, Volume: 328, Issue:7438

    Topics: Aspirin; Drug Resistance; Humans; Ischemia; Platelet Aggregation Inhibitors; Recurrence

2004
Day-hospital treatment of acute pericarditis: a management program for outpatient therapy.
    Journal of the American College of Cardiology, 2004, Mar-17, Volume: 43, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Day Care, Medical; Decision Tree

2004
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke.
    Thrombosis research, 2003, Volume: 112, Issue:5-6

    Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Case-Control Studies; Cyclooxygenase 1; DNA Muta

2003
Is the endovascular treatment of carotid stenosis in high-risk patients really safer than carotid endarterectomy?
    Cerebrovascular diseases (Basel, Switzerland), 2004, Volume: 17, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Carotid Stenosis; Endarterectomy, Car

2004
Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia.
    Thrombosis and haemostasis, 2004, Volume: 91, Issue:5

    Topics: Afibrinogenemia; Aspirin; Blood Coagulation Tests; Drug Therapy, Combination; Heparin; Hirudins; Hum

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
    The American journal of cardiology, 2004, Jun-15, Volume: 93, Issue:12

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti

2004
Paroxysmal dysarthria and ataxia after midbrain infarction.
    Neurology, 2004, Jul-27, Volume: 63, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Cerebellum; Diplopia; Dysarthria; Gait Ataxia; Humans; Infarction, Mi

2004
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
    Neurology, 2004, Sep-14, Volume: 63, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biomarkers; Brain Infarction; Brain Ischemia; Coho

2004
[Ulcerative colitis. Acute episode].
    Zeitschrift fur Gastroenterologie, 2004, Volume: 42, Issue:9

    Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammator

2004
[Clopidogrel protection is not increased further by ASS!].
    Praxis, 2004, Aug-25, Volume: 93, Issue:35

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische

2004
[Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications].
    Vnitrni lekarstvi, 2004, Volume: 50, Issue:8

    Topics: Adult; Aged; Angina, Unstable; Aspirin; Drug Resistance; Female; Humans; Male; Myocardial Infarction

2004
Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.
    Age and ageing, 2005, Volume: 34, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death;

2005
Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage.
    Journal of neurosurgery, 2004, Volume: 101, Issue:6

    Topics: Adult; Aged; Aspirin; Female; Humans; Incidence; Male; Medical Records; Middle Aged; Platelet Aggreg

2004
Long-term combination therapy with aspirin and clopidogrel.
    Journal of cardiovascular pharmacology and therapeutics, 2004, Volume: 9, Issue:4

    Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me

2004
[Stroke prevention in atrial fibrillation -- transfer of study results to the practice].
    Wiener klinische Wochenschrift, 2004, Dec-30, Volume: 116, Issue:24

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla

2004
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Annals of internal medicine, 2005, Feb-15, Volume: 142, Issue:4

    Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A

2005
Clinical characteristics of patients with ischemic ocular nerve palsies and lacunar brain infarcts: a retrospective comparative study.
    Acta neurologica Scandinavica, 2005, Volume: 111, Issue:5

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain I

2005
Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Allergens; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Exercis

2005
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic;

2005
A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs.
    Alimentary pharmacology & therapeutics, 2005, Volume: 21 Suppl 2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Endoscopy, Gastroi

2005
S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits.
    Atherosclerosis, 2005, Volume: 183, Issue:1

    Topics: Animals; Aortic Diseases; Aspirin; Atherosclerosis; Catheterization; Diet, Atherogenic; Drug Evaluat

2005
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Link between platelet activity and outcomes after an ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2005, Volume: 20, Issue:2

    Topics: Aged; Aspirin; Blood Platelets; Endpoint Determination; Female; Flow Cytometry; Humans; Logistic Mod

2005
Weight restoration in a patient with anorexia nervosa on dialysis.
    The International journal of eating disorders, 2005, Volume: 38, Issue:4

    Topics: Adult; Anorexia Nervosa; Aspirin; Barbiturates; Body Mass Index; Body Weight; Caffeine; Combined Mod

2005
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
    Diabetes care, 2006, Volume: 29, Issue:1

    Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co

2006
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2006, Volume: 29, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum

2006
Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:2

    Topics: Acetaminophen; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Colitis, Ul

2006
[Percutaneous closure of patent foramen ovale-- Against].
    Deutsche medizinische Wochenschrift (1946), 2006, Apr-07, Volume: 131, Issue:14

    Topics: Aspirin; Evidence-Based Medicine; Heart Septal Defects, Atrial; Humans; Platelet Aggregation Inhibit

2006
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest

2006
Acute migraine treatment: patterns of use and satisfaction in a clinical population.
    Headache, 2006, Volume: 46, Issue:5

    Topics: Acetaminophen; Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffein

2006
Large subcortical infarcts: clinical features, risk factors, and long-term prognosis compared with cortical and small deep infarcts.
    Stroke, 2006, Volume: 37, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain; Cerebral Cortex; Cerebral Infarction; Cohort Studies

2006
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Circulation, 2006, Jun-27, Volume: 113, Issue:25

    Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygena

2006
The aspirin resistance controversy: clinical entity or platelet heterogeneity?
    Circulation, 2006, Jun-27, Volume: 113, Issue:25

    Topics: Aspirin; Coronary Artery Disease; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Dr

2006
A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk.
    Medical hypotheses, 2006, Volume: 67, Issue:5

    Topics: Adult; Aged; Aspirin; Databases, Factual; Foramen Ovale, Patent; Humans; Middle Aged; Recurrence; Ri

2006
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
    Circulation, 2006, Jul-04, Volume: 114, Issue:1 Suppl

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality

2006
[Gastroenterology in family practice. Updates for your "stomach patient"].
    MMW Fortschritte der Medizin, 2006, Jun-01, Volume: 148, Issue:22

    Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Dyspepsia; Esophagitis, Peptic; Family Practice; Heartburn;

2006
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:8

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxapari

2006
The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis.
    AJNR. American journal of neuroradiology, 2006, Volume: 27, Issue:7

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Arteries; Carotid St

2006
[Treating ischemic stroke as an emergency to prevent cerebral infarction or limit its spread].
    La Revue du praticien, 2006, Sep-15, Volume: 56, Issue:13

    Topics: Aspirin; Cerebral Infarction; Emergencies; Fibrinolytic Agents; Humans; Ischemic Attack, Transient;

2006
[Transient ischemic stroke].
    La Revue du praticien, 2006, Sep-15, Volume: 56, Issue:13

    Topics: Administration, Oral; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Fibrinolytic Agents;

2006
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
    La Revue du praticien, 2006, Sep-15, Volume: 56, Issue:13

    Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug

2006
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:12

    Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Clopidogrel; Coronary Disease; Diabetes Complic

2006
Effects of policosanol on patients with ischemic stroke: a pilot open study.
    Journal of medicinal food, 2006,Fall, Volume: 9, Issue:3

    Topics: Aged; Anticholesteremic Agents; Aspirin; Fatty Alcohols; Female; Follow-Up Studies; Humans; Lipids;

2006
Platelet activation and cardiovascular outcomes in acute coronary syndromes.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:12

    Topics: Acute Disease; Aspirin; Coronary Disease; Humans; Platelet Activation; Platelet Aggregation Inhibito

2006
Platelet hyperactivity and risk of recurrent thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:12

    Topics: Aspirin; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pred

2006
[Antiplatelet therapy after aspirin-induced upper gastrointestinal bleeding].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2006, Nov-02, Volume: 126, Issue:21

    Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combinatio

2006
Clinical trials and dipyridamole formulation selection.
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 23, Issue:1

    Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug

2007
Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States).
    Cancer causes & control : CCC, 2006, Volume: 17, Issue:10

    Topics: Adenomatous Polyps; Aspirin; Body Mass Index; Colorectal Neoplasms; Confidence Intervals; Female; Hu

2006
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
    Cardiology, 2007, Volume: 108, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma

2007
Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
    Circulation, 2006, Nov-28, Volume: 114, Issue:22

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Electr

2006
Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
    American heart journal, 2007, Volume: 153, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Hospit

2007
The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kardiologia polska, 2006, Volume: 64, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Electrocardiography; Female; Genetic Markers; Humans;

2006
Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
    Kardiologia polska, 2007, Volume: 65, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel;

2007
Non-ST-elevation acute coronary syndromes.
    Lancet (London, England), 2007, Mar-10, Volume: 369, Issue:9564

    Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Cardiac Catheterization; Coronary Angiograph

2007
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:6

    Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Co

2007
Myopericarditis versus viral or idiopathic acute pericarditis.
    Heart (British Cardiac Society), 2008, Volume: 94, Issue:4

    Topics: Acute Disease; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac T

2008
Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2007, Volume: 20, Issue:1-4

    Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Base Sequence; Cyclooxygenas

2007
Successful pregnancy with the use of nitric oxide donors and heparin after recurrent severe preeclampsia in a woman with scleroderma.
    American journal of obstetrics and gynecology, 2007, Volume: 197, Issue:2

    Topics: Adult; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Nitric Oxide Donors; Pre-Eclampsia; P

2007
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
    Ear, nose, & throat journal, 2007, Volume: 86, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Child, Preschool; Chronic Diseas

2007
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
    American heart journal, 2007, Volume: 154, Issue:4

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hum

2007
Redo pedal bypass surgery after pedal graft failure: gain or gadget?
    Annals of vascular surgery, 2007, Volume: 21, Issue:6

    Topics: Aged; Anastomosis, Surgical; Anticoagulants; Arteries; Aspirin; Blood Vessel Prosthesis; Blood Vesse

2007
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
    Ugeskrift for laeger, 2007, Oct-01, Volume: 169, Issue:40

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents;

2007
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
    Acta neurologica Scandinavica, 2008, Volume: 117, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic

2008
[A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation].
    Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Follow-Up Stud

2007
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Jan-01, Volume: 71, Issue:1

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin;

2008
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2008, Volume: 35, Issue:3

    Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient;

2008
Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:1

    Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Epine

2008
Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention.
    Heart and vessels, 2008, Volume: 23, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combi

2008
Laboratory-defined aspirin resistance and recurrent cardiovascular events.
    Archives of internal medicine, 2008, Mar-10, Volume: 168, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Recurren

2008
Is aspirin resistance due to noncompliance?
    Archives of internal medicine, 2008, Mar-10, Volume: 168, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Patient Compliance; Platelet Aggregation

2008
[Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].
    Nederlands tijdschrift voor geneeskunde, 2008, Feb-23, Volume: 152, Issue:8

    Topics: Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Re

2008
Single antiplatelet therapy for patients with previous gastrointestinal bleeds.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:6

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Gastrointest

2008
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
    Annals of medicine, 2008, Volume: 40, Issue:4

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Coronary Disease; Disease-Free Survival; Female;

2008
Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:5

    Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Dyspepsia

2008
Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
    Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:8

    Topics: Animals; Aspirin; Base Sequence; Blood Vessels; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase I

2008
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
    Lancet (London, England), 1980, Oct-04, Volume: 2, Issue:8197

    Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence;

1980
[Prevention of recurrent myocardial infarct].
    Duodecim; laaketieteellinen aikakauskirja, 1981, Volume: 97, Issue:5

    Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone

1981
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
    Controlled clinical trials, 1982, Volume: 3, Issue:3

    Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di

1982
[Second prevention following myocardial infarct].
    Schweizerische medizinische Wochenschrift, 1984, Jan-21, Volume: 114, Issue:3

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Humans; Myocardial Inf

1984
Secondary prevention of coronary heart disease.
    Acta cardiologica, 1984, Volume: 39, Issue:4

    Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B

1984
[Postoperative antithrombotic therapy in acute occlusion of the major arteries of the extremities].
    Vestnik khirurgii imeni I. I. Grekova, 1980, Volume: 125, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Arm; Arterial Occlusive Diseases; Aspirin; Dextrans; Female;

1980
Antithrombotic treatment.
    British medical journal (Clinical research ed.), 1983, Jul-16, Volume: 287, Issue:6386

    Topics: Ancrod; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Drug Administration Schedule; He

1983
[Acetylsalicylic acid--additive intolerance phenomenon in chronic recurring urticaria].
    Dermatologische Monatschrift, 1982, Volume: 168, Issue:8

    Topics: Adolescent; Adult; Aged; Aspirin; Drug Eruptions; Female; Food Coloring Agents; Food Preservatives;

1982
[Incidence of recurrence after successful transluminal coronary angioplasty].
    Deutsche medizinische Wochenschrift (1946), 1983, Sep-16, Volume: 108, Issue:37

    Topics: Angioplasty, Balloon; Aspirin; Coronary Disease; Exercise Test; Humans; Isosorbide Dinitrate; Premed

1983
Effect of antiplatelet therapy on restenosis after experimental angioplasty.
    The American journal of cardiology, 1984, Jun-15, Volume: 53, Issue:12

    Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Iliac Arter

1984
Role of percutaneous transluminal coronary angioplasty in patients with variant angina and coexistent coronary stenosis refractory to maximal medical therapy.
    Clinical cardiology, 1984, Volume: 7, Issue:12

    Topics: Adult; Angina Pectoris, Variant; Angiography; Angioplasty, Balloon; Aspirin; Constriction, Pathologi

1984
[Anticoagulants or thrombocyte aggregation inhibitors in the prevention of recurrent heart infarction?].
    MMW, Munchener medizinische Wochenschrift, 1983, Apr-08, Volume: 125, Issue:14

    Topics: Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence

1983
Lupus anticoagulant in pregnancy.
    British journal of obstetrics and gynaecology, 1984, Volume: 91, Issue:4

    Topics: Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Chorea; Drug Therapy, Combination;

1984
[Acetosal and the heart].
    Nederlands tijdschrift voor geneeskunde, 1984, Oct-13, Volume: 128, Issue:41

    Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence

1984
Aspirin and recurrent hyphema after blunt ocular trauma.
    American journal of ophthalmology, 1983, Volume: 96, Issue:6

    Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Eye Injuries; Female; Humans; Hyphema; Male; Mi

1983
[Platelet antiaggregants in post-myocardial infarct patients: why, which and in what doses?].
    Giornale italiano di cardiologia, 1983, Volume: 13, Issue:11

    Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazo

1983
Aspirin and recurrent hyphema after blunt ocular trauma.
    American journal of ophthalmology, 1984, Volume: 97, Issue:5

    Topics: Aspirin; Eye Injuries; Humans; Hyphema; Recurrence

1984
Aspirin in the prevention of myocardial infarction. Current status.
    Drugs, 1984, Volume: 28, Issue:1

    Topics: Angina Pectoris; Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarct

1984
Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
    Advances in cardiology, 1982, Volume: 31

    Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Humans

1982
Non-surgical reperfusion in acute myocardial infarction.
    Herz, 1981, Volume: 6, Issue:1

    Topics: Aspirin; Coronary Circulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Human

1981
Etiologic factors for recurrent carotid artery stenosis.
    Surgery, 1983, Volume: 93, Issue:2

    Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Constriction, Pathologic; Coronary D

1983
Analgesic ingestion and other factors preceding relapse in ulcerative colitis.
    Gut, 1983, Volume: 24, Issue:3

    Topics: Acetaminophen; Adult; Aged; Analgesics; Aspirin; Colitis, Ulcerative; Female; Humans; Male; Middle A

1983
Myocardial infarction and aspirin.
    The New Zealand medical journal, 1980, Aug-13, Volume: 92, Issue:665

    Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone

1980
Analgesic abuse and the kidney.
    Kidney international, 1980, Volume: 17, Issue:2

    Topics: Aged; Analgesics; Aspirin; Caffeine; Codeine; Drug Combinations; Humans; Kidney; Kidney Diseases; Ki

1980
[Pro and con: Aggregation inhibitors in the prophylaxis of myocardial infarct. Arguments in favor of aggregation inhibitors].
    Der Internist, 1980, Volume: 21, Issue:7

    Topics: Aspirin; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Plat

1980
[Pro and con: Anticoagulation or thrombocyte function inhibitors in the prophylaxis of myocardial infarct? Arguments in favor of thrombocyte function inhibitors].
    Der Internist, 1980, Volume: 21, Issue:7

    Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Phenprocoumon; Platelet Agg

1980
[Summary: Secondary prophylaxis following myocardial re-infarct. Anticoagulants or thrombocyte function inhibitors?].
    Der Internist, 1980, Volume: 21, Issue:7

    Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation; R

1980
Secondary prevention in myocardial infarction survivors.
    Circulation, 1982, Volume: 65, Issue:1

    Topics: Anticoagulants; Aspirin; Diabetes Mellitus; Diet, Reducing; Humans; Hypertension; Lipids; Myocardial

1982
The use of indomethacin in the treatment of pericarditis in childhood.
    The Journal of pediatrics, 1982, Volume: 100, Issue:6

    Topics: Adolescent; Aspirin; Child; Female; Humans; Indomethacin; Male; Pericarditis; Prednisone; Radiograph

1982
Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks.
    Advances in shock research, 1982, Volume: 8

    Topics: Aspirin; Chlorpheniramine; Cimetidine; Epinephrine; Humans; Hypotension; Infusions, Parenteral; Pros

1982
Preventing death after myocardial infarction.
    Comprehensive therapy, 1980, Volume: 6, Issue:6

    Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazone

1980
Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review.
    Allergy, 1980, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aspirin; Bronchial Spasm; Child; Child, Preschool; Drug Hypers

1980
Hyperlipidaemia advances and retreats.
    British medical journal, 1980, Sep-13, Volume: 281, Issue:6242

    Topics: Aspirin; Humans; Myocardial Infarction; Recurrence

1980
[Sulfinpyrazone (Anturan) after myocardial infarction].
    Ugeskrift for laeger, 1980, Sep-22, Volume: 142, Issue:39

    Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Sulfinpyrazone

1980
Fever caused by hydroxyurea.
    Archives of internal medicine, 1981, Volume: 141, Issue:2

    Topics: Aspirin; Female; Fever; Humans; Hydroxyurea; Middle Aged; Psoriasis; Recurrence

1981
Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction.
    British heart journal, 1995, Volume: 74, Issue:2

    Topics: Aspirin; Drug Administration Schedule; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myoc

1995
Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty.
    Journal of cardiovascular pharmacology, 1995, Volume: 25, Issue:6

    Topics: Administration, Oral; Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Cholesterol, Dietary

1995
Immunosuppressive therapy prevents recurrent pericarditis.
    Journal of the American College of Cardiology, 1995, Nov-01, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immu

1995
[Aspirin--yes, but 30 mg??].
    Zeitschrift fur Kardiologie, 1995, Volume: 84, Issue:5

    Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Rec

1995
Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach.
    Postgraduate medical journal, 1995, Volume: 71, Issue:836

    Topics: Algorithms; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Recur

1995
[Results of endoprostheses in the iliac arteries; an experience apropos of 47 implantations].
    Archives des maladies du coeur et des vaisseaux, 1994, Volume: 87, Issue:9

    Topics: Angiography; Angioplasty, Balloon; Aortic Dissection; Aspirin; Blood Vessel Prosthesis; Female; Foll

1994
[Prevention of reinfarction with 100 mg or 30 mg aspirin daily?].
    Zeitschrift fur Kardiologie, 1995, Volume: 84, Issue:6

    Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti

1995
Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model.
    European heart journal, 1995, Volume: 16, Issue:2

    Topics: Animals; Aspirin; Blood Flow Velocity; Blood Pressure; Disease Models, Animal; Drug Therapy, Combina

1995
[Can early recurrent hemorrhage in gastroduodenal ulcer be predicted?].
    Gastroenterologie clinique et biologique, 1994, Volume: 18, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Duodenal Ulcer; En

1994
Coronary stenting without anticoagulation.
    Catheterization and cardiovascular diagnosis, 1995, Volume: 34, Issue:2

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Dissection; Aspirin; Coronary An

1995
Effect of intraventricular haemorrhage and rebleeding following subarachnoid haemorrhage on CSF eicosanoids.
    Acta neurochirurgica, 1994, Volume: 129, Issue:3-4

    Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Brain Damage, Chronic; Cerebral Ventricles; Dexamethasone; Di

1994
[Intracranial hemorrhage following second thrombolytic treatment of myocardial reinfarction].
    Revista espanola de cardiologia, 1994, Volume: 47, Issue:12

    Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Heparin; Humans; Male; Myocardial Infarction; Recurrence

1994
The management of thrombosis in the antiphospholipid-antibody syndrome.
    The New England journal of medicine, 1995, Apr-13, Volume: 332, Issue:15

    Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu

1995
The management of thrombosis in the antiphospholipid-antibody syndrome.
    The New England journal of medicine, 1995, Apr-13, Volume: 332, Issue:15

    Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu

1995
The management of thrombosis in the antiphospholipid-antibody syndrome.
    The New England journal of medicine, 1995, Apr-13, Volume: 332, Issue:15

    Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu

1995
The management of thrombosis in the antiphospholipid-antibody syndrome.
    The New England journal of medicine, 1995, Apr-13, Volume: 332, Issue:15

    Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu

1995
Anticoagulant treatment or antiplatelet therapy after a single carotid TIA?
    Stroke, 1995, Volume: 26, Issue:3

    Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Heparin; Humans; Isc

1995
Anticoagulants for atrial fibrillation.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged;

1993
Aspirin and prevention of stroke.
    Lancet (London, England), 1994, Jan-22, Volume: 343, Issue:8891

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Recurrence

1994
[Sliding indications for balloon angioplasty].
    Nederlands tijdschrift voor geneeskunde, 1994, Jul-23, Volume: 138, Issue:30

    Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspi

1994
Acute myocardial infarction in women: survival analysis in first six months.
    BMJ (Clinical research ed.), 1994, Sep-03, Volume: 309, Issue:6954

    Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aspirin; Coronary Care Units; Female; Follow-

1994
Antiphospholipid syndrome: clinical and therapeutic aspects.
    Lupus, 1994, Volume: 3, Issue:2

    Topics: Adolescent; Adult; Antiphospholipid Syndrome; Aspirin; Dose-Response Relationship, Drug; Female; Hum

1994
Platelet activation and arterial thrombosis. Report of a meeting of Physicians and Scientists, University of Texas Health Science Center at Houston and Texas Heart Institute, Houston.
    Lancet (London, England), 1994, Oct-08, Volume: 344, Issue:8928

    Topics: Aspirin; Hemorheology; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platel

1994
[Transthoracic and transesophageal follow-up in patients with left atrial thrombosis].
    Zeitschrift fur Kardiologie, 1994, Volume: 83, Issue:7

    Topics: Aged; Aspirin; Combined Modality Therapy; Echocardiography; Echocardiography, Doppler, Color; Echoca

1994
Development of aspirin resistance in persons with previous ischemic stroke.
    Stroke, 1994, Volume: 25, Issue:12

    Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular D

1994
Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
    Transactions of the Association of American Physicians, 1993, Volume: 106

    Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Dogs;

1993
Factors associated with failure of aspirin treatment.
    Stroke, 1994, Volume: 25, Issue:8

    Topics: Aspirin; Case-Control Studies; Cerebrovascular Disorders; Humans; Recurrence; Risk Factors

1994
[Emergency intracoronary stent implantation: complications and experiences with 124 patients].
    Zeitschrift fur Kardiologie, 1994, Volume: 83, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Tests; Co

1994
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis.
    The American journal of physiology, 1994, Volume: 267, Issue:2 Pt 2

    Topics: Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Fibrinolytic Ag

1994
[Intranasal provocation with lysine acetylsalicylic acid].
    HNO, 1993, Volume: 41, Issue:12

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Child; Drug Hyper

1993
Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention.
    Stroke, 1994, Volume: 25, Issue:4

    Topics: Adult; Aged; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Echocardiography, Transesophag

1994
Guidelines for medical treatment for stroke prevention. American College of Physicians.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?
    Stroke, 1994, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Disorders; Brain Ischemia; Cerebral Infar

1994
[Chronic recurrent thrombotic thrombocytopenic purpura (Moschcowitz disease). An unusual long-term course in a 43-year-old patient].
    Der Internist, 1993, Volume: 34, Issue:10

    Topics: Adult; Aspirin; Biopsy; Cerebral Angiography; Cerebral Infarction; Combined Modality Therapy; Female

1993
Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.
    Thrombosis research, 1993, Sep-01, Volume: 71, Issue:5

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Carotid Artery, Internal; Cerebrovascular Disorders;

1993
Does external ultrasound accelerate thrombolysis? Results from a rabbit model.
    Circulation, 1994, Volume: 89, Issue:1

    Topics: Animals; Aspirin; Femoral Artery; Platelet Activation; Rabbits; Recurrence; Regional Blood Flow; Rep

1994
Branch retinal artery occlusion in pregnancy.
    British journal of obstetrics and gynaecology, 1994, Volume: 101, Issue:1

    Topics: Adult; Aspirin; Female; Headache; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Recurr

1994
[Hereditary spherocytosis].
    Deutsche medizinische Wochenschrift (1946), 1994, Feb-04, Volume: 119, Issue:5

    Topics: Aspirin; Combined Modality Therapy; Erythrocyte Count; Humans; Recurrence; Spherocytosis, Hereditary

1994
Recent developments in secondary prevention of stroke.
    Scottish medical journal, 1993, Volume: 38, Issue:3 Suppl

    Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Hypercholesterolemia; Myocardia

1993
Anticoagulants, antiaggregants or nothing following carotid endarterectomy?
    European journal of vascular surgery, 1993, Volume: 7, Issue:4

    Topics: Aged; Aspirin; Carotid Stenosis; Cause of Death; Endarterectomy, Carotid; Female; Follow-Up Studies;

1993
Indications and results after Strecker-stent-application in iliac and SFA.
    International angiology : a journal of the International Union of Angiology, 1993, Volume: 12, Issue:2

    Topics: Arterial Occlusive Diseases; Aspirin; Female; Femoral Artery; Follow-Up Studies; Heparin; Humans; Il

1993
Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis.
    BMJ (Clinical research ed.), 1993, Aug-07, Volume: 307, Issue:6900

    Topics: Age Factors; Aged; Aspirin; Female; Humans; London; Male; Middle Aged; Myocardial Infarction; Progno

1993
Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies.
    Acta obstetricia et gynecologica Scandinavica, 1993, Volume: 72, Issue:1

    Topics: Abortion, Spontaneous; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug

1993
Aspirin versus coumadin.
    Circulation, 1993, Volume: 88, Issue:4 Pt 1

    Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Thrombolytic Therapy; Warfarin

1993
Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group.
    The American journal of cardiology, 1993, Mar-01, Volume: 71, Issue:7

    Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female;

1993
Ischemic stroke, Part 2: Optimal treatment and prevention.
    Geriatrics, 1993, Volume: 48, Issue:3

    Topics: Aged; Aspirin; Brain Edema; Brain Ischemia; Cerebral Infarction; Heparin; Humans; Recurrence; Risk F

1993
Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    International journal of cardiology, 1993, Volume: 38, Issue:3

    Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Epoprostenol; Myocardial Inf

1993
Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age.
    The American journal of medicine, 1993, Volume: 94, Issue:4

    Topics: Adult; Age Factors; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Fema

1993
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
    Journal of the American College of Cardiology, 1993, Volume: 22, Issue:1

    Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Dogs; Drug Therapy, Combination; Hirudin Therap

1993
Migraine after electroconvulsive therapy.
    Convulsive therapy, 1995, Volume: 11, Issue:3

    Topics: Antidepressive Agents; Aspirin; Combined Modality Therapy; Depressive Disorder; Dose-Response Relati

1995
Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes.
    Annals of internal medicine, 1996, Feb-01, Volume: 124, Issue:3

    Topics: Aged; Aspirin; Contraindications; Female; Health Status Indicators; Humans; Male; Multivariate Analy

1996
Effective treatment with interferon-alpha in chronic recurrent multifocal osteomyelitis.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 1995, Volume: 15, Issue:10

    Topics: Adult; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-a

1995
[Response to the letter by K. Schrör on: Prevention of reinfarction with 100 mg or 30 mg ASS daily].
    Zeitschrift fur Kardiologie, 1995, Volume: 84, Issue:12

    Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti

1995
[Response to the editorial by J. C. Frölich: Aspirin--yes, but 30 mg??].
    Zeitschrift fur Kardiologie, 1995, Volume: 84, Issue:12

    Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti

1995
Uterine Doppler wave form and the prediction of the recurrence of pre-eclampsia and intra-uterine growth retardation in patients treated with low-dose aspirin.
    European journal of obstetrics, gynecology, and reproductive biology, 1995, Volume: 62, Issue:2

    Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Follow-Up Studie

1995
[Drug therapy as secondary prevention following myocardial infarction].
    Praxis, 1996, Apr-23, Volume: 85, Issue:17

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic

1996
A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
    Heart (British Cardiac Society), 1996, Volume: 75, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cardiac Care Facilities; Cardiology; Cholesterol;

1996
[Response to the letter by W. Förster on: prevention of reinfarction with 100 mg or 30 mg aspirin daily].
    Zeitschrift fur Kardiologie, 1996, Volume: 85, Issue:5

    Topics: Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Myocardial Infarction;

1996
Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin.
    Catheterization and cardiovascular diagnosis, 1996, Volume: 37, Issue:4

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Cor

1996
Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Cardiovascular research, 1995, Volume: 30, Issue:6

    Topics: Animals; Aspirin; Coronary Circulation; Coronary Thrombosis; Dogs; Drug Synergism; Drug Therapy, Com

1995
Pathogenetic factors in chronic subdural haematoma and causes of recurrence after drainage.
    Acta neurochirurgica, 1995, Volume: 137, Issue:1-2

    Topics: Adult; Aged; Aspirin; Chronic Disease; Drainage; Female; Hematoma, Subdural; Humans; Male; Middle Ag

1995
Primary stent implantation without coumadin in acute myocardial infarction.
    Journal of the American College of Cardiology, 1996, Volume: 28, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography;

1996
Stenting in the carotid artery: initial experience in 110 patients.
    Journal of endovascular surgery : the official journal of the International Society for Endovascular Surgery, 1996, Volume: 3, Issue:1

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery

1996
ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
    European heart journal, 1996, Volume: 17, Issue:10

    Topics: Adult; Aged; Aspirin; Coronary Angiography; Coronary Circulation; Dose-Response Relationship, Drug;

1996
Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
    Thrombosis and haemostasis, 1996, Volume: 76, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Benzamidines; Cell Movement; Cells, Cultured; Coro

1996
Fraud and ethics charges hit stroke drug trial.
    Science (New York, N.Y.), 1996, Dec-20, Volume: 274, Issue:5295

    Topics: Aspirin; Brain Diseases; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dipyridamol

1996
Anticoagulants in acute MI.
    The Journal of family practice, 1997, Volume: 44, Issue:1

    Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Heparin; Humans; Meta-Analysis as Topic; Myocard

1997
Ticlopidine and aspirin interactions.
    Heart (British Cardiac Society), 1997, Volume: 77, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, C

1997
[The in-vivo test of the inhibition of leukocyte natural migration with aspirin and analgin in the specific diagnosis of the asthmatic triad].
    Terapevticheskii arkhiv, 1996, Volume: 68, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cell Migration Inhibition; Dipyrone

1996
[Single-center experience with the Palmaz-Schatz intracoronary stent: the immediate results and medium- and long-term follow-up].
    Cardiologia (Rome, Italy), 1996, Volume: 41, Issue:11

    Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary

1996
Aspirin after thrombolysis for MI.
    The Journal of family practice, 1997, Volume: 44, Issue:3

    Topics: Anistreplase; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; My

1997
Therapeutic options in atrial flutter and fibrillation.
    Hospital practice (1995), 1997, May-15, Volume: 32, Issue:5

    Topics: Aged; Algorithms; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive

1997
[Recurrent infarct during aspirin therapy].
    Der Internist, 1997, Volume: 38, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Dose-Response Relationship, Drug;

1997
[Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation].
    Sozial- und Praventivmedizin, 1997, Volume: 42, Issue:2

    Topics: Adult; Aspirin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Humans; Middle Aged; Models

1997
Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Adult; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Diabetes Complications;

1997
Obstetric outcome in antiphospholipid syndrome.
    Lupus, 1997, Volume: 6, Issue:6

    Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anticardiolipin;

1997
Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study.
    Neurological research, 1997, Volume: 19, Issue:4

    Topics: Aged; Angina Pectoris; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; F

1997
Prevention of subsequent coronary events.
    Iowa medicine : journal of the Iowa Medical Society, 1997, Volume: 87, Issue:7

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp

1997
[Acute glaucoma caused by massive subretinal hemorrhage in age-related macular degeneration and disordered thrombocyte function].
    Klinische Monatsblatter fur Augenheilkunde, 1997, Volume: 210, Issue:6

    Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Eye Enucleation; Female; Glau

1997
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Thrombosis and haemostasis, 1997, Volume: 78, Issue:4

    Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Ev

1997
A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis.
    Archives of internal medicine, 1997, Oct-13, Volume: 157, Issue:18

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow

1997
[Recurrent fetal death and antiphospholipid antibody syndrome. A case report].
    Ginecologia y obstetricia de Mexico, 1997, Volume: 65

    Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome;

1997
[Superaspirin in the platelet aggregation inhibitor therapy].
    Recenti progressi in medicina, 1997, Volume: 88, Issue:12

    Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fa

1997
Aspirin in the management of recurrent herpes simplex virus infection.
    Annals of internal medicine, 1998, Apr-15, Volume: 128, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Herpes Genitalis; Herpes Labialis;

1998
Carotid artery dissection presenting as a painless Horner's syndrome in a pilot: fit to fly?
    Aviation, space, and environmental medicine, 1998, Volume: 69, Issue:3

    Topics: Aerospace Medicine; Aortic Dissection; Aspirin; Carotid Artery, Internal; Cerebrovascular Disorders;

1998
[Coronary stents].
    Revue medicale de Bruxelles, 1998, Volume: 19, Issue:1

    Topics: Aspirin; Belgium; Coronary Disease; Humans; Myocardial Revascularization; Platelet Aggregation Inhib

1998
Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer.
    Gastroenterology, 1998, Volume: 114, Issue:5

    Topics: Aspirin; Female; Humans; Intestinal Diseases; Male; Middle Aged; Peptic Ulcer; Postoperative Complic

1998
Titration of antiplatelet treatment in pregnant women at risk of preeclampsia.
    Thrombosis and haemostasis, 1998, Volume: 79, Issue:4

    Topics: Abortion, Spontaneous; Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation;

1998
A late complication of internal carotid artery stenting.
    Journal of vascular surgery, 1998, Volume: 27, Issue:4

    Topics: Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Carotid Ste

1998
Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home.
    Journal of the American Geriatrics Society, 1998, Volume: 46, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Drug Utilization; Female; Humans; Male; Middle Aged; Myocardial In

1998
Clinical and angiographic outcome of Micro Stent II implantation in native coronary arteries.
    The American journal of cardiology, 1998, Jan-15, Volume: 81, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Blood Vessel Prosthesis Implantation; Coro

1998
[Secondary prevention of recurrent transient ischemic attacks].
    Der Internist, 1998, Volume: 39, Issue:4

    Topics: Anticoagulants; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic At

1998
Cogan's syndrome with Takayasu's arteritis.
    British journal of rheumatology, 1998, Volume: 37, Issue:4

    Topics: Angiography; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents

1998
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
    Catheterization and cardiovascular diagnosis, 1998, Volume: 44, Issue:2

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp

1998
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
    Revista espanola de cardiologia, 1998, Volume: 51, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female;

1998
[An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
    Revue medicale de Liege, 1998, Volume: 53, Issue:5

    Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Belgium; Cerebrovascular Disorders; Cost-Benefit An

1998
Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study.
    European journal of obstetrics, gynecology, and reproductive biology, 1998, Volume: 80, Issue:1

    Topics: Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Gestational Age; Heparin, Low-

1998
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
    Journal of the American College of Cardiology, 1998, Volume: 32, Issue:4

    Topics: Administration, Oral; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhi

1998
[When salicylates do not help. Practice in recurrent TIA (Transient Ischemic Attack) varies at Swedish hospitals].
    Lakartidningen, 1998, Sep-09, Volume: 95, Issue:37

    Topics: Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient

1998
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
    The American journal of cardiology, 1998, Nov-15, Volume: 82, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow

1998
Limitations of acetaminophen, aspirin, and caffeine in alleviating migraine.
    Archives of neurology, 1998, Volume: 55, Issue:12

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine;

1998
Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Thrombosis and haemostasis, 1998, Volume: 80, Issue:6

    Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Aspirin; Co

1998
A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Thrombosis and haemostasis, 1998, Volume: 80, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; Cost-Benef

1998
Intracoronary Multi-link stents: experience in 218 patients using aspirin alone.
    Heart (British Cardiac Society), 1998, Volume: 80, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Vesse

1998
Gallstone recurrence after successful shock wave therapy: the magnitude of the problem and the predictive factors.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:2

    Topics: Actuarial Analysis; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Aci

1999
Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?
    Archives of internal medicine, 1999, Mar-22, Volume: 159, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Hypolipidemic Agent

1999
Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
    Annals of internal medicine, 1999, Apr-20, Volume: 130, Issue:8

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorder

1999
Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient.
    Rhinology, 1999, Volume: 37, Issue:1

    Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Biopsy, Needle; Eosinophilia; Eosinophils; Follow-Up Studi

1999
[Does idiopathic naso-sinusal polyposis exist in children?].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1999, Volume: 6, Issue:4

    Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bacterial

1999
[A case of aspirin triad].
    Vestnik otorinolaringologii, 1999, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Follow-Up

1999
[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa].
    Laryngo- rhino- otologie, 1999, Volume: 78, Issue:8

    Topics: Adult; Aged; Aspirin; Drug Hypersensitivity; Eosinophilia; Eosinophils; Female; Humans; Male; Middle

1999
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
    The American journal of cardiology, 1999, Sep-15, Volume: 84, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise

1999
A 42-year-old man with recurrent myocardial infarction and normal appearing coronary arteries.
    International journal of cardiology, 1999, May-15, Volume: 69, Issue:2

    Topics: Adult; Aspirin; Coronary Thrombosis; Humans; Male; Microvascular Angina; Myocardial Infarction; Plat

1999
Persistent atrial standstill in a cat.
    Australian veterinary journal, 1999, Volume: 77, Issue:9

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Arrhythmias, Cardiac; Asp

1999
Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy.
    Eye (London, England), 1999, Volume: 13 ( Pt 3a)

    Topics: Adult; Age Factors; Aged; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Follow-Up

1999
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
    The American journal of medicine, 1999, Volume: 107, Issue:6

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C

1999
[Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:1

    Topics: Adult; Aspirin; Bone Marrow Transplantation; Dipyridamole; Female; Humans; Leukemia, Myeloid, Acute;

2000
Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 1999, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Aged; Aspirin; Bacterial Toxins; Child; Child, Preschool; Clinical Trials as Topi

1999
Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up.
    The Canadian journal of cardiology, 2000, Volume: 16, Issue:4

    Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Female; Fibrinolytic Agents; Follow-Up

2000
[Prevention of embolism in atrial septal defects?].
    Deutsche medizinische Wochenschrift (1946), 2000, Apr-20, Volume: 125 Suppl 1

    Topics: Adult; Age Factors; Anticoagulants; Aspirin; Coumarins; Embolism; Female; Fibrinolytic Agents; Heart

2000
Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease;

2000
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Clinical therapeutics, 2000, Volume: 22, Issue:3

    Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel

2000
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
    Archives of internal medicine, 2000, Oct-09, Volume: 160, Issue:18

    Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi

2000
[Undertreatment in secondary prevention of patients with coronary heart disease after revascularization].
    Herz, 2000, Volume: 25, Issue:6

    Topics: Adrenergic beta-Antagonists; Aftercare; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic

2000
Transient ischemic attacks after dipyridamole-aspirin therapy.
    Journal of neurology, 2000, Volume: 247, Issue:10

    Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug The

2000
[A case of choanal polyp in a man with aspirin triad and pollinosis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2000, Volume: 9, Issue:52

    Topics: Adult; Aspirin; Drug Hypersensitivity; Humans; Male; Nasal Polyps; Recurrence; Rhinitis, Allergic, S

2000
Multifocal pyogranulomatous osteomyelitis resembling chronic recurrent multifocal osteomyelitis in a lemur.
    Journal of the American Veterinary Medical Association, 2001, Jan-15, Volume: 218, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy, Needle; Chronic Disease; Femur; F

2001
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
    Zeitschrift fur Kardiologie, 2000, Volume: 89, Issue:12

    Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulatio

2000
Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Feb-27, Volume: 98, Issue:5

    Topics: Animals; Aspirin; Constriction, Pathologic; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Mice, Kn

2001
ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation?
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Feb-06, Volume: 164, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2001
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
    Zeitschrift fur Kardiologie, 2001, Volume: 90, Issue:2

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clinical Trials as Topic; C

2001
Heparin and aspirin in stroke.
    Lancet (London, England), 2001, Mar-31, Volume: 357, Issue:9261

    Topics: Aspirin; Heparin, Low-Molecular-Weight; Humans; Recurrence; Risk Factors; Stroke

2001
Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.
    Annals of the rheumatic diseases, 2001, Volume: 60, Issue:5

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Asp

2001
Antiphospholipid antibodies in women at risk for preeclampsia.
    American journal of obstetrics and gynecology, 2001, Volume: 184, Issue:5

    Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Aspirin; Blood Pressure; Enzyme-Li

2001
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
    Japanese circulation journal, 2001, Volume: 65, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang

2001
Involvement of aspirin-sensitive oxylipins in vulvovaginal candidiasis.
    FEMS microbiology letters, 2001, Apr-20, Volume: 198, Issue:1

    Topics: Antifungal Agents; Arachidonic Acids; Aspirin; Candida albicans; Candidiasis, Vulvovaginal; Clotrima

2001
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
    Circulation, 2001, May-01, Volume: 103, Issue:17

    Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Com

2001
Second stroke.
    Journal of dental hygiene : JDH, 2000,Spring, Volume: 74, Issue:2

    Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Chemoprevention; Dipyridamole; Drug Approval; Drug

2000
Status of secondary prevention in patients undergoing coronary revascularization.
    The American journal of cardiology, 2001, May-15, Volume: 87, Issue:10

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor

2001
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
    International journal of cardiology, 2001, Volume: 78, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos

2001
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
    Journal of thrombosis and thrombolysis, 2001, Volume: 11, Issue:2

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod

2001
Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy.
    The Pediatric infectious disease journal, 2001, Volume: 20, Issue:6

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Cyclos

2001
Transient ischaemic attacks: a GP guide.
    The Practitioner, 2001, Volume: 245, Issue:1623

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Carotid Arteries; Diagnosis, Differentia

2001
Low-dose aspirin is effective for treatment of recurrent miscarriage in patients with decreased coagulation factor XII.
    Fertility and sterility, 2001, Volume: 76, Issue:1

    Topics: Abortion, Spontaneous; Adult; Aspirin; Dose-Response Relationship, Drug; Factor XII Deficiency; Fema

2001
Nonsteroidal anti-inflammatory drug-associated colitis with a histology of collagenous colitis.
    Endoscopy, 2001, Volume: 33, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis; Collagen; Colonoscopy; Diarrhea; Fe

2001
Late acute thrombosis after paclitaxel eluting stent implantation.
    Heart (British Cardiac Society), 2001, Volume: 86, Issue:3

    Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant

2001
[Treatment of ASS-Associated Polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist - a prospective drug study on its antiinflammatory effects].
    Laryngo- rhino- otologie, 2001, Volume: 80, Issue:10

    Topics: Acetates; Adult; Anti-Asthmatic Agents; Aspirin; Asthma; Cyclopropanes; Female; Humans; Leukotriene

2001
Aspirin and warfarin equally good for stroke patients.
    BMJ (Clinical research ed.), 2001, Nov-24, Volume: 323, Issue:7323

    Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Warfarin

2001
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
    The New England journal of medicine, 2001, Dec-13, Volume: 345, Issue:24

    Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Female; Follow-Up Stu

2001
Initiative raises use of interventions that prevent second heart attacks.
    Report on medical guidelines & outcomes research, 2000, Jul-07, Volume: 11, Issue:14

    Topics: Adrenergic beta-Antagonists; Aspirin; Cholesterol; Humans; Hypolipidemic Agents; Myocardial Infarcti

2000
Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: intermediate-term risk of recurrent neurological events.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2002, Volume: 55, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Catheters, Indwelling; Embolism, Paradoxical; Fema

2002
[Long-term prophylaxis with omeprazol is superior to eradication therapy in H. pylori-positive NSAIDs taking patients].
    Zeitschrift fur Gastroenterologie, 2002, Volume: 40, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Helicobacter Inf

2002
Natural history of small and medium-sized side branches after coronary stent implantation.
    American heart journal, 2002, Volume: 143, Issue:4

    Topics: Acute Disease; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary An

2002
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.
    Obstetrics and gynecology, 2002, Volume: 100, Issue:1

    Topics: Abortion, Spontaneous; Adult; Antibodies, Antiphospholipid; Aspirin; Controlled Clinical Trials as T

2002
[Severe Reye syndrome: report of 14 cases managed in a pediatric intensive care unit over 11 years].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2002, Volume: 9, Issue:6

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Edema; Child; Child, Preschoo

2002
Recurrent haemolytic uraemic syndrome.
    Padiatrie und Padologie, 1976, Volume: 11, Issue:3

    Topics: Adenoviridae; Antibodies, Viral; Anticoagulants; Aspirin; Child, Preschool; Dicumarol; Diphtheria To

1976
Aspirin for the treatment of recurrent toxaemia.
    Lancet (London, England), 1978, Jul-01, Volume: 2, Issue:8079

    Topics: Adult; Aspirin; Female; Humans; Pre-Eclampsia; Pregnancy; Pregnancy Trimester, Third; Recurrence; Th

1978
[Therapeutic effectiveness of aspirin].
    Zahnarztliche Mitteilungen, 1978, Jun-16, Volume: 68, Issue:12

    Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Recurrence; Thromboembolism

1978
The detrimental effect of aspirin on hyphema rebleed.
    Annals of ophthalmology, 1979, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Eye Injuries; Humans; Hyphema; Iris; Middle Age

1979
Moves beginning to approve new indications for aspirin use.
    JAMA, 1979, Oct-19, Volume: 242, Issue:16

    Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Recurrence; Sex Factors

1979
Statistical evidence of the German-Austrian secondary prevention trial.
    Thrombosis and haemostasis, 1979, Feb-28, Volume: 41, Issue:1

    Topics: Actuarial Analysis; Aspirin; Austria; Germany; Humans; Myocardial Infarction; Phenprocoumon; Recurre

1979
Prevention of subsequent infarctions and transient ischemic attacks.
    Advances in neurology, 1979, Volume: 25

    Topics: Aged; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Ischemic Attack, Transient; Middle Aged;

1979
[Deforming, recurrent nasal polyposis in the adult].
    Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 1979, Volume: 96, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Aspirin; Asthma; Child; Cystic Fibrosis; Drug Hypersensitivity; Huma

1979
TIA, stroke, and mitral valve prolapse.
    Neurology, 1979, Volume: 29, Issue:6

    Topics: Adult; Aged; Aspirin; Carotid Artery Thrombosis; Cerebrovascular Disorders; Dipyridamole; Echocardio

1979
Chronic and recurrent urticaria: new concepts of drug-group sensitivity.
    Annals of allergy, 1977, Volume: 39, Issue:6

    Topics: Aspirin; Barbiturates; Blood Coagulation Tests; Chronic Disease; Cross Reactions; Dose-Response Rela

1977
Influence of aspirin on healing of chronic gastric ulcers in dogs.
    Digestion, 1977, Volume: 16, Issue:1-2

    Topics: Acetates; Animals; Aspirin; Chronic Disease; Dogs; Gastric Mucosa; Gastroscopy; Male; Peptic Ulcer P

1977
Antiplatelet agents in coronary disease: are they of prophylactic value?
    Drugs, 1978, Volume: 15, Issue:6

    Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin

1978
[Treatment of recurrent rheumatism with acetylsalicylic acid and its pharmacokinetics].
    Terapevticheskii arkhiv, 1978, Volume: 50, Issue:9

    Topics: Adult; Aspirin; Humans; Middle Aged; Recurrence; Rheumatic Fever

1978
Cricoarytenoid arthritis and airway obstruction in juvenile rheumatoid arthritis.
    Pediatrics, 1977, Volume: 59, Issue:2

    Topics: Airway Obstruction; Arthritis, Juvenile; Aspirin; Child, Preschool; Dexamethasone; Humans; Laryngeal

1977
[Modern aspects in the pathogenesis of urticaria with special reference to intolerance phenomena].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1977, Volume: 28, Issue:2

    Topics: Anaphylaxis; Antigen-Antibody Reactions; Aspirin; Autoantigens; Chronic Disease; Cold Temperature; D

1977
The effect of aspirin on rebleeding in traumatic hyphema.
    Transactions of the American Ophthalmological Society, 1976, Volume: 74

    Topics: Aspirin; Child; Hemorrhage; Humans; Hyphema; Recurrence

1976
A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes.
    The British journal of dermatology, 1976, Volume: 95, Issue:1

    Topics: Adolescent; Adult; Aged; Aspirin; Azo Compounds; Benzoates; Drug Hypersensitivity; Female; Follow-Up

1976
Effects of acetylsalicylic acid (ASA), ASA plus L-glutamine and L-glutamine on healing of chronic gastric ulcer in the rat.
    Digestion, 1976, Volume: 14, Issue:1

    Topics: Animals; Aspirin; Chronic Disease; Drug Evaluation, Preclinical; Glutamine; Male; Rats; Recurrence;

1976
Primary and secondary prevention trials in coronary heart disease.
    Postgraduate medical journal, 1976, Volume: 52, Issue:609

    Topics: Adult; Aspirin; Coronary Disease; Diet; Diet, Atherogenic; Evaluation Studies as Topic; Humans; Male

1976
Gastric devascularization: an alternate approach to the surgical treatment of massive, diffuse hemorrhage from gastritis.
    Southern medical journal, 1976, Volume: 69, Issue:7

    Topics: Adult; Age Factors; Alcoholism; Aspirin; Burns; Child, Preschool; Female; Gastrectomy; Gastritis; Ga

1976
[The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1976, Feb-01, Volume: 31, Issue:3

    Topics: Animals; Anticoagulants; Aspirin; Dogs; Drug Hypersensitivity; Gastrointestinal Hemorrhage; Humans;

1976
Increased platelet aggregability in young patients with stroke. Diagnosis and therapy.
    Archives of neurology, 1975, Volume: 32, Issue:1

    Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Cell Survival; Cerebrovascular Di

1975
The effect of aspirin on rebleeding in traumatic hyphema.
    American journal of ophthalmology, 1975, Volume: 80, Issue:3 Pt 2

    Topics: Aspirin; Eye Injuries; Hemorrhage; Humans; Hyphema; Platelet Adhesiveness; Recurrence

1975
Factors relevant to the prognosis of chronic gastric ulcer.
    Gut, 1975, Volume: 16, Issue:9

    Topics: Age Factors; Aspirin; Chronic Disease; Female; Follow-Up Studies; Humans; Male; Prognosis; Recurrenc

1975
[Proceedings: Case of acute idiopathic recurring pericarditis].
    Archives francaises de pediatrie, 1975, Volume: 32, Issue:3

    Topics: Acute Disease; Aspirin; Child; Cortisone; Humans; Indomethacin; Male; Pericarditis; Recurrence

1975
Growing pains: fact or fiction?
    Postgraduate medicine, 1976, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Age Factors; Arthritis, Juvenile; Aspirin; Child; Diagnosis, Differential; Extrem

1976
Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis.
    Circulation, 1976, Volume: 53, Issue:4

    Topics: Adult; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Male; Methods; Middle Aged; Platelet

1976
Recurring and chronic urticaria: identification of etiologies.
    Annals of allergy, 1976, Volume: 36, Issue:6

    Topics: Aspirin; Barbiturates; Blood Coagulation Tests; Bromides; Chronic Disease; Drug Hypersensitivity; Hu

1976
Secondary prevention of coronary heart disease in patients after acute myocardial infarction at the Soroka Medical Center.
    Israel journal of medical sciences, 1992, Volume: 28, Issue:12

    Topics: Adrenergic beta-Antagonists; Adult; Aftercare; Aged; Aspirin; Calcium Channel Blockers; Clinical Pro

1992
[Drug treatments of atrial fibrillation].
    Archives des maladies du coeur et des vaisseaux, 1992, Volume: 85 Spec No 4

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; H

1992
Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty.
    Journal of cardiovascular pharmacology, 1992, Volume: 19, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Cyclic AMP; Female; Humans; Male; Platele

1992
Fixed drug eruption in a mother and her son.
    Cutis, 1992, Volume: 50, Issue:1

    Topics: Adult; Anxiety; Aspirin; Child; Dimenhydrinate; Drug Eruptions; Food Hypersensitivity; Humans; Male;

1992
The effect of antiplatelet therapy on platelet accumulation after experimental angioplasty in the rabbit iliac model.
    International journal of cardiology, 1992, Volume: 36, Issue:1

    Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Dipyridamole; Disease Models, Animal; Drug

1992
[Prevention of recurrence of myocardial infarction].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, Aug-10, Volume: 81, Issue:8

    Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery By

1992
Dilated cardiomyopathy with recurrent intraventricular thrombosis.
    Japanese heart journal, 1992, Volume: 33, Issue:4

    Topics: Aspirin; Cardiomyopathy, Dilated; Coronary Thrombosis; Echocardiography; Electrocardiography; Heart

1992
Gastric changes in coronary-operated patients with low-dose aspirin.
    Scandinavian journal of gastroenterology, 1992, Volume: 27, Issue:11

    Topics: Adult; Aged; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Fe

1992
Efficacy of cryotherapy in vernal catarrh.
    Annals of ophthalmology, 1992, Volume: 24, Issue:7

    Topics: Adolescent; Adult; Aspirin; Child; Conjunctiva; Conjunctivitis, Allergic; Cryosurgery; Female; Follo

1992
Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy.
    Journal of the American College of Cardiology, 1992, Mar-01, Volume: 19, Issue:3

    Topics: Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Heparin; Humans; Recurrence; Streptokinase; Th

1992
Aspirin as a risk factor for hemorrhage in patients with head injuries.
    Neurosurgical review, 1992, Volume: 15, Issue:1

    Topics: Adult; Aged; Aspirin; Brain Concussion; Cerebral Hemorrhage; Female; Hematoma, Epidural, Cranial; He

1992
Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.
    The American journal of cardiology, 1992, Jun-01, Volume: 69, Issue:17

    Topics: Administration, Oral; Adult; Aspirin; Atenolol; Combined Modality Therapy; Female; Humans; Infusions

1992
Complications after intracoronary stent implantation: three cases.
    Cardiology, 1992, Volume: 80, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Di

1992
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method].
    Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50, Issue:2

    Topics: Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction

1992
Changes in drug treatment and case fatality of patients with acute myocardial infarction. Observations from the Newcastle MONICA Project, 1984/1985 to 1988/1990.
    The Medical journal of Australia, 1992, Jul-20, Volume: 157, Issue:2

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Diuretics;

1992
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
    Annals of internal medicine, 1992, Aug-15, Volume: 117, Issue:4

    Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa

1992
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
    Annals of internal medicine, 1992, Aug-15, Volume: 117, Issue:4

    Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa

1992
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
    Annals of internal medicine, 1992, Aug-15, Volume: 117, Issue:4

    Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa

1992
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
    Annals of internal medicine, 1992, Aug-15, Volume: 117, Issue:4

    Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa

1992
Adjunctive therapies in thrombolysis. Introduction.
    The American journal of cardiology, 1991, Jan-25, Volume: 67, Issue:3

    Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Heparin; Humans; Myocardial Infarcti

1991
Aspirin, warfarin, and recurrent stroke.
    Lancet (London, England), 1991, Jun-01, Volume: 337, Issue:8753

    Topics: Aged; Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Recurrence; Warfarin

1991
Aspirin, warfarin, and recurrent stroke.
    Lancet (London, England), 1991, Jul-13, Volume: 338, Issue:8759

    Topics: Aspirin; Cerebrovascular Disorders; Humans; Recurrence; Warfarin

1991
Reocclusion after thrombolysis: a problem solved by hirudin?
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1991, Volume: 2, Issue:1

    Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Hirudin Therapy; H

1991
Experimental reactivation of chronic gastric lesions exposed to different aggressive conditions.
    Digestion, 1991, Volume: 50, Issue:1

    Topics: Acetates; Animals; Aspirin; Chronic Disease; Ethanol; Female; Gastric Acid; Gastric Mucosa; Random A

1991
[Clinical interventions for prevention and therapy of restenosis of coronary heart disease].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1991, Volume: 97

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Follow-Up Stud

1991
[A clinical trial of the secondary prevention of reinfarction with low dose aspirin].
    Zhonghua xin xue guan bing za zhi, 1991, Volume: 19, Issue:6

    Topics: Aged; Aspirin; China; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; R

1991
[Effect of antiplatelet therapy on prevention of thrombotic diseases].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1991, Jun-10, Volume: 80, Issue:6

    Topics: Arachidonic Acid; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Humans; Myocardial Infa

1991
[Rate of recurrence following PTA of pelvic-leg arteries in relation to selected risk factors and antithrombotic after care].
    VASA. Supplementum, 1991, Volume: 33

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Coumarins; Fo

1991
[Recurrent thromboembolism due to increased acetylsalicylic acid-resistant platelet aggregation].
    Deutsche medizinische Wochenschrift (1946), 1991, Sep-06, Volume: 116, Issue:36

    Topics: Aspirin; Fibrin; Humans; Male; Middle Aged; Platelet Aggregation; Recurrence; Thromboembolism; Ticlo

1991
Conservative management complications after thrombolytic therapy.
    American heart journal, 1991, Volume: 121, Issue:2 Pt 1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Drug Therapy, Combination;

1991
Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Circulation, 1991, Volume: 83, Issue:3

    Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins

1991
Coronary bypasses 10 years on.
    BMJ (Clinical research ed.), 1991, Sep-21, Volume: 303, Issue:6804

    Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male;

1991
[The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities].
    Deutsche medizinische Wochenschrift (1946), 1991, Nov-22, Volume: 116, Issue:47

    Topics: Adult; Antibodies; Antiphospholipid Syndrome; Aspirin; Blindness; Female; Humans; Nervous System Dis

1991
Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty.
    European heart journal, 1991, Volume: 12, Issue:9

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cholesterol; Cholesterol, HDL; Cholesterol, LD

1991
Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study.
    Prostaglandins, leukotrienes, and essential fatty acids, 1991, Volume: 42, Issue:2

    Topics: Aspirin; Dose-Response Relationship, Drug; Follow-Up Studies; Germany; Humans; Middle Aged; Myocardi

1991
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
    Journal of the American College of Cardiology, 1990, Volume: 16, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antithrombins; Arginine; Aspirin; Coronary Circulation; Coronary Di

1990
Pharmacological therapy after coronary angioplasty. Early experience with low molecular weight heparin for prophylaxis of reocclusion.
    Klinische Wochenschrift, 1990, Mar-05, Volume: 68, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Heparin, Low-M

1990
Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group.
    The American journal of cardiology, 1990, Oct-15, Volume: 66, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; C

1990
[Coronary endoprostheses (stents)].
    Herz, 1990, Volume: 15, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Angiography; Coronary Dis

1990
[Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1990, Aug-01, Volume: 45, Issue:15

    Topics: Aged; Aspirin; Berlin; Blood Coagulation Tests; Follow-Up Studies; Humans; Middle Aged; Myocardial I

1990
[Thrombotic thrombocytopenic purpura: a benign disease with a very severe acute phase].
    Nederlands tijdschrift voor geneeskunde, 1990, Mar-03, Volume: 134, Issue:9

    Topics: Adult; Aspirin; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Plasmapheresis

1990
Acute infarction during triple-vessel coronary angioplasty due to acute occlusion of a nonattempted vessel.
    Catheterization and cardiovascular diagnosis, 1990, Volume: 20, Issue:1

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Combined Modality Therapy;

1990
Value of a centralised approach in the management of haematemesis and melaena: experience in a district general hospital.
    Gut, 1990, Volume: 31, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Femal

1990
[Late results following thrombendarterectomy of the carotid artery].
    Medizinische Klinik (Munich, Germany : 1983), 1990, May-15, Volume: 85, Issue:5

    Topics: Aged; Aspirin; Carotid Artery Thrombosis; Endarterectomy; Female; Humans; Male; Middle Aged; Postope

1990
[The patient following PTCA].
    Wiener medizinische Wochenschrift (1946), 1990, Jun-15, Volume: 140, Issue:10-11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Coronary Disease; Exercise Test;

1990
Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarction.
    The American journal of cardiology, 1989, Jul-15, Volume: 64, Issue:3

    Topics: Adult; Aged; Aspirin; Blood Coagulation; Electrocardiography; Heparin; Humans; Middle Aged; Myocardi

1989
Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Circulation, 1989, Volume: 80, Issue:6

    Topics: Amino Acid Sequence; Animals; Aspirin; Dogs; Femoral Artery; Microscopy, Electron, Scanning; Molecul

1989
Ranitidine maintenance treatment of non-steroidal anti-inflammatory drug-induced duodenal ulceration.
    Alimentary pharmacology & therapeutics, 1989, Volume: 3, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Duodenal Ulcer; Du

1989
Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries.
    Radiology, 1989, Volume: 170, Issue:3 Pt 1

    Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Constriction, Pathologi

1989
Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1989, Volume: 29, Issue:4

    Topics: Adult; Aspirin; Blood Transfusion; Combined Modality Therapy; Dipyridamole; Drug Therapy, Combinatio

1989
[The effectiveness of antiplatelet therapy in ischemic cerebrovascular attacks in the chronic stage].
    Ceskoslovenska neurologie a neurochirurgie, 1989, Volume: 52, Issue:5

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Female; Hemiplegia; Humans; Male; Middle Aged; Pentoxifylline

1989
Idiopathic recurrent branch retinal arterial occlusion.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1989, Volume: 107, Issue:5

    Topics: Adult; Aspirin; Female; Fluorescein Angiography; Fundus Oculi; Humans; Recurrence; Retina; Retinal A

1989
Late carotid restenosis: aetiologic factors for recurrent carotid artery stenosis during long-term follow-up.
    European journal of vascular surgery, 1989, Volume: 3, Issue:3

    Topics: Adult; Aged; Aspirin; Carotid Artery Diseases; Cholesterol; Cholesterol, HDL; Constriction, Patholog

1989
[Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)].
    Minerva medica, 1985, Oct-27, Volume: 76, Issue:41

    Topics: Adenosine Diphosphate; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Isoxsuprine; Male; Oxa

1985
Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
    Lancet (London, England), 1986, Apr-05, Volume: 1, Issue:8484

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Atrial Fibrillatio

1986
Secondary prevention after myocardial infarction.
    Lancet (London, England), 1986, Jul-19, Volume: 2, Issue:8499

    Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Artery Bypass; Humans; Lipids; Myocar

1986
[Secondary prevention following myocardial infarct].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1986, Sep-30, Volume: 75, Issue:40

    Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Death, Sudden; Humans; Myocardial Infarction;

1986
Indium-111-labeled platelet scintigraphy in carotid atherosclerosis.
    Stroke, 1989, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Blood Platelets; Carotid Artery Diseases;

1989
Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody.
    American journal of obstetrics and gynecology, 1989, Volume: 160, Issue:2

    Topics: Aspirin; Autoantibodies; Female; Fetal Death; Humans; Lupus Erythematosus, Systemic; Phospholipids;

1989
Management of patients after thrombolytic therapy for acute myocardial infarction.
    Clinical cardiology, 1985, Volume: 8, Issue:9

    Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Circulati

1985
[Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis].
    Zeitschrift fur Kardiologie, 1986, Volume: 75 Suppl 5

    Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Circulation; Coro

1986
Reocclusions after percutaneous transluminal coronary angioplasty.
    Transplantation proceedings, 1987, Volume: 19, Issue:4 Suppl 5

    Topics: Angioplasty, Balloon; Animals; Aspirin; Constriction, Pathologic; Coronary Disease; Dipyridamole; Hu

1987
Restenosis after arterial angioplasty: a hemorrheologic response to injury.
    The American journal of cardiology, 1987, Jul-31, Volume: 60, Issue:3

    Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Arteries; Aspirin; Microscopy, Electron,

1987
The Frankfurt experience in restenosis after coronary angioplasty.
    The American journal of cardiology, 1987, Jul-31, Volume: 60, Issue:3

    Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Follow-Up Studies; German

1987
Laboratory test results as predictors of recurrent coronary artery stenosis following angioplasty.
    Archives of pathology & laboratory medicine, 1987, Volume: 111, Issue:12

    Topics: Aged; Angioplasty, Balloon; Aspirin; Cholesterol; Clinical Laboratory Techniques; Coronary Disease;

1987
Feline aortic thromboemboli: t-PA thrombolysis followed by aspirin therapy and rethrombosis.
    The Veterinary clinics of North America. Small animal practice, 1988, Volume: 18, Issue:1

    Topics: Animals; Aortic Diseases; Aspirin; Cat Diseases; Cats; Female; Recurrence; Thromboembolism; Tissue P

1988
Recurrence rate after successful coronary angioplasty.
    European heart journal, 1985, Volume: 6, Issue:3

    Topics: Angiography; Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Combined Modality Therapy; Con

1985
Clinical experience of percutaneous transluminal coronary angioplasty--technique and results.
    Japanese circulation journal, 1985, Volume: 49, Issue:6

    Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease;

1985
Preventive effects of batroxobin on experimental canine coronary thrombosis.
    Clinical cardiology, 1988, Volume: 11, Issue:4

    Topics: Animals; Aspirin; Batroxobin; Coronary Disease; Coronary Thrombosis; Disease Models, Animal; Dogs; E

1988
Platelet kinetics following carotid endarterectomy: the effect of aspirin and patch angioplasty.
    European journal of vascular surgery, 1988, Volume: 2, Issue:2

    Topics: Aspirin; Blood Vessel Prosthesis; Carotid Arteries; Carotid Artery Diseases; Dipyridamole; Endartere

1988
Aspirin and secondary bleeding after traumatic hyphema.
    Annals of ophthalmology, 1988, Volume: 20, Issue:10

    Topics: Aspirin; Eye Injuries; Humans; Hyphema; Recurrence; Statistics as Topic

1988
Which peptic ulcer patients bleed?
    Gut, 1988, Volume: 29, Issue:1

    Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Mi

1988
Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intravenous streptokinase.
    American heart journal, 1988, Volume: 115, Issue:4

    Topics: Angiography; Aspirin; Dipyridamole; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardi

1988
Aspirin sensitivity and recurrent polyposis.
    Clinical otolaryngology and allied sciences, 1988, Volume: 13, Issue:1

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Recurrence

1988
Childhood membranoproliferative glomerulonephritis: an approach to management.
    Kidney international, 1986, Volume: 29, Issue:5

    Topics: Aspirin; Azathioprine; Child; Cyclophosphamide; Dipyridamole; Drug Administration Schedule; Drug The

1986
Relapsing Kawasaki's disease.
    International journal of cardiology, 1987, Volume: 15, Issue:2

    Topics: Aspirin; Dermatitis; Female; Fever; Humans; Infant; Mucocutaneous Lymph Node Syndrome; Recurrence

1987
Transient ischemic attacks at high altitude.
    Critical care medicine, 1986, Volume: 14, Issue:5

    Topics: Adult; Altitude Sickness; Aspirin; Fluid Therapy; Humans; Hypoxia; Ischemic Attack, Transient; Male;

1986
Exacerbating factors in recurrent urticaria.
    International journal of dermatology, 1986, Volume: 25, Issue:5

    Topics: Adult; Angioedema; Aspirin; Chronic Disease; Female; Hot Temperature; Humans; Male; Recurrence; Urti

1986
Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress syndrome.
    Chest, 1986, Volume: 90, Issue:3

    Topics: Aspirin; Humans; Leukocytes; Male; Middle Aged; Pulmonary Alveoli; Pulmonary Edema; Recurrence; Resp

1986
Carotid endarterectomy. One solution to the stroke problem.
    The American surgeon, 1985, Volume: 51, Issue:2

    Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr

1985
Peripheral vascular disease: treatment and referral of the elderly. Part II.
    Geriatrics, 1985, Volume: 40, Issue:7

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular

1985
Antiplatelet drugs improve the patency rates after femoro-popliteal endarterectomy.
    VASA. Zeitschrift fur Gefasskrankheiten, 1985, Volume: 14, Issue:3

    Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Dipyridamole; Endarterectomy; Female; Femoral

1985
The incidence of rebleeding in traumatic hyphema.
    Annals of ophthalmology, 1985, Volume: 17, Issue:9

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Analysis of Variance; Aspirin; Child;

1985
[Diagnostic and therapeutic methods in the asthmatic triad].
    Terapevticheskii arkhiv, 1985, Volume: 57, Issue:11

    Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Child; Desensitization, Immunologic

1985
White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction.
    Thrombosis and haemostasis, 1985, Oct-30, Volume: 54, Issue:3

    Topics: Adult; Aged; Aspirin; Cholesterol; Coronary Disease; Dipyridamole; Diuretics; Female; Hematocrit; Hu

1985
Effect of aspirin in amaurosis fugax.
    Lancet (London, England), 1971, Oct-02, Volume: 2, Issue:7727

    Topics: Aspirin; Blindness; Dipyridamole; Recurrence; Retinal Vessels; Thrombosis

1971
Aspirin and recurrent painful toes and fingers in thrombocythaemia.
    Lancet (London, England), 1972, Feb-19, Volume: 1, Issue:7747

    Topics: Aged; Aspirin; Blood Platelet Disorders; Fingers; Humans; Male; Middle Aged; Pain; Platelet Adhesive

1972
Urticaria and angioedema.
    New York state journal of medicine, 1972, Apr-15, Volume: 72, Issue:8

    Topics: Adult; Anaphylaxis; Angioedema; Aspirin; Cold Temperature; Female; Histamine Release; Humans; Male;

1972
Delayed febrile pleuropericarditis after sepsis. A possible analogue of the postcardiotomy syndrome.
    Annals of internal medicine, 1973, Volume: 79, Issue:2

    Topics: Adult; Aspirin; Blood Sedimentation; Cardiomegaly; Erythrocytes; Female; Fever; Heart Auscultation;

1973
The natural history of duodenal ulceration.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1972, Apr-08, Volume: 46, Issue:15

    Topics: Aspirin; Duodenal Ulcer; Female; Gastric Acidity Determination; Gastric Juice; Gastrointestinal Hemo

1972
[Recurrent gastric hemorrhage caused by salicylic acid].
    Orvosi hetilap, 1974, Dec-29, Volume: 115, Issue:52

    Topics: Aspirin; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Hematemesis; Humans; Male; Melena

1974
The management of a patient with a duodenal ulcer.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1972, Nov-25, Volume: 46, Issue:47

    Topics: Adult; Alcohol Drinking; Alkalies; Aspirin; Chronic Disease; Diet Therapy; Duodenal Ulcer; Humans; P

1972
[Comparative evaluation of different methods of secondary prevention of rheumatism].
    Sovetskaia meditsina, 1973, Volume: 36, Issue:3

    Topics: Aspirin; Disability Evaluation; Humans; Laryngitis; Penicillin G Benzathine; Penicillins; Recurrence

1973